

Exhibit 594

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NORTH CAROLINA

IN RE:)
)
CAMP LEJEUNE WATER) Case No. 7:23-cv-00897
LITIGATION)
)
This Document Relates to)
ALL CASES)

TUESDAY, JUNE 24, 2025

- - -

Videotaped Deposition of TIMOTHY M. MALLON, M.D.,
M.P.H., taken pursuant to notice and conducted at Keller
Postman, 1101 Connecticut Ave NW #1100, Washington, DC,
20036, at 9:43 a.m. EDT, on the above date, before Jennifer
A. Dunn, Registered Merit Reporter, Certified Realtime
Reporter, California, Illinois & Texas Certified Shorthand
Reporter, and Missouri Certified Court Reporter.

Job No. MDLG7448979

A P P E A R A N C E S

BELL LEGAL GROUP

BY: RANDOLPH L. LEE, ESQ.
rlee@belllegalgroup.com

BY: JIM ROBERTS, ESQ.
219 Ridge Street
Georgetown, South Carolina 29440
Tel: (843) 546-2408

and

DOWLING PLLC

BY: MIKE DOWLING, ESQ. (via Zoom)
mike@dowlingfirm.com
410 N Boylan Avenue
Raleigh, North Carolina 27603
Tel: (919) 529-3351

and

MANDELL, BOISCLAIR & MANDELL, LTD.

BY: ZACHARY MANDELL, ESQ. (via Zoom)
One Park Row, 2nd Floor
Providence, Rhode Island 02903
Tel: (401) 273-8330
Counsel for Plaintiffs

U.S. DEPARTMENT OF JUSTICE

Civil Division Torts Branch

Environmental Torts Litigation Section

BY: SHARON V. SPRAYREGEN, ESQ.

sharon.v.sprayregen@usdoj.gov

BY: CARSON M. GARAND, ESQ.

carson.m.garand@usdoj.gov

BY: CORY BOYER, ESQ.

BY: NATHAN BU, ESQ. (via Zoom)

nathan.bu@usdoj.gov

1100 L Street NW

Washington, DC 20005

Tel: (202) 552-9843

Counsel for the United States of America

ALSO PRESENT:

GORDON THOMAS - Videographer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I N D E X

PAGE

TIMOTHY M. MALLON, M.D., M.P.H.

Examination by Ms. Sprayregen 7

Examination by Mr. Lee 221

Examination by Ms. Sprayregen 234

Certificate of Court Reporter 236

Letter for Signature 237

Witness Signature Page 238

Errata Sheet 239

E X H I B I T S

NUMBER	DESCRIPTION	PAGE
Exhibit 1	Downs Specific Causation Report	11
Exhibit 2	Tukes Specific Causation Report	11
Exhibit 3	Downs Materials Considered List	11
Exhibit 4	Tukes Materials Considered List	11
Exhibit 5	Downs & Tukes First Supplemental Materials Considered List	11
Exhibit 6	Downs & Tukes Second Supplemental Materials Considered List	11
Exhibit 7	Deposition of Timothy M. Mallon taken on April 25, 2025	30
Exhibit 8	Mayo Clinic Printout - Disease & Conditions of Kidney Cancer	69
Exhibit 9	SEER Program Printout titled: "Cancer Stat Facts: Kidney and Renal Pelvis Cancer"	81
Exhibit 10	Tukes Genetic Testing 01553_TUKES_0000000516 through 01553_TUKES_0000000436	109
Exhibit 11	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer HERED-RCC-1	112
Exhibit 12	Analysis of Groundwater Flow, Contaminant Fate and Transport, and Distribution of Drinking Water at Tarawa Terrace and Vicinity, U.S. Marine Corps Base Camp Lejeune, North Carolina; Historical Reconstruction and Present Day Conditions. Chapter A: Summary of Findings CLJA_ WATERMODELING_09-0000615638 through 15753	120

E X H I B I T S (Cont.)

NUMBER	DESCRIPTION	PAGE
Exhibit 13	Reynolds Cumulative Exposure Expert Report	126
Exhibit 14	Bove 2014a Study	155
Exhibit 15	Notice of Deposition of and Request Request for Production of Documents to Dr. Timothy Mallon	188
Exhibit 16	Plaintiffs' Objections and Responses to Defendant's Notice of Deposition and Subpoena of Dr. Timothy Mallon	190
Exhibit 17	Legal Expert Fee Schedule	191
Exhibit 18	Bove 2024 Cancer Incidence Study	197
Exhibit 19	Aschengrau study entitled: "Cancer Risk and Tetrachloroethylene-contaminated Drinking Water in Massachusetts"	204

P R O C E E D I N G S

(Tuesday, June 24, 2025 at 9:43 a.m. EDT)

THE VIDEOGRAPHER: We are now on the record.
My name is Gordon Thomas. I'm a videographer for
Golkow.

Today's date is June 24th, 2025, and the time
is 9:43 a.m.

This video deposition is being held at 1101
Connecticut Avenue Northwest, Suite 1100, Washington,
DC, 02236.

In the matter of In Re: Camp Lejeune Water
Litigation, filed in the United States District Court
for the Eastern District of North Carolina.

The deponent is Dr. Timothy Mallon.

Will counsel please identify themselves?

MS. SPRAYREGEN: Sharon Sprayregen for the
United States.

MR. GARAND: Carson Garand for the United
States.

MR. BOYER: Cory Boyer for the United States.

MR. LEE: Randy Lee and Jim Roberts for the
plaintiffs.

THE VIDEOGRAPHER: The court reporter is
Jennifer Dunn, and will now swear in the witness.

1 TIMOTHY MALLON, M.D., M.P.H.,
2 of lawful age, having been first duly sworn to tell the
3 truth, the whole truth and nothing but the truth, deposes
4 and says on behalf of the Defendants, as follows:

5 EXAMINATION

6 BY MS. SPRAYREGEN:

7 Q Good morning, Dr. Mallon.

8 A Good morning.

9 Q I know we've done this before, but for the record,
10 I represent the United States. My name is Sharon
11 Sprayregen. And this is a court proceeding, even though we
12 are not in a courtroom, and you are under oath.

13 Do you understand you are obligated to tell the
14 truth?

15 A Yes.

16 Q Can you please state your full name and address
17 for the record?

18 A Timothy Michael Mallon. My address is 6508 Folded
19 Leaf Square in Columbia, Maryland, 21044.

20 Q The court reporter, as we've all discussed, is
21 taking down everything we say. It is important that you
22 answer every question verbally.

23 For example, you must say "yes or no," rather than
24 nodding or shaking your head.

25 Do you understand?

1 A Yes.

2 Q We should try not to interrupt each other,
3 otherwise the court reporter will not be able to record us
4 accurately. Please wait until I have finished my question
5 before you start to answer, and I will not interrupt while
6 you are speaking.

7 Because we are doing this over videoconference,
8 there will be some lag, but let's do our best to make this
9 work for our court reporter. Okay?

10 A Yes.

11 Q If you don't understand a question, please let me
12 know and I will try to clarify it. If you do -- if you do
13 not ask for clarification, I will assume you understood the
14 question; is that fair?

15 A Yes.

16 Q During the deposition, you may hear one of your
17 attorneys say: "Objection." Unless your attorney instructs
18 you not to answer the question, please answer the question
19 after the objection has been made. Okay?

20 A Yes.

21 Q You may take breaks. Please just answer the
22 question that is pending before you ask to take a break; is
23 that fair?

24 A Yes.

25 Q Is there any reason why you are unable to give

1 truthful and accurate testimony today?

2 A No.

3 Q How did you first become aware of the Camp Lejeune
4 Water Litigation?

5 A Probably an ad on TV.

6 Q When was that?

7 A 2022. Around there.

8 Q Who first contacted you about working on this
9 matter?

10 A I think Kevin Dean.

11 Q When were you formally retained?

12 A October of 2024.

13 Q And which law firm, if you know, retained you?

14 A I think the Bell Legal Group.

15 Q Did you speak with Plaintiff's counsel prior to
16 being formally retained?

17 A No.

18 Q So you were retained on your very first
19 interaction with your -- withdrawn.

20 When speaking to Plaintiff's counsel for the first
21 time is when you were retained?

22 A Yes. I had to think about that.

23 Q What was your assignment in this litigation?

24 A I was assigned to do a general causation report
25 for kidney cancer and for leukemia, and then subsequently I

1 did two specific causation reports, one for Mr. Downs and
2 another for Ms. Tukes.

3 Q When did you learn about Mr. Downs' case?

4 A Probably January of 2025, maybe.

5 Q And your report was submitted in February of 2025;
6 is that right?

7 A That's right.

8 Q So you learned about Mr. Downs' case approximately
9 a month before you submitted your report?

10 A Yeah, I didn't have a lot of time.

11 Q And when did you learn about Mrs. Tukes' case?

12 A About the same time frame.

13 Q And what was your assignment to be in the specific
14 causation case of this litigation?

15 A My assignment was to prepare these two reports and
16 then to be available for deposition.

17 Q And what did you understand the two reports to be
18 about?

19 A Well, with specific causation, I'm looking at
20 their -- the two claimants' exposures and the relationship
21 with their kidney cancer.

22 MS. SPRAYREGEN: Okay. I am now going to
23 introduce a number of exhibits.

24 For the court reporter, tab 2 will be
25 Exhibit 1.

1 And tab 3 will be Exhibit 2.

2 And tab 4 will be Exhibit 3.

3 And tab 5 will be Exhibit 4.

4 And tab 6 will be Exhibit 5.

5 And tab 7 will be Exhibit 6.

6 (Mallon Exhibits 1 through 6 marked for
7 identification.)

8 BY MS. SPRAYREGEN:

9 Q So can you please take out Exhibit 2? Let me know
10 when you have it in front of you. So Exhibit 2 should be
11 the specific causation report for Mr. Downs; is that right?

12 Oh, excuse me. Exhibit 2 is the specific -- is
13 for Ms. Tukes.

14 So please take out -- we can start with Ms. Tukes.

15 So I'm showing you what's been marked for
16 identification as Exhibit 2.

17 And you recognize this document as your specific
18 causation report for Mrs. Tukes?

19 A Yes.

20 Q Does this report contain all of the opinions you
21 intend to offer in this case regarding Mrs. Tukes?

22 A Yes.

23 Q Do you agree with all the opinions and statements
24 in this report?

25 A Yes.

1 Q Can you please take out Exhibit 1?

2 A I have it in front of me.

3 Q Do you recognize this document as your specific
4 causation report for Mr. Downs?

5 A Yes.

6 Q Does this report contain all of the opinions you
7 intend to offer in this case regarding Mr. Downs?

8 A Yes.

9 Q Do you agree with all the opinions and statements
10 made in this report?

11 A Yes.

12 Q Can you please take a look at Exhibit 3?
13 And this is the Materials Considered List for
14 Mr. Downs; is that right?

15 A Yes.

16 Q And please take a look at Exhibit 4.
17 This is the Materials Considered List for
18 Mrs. Tukes; is that right?

19 A Yes.

20 Q And please take a look at Exhibit 5.

21 A I have it.

22 Q This is the First Supplemental Materials
23 Considered List for both Mr. Downs and Mrs. Tukes; is that
24 right?

25 A Yes.

1 Q And please take a look at Exhibit 6.

2 A Exhibit 6, yes.

3 Q This is the Second Supplemental Materials
4 Considered List for both Mr. Downs and Mrs. Tukes; is that
5 right?

6 A Yes.

7 Q Do the Materials Considered Lists that I've just
8 shown you contain all the materials you considered for the
9 specific causation reports of this case?

10 A I looked over the medical records for Mr. Downs.
11 I got late in the process his information regarding his
12 metastasis. It's sufficient.

13 Q When you say "it's sufficient," you're saying it's
14 a complete and accurate copy of all the materials you
15 considered for Mr. Downs?

16 A With the exception of what I just said in terms of
17 his supplemental medical information regarding the
18 metastasis, I didn't get that till late in the process, I
19 don't think it's necessarily listed here, but Dr. Stadler
20 covered that in his -- in his report, so I'm good.

21 Q So what you're saying is you think there may be
22 some documents for Mr. Downs that you reviewed that are not
23 listed on the Materials Considered Lists for Mr. Downs; is
24 that right?

25 A I think there were 4,000 additional pages of

1 medical records, Counsel, that I'm not sure I completely
2 addressed here. So to be fair, there may be a few pages
3 that are not listed.

4 Q Understood. I will communicate with Counsel about
5 that.

6 Did you review the reports of any of the United
7 States general causation experts?

8 A I did.

9 Q You did?

10 A Yes.

11 Q Did you review Dr. Goodman's kidney cancer general
12 causation report?

13 A Yes.

14 Q Did you review Dr. Shields' general causation
15 report?

16 A Yes. I should say in both cases, not till after I
17 had written my general causation report and not until after
18 I had written the Downs and the Tukes report, so it was
19 subsequent to my writing these two reports.

20 Q I don't believe that the Goodman report and the
21 Shields' report are on the Materials Considered List for the
22 Tukes and Downs reports.

23 A The reason being, I didn't see those until
24 subsequent to the report being written.

25 Q So they were not considered for the report is what

1 you're saying?

2 A Correct.

3 Q But you did see them?

4 A Subsequently.

5 Q Subsequently. And did you review Dr. McCabe's
6 kidney cancer report?

7 A Yes.

8 Q And is that the same as Dr. Goodman and Dr.
9 Shields, you reviewed it subsequent to drafting your
10 specific causation reports for --

11 A Did we list --

12 Q Tukes -- Mr. Downs and Ms. Tukes?

13 A I believe I saw McCabe before I wrote this, but
14 I'm not certain of that.

15 Q So your reports were submitted on February 7th; is
16 that right?

17 A I believe so, yeah.

18 Q Dr. McCabe's report was also submitted on
19 February 7th?

20 A So I couldn't have seen it before then.

21 Q But you did see Dr. McCabe's kidney cancer report
22 afterwards?

23 A Subsequently, yes.

24 Q Did you see any of -- did you review any of
25 Dr. McCabe's other general causation reports?

1 A Not that I recall.

2 Q And did you review Dr. Lipscomb's general
3 causation report?

4 A Yes.

5 Q Did you review the reports of any of the
6 plaintiffs' general causation experts in this case?

7 A Yes. I had the opportunity to do that.

8 Q So did you review Dr. Bird's kidney cancer --

9 A Yes.

10 Q Withdrawn. Yeah, withdrawn.

11 Did you review Dr. Bird's kidney cancer general
12 causation report both for --

13 A I'm sorry, go ahead.

14 Q That's okay. I do it, too, but both for my sake
15 and the court reporter's, please let me finish my question.
16 I understand it's difficult. I also have the tendency to
17 want to jump in. So let's start again.

18 Before submitting your specific causation reports
19 for Mr. Downs and Ms. Tukes, you reviewed Dr. Bird's general
20 causation kidney cancer report; is that right?

21 A No, that's not correct.

22 Q Okay. When did you review Dr. Bird's general
23 causation kidney cancer report?

24 A A week ago.

25 Q For the first time?

1 A For the first time.

2 Q And you're referring to his report, not his
3 deposition transcript?

4 A His deposition transcript. I don't think I ever
5 saw his report.

6 Q Okay. And going back to what you testified about
7 reviewing for the U.S. general causation experts, did you
8 review Dr. Goodman's kidney cancer report or her deposition
9 transcript, or both?

10 A Both.

11 Q And for Dr. Shields, did you review his report,
12 his deposition transcript, or both?

13 A I reviewed his report, his almost 600-page report,
14 and I skimmed through his deposition transcript, but didn't
15 read it.

16 Q And for Dr. McCabe, did you review his deposition
17 transcript, his kidney cancer general causation report, or
18 both?

19 A I think I reviewed his report.

20 Q And for Dr. Lipscomb, did you review his
21 deposition transcript or his general causation report, or
22 both?

23 A The transcript.

24 Q And what -- withdrawn.

25 Did you review Dr. Hatten's general causation

1 kidney cancer report?

2 A Not that I recall.

3 Q Did you review Dr. Hatten's general causation
4 deposition?

5 A No.

6 Q So you've reviewed nothing of Dr. Hatten's; is
7 that correct?

8 A Correct.

9 Q Have you reviewed Dr. Gilbert's report or her
10 deposition transcript, or both?

11 A I did review her report. I did -- I don't recall
12 reviewing her deposition transcript.

13 Q I'm sorry, I didn't hear you. Was that a "I did
14 review her report?

15 A I did review her report.

16 Q Thank you. And did you review Dr. Savitz's
17 general causation rebuttal report, his deposition
18 transcript, or both?

19 A I did review his deposition -- not his deposition.
20 I reviewed his general causation rebuttal, but didn't review
21 anything else.

22 Q And for Dr. Madigan, did you review his general
23 causation rebuttal report, his deposition transcript, or
24 both?

25 A Same answer. I reviewed his rebuttal, but not any

1 deposition.

2 Q And I know the answer to the first one, but for
3 keeping the record clean, I'm going to ask it.

4 Did you review the -- Dr. Stadler's specific
5 causation report?

6 A Yes.

7 Q And I should have let you know that I am now
8 transitioning to the United States experts. I am not trying
9 to pull one over on you.

10 Did you review Dr. Vance's report?

11 A No.

12 Q You did not review Dr. Vance's report?

13 A Correct.

14 Q Did you review Dr. Johnstone's report?

15 A Only the draft deposition report.

16 Q I'm sorry. The -- could you repeat that?

17 A The draft deposition transcript.

18 Q Thank you. And did you review Dr. Lakind's
19 report?

20 A No.

21 Q Did you review Dr. Bailey's report?

22 A No.

23 Q Did you ask to see either Dr. Lakind or
24 Dr. Bailey's reports?

25 A I don't recall. I mean, I specifically thought

1 about it, but there was just not enough time, so I didn't
2 review either report.

3 Q My question was: Did you ask to see them, not if
4 you thought about asking to see them.

5 A So the answer is: No. I did not ask to see them.

6 Q Did you review the reports of any of the
7 plaintiffs' other specific causation experts in this case?

8 A No.

9 Q I believe you reviewed Dr. Reynolds' report; is
10 that correct?

11 A Yes. You said: "Plaintiffs," so, yes. I did
12 review that.

13 Q Did -- do you agree with the opinions
14 Dr. Reynolds' offered?

15 A Yes, mm-hmm.

16 Q Did you review Dr. Allen's rebuttal report?

17 A Yes, I did.

18 Q Did you agree with the opinions Dr. Allen offered?

19 A I did.

20 Q Did you review Dr. Lotan's report?

21 A Yes.

22 Q Did you review Dr. Margulis' report?

23 A Yeah.

24 Q Did you review Dr. Josephson's report?

25 A I believe you just asked me about that. And I

1 said: Yes. I saw the draft after the deposition
2 transcript.

3 Q No, I never asked you about Dr. Josephson.

4 A Yeah. Name recognition.

5 Q I understand. I am taking depositions of you and
6 Dr. Madigan, so I fully empathize.

7 A Thank you.

8 Q So you have not reviewed Dr. Josephson's report;
9 is that correct?

10 A Yes.

11 Q And did you review Dr. Smith's rebuttal report?

12 A No.

13 Q Did you consider any materials not listed in your
14 Materials Considered Lists that were entered as exhibits
15 today?

16 A No.

17 Q No academics, texts, studies, or treatises, that
18 weren't listed?

19 A Everything I've considered is listed on the first,
20 second, and third supplemental deposition -- or Supplemental
21 Materials Considered List.

22 Q For the record, you're talking about the two
23 original Materials Considered List and the First and Second
24 Supplemental Materials Considered Lists; is that --

25 A That's correct.

1 Q Again. And I really understand the desire to jump
2 in, but please try to let me finish my question. I really
3 get it.

4 Did you speak with any other Plaintiffs' experts
5 in the course of preparing your reports for Mr. Downs and
6 Ms. Tukes?

7 A No.

8 Q So please take out Ms. Tukes' report, which is
9 Exhibit 2. And turn to the back where it has your CV.

10 Can you flip through your CV quickly, and let me
11 know if you recognize this document as your current CV?

12 A I just want to make sure all the publications are
13 current. Yes. It is my current CV.

14 Q Can you please turn to the third page of your
15 current CV?

16 A It would help if the pages were numbered.

17 Q It's the page that has on the top: "Department of
18 Preventive Medicine and Biostatistics," with the dates
19 July 12th to June 2016.

20 A Yes, I can see that.

21 Q The ninth point says that you are a preceptor or
22 you were, excuse me, a preceptor for occupational medicine
23 residence and medical students, served as course director
24 for four occupational medical -- I'm going to start again.

25 The bullet point that I was trying to read says:

1 "Preceptor for occupational medicine residents and medical
2 students. Served as course director for four occupational
3 medicine courses."

4 Did I read that correctly?

5 A Yes.

6 Q And can you now turn to the fifth page of your CV,
7 the one that has "Prior Teaching Activities," at the bottom
8 of it?

9 A Okay.

10 Q And under "Prior Teaching Activities" is listed
11 the course "PM0973. OEM Journal Club Co-Course Director."

12 "PM0542. Clinical Occupational Environmental
13 Medicine Course Co-Director."

14 "PM0655. Safety and Injury Prevention Course
15 Director."

16 "PM0642. Clinical PM Services and Selected Topics
17 and OEM Co-Course Director."

18 "PM0558. Intro to Preventive Occupational
19 Medicine Residency's Course Co-Director."

20 "PM0549. Toxicology Course Lecturer."

21 Did I read that correctly?

22 A Yes.

23 Q And in your CV, the bullet point that we just
24 discussed under the -- when you were at the Department of
25 Preventive Medicine and Biostatistics between July 12th and

1 June 2000 -- July 2012 and June 2016, the course director
2 for four courses, does that refer to four of the courses
3 that are listed on the subsequent page of your CV?

4 A I think it said five. But yes, these are the
5 courses I was referring to.

6 Q For the record, you may want to update your CV.

7 A Thank you.

8 Q And then on the fourth page of your CV, under
9 "Department of Preventive Medicine and Biostatistics,"
10 between July 2004 and June 2010, you have a bullet point
11 that says the same thing as what we just read, that you
12 served as a course director for four occupational medicine
13 courses.

14 Do you see that?

15 A Which line down?

16 Q The tenth line down.

17 A Yes.

18 Q And are you referring to the same courses that are
19 listed on the next page of your CV?

20 A Yes.

21 Q So how many times were you a course director for
22 PM0973?

23 A How many times? So I was in the residency from
24 2004 to 2016. So what's that, 12 years.

25 So I was co-course director for PM0973 for 12

1 years.

2 Q And how many times were you a co-course director
3 for PMO542?

4 A Same.

5 Q For 12 years?

6 A Yes.

7 Q And how many times were you a course director for
8 safety and injury prevention?

9 A Probably, I want to say two years.

10 Q And how many times were you a co-course director
11 for clinical PM services and selected topics in OEM?

12 A 12 years.

13 Q And how many times were you a co-course director
14 for Intro to Preventive Occupational Medicine Residencies?

15 A 12 years.

16 Q And for how many years were you a course lecturer
17 in toxicology?

18 A Certainly from '04 to 2010, so that's six years.
19 And then -- let's just say six years.

20 Q What does it mean to be a course director?

21 A Well, so in this setting, I would organize the
22 course content, the curriculum. I would arrange for
23 speakers to come in and speak on selected topics, and I
24 would make sure that every -- every topic that is kind of
25 mandated by the curriculum was covered in terms of a

1 lecturer.

2 And then usually the associate residency director
3 and myself would split up, you know, it was a term of 12
4 weeks, so probably each of us would have, as a minimum, two
5 or three lectures that we would each do, and then we would
6 arrange for speaker -- guest speakers to come in and give
7 presentations on the remaining topics.

8 Q Is being a course director different from being a
9 law professor, teaching a course in law school, if you know?

10 A Probably not much different.

11 Q Do you know how law school courses are organized?

12 A I did take one law school course in environmental
13 law at the University of Michigan, at the law school.

14 Q Is being a course director different from teaching
15 a large undergraduate course as a professor?

16 A Not in my experience.

17 Q The reason I'm asking is because what you
18 described to me sounds different from a course where a law
19 professor teaches the course and gives every single lecture
20 in the class or almost every lecture in the class and isn't
21 supervising a number of other people.

22 A Well, I understand. Your experience is different
23 than mine.

24 Q Were you a course director or a co-course director
25 for any other courses that are not listed on your CV?

1 A You know, there is one that we talked about last
2 time, and that was the occupational and environmental
3 epidemiology course. And I was the -- a co-course director
4 for that course for, I think two years, and I was a lecturer
5 for probably another couple of years after that, so a total
6 of four years.

7 Q And what does it mean to be a lecturer for the
8 course?

9 A Well, I probably gave one or two lectures during
10 the duration of the course.

11 Q So the occupational and environmental epidemiology
12 course that you were a course director for, is --

13 A I don't think it's mentioned any place else in the
14 CV.

15 Q Not PMO542; is that correct?

16 A Correct.

17 Q And were you ever a course director for a
18 toxicology course?

19 A In 2004, the current residency program director
20 left, so the following year I was a course director for the
21 toxicology course, so that would be in 2005, where I was the
22 course director, so I gave several lectures, and as
23 discussed previously, I arranged for guest lecturers to come
24 in and give talks on some of the other content in the
25 course.

1 Q I believe you testified at the last deposition
2 that you were the program director for the toxicology course
3 for at least a couple of years; is that correct, or did you
4 misremember when you said that?

5 A No. I thought what I said before and what I said
6 today was consistent.

7 Q Okay. So you're saying you were a course director
8 for one year and you were a program director for at least a
9 couple of years?

10 A No, no, no. Course director is course director.
11 Program director refers to the residency program.

12 Two different things.

13 Q Could you explain that a little bit more to me
14 since this is not my field?

15 A So the occupational and environmental medicine
16 residency program is a residency program accredited by the
17 Accreditation Council for Graduate Medical Education, and so
18 they certified our residency program as being part of the 67
19 or 70 or so residencies that are accredited at the Uniformed
20 Services University.

21 Also, under the American Board of Preventive
22 Medicine, they authorize us to train residents, and so the
23 ACGME gives their blessing that we've met all the
24 requirements and criteria, so as program director, I make
25 sure that every aspect of the residency program meets all of

1 the requirements of the ACGME, the Accreditation Counsel of
2 Graduate Medical Education, as program director.

3 Course director, it's specifically for that one
4 course where I organize and provide lectures for the
5 residents as a particular course director.

6 Q So what you just said now makes sense, but I can
7 show you the testimony. I believe what you testified is
8 that you were the program director for the toxicology
9 course; is that correct?

10 MR. LEE: Objection to form. You can show
11 him whatever you want to.

12 BY MS. SPRAYREGEN:

13 Q I can. Can you answer the question? If not, I
14 can show it to you.

15 A Well, so if I misspoke and called it a program
16 director when I was a course director, I stand corrected.

17 Q So can you clarify for me what you were?

18 A Both. I was both the program director and the
19 course director. Course director for the toxicology course.

20 Q And program director for?

21 A The residency program.

22 Q The residency program.

23 You know what, let's just make this easier. You
24 want to introduce -- for the record, I'm going to introduce
25 Exhibit 7, which is Dr. Mallon's deposition.

1 (Exhibit 7 marked for identification.)

2 THE WITNESS: Did you get the errata sheet,
3 Counselor?

4 MS. SPRAYREGEN: I don't know if I did.

5 THE WITNESS: Okay. There was really nothing
6 of substantive change.

7 BY MS. SPRAYREGEN:

8 Q And if you turn to page 15 of the transcript, it's
9 on page 5 of the document.

10 A Page 5. I'm there.

11 Q Okay. Thanks. I'm just trying to understand what
12 you did. I totally understand if you misremembered, I'm not
13 trying to play gotcha here.

14 On page 15, it says, QUESTION: "And did you teach
15 any other courses in epidemiology?

16 "ANSWER: Not as a course director, but I provided
17 lectures in a variety of classes that incorporated
18 epidemiology."

19 And that's on lines 14 to 19.

20 And then in terms of -- when I asked what courses
21 did you give lectures in that -- what courses did you give
22 lectures in? The answers that I see are on page 16 of the
23 transcript: "General epidemiology."

24 That's at lines 10 to 11.

25 "Intro to OEH," which is on 16, lines 9 to 11.

1 And then "Biostatistics," which is on page 18,
2 lines 13 to 16.

3 So does that still sound right to you?

4 A Well, in terms of the biostatistics, I was never a
5 course lecturer in that, but I had to teach and review with
6 the residents the biostatistics that they were learning, so
7 we did more review and we covered the biostatistics and the
8 epidemiology as part of their training, in preparation for
9 the boards -- the Board of Preventive Medicine Board.

10 Q Did you ever teach a class in biostatistics?

11 A Not specifically, no.

12 Q So when you were teaching residents, was this the
13 equivalent to tutoring?

14 A Yes, I think you could -- you could summarize it
15 that way.

16 Q Other than what I've just discussed and the
17 lectures in toxicology, did you give lectures in any other
18 courses that you can recall?

19 A Not that I can recall.

20 Q And when you testified that you were a course
21 lecturer in toxicology -- toxicology, were you referring to
22 PMO549?

23 A Yes.

24 Q And is it accurate to say that you gave a few
25 lectures every year in toxicology for about six years?

1 A Yes.

2 Q Do you recall testifying about your work studying
3 the association between burn pit exposures and certain
4 diseases, right?

5 A Yes, ma'am.

6 Q Do you consider this investigation to be
7 epidemiology?

8 A I do.

9 Q Do you consider your work on this investigation to
10 be toxicology?

11 A It involves certainly components of toxicology,
12 for sure.

13 Q Can you explain how your work on that
14 investigation was toxicology?

15 A Absolutely. So the premise for our analysis was
16 that we recognize that the troops -- the deployed troops
17 were exposed to up to 400 different chemicals that were
18 present in the burn pit smoke, and so we -- we specifically
19 had sampling, environmental sampling, which is unusual, for
20 the troops, the 200 troops that were deployed.

21 An Air Force bioenvironmental engineer had
22 collected breathing zone samples for these 200 troops during
23 the time that they were exposed to burn pits and they were
24 deployed in both Iraq and Afghanistan.

25 So we took that information and then we looked at

1 their blood samples that were collected and we analyzed the
2 blood samples for those same components that were in the
3 burn pit smoke, and so we had to use molecular, you know,
4 molecular -- molecular genetics, really, to look at
5 alterations in biomarkers of exposure.

6 So specifically looking at mRNA alterations, micro
7 RNA alterations, as a direct result of chemical exposure.
8 So that component alone speaks to the toxicology, the
9 toxicologic basis of that research.

10 And then the epidemiology part of it is we
11 structured the -- we structured the research such that we
12 had 200 cases of people exposed, and we had 200 controls
13 that we selected from other people that were not deployed,
14 and we compared the health outcomes in the deployed group
15 and we compared that to the health outcomes in the
16 non-deployed group, and what we found out was that there was
17 an increase in respiratory hazards related to deployment
18 exposure compared to the non-deployed troop, and so I think
19 this was a pretty solid epidemiologic study.

20 One of my co-workers, one of my co-PIs in this
21 study, a doctor of Ph.D. and epidemiology as a result of
22 this work, so I think that you could safely say it was a
23 very solid epidemiology project.

24 Q Can you please turn to the second page of your CV?
25 I know it's not labeled, but it's the one that has Veteran's

1 Evaluation Services at the top.

2 A What page?

3 Q The second page of the CV.

4 A ES, okay.

5 Q Yeah. Under Section 6: "Prior Positions Held."

6 You see "Health Research System Administration
7 Comp Injury Counter Measures"?

8 A Yes.

9 Q And then the third bullet point is: "Prepare
10 recommendations for program director and Lee review"?

11 A Yes, ma'am.

12 Q What was that?

13 A This was in support of HRSA, and part of HRSA's
14 mission is to coordinate the review of vaccine injuries for
15 both pediatric and for adult patients. And this work was
16 basically for a period of a year until the program was put
17 on hold by Congress and by litigation, they -- until the
18 program was paused, I would look at vaccine injury cases and
19 review the medical documentation and provide a
20 recommendation to the medical director of the program,
21 whether or not people should be compensated based on their
22 vaccine injury.

23 And I did that based on the extent of the medical
24 record documentation that supported injury, or lack of
25 injury, in those case files.

1 Q And moving up on the page, under the -- your work
2 for the Veteran's Evaluation Services between October 2017
3 to present, do you see where I'm looking on the page?

4 A On the top.

5 Q Yes. The third bullet point says: "Address
6 causal connection between exposure and related health
7 outcomes."

8 Do you see that?

9 A Yes.

10 Q What did you do for that?

11 A Well, it says there is what I currently do for the
12 VA, which is to review veterans' claims, and as part of
13 that, we have essentially what the VA has in their medical
14 documentation, they send the medical file to VES, and they
15 have a physician reviewer look at the medical documentation
16 in the claim file.

17 And there's a variety of conditions that people
18 can submit claims for, but, essentially, to summarize, a lot
19 of it is the presumptive conditions that are identified in
20 the Camp Lejeune Litigation -- not litigation. In the
21 Justice Act.

22 The VA regulations identify what are those
23 presumptive conditions, so I'll review the medical records
24 for any presumptive conditions and then any additional
25 conditions that might be related to exposure to Camp

1 Lejeune, all the VA will specifically ask which questions
2 they want me to answer in regards to the exposure and the
3 health outcome that's present in the claim file, and I'll
4 submit a medical opinion as it relates to an individual
5 veteran's claim.

6 Q Do you refer to this in your prior litigation as
7 writing specific causation reports for the VA?

8 A I don't believe I did. Because it wasn't -- it
9 wasn't something that I was ever deposed on. It wasn't
10 something that ever went to court. It was just basically
11 doing my job for the VA, which is to review cases and make a
12 determination and submit the opinion.

13 Q You're not an attorney, correct?

14 A Correct.

15 Q And you're not an economist, correct?

16 A I'm sorry?

17 Q You're not an economist; is that correct?

18 A That's correct.

19 Q And you're not a geneticist; is that correct?

20 A I am not formally a geneticist, that's correct.

21 Q Do you have any training in genetics?

22 A I thought you might ask me that question. Yes.

23 I do have training in genetics. I took a genetics
24 course in medical school, and I had a senior research
25 project as a undergraduate -- undergraduate mas -- not

1 master's, just my BS.

2 My senior research project was in molecular
3 genetics, looking at alterations in coding for -- I don't
4 recall all the specifics, but my molecular biology
5 professor, that was his line of research, and I supported
6 his research as part of my senior thesis for my BS in
7 biology.

8 Q You've never taught any courses in genetics; is
9 that correct?

10 A That's correct.

11 Q And you've never taught any courses in molecular
12 pathology; is that correct?

13 A Correct.

14 Q And you've never published in the peer-reviewed
15 literature on genetics; is that correct?

16 A Correct.

17 Q And you've never published in the peer-reviewed
18 literature on molecular pathology; is that correct?

19 A Well, I think that the alterations in microRNA
20 that we saw in the burn pit exposures would probably meet
21 the criteria for what you just said, in molecular genetic
22 alterations due to burn pit exposures.

23 Q Other than what you just described about the
24 molecular alternations due to burn pit exposures, have you
25 published in the peer-reviewed literature in molecular

1 pathology?

2 A No.

3 Q You don't have any certifications in genetics; is
4 that correct?

5 A That's correct.

6 Q And you don't have any certifications in molecular
7 pathology; is that correct?

8 A Correct.

9 Q And you don't have any degrees in statistics; is
10 that correct?

11 A Statistics. No degrees, but, you know, it's a --
12 it's a very large component of training for a master's in
13 public health.

14 Q And you've never published in the peer-reviewed
15 literature regarding the effects of TCE on kidney cancer; is
16 that correct?

17 A Correct.

18 Q You've never published in the peer-reviewed
19 literature regarding the effects of PCE on kidney cancer; is
20 that correct?

21 A That's correct.

22 Q And the same for vinyl chloride; is that correct?

23 A Yes.

24 Q And the same for benzene; is that correct?

25 A Yes.

1 Q And you're not an oncologist; is that correct?

2 A That's correct.

3 Q And you're not a urologist; is that correct?

4 A That's correct.

5 Q And you're not a surgeon; is that correct?

6 A Correct.

7 Q And you're not an immunologist; is that correct?

8 A That's correct.

9 Q Would you agree that a doctor who is a clinician
10 is directly involved in the diagnosis, treat -- and
11 treatment and care of patients?

12 A Was that a question, Counselor?

13 Q I'm -- yes.

14 A Could you clarify that, please?

15 Q How would you define a clinician?

16 A Well, clinician in what area?

17 Q I'll move on. When was the last time you saw
18 patients?

19 A That's a good question. So what I do daily is to
20 review medical records on veterans who are essentially
21 patients, and so I do that daily.

22 Q When you review these medical records, are you --
23 do you consider the veterans -- withdrawn.

24 Do you consider the medical records of the -- I'll
25 strike that.

1 Do you consider the veterans patients when you're
2 reviewing your medical records?

3 A To the extent that anybody in a patient when
4 you're doing disability reviews, yes.

5 Q When was the last time you diagnosed and treated a
6 patient?

7 A That's probably 20 years ago.

8 Q And what --

9 A I take that back, Counselor, because during the
10 residency program, I precepted residents up until 2016 in
11 the clinical occupational medicine clinic at Walter Reed
12 Army Medical Center or now National Military Medical Center.

13 And so, you know, we saw patients day in and day
14 out and we had to teach the residents how to do that.

15 So seeing patients -- seeing patients with
16 occupational injuries, occupational exposures, that had to
17 be evaluated with, evaluated in terms of HIV, bloodborne
18 pathogens, you know, the list goes on.

19 Q Have you ever treated a patient for kidney cancer?

20 A I will say that during my residency training in
21 the -- my internship year, I had the opportunity to treat
22 patients with kidney cancer.

23 Q Since being a resident, have you treated a patient
24 for kidney cancer?

25 A Not since then, no.

1 Q Have you ever diagnosed a patient with kidney
2 cancer?

3 A No.

4 Q When were you a resident?

5 A I graduated from my last residency program in --
6 let's see, 1996.

7 Q Can you turn to the transcript, which is Exhibit
8 11, page -- excuse me, Exhibit 7.

9 A The depo transcript?

10 Q The depo transcript. And it is Exhibit 7. My
11 bad.

12 Page 290, and it is on the 74th page of the
13 document.

14 A Page 290.

15 Q The bottom numbers, it's on page 74.

16 A 74. 290. Okay.

17 Q So starting on page 290, in response to a question
18 at line 20, you answered: "I believe I talk about it in my
19 CV. I have been doing, for the last eight years, work for
20 Veteran's Evaluation Services, writing specific causation
21 reports for veterans who worked at Camp Lejeune and
22 developed cancer and noncancer outcomes, and those reports
23 are submitted to the VA through the Veteran's Evaluation
24 Services.

25 Did I read that correctly?

1 A Yes, you did.

2 Q And is that what you -- what the line in your CV
3 that we talked about that says, quote: Address causal
4 connection between exposures and related outcomes refers to?

5 A Yes.

6 Q What specific steps do you take to determine
7 whether, in your opinion, a veteran's kidney cancer was
8 related to his or her time at Camp Lejeune?

9 A I would say it's a weight of the evidence review
10 of the information that's available in terms of exposure
11 reports, review of individual risk factors that might
12 contribute to the health outcome of concern, looking at the
13 extent of the medical literature to see what is and what is
14 not supported in the medical literature regarding any
15 associations between the exposures and health outcomes of
16 concern. That's the short version.

17 Q The first thing you mention was exposure reports.
18 Right?

19 A Yes.

20 Q What exposure reports are available?

21 A For whom?

22 Q For these veterans that you were evaluating to
23 determine whether or not their time at Camp Lejeune is
24 related to their kidney cancer?

25 A Well, fortunately, the VA produces a VA exposure

1 memorandum, and in it is a summary of the ILER, I-L-E-R,
2 which is an individual longitudinal exposure record.

3 And in there, they summarize what the individual
4 exposure is that each veteran had, the best available
5 information based on industrial hygiene sampling, based on a
6 review of the military occupational specialty in regards to
7 the specific veteran of concern.

8 So the ILER is a nice summary of what the
9 exposures are. So that is part of the VA exposure
10 memorandum that is included in every single VA case that
11 gets submitted.

12 So I review that as part of the record.

13 Q Do any of these ILERs quantify a veteran's
14 exposure to any of the VOCs involved in this case?

15 A Yes.

16 Q How do they do that?

17 A Well, as I mentioned before, the ILER is a summary
18 of what is uploaded by the service deployment health
19 environmental specialist.

20 So, as in the case of the burn pit exposures,
21 there was a bioenvironmental engineer who was deployed with
22 the troops, and they sample the environmental exposures that
23 the troops encounter when they're deployed.

24 And that information that is collected gets
25 uploaded into the ILER for every specific veteran who's

1 deployed, when they collect that information.

2 It's not always there. Probably 90 percent of the
3 time it's not there, but to the extent that it's available,
4 it gets uploaded into the ILER.

5 Q And you also -- you do these reports for
6 individuals who were stationed at Camp Lejeune; is that
7 correct?

8 A Yes.

9 Q Is there an ILER for individuals who are stationed
10 at Camp Lejeune?

11 A Yes.

12 Q How is their exposure quantified?

13 A You know, that's a great question. It's
14 quantified most commonly by the duration of exposure, so the
15 VA tracks the number of months that an individual was
16 stationed at Camp Lejeune. It also tracks the military
17 occupational specialty of the veteran who was stationed at
18 Camp Lejeune.

19 So it's a combination of both recognizing that
20 there's a drinking water exposure, ingestion, and inhalation
21 when they shower, plus recognizing that there are military
22 occupational exposures. If the person's a mechanic, if
23 they're, you know, if they're an engine mechanic, a aviation
24 mechanic, understanding the MOS and the specific exposures
25 that are related to the MOS gives me the ability to

1 understand what the total environmental exposure and
2 occupational exposure component looks like.

3 And I include discussion in every report of both
4 the environmental and the occupational exposure for each
5 veteran that I do.

6 Q Do the reports state where on base the veteran
7 lived and worked?

8 A To the extent that that's available, but almost
9 every report doesn't get into that level of detail in terms
10 of where they stayed on base.

11 Q So would it be fair to say for the vast majority
12 of veterans, when you're looking at their exposure, you're
13 looking at their MOS and the time they spent at Camp Lejeune
14 only?

15 A I would say, but you have to put it in the
16 perspective that I'm familiar with Morris Maslia's report,
17 where he did the environmental model -- modeling. I had
18 read that report long before I knew anything of the
19 plaintiffs' cases, and so I was familiar with the
20 environmental modeling and I knew that there was ongoing
21 exposure that was very closely characterized by Morris and
22 his team, Dr. Bove, so that information was available, and I
23 had to use that in terms of my causation determinations.

24 Q So in your specific causation reports, and we'll
25 get to this a little later, you discussed the Bove 2014a

1 article, right?

2 A Yes.

3 Q And you discuss Table 6 of that article, correct?

4 A Yes.

5 Q And that group's exposures into low, medium, and
6 high; is that right?

7 A Yes.

8 Q Do you use that Table 6 when you're doing these
9 specific causation reports that we're discussing now?

10 A Yes.

11 Q You do?

12 A I do.

13 Q And you have enough information to determine the
14 microgram per liter months, excuse me, the cumulative
15 microgram per liter months that the individuals who are
16 evaluating have consumed?

17 A I'm happy to say yes.

18 Q And how do you have enough information to
19 determine the cumulative microgram per liter months that
20 these individuals have consumed?

21 A Well, I base the determination based on the
22 individual exposure reports that Dr. Kelly Reynolds put
23 together.

24 Q I'm not talking about -- I appreciate that. I'm
25 not talking about Mr. Downs and Mrs. Tukes. I'm talking

1 about the specific causation reports that you do for your
2 work at the Veteran's Evaluation Services, do you use the
3 Bove 2014a Table 6?

4 A I would say that most of the reports that I do
5 don't require that because the level of detail that the VA
6 provides is not sufficient to be able to go into Table 6 and
7 make a determination.

8 I can only use what information is available in
9 the record, you can't make that up.

10 Q I completely understand that, and that was what I
11 was trying to ask. Is there information, when you're doing
12 these reports for the Veteran's Evaluation Services, that
13 allow you to quantify an individual's exposure using the
14 Bove 2014a Table 6?

15 A Well, I would say, to put it in context, I was --
16 I was thrilled when they published the ATSDR 2018 report and
17 the subsequent 2024 mortality and incident studies, where
18 they looked at exposure duration and that -- that provided
19 more assurance that as I looked at exposure duration of
20 veterans that I was on the right track in terms of
21 recognizing that the longer the exposure occurred, the
22 greater the likelihood of that causation was actually
23 occurring.

24 Q Would it be fair to say that for most of the
25 veterans you're evaluating for the Veteran's Evaluation

1 Services, you were determining their exposure based on their
2 duration of time at Camp Lejeune?

3 A Yes.

4 MR. LEE: Sharon, when get a chance, about an
5 hour and 15 minutes. Whenever you're ready to take a
6 break.

7 MS. SPRAYREGEN: I can take a break.

8 THE VIDEOGRAPHER: The time is 10:58 a.m. We
9 are going off the record.

10 (Recess taken from 10:58 to 11:09 a.m.)

11 THE VIDEOGRAPHER: The time is 11:09 a.m.
12 We're going back on the record.

13 Please proceed, Counsel.

14 BY MS. SPRAYREGEN:

15 Q Just a few more questions about your work
16 evaluating veteran for the Veteran's Evaluation Services.

17 You evaluate whether veterans who served as Camp
18 Lejeune and were diagnosed with kidney cancer, whether that
19 kidney cancer is related to their time at Camp Lejeune; is
20 that correct?

21 A Yes.

22 Q And of those evaluations, what percentage do you
23 find that the veterans' kidney cancer was, in fact, related
24 to their time at Camp Lejeune?

25 A That's hard to say, because I don't have the

1 reports in front of me.

2 Well, most of it's based on duration of time
3 spent. The majority of people who submit claims don't have
4 sufficient time at Camp Lejeune to meet the, in my mind, the
5 threshold.

6 So I would say 10 percent positive, 90 percent
7 negative in terms of opinions.

8 Q And what is the threshold of time spent in your
9 mind?

10 A That's a good question. You know, the VA says 30
11 days is sufficient, but, you know, if you look at the Bove
12 studies, I think it gives -- it provides a little more
13 guidance than the seat of the pants.

14 As you look at the duration, the longer the
15 duration the greater the risk, and I think, you know, if you
16 look at the risk, even two quarters of exposure, which is
17 essentially six months, shows some increased risk, and that
18 risk, particularly as it goes beyond 10 quarters, is even
19 more markedly elevated in some cases.

20 So I think -- I think Dr. Bove, his studies, the
21 2024 studies, in particular, provides some guidance in terms
22 of duration.

23 Q And you're looking at those Bove 2024 studies when
24 you are doing your work for the Veteran's Evaluation
25 Services; is that correct?

1 A Yes.

2 Q And you also evaluated whether veterans with
3 leukemia -- withdrawn.

4 You've also evaluated whether veterans who have
5 leukemia is -- and whether their leukemia is, in fact,
6 related to their time at Camp Lejeune?

7 A Yes.

8 Q And about what percentage of those leukemia do you
9 find that disease is, in fact, related to their time at Camp
10 Lejeune?

11 A Well, that's -- that's -- well, the leukemia, in
12 particular, the four carcinogens of interest in this case in
13 terms of the risk and the genotoxic nature of their
14 carcinogens that we're talking about, the duration tends to
15 be a much narrower window to get to the point where there's
16 markedly increased risk.

17 And so that gets closer to the 30-day mark because
18 of just the toxicity of -- of the genotoxic chemicals and
19 what's seen in terms of an earlier development of cancer
20 related to the, you know, particularly AML and ALL, I think
21 they're -- the risk is greater. It's just a more potent
22 carcinogen as it relates to the leukemia than to the kidney
23 cancer, the duration is longer for kidney cancer.

24 That's just my sense of things.

25 Q My question to you was about what percentage of

1 the leukemia evaluations that you do, of those that were
2 Camp Lejeune, that you find that the leukemia was related to
3 their time at Camp Lejeune?

4 A Thank you for that clarification.

5 The answer -- that's hard to say, you know, I
6 would say off the cuff 50/50.

7 Q So for leukemia it's 50/50, but for kidney cancer
8 it's about 10 percent; is that right?

9 A Yes.

10 Q Are you aware that only three of the nine water
11 systems had contaminated water?

12 A I know that there were 10 contaminated wells in
13 the Camp Lejeune system. The ATSDR, in their report, talked
14 about not only the wells that were closed in the 1985 time
15 frame, but going back to the early 1950s, the contamination
16 was pretty extensive.

17 Q I was asking not about the wells but about the
18 water systems.

19 Do you know that only that they're -- that only
20 three of the water systems had contaminated water?

21 A Well, I'm not sure what you mean by that,
22 Counselor.

23 Q So there are water treatment plants that service
24 various areas -- withdrawn.

25 The various areas of the base were serviced by

1 different water treatment plants. And were you aware of
2 that?

3 A I am aware that the wells, the wells that supplied
4 Camp Lejeune supplied different water treatment plants. I
5 think there were three different water treatment plants that
6 those 10 wells fed into in.

7 Q So are you aware that the water treatment plants
8 that were not fed in by those wells did not contain
9 contaminated water?

10 A I'm not aware of that.

11 Q So you were not aware of the fact that there was
12 not contaminated water at Camp Johnson?

13 A I'm sorry?

14 Q Were you aware of the fact there was not
15 contaminated water at Camp Johnson?

16 A What is Camp Johnson?

17 Q It's a part of the base.

18 A That may be true, but I'm not sure how that's
19 relevant in this case. What I did -- what I did want to say
20 is because those contaminated wells fed those water
21 treatment plants, even though there might have been some
22 uncontaminated water feeding into the system, there was
23 sufficient water that was contaminant feeding into those
24 water treatment plants that the output from the water
25 treatment plant was contaminated.

1 Q Have you heard of Camp Geiger?

2 A I believe that that's one of maybe the outlying
3 areas.

4 Q Were you aware that the water at Camp Geiger was
5 not contaminated?

6 A Could you spell that? I'm not sure I'm hearing
7 you correctly.

8 Q I said were you aware that the water at Camp
9 Geiger was not contaminated?

10 A I'm not sure. I think the -- I think the general
11 position of the ATSDR was that all of the outlying areas,
12 including Camp Lejeune and its surroundings, were all
13 considered to be contaminated. That was my understanding.

14 I don't think that the VA excludes anybody from
15 consideration because the general consensus was the water
16 system was contaminated.

17 Q Have you ever given a presentation or spoken
18 publicly about Camp Lejeune?

19 A No, I was invited to but I declined.

20 Q Have you ever examined Mr. Downs?

21 A No.

22 Q Have you ever communicated with Mr. Downs?

23 A No.

24 Q Have you ever examined Mrs. Tukes?

25 A Well, just to be clear, both for Downs and Tukes,

1 I reviewed their medical records, but I've never physically
2 examined them.

3 Q Have you ever communicated with Mrs. Tukes?

4 A No.

5 Q Other than in this case, have you ever authored an
6 expert opinion on the etiology of kidney cancer?

7 A In answer to your question, yes, I've offered
8 medical opinions regarding the etiology of kidney cancer
9 cases in veterans who submitted claims to the VA.

10 Q Other than your work for the Veteran's Evaluation
11 Services, have you ever offered an opinion on the etiology
12 of kidney cancer?

13 A No.

14 Q You're not an exposure -- withdrawn.

15 You're not an expert in exposure assessment; is
16 that correct?

17 A Can you clarify the question?

18 Q Have you ever taken any college or graduate
19 courses that would provide you with the scientific
20 experience to perform an exposure assessment?

21 A I took a weeklong EPA course back in my residency
22 program where it was an EPA risk assessment course that the
23 Army Center for Health Promotion and Preventive Medicine set
24 up for the residents for -- there were three of us that
25 attended that course. It was a weeklong course on risk

1 assessment.

2 Q You don't consider yourself to be an expert in
3 risk assessment? Again, I totally get it, but please let me
4 finish talking just for her sake. If she were here, she'd
5 be yelling at us. And again, I understand, because you know
6 where I'm going.

7 Other than the EPA course on risk assessment, have
8 you taken any other college or graduate level courses that
9 provide you with scientific expertise in risk assessment?

10 A What do you mean by "risk assessment," Counselor?

11 Q Have you -- withdrawn. Have you read the EPA's
12 risk assessment guidance for superfunds?

13 A It was part of the course curriculum for that
14 weeklong course that I took.

15 Q And this was when you were in college?

16 A This was in residency program in the 1995 time
17 frame.

18 Q So after the 1990 timeframe, have you ever read
19 the EPA's risk assessment guidance for superfunds?

20 A I haven't looked at it again.

21 Q Have you read the EPA's guidelines for
22 carcinogenic risk assessment?

23 A Nothing beyond that weeklong course.

24 Q Have you read the EPA's Exposure Factors Handbook?

25 A Nothing since that EPA course.

1 Q Have you ever ran ATSDR's PHAST, P-H-A-S-T, model?

2 A No.

3 Q Have you ever ran ATSDR's SHOWER model?

4 A No.

5 Q Have you ever run any other risk assessment
6 models, such as L-E-A-D 99 or Crystal Ball?

7 A No.

8 Q Are you a member of any professional societies
9 that include a focus on risk assessment?

10 A No.

11 Q Have you written any papers on risk assessment?

12 A No. We did write -- we did write one paper on,
13 that was on my CV that lists the environmental exposure
14 assessments for deployed troops.

15 I don't think it was specific to Iraq or
16 Afghanistan, but we -- Dr. Carl and I authored a paper
17 regarding the need for environmental assessment and what was
18 required to complete that task for the military.

19 Q Other than that paper, have you written any papers
20 that were published in peer-reviewed journals on risk
21 assessment?

22 A No.

23 Q Have you been asked by journals to review
24 manuscripts on risk assessment?

25 A Not that I can recall.

1 Q Have you ever been subject to any disciplinary
2 action or censured by any licensing body?

3 A No.

4 Q Have you ever been subject to any disciplinary
5 action by any court or tribunal?

6 A No.

7 Q Can you look at the Tukes report, please, and go
8 to page 4?

9 A Page 4.

10 Q So the first paragraph says: "The methodology I
11 used to form my opinions in this case aligns with the
12 standard practices that I and other experts utilize when
13 conducting similar analyses, specifically my approach
14 included the following, as stated in my general causation
15 report, with additional methodology for these specific
16 causation opinions."

17 Did I read that correctly?

18 A Yes.

19 Q And you described your methodology with the same
20 language in the Downs report; is that right?

21 A Yes.

22 Q And you used the same methodology in both reports.
23 Right?

24 A Yes.

25 Q What does it mean when you say "additional

1 methodologies for these specific causation opinions"?

2 A Well, what's different about the specific
3 causation reports is that we have a exposure reports that
4 were prepared by Dr. Kelly Reynolds, and we were able to
5 factor that information into our causation assessment.

6 Q In terms of the searches that you did on PubMed
7 and the Cochrane Databases, did you do anything differently
8 or additionally for this report?

9 A No.

10 Q Did you do any searches on PubMed and in the
11 Cochrane Database for this report, or did you rely on the
12 searches that you had previously done for your general
13 causation reports?

14 A You know, I did an update, I did an additional
15 search. It was Google Scholar. I don't think I did any
16 additional PubMed work, but using Google Scholar with -- for
17 additional publications subsequent to the -- to the paper
18 that I used in my general causation report. And I was able
19 to come up with the one article that's I think we -- we
20 submitted in our supplemental list of materials considered.

21 So, yes.

22 Q What search terms did you use when searching
23 Google Scholar for the literature --

24 A Sorry, go ahead.

25 Q -- in this report?

1 A Well, the search terms included the ones clearly
2 for the exposures of interest, and then for kidney cancer
3 just generally, and I have nothing else to add.

4 Q I wasn't sure if you were done. I'm sorry.
5 Do you -- withdrawn.

6 You don't list in your report the specific
7 searches that you used in Google Scholar; is that correct?

8 A That's correct.

9 Q Are the search terms and searches that you used in
10 Google Scholar saved somewhere where we would have access to
11 them?

12 A I'm sorry, I don't.

13 Q So it's not possible for anyone to reproduce your
14 searches; is that right?

15 A That's correct.

16 Q Did anyone provide you with any studies for your
17 specific causation reports?

18 A No.

19 Q Other than what we've discussed in Google Scholar
20 and your reliance on the general causation searches and your
21 review of Dr. Reynolds' reports, did you do anything else to
22 obtain studies to -- that were reviewed for this report, for
23 these two reports?

24 A Nothing beyond what we just said.

25 Q Would you agree that renal cancer -- withdrawn.

1 Would you agree that renal cell carcinoma and
2 upper tract urothelial cancer are both cancers arising in
3 the kidney?

4 A I think by definition, that's correct.

5 Q But they arise in different types of kidney
6 tissue, right?

7 A Different kidney tissue, that's correct.

8 Q And their treatments differ; is that right?

9 A Well, since I don't treat kidney cancer, I'm not
10 an expert in that area, and I would not hazard to guess the
11 difference in treatments.

12 Q Do their etiologies differ?

13 A That's a good question. I would say that I
14 specifically looked at renal cell carcinoma, which is a -- I
15 mean, a lower tract rather than a upper tract that you're
16 referring to, and I looked at the etiology related to renal
17 cell carcinoma because Ms. Tukes had renal cell carcinoma
18 and Mr. Downs had renal cell carcinoma, so my focus wasn't
19 upper tract.

20 When you look at my report, it specifically refers
21 to RCC NOS, and I think we had this conversation in the
22 general causation report also, where I clarified that that's
23 the risk that I looked at and that hasn't changed.

24 Q So you don't know whether or not their etiologies
25 differ; is that correct?

1 A My sense of things is that the etiologies are the
2 same.

3 Q Would you agree with me that within renal cell
4 carcinoma there are multiple histologic subtypes?

5 A Yes, there are.

6 Q And would you agree that histology is relevant to
7 cancer aggressiveness?

8 MR. LEE: Objection to form. You can answer.

9 THE WITNESS: Could you clarify that?

10 Because I'm not sure you asked that question.

11 BY MS. SPRAYREGEN:

12 Q Certain subtypes of renal cell carcinoma are more
13 aggressive cancers than other subtypes of renal cell
14 carcinoma, would you agree with that?

15 A I think that the answer to that is yes. There are
16 some cell types that are more aggressive than others.

17 Q Would you agree that the most common renal cell
18 carcinoma subtype is clear cell renal carcinoma?

19 A Yes.

20 Q What are some other renal carcinoma subtypes?

21 A Well, I think there's clear cell. There's
22 papillary. Those are the two big ones that are relevant in
23 this case.

24 Q So you would agree that Mr. Downs has clear cell
25 renal -- clear cell renal carcinoma; is that correct?

1 A Yes.

2 Q What is your understanding of the subtype or
3 subtypes of renal cell carcinoma that Ms. Tukes had?

4 A Well, Counselor, I'm not sure that I saw all the
5 pathology reports as it relates to Ms. Tukes.

6 What my understanding is is that she had both
7 papillary and clear cell renal cell carcinoma.

8 Q Are you aware of whether any of the subtypes of
9 renal cell carcinoma are more associated with genetic
10 predisposition -- with a genetic predisposition?

11 A Yes.

12 Q Which ones?

13 A The papillary. I'm also aware there's a genetic
14 test that when you're testing for the papillary hereditary
15 carcinoma, that there's a MET gene that is tested for and is
16 positive in papillary carcinoma cases.

17 Q Are you referring to papillary or clear cell
18 papillary carcinoma?

19 A That's a good question. So -- could you repeat
20 the question?

21 Q When you say there is -- withdrawn. Do you
22 know -- withdrawn. I'll start with this.

23 Do you know if clear cell papillary and papillary
24 are different subtypes of renal cell carcinoma?

25 A You know, pathologists are a breed apart, and what

1 you get from one pathologist and what you get from a
2 different pathologist may be completely different for the
3 same pathology that's present in a -- in a particular case.

4 The pathology reports that I saw and read say that
5 Ms. Tukes had clear cell renal cell carcinoma, papillary
6 cell carcinoma, and it may be a subtype of clear because I
7 think that's what they said in their pathology report and
8 there may be a completely different papillary carcinoma,
9 which is different.

10 Q You said "it may be a subtype of clear." What are
11 you referring to?

12 A I'm referring to the pathology report for
13 Ms. Tukes.

14 Q Sorry. I'm confused by what you just said. I'm
15 not trying to be difficult here.

16 You said you know that she had clear cell renal
17 carcinoma and you know she had subpapillary carcinoma. And
18 then you said it might be a subtype of renal cell carcinoma.

19 What might be a subtype of renal carcinoma?

20 A The papillary. So in the pathology report that I
21 read, it tried to differentiate and say that she had both
22 elements of clear cell and papillary cell in the same -- in
23 the same kidney.

24 Q Going back to my original question.

25 Do you know if histologically there's a difference

1 between papillary and clear cell papillary?

2 A Not specifically.

3 Q Would you agree that the cause of kidney cancer is
4 multifactorial?

5 A I believe that there are risk factors that have
6 been attributed to kidney cancer, yes.

7 Q By that, I mean, there's no single factor that
8 explains why kidney cancer develops. Instead, there are
9 multiple influences that work together to increase a
10 person's risk.

11 Would you agree with that statement?

12 A Yes.

13 Q Would you agree that smoking is a risk factor for
14 developing kidney cancer?

15 A Yes. Potentially.

16 Q I'm sorry. I didn't mean to cut you off.

17 A I said potentially.

18 Q Would you agree that family history of kidney
19 cancer is a risk factor for developing kidney cancer?

20 A Yes.

21 Q Would you agree that obesity is a risk factor for
22 developing kidney cancer?

23 A It is.

24 Q Would you agree that diabetes is a risk factor for
25 developing kidney cancer?

1 MR. LEE: Objection to form.

2 THE WITNESS: Just to be clear. I think that
3 there are degrees of risk related to the risk factors.

4 So, for example, diabetes is not felt to be
5 nearly as high a risk factor in terms of categorizing
6 risk from what I've read. But, yes, it's a risk
7 factor.

8 BY MS. SPRAYREGEN:

9 Q So what you're saying is that some risk factors
10 increase the risk of kidney cancer more than other risk
11 factors; is that correct?

12 A That's correct.

13 Q Would you agree that high blood pressure is a risk
14 factor for developing kidney cancer?

15 A Yes.

16 Q Would you agree that being of an older age is a
17 risk factor for developing kidney cancer?

18 A Not so much. It is a risk factor, but it's on
19 order of magnitude a risk -- age is considered a less
20 significant risk or contributor than other risk factors.

21 Q So what you're saying -- and I'm really not trying
22 to change it, is that it is a risk factor, but it's less of
23 a risk factor than the other risk factors we've just
24 discussed?

25 A Yes.

1 Q Would you agree that race is a risk factor, and
2 specifically African Americans are more likely to have a
3 high risk of developing kidney cancer than Americans of
4 other races?

5 A Yes.

6 Q And would you agree that -- withdrawn.

7 A Can we look at my causation report on race,
8 because I -- I specifically spoke to that issue, and I
9 believe that --

10 Q I had questions about that later in your report.

11 A Because there were some -- there were some
12 articles that I had read recently about her -- her various
13 risk factors.

14 So in terms of race, I said that she was at
15 slightly increased risk, so I don't have any additional
16 comment beyond that.

17 Q Well, I'm right now not asking you about Ms. Tukes
18 and Mr. Downs. Just so you know, I'm asking you about risk
19 factors for kidney cancer.

20 Do you understand that?

21 A Yes, mm-hmm.

22 Q Would you agree that many, if not most individuals
23 with one or more risk factors for kidney cancer, do not
24 develop kidney cancer?

25 A Could you repeat that question?

1 Q Would you agree that many, if not most individuals
2 with one or more risk factors for kidney cancer, do not
3 develop kidney cancer?

4 A I would agree that it's -- it's a possibility.

5 Q What I'm saying, for example, is would you agree
6 that many, if not most people who smoke, do not develop
7 kidney cancer?

8 A So looking at the epidemiology of kidney cancer
9 and the risk related to smoking, smoking is one of the
10 greatest risks for development of kidney cancer, and not
11 everyone who smokes develops kidney cancer, that is true,
12 but there's a 2.5-fold increase risk of developing kidney
13 cancer for people who smoke.

14 Q Understood. But even taking what you said as
15 true, and I don't know whether or not it is.

16 MR. LEE: Objection to form.

17 MS. SPRAYREGEN: Withdrawn.

18 BY MS. SPRAYREGEN:

19 Q I will assume that what you said is correct. Even
20 if there is a 2.5 percent increased risk --

21 A Fold.

22 Q -- fold. Withdrawn.

23 Can you say what you just said again?

24 A There's a 2.5-fold increased risk of kidney cancer
25 in smoking. And that risk is greater for the amount of

1 smoking and the duration of smoking.

2 Q Even taking into account a 2.5-fold increased risk
3 of kidney cancer among smokers, would you agree that many,
4 if not most individuals who smoke, do not end up developing
5 kidney cancer?

6 A That's true.

7 Q And the same for obesity.

8 Even though it increases your likelihood or it
9 increases the risk of developing kidney cancer, many, if not
10 most people who are obese, do not, in fact, develop kidney
11 cancer?

12 A That's correct.

13 Q Would you agree that having one or more risk
14 factors for kidney cancer does not make it more likely than
15 not that a patient will develop kidney cancer?

16 A Would you repeat the question, please?

17 Q Would you agree that having one or more risk
18 factors for kidney cancer does not make it more likely than
19 not that a patient will develop kidney cancer?

20 A I agree that the more risk factors you have make
21 it more likely that you'll develop kidney cancer.

22 Q Would you agree that there is -- you can --
23 withdrawn.

24 Would you agree that some individuals who develop
25 kidney cancer do not have any risk factors for kidney

1 cancer?

2 A I believe that's true.

3 My understanding, Counselor, is that it breaks
4 down a third, a third, a third.

5 A third maybe potentially idiopathic. A third are
6 likely related to a genetic component, family history. And
7 a third are related to environmental and occupational risks.

8 MS. SPRAYREGEN: I'm going to introduce
9 Exhibit 8.

10 (Mallon Exhibit 8 marked for identification.)

11 BY MS. SPRAYREGEN:

12 Q In your report, you cite to the Mayo Clinic
13 website. What I've handed you is what I -- the printout
14 from the website that you cited in your report.

15 Can you take a look and see if this looks like
16 what you referred to?

17 A I use the Mayo Clinic a lot, and it's probably my
18 go-to source for risk factors related to kidney cancer and
19 all other cancers, for that matter.

20 So, this, yes, it does look familiar.

21 Q Can you turn to page 3 of Exhibit 8?

22 A The pages aren't numbered.

23 Q That's right. That's it.

24 A This one?

25 Q Yes. Do you see where it says: "Causes"?

1 A Causes.

2 Q The very bottom of the page?

3 A Yes.

4 Q And it says: "It's not clear what causes most
5 kidney cancers."

6 Do you see that?

7 A It does say that.

8 Q My understanding of that statement is that more
9 than half of kidney cancers have an unknown cause; is that
10 your understanding of that statement?

11 A I don't read that statement to say what you said.

12 Q So what do you read that statement to say?

13 A It doesn't quantify what percentage is known and
14 what percentage is unknown. It just says it's not clear
15 what causes kidney cancer.

16 Q So my understanding is if something says it's not
17 clear what causes most kidney cancers, that means that more
18 than 50 percent of the cases of kidney cancers have a cause
19 that is not clear?

20 MR. LEE: Objection to form.

21 Is that a question?

22 BY MS. SPRAYREGEN:

23 Q Is that your understanding as well?

24 A I can see where you would make that judgment based
25 on a more likely than not determination.

1 Q Would you agree that some risk factors are more
2 prevalent in society and, therefore, explain more kidney
3 cancers than others?

4 A Yes.

5 Q And you already made this statement, but I'm going
6 to ask it as a question for clarity of the record.

7 Would you agree that smoking a history of one pack
8 per year may increase a patient's risk of kidney cancer more
9 than a smoking history of 10 packs a year?

10 A Could you repeat the question?

11 Q I'll rephrase it.

12 Would you agree that smoking 10 pack-years
13 generally has a different risk than smoking one pack-year?

14 A Yes.

15 Q And so that there is a what could be called a
16 dose-response relationship to the amount of smoking?

17 MR. LEE: Objection to form. You can answer.

18 THE WITNESS: I do agree that the dose and
19 the duration significantly affect the risk.

20 BY MS. SPRAYREGEN:

21 Q I don't love those words either, I'm not going to
22 lie.

23 Would you agree that having a BMI of 35 carries a
24 different risk and an increased risk than having a BMI of,
25 say, 27?

1 A Yes.

2 Q And would you agree that a smoking history of one
3 pack-year may increase patient A's cancer risk more than
4 patient B's risk?

5 A Could you clarify that question? Because when you
6 ask me that question, I think about dose and duration of
7 smoking, or dose and duration of, you know, what named the
8 risk factor. And what matters a lot is whether the smoking
9 continues or if the smoking stops.

10 Because with smoking cessation, the risk
11 significantly reduces over time.

12 Q We're going to talk about that. I think you
13 misheard me when I spoke.

14 A Perhaps.

15 Q I'm talking about two people who have the exact
16 same smoking history.

17 Would you agree that that same smoking history may
18 increase one person's risk of kidney cancer more than
19 another person's risk of kidney cancer?

20 A No.

21 Q No.

22 A No. I agree that smoking has a standard set of
23 risks, one pack-year of smoking in person A. One pack-year
24 of smoking in person B. Same risk.

25 Q Would you agree that cancer is caused by genetic

1 mutations?

2 MR. LEE: Objection to form.

3 THE WITNESS: Not all mutations -- not all
4 genetic mutations lead to kidney cancer.

5 MS. SPRAYREGEN: That wasn't my question.

6 THE WITNESS: Could you repeat your question?

7 BY MS. SPRAYREGEN:

8 Q That at a molecular level, cancer is caused by
9 genetic mutations, or can be caused by genetic mutations?

10 A I agree with that.

11 Q And those mutations can occur randomly?

12 A Sometimes they do.

13 Q And would you agree that those mutations often do
14 occur randomly?

15 A I agree that there are conditions under which the
16 mutations are more frequent in occurrence, specifically
17 related to this case and these four chemical carcinogens of
18 interest, where there's exposure, those mutations occur more
19 frequently.

20 Q I wasn't talking about this case and the
21 particular contaminants of concern. I'm just talking about
22 carcinogenesis more broadly, and in the context of
23 carcinogenesis more broadly, would you agree that mutations
24 that cause cancer often do occur randomly?

25 A I would not commit to that. I would say that

1 mutations that occur usually require some protuberation in
2 the ecosystem of, if you will, the -- the cancer milieu.
3 Something triggers the mutation. It doesn't randomly just
4 occur on its own.

5 Q We just discussed that some cancers have an
6 unknown cause, right?

7 A The line from the Mayo Clinic handout that you
8 gave me said it's not clear what causes most kidney cancers,
9 yes.

10 Q And physicians refer to a cause with no known
11 cause as idiopathic, right?

12 A Yes.

13 Q And would you agree that no known cause is not the
14 same thing as no cause?

15 A Correct.

16 Q So a cancer that is idiopathic in origin is still
17 caused by something. We just can't identify what that
18 something is?

19 A I agree with that.

20 Q And would you agree that we don't fully understand
21 the causes of kidney cancer?

22 A Agreed. If you agree with your first premise, the
23 answer is yes.

24 Q And do you agree with my first premise?

25 A If we're not talking about these two cases in

1 particular, in general they're -- yes.

2 Q I'm not talking about these two cases in
3 particular. In general, would you agree that we don't fully
4 understand the causes of kidney cancer?

5 A I look to the Mayo Clinic as one of my leading
6 medical advisors, and I agree that they state that it's not
7 clear what causes most kidney cancers.

8 Q Would you agree that science is continuing to
9 identify new potential causes of kidney cancer?

10 A Yes.

11 Q In your experience, examining kidney cancer
12 patients for the VA, are unexplained causes common?

13 A Well, as I spoke to -- just a couple of moments
14 ago, I agree that there's a breakdown. There are some
15 unexplained causes, a third. There are some that are
16 genetically family history related, a third. And there are
17 some exposure related, another third.

18 Q Where -- what is your source for that statement?

19 A I would say going back to the environmental
20 medicine course that I took in medical school at Syracuse.

21 Q Do you have a specific article or that --
22 that makes that statement?

23 A It was part of the courses curriculum. I don't
24 know that I have anything more recent to provide. I'm sure
25 I could do a Google search and find it for you.

1 Q That's okay. And when was this course curriculum,
2 when was this course?

3 A That would have been in 1991.

4 Q Do you have any knowledge about what percentage of
5 clear cell RCCs are idiopathic?

6 A No.

7 Q Do you have any knowledge of what percentage of
8 clear cell papillary renal cancers are idiopathic?

9 A No. Other than what we just talked about.

10 Q What are you referring to?

11 A Well, in terms of idiopathic in general, you know,
12 a third, a third, a third.

13 Q Right. My question was specific to clear cell
14 papillary renal cancer.

15 Do you have any knowledge of what percentage of
16 that histological subtype are idiopathic?

17 A I would say the same breakdown applies to the
18 specific, you know, renal cell, clear cell, papillary, clear
19 cell. In terms of idiopathic, family history and exposure
20 related.

21 Q What is your -- the basis for that statement?

22 A Going back to that course that I took in medical
23 school.

24 Q In the early 1990s?

25 A Yes.

1 Q So if we agree -- we've agreed that there are --
2 that no known cause is not the same thing as no cause.

3 Right?

4 A No known cause is not the same, correct.

5 Q Right. And would you say -- I think you have
6 agreed to this, but I'll just ask it again.

7 If I'm asking this a second time, I apologize.

8 Would you -- would you say it's -- there are
9 potential causes of kidney cancer that we may not know
10 about?

11 A Yes.

12 Q And that's the known causes of kidney cancer are
13 not the same as the potential causes of kidney cancer.

14 Right?

15 A They're different, yes.

16 Q So the list of risk factors in your report is not
17 comprehensive -- is not a comprehensive list of potential
18 causes, given that there are potential causes that we don't
19 know about?

20 A It's hard to capture infinity, Counselor.

21 Q But would you agree with that statement?

22 A Yes. But I would say that, you know, it's
23 accurate to 99 percent.

24 The published literature lists these same risk
25 factors, so to the extent that where our current knowledge

1 is as it relates to risk factors in kidney cancer, these
2 are -- these are what's known.

3 Q You're saying with respect to our current
4 knowledge. And my question is: Is there a possibility that
5 knowledge will be gained in the future and there are things
6 we just don't know now?

7 A Well, I hope that's true, you know, that we
8 continue to learn as a society what causes things so we can
9 do a better job of preventing them.

10 Q So, for example, some idiopathic cases might be
11 caused by unidentified environmental exposures?

12 A Yes.

13 Q And just because an environmental exposure to a
14 carcinogen is unidentified, it doesn't mean that that did
15 not occur, right?

16 A Yes.

17 Q And would you agree that our bodies are exposed to
18 carcinogens on a daily basis?

19 A Yes.

20 Q And that it's impossible to live a life free from
21 exposure to all carcinogens?

22 A Yes.

23 Q Would it be fair to say that an individual
24 instance of cancer might have occurred regardless of the
25 presence of a risk factor?

1 A Could you repeat the question, please?

2 Q Sure. I'll change it. I'll make it more
3 specific.

4 So I think we've agreed that some smokers may
5 develop kidney cancer, but not everyone who smokes develops
6 kidney cancer, right?

7 A Yes.

8 Q Would you agree that some of those smokers who
9 developed kidney cancer may have developed kidney cancer
10 even if they hadn't smoked?

11 A You asked that question, and I answered it "yes"
12 previously.

13 Q So if a kidney cancer -- withdrawn.

14 So if a kidney cancer patient's only identifiable
15 risk factor was a one pack-year smoking history, that
16 patient's cancer may still have been caused by some risk
17 factor that we cannot identify or don't understand yet.

18 Right?

19 A You know, I think on balance, I go with the risk
20 factor that I know there is to be weighed against the
21 unknown idiopathic risk factor.

22 I would have to say that that one pack-year of
23 smoking is greater than -- greater known risk, rather, than
24 the unknown idiopathic risk.

25 Q I understand what you're saying, but my -- my

1 question is: In a particular patient who has a one
2 pack-year smoking history, it's possible that particular
3 patient may have had some risk factor that we haven't
4 identified yet, that is what caused the cancer in that one
5 particular patient?

6 A That's correct.

7 Q Would you agree that it's possible for a member of
8 the general public to develop kidney cancer without exposure
9 to any potential risk factor?

10 A Per our discussion on idiopathic, yes.

11 Q Would you agree that there is some background risk
12 for developing kidney cancer?

13 A I think there's a 15 or 100,000 cancer incidence
14 in the United States for kidney cancer, so, yes.

15 Q So we're going to get to the numbers right now.
16 I'm going to introduce exhibit --

17 MR. LEE: Sharon, it's been another hour. Do
18 you want to take another a 10-minute break?

19 MS. SPRAYREGEN: Sure.

20 THE VIDEOGRAPHER: The time is 12:05 p.m.
21 We're going off the record.

22 (Recess taken from 12:05 to 12:18 p.m.)

23 THE VIDEOGRAPHER: The time is 12:18 p.m. We
24 are going back on the record.

25 Please proceed, Counsel.

1 MS. SPRAYREGEN: I would like to introduce
2 Exhibit 9.

3 (Mallon Exhibit 9 marked for identification.)

4 MR. LEE: What is Exhibit 9?

5 BY MS. SPRAYREGEN:

6 Q I will represent to you that Exhibit 9 is a
7 printout from the National Cancer Institute: Surveillance,
8 Epidemiology, and End Results Program.

9 A SEER.

10 Q SEER, exactly.

11 A Okay.

12 Q Given that you just said "SEER," I take it you've
13 heard of it?

14 A Yes. So what's the date on this, Counselor?

15 Q So I printed this out a couple of days ago.

16 A Okay.

17 Q I believe there is a timestamp on it that says
18 "June 2nd, 2025."

19 A Unfortunately, there's a two-year lag, that's why
20 I ask, between the statistics in SEER and the present day.

21 So with that understanding, so we're talking about
22 2023 data when you're looking at these charts.

23 Q Okay. With that understanding, can you turn to
24 page 5?

25 A Let's see, three, four, five.

1 Q And it's the page that looks like this. You were
2 right. I was wrong. You were right. I was wrong. It's
3 the page that looks like this.

4 And would you agree that according to SEER, and I
5 quote: Compared to other cancers, kidney and renal pelvis
6 cancer is fairly common?

7 A That's what it says, yes.

8 Q And on the first page it says that there were
9 approximately 80,000 new cases of kidney cancer and renal
10 pelvis cancer in 2025.

11 Do you see that?

12 A Yes.

13 Q And it's your contention that that, in fact, is
14 data from 2023; is that right?

15 A No, I think this is updated data. These charts
16 are 2023, but I think this is current data because that's
17 consistent with what I read also.

18 It's down a little bit from what it was in 2024.
19 My epidemiology said 81,600, but that was 2024 data.

20 This is -- I knew it was going to be less in 2025,
21 but that's -- this is only an estimate. We haven't finished
22 all of 2025, that's why it's -- it's just a projection.

23 Q You are not disputing the figure that is on page 1
24 of Exhibit 15, are you?

25 A Well, only so far as to say that we haven't

1 finished all of 2025, so I can't represent 2025 data because
2 it wouldn't be complete. So it's got to be 2024 data.

3 Q I will admit, I do not know what time period
4 they're using.

5 Would you agree --

6 A But we're not far off. 81,000. 80,900.

7 Q And it says that kidney cancer accounts for
8 4 percent of all new cancer cases in the United States.

9 Do you have any reason to dispute that figure?

10 A No.

11 Q I'm turning to page 12.

12 A Got two charts?

13 Q You're on the right page. I am not.

14 If you look at the top chart, our interpretation
15 of the top chart is that since 2005, there have been roughly
16 between 14 and 16 new kidney cancer cases for every 100,000
17 people each year?

18 A Between 14 and 16, I believe that's true. There's
19 been a 2 percent increase in incidence over that time frame.

20 Q And that was my next question.

21 So you would agree that the lifetime risk of
22 developing kidney or renal cancer is about 1.8 percent?

23 A Yes.

24 Q And that is on page 2.

25 A I think it's -- as least what I understood, it's a

1 little higher, 2.3. I thought the 2.3 was for men and the
2 1.8 was for women, but close enough.

3 Q So according to this data, for every 100,000
4 people, about 1,800 will develop kidney cancer at some point
5 during their lifetime?

6 A I'm not following that, but I think it's true.

7 Q 100,000 people, I don't know if I misspoke.

8 About 1,800 will develop kidney cancer at some
9 point during their lifetime?

10 A So the incidence rate is 2.3, and you multiply
11 that by 330 million, yeah, that's probably true. I don't
12 have my calculator. I'll accept your --

13 Q Would you agree that a reliable methodology for
14 determining the etiology of a disease should take into
15 account the background risk?

16 A You know, in the eight years of doing these cancer
17 risk assessments for the VA, not once have I looked at the
18 background risk.

19 Q You didn't conduct any chemical tests to determine
20 whether Mr. Downs or Mrs. Tukes kidney cancers were caused
21 by a toxic exposure, right?

22 A I personally didn't, but I will say that the
23 record would suggest that they did do testing. They looked
24 for potential increased risk in the genetics of the -- of
25 Ms. Tukes.

1 Q I'm talking not about genetics, but would you
2 agree that there are no blood tests indicating that -- there
3 are no blood tests that one can do to indicate whether or
4 not a cancer's caused by a toxic exposure?

5 A By a toxic exposure? So the answer to that
6 question is very complicated, Counselor.

7 I think there are times that genetic testing can
8 confirm that there is or there isn't a likelihood of
9 increased risk based on those genotoxic exposures from the
10 carcinogens, including the four that were present at Camp
11 Lejeune.

12 Q I'm not talking about whether there is, as
13 Dr. Allen hypothesized that someone is more likely to
14 develop cancer if they're exposed.

15 I'm saying something slightly different, which is,
16 there's no blood tests to look at the -- or no tissue tests
17 to look at the particular cancer that one has developed and
18 to determine whether or not it was caused by a toxic
19 exposure?

20 A Well, I'm not trying to split hairs, Counselor.
21 The blood tests that they do for the genetic testing is
22 blood tests that they have available that they can look for
23 increased propensity or susceptibility for developing
24 cancer, as in the case of Ms. Tukes.

25 Q Are you aware of any tests, like a biomarker test,

1 that would indicate whether the kidney cancer was related to
2 a toxic exposure?

3 A Yes. There's -- in the articles that I
4 referenced, there is one study that looked at -- they looked
5 at TCA as a biomarker of exposure.

6 And in terms of biomarker of effect, there is a
7 genetic allele that they detected. The presence of which
8 would be indicative of an increased risk of developing
9 kidney cancer.

10 Q But my question is: Is there anything that you
11 can test in the kidney cancer itself, the tissue sample, to
12 determine whether it was caused by a toxic exposure?

13 A Well, to the extent that if they're testing the
14 kidney directly or the blood that flows in and out of the
15 kidney, it seems like it's kind of the same thing. They're
16 looking at genetic markers of risks, if you will, that are
17 present in the blood on the person that's being tested, and
18 that has to -- I mean, ultimately has to interface with the
19 kidney because that's where the cancer develops.

20 Q So as I understand it, you're talking about
21 genetic markers of risk, and I'm talking about testing the
22 kidney cancer tissue itself to determine whether or not the
23 sample can say that it was caused by or can lead one to
24 believe that it was caused by a chemical?

25 A The presence of the allele, where one is present,

1 one's missing, is indicative of exposure that caused the
2 kidney cancer.

3 Q The presence of the allele is indicative of the
4 fact that someone was actually exposed; is that what you're
5 saying?

6 A Exactly.

7 Q What article is that?

8 A I knew you were going to ask me.

9 Do you have my previous sheets, Counsel? Because
10 otherwise I have to get out my full list of references.

11 Q I'm sorry, are you asking me? I thought you were
12 talking to Randy. Do I have what?

13 A Do you have the full list of articles that I
14 reference? Because I'll be glad to point it out to you.

15 Q The full list of articles in your --

16 A My Materials Considered List.

17 Q I provided you with the Materials Considered
18 Lists.

19 A Yeah, okay. Let's have a look.

20 Which exhibit was that?

21 Q The Materials Considered Lists were Exhibits 3, 4,
22 5, and 6.

23 A Okay. I think it has to do with the general
24 causation. So if you have my general causation report with
25 you.

1 Q I do. Why don't we get to that later. I will ask
2 about that later.

3 A Okay.

4 Q So you performed a differential diagnosis on
5 Mr. Downs and Mrs. Tukes, right?

6 A Yes.

7 Q And to do that, you ruled in risk factors for
8 developing kidney cancer, right?

9 A Yes.

10 Q And then you ruled out known risk factors for
11 kidney cancer that were not applicable to each Plaintiff.

12 Right?

13 A Yes.

14 Q Is there a difference between a differential
15 diagnosis and a differential etiology?

16 A Could you clarify your question?

17 Q How would you define "differential etiology"?

18 A Differential etiology suggests different causes.

19 Q And how do you define "differential diagnosis"?

20 A Examining potential for different causes. So
21 they're the same.

22 Q So in your mind, a differential diagnosis and
23 differential etiology are the same thing?

24 A Yeah.

25 Q And for Mr. Downs, let's turn to page 19.

1 A Of his report?

2 Q Of his report, yes. Are you there?

3 A Yes.

4 Q And the last paragraph above Section 10 reads:

5 "In sum, Mr. Downs' exposure to the water at Camp Lejeune
6 was more likely than not the cause of his kidney cancer.
7 The other risk factors noted above may have contributed to
8 his kidney cancer, but they are all relatively small
9 compared to the very significant risk of toxic water at Camp
10 Lejeune."

11 Did I read that correctly?

12 A Yes, you did.

13 Q And can you turn to page 18 of Mrs. Tukes' report?

14 A I bet it says the same thing. Page 18.

15 Q Mm-hmm. The very last paragraph says: "Given
16 there are no other significant potential risk factors for
17 Mrs. Tukes' development of kidney cancer, other than a very
18 slight elevated risk due to her hypertension and weight, it
19 is clear Mrs. Tukes -- Ms. Tukes' exposure to toxins at Camp
20 Lejeune was a substantial contributing factor and cause of
21 her kidney cancer. I'm able to conclude, based on this
22 differential diagnosis, that Mrs. Tukes' kidney cancer was
23 more likely than not caused by exposure to water at Camp
24 Lejeune."

25 Did I read that correctly?

1 A Yes, you did.

2 Q And you employed differential diagnosis as part of
3 your -- what you do at the VA; is that correct?

4 A Yes.

5 Q Do you have any experience performing a
6 differential diagnosis outside of that work?

7 A Sure. During the 30-plus years of occupation at
8 medicine work that I did for the U.S. Army and for --

9 Q So we discussed that many, if not most, cases of
10 kidney cancer are unknown, right?

11 A We did discuss that topic, yes.

12 Q And when conducting your differential diagnosis,
13 did you consider the fact that a cause of most kidney
14 cancers is unknown?

15 A I considered it, yes.

16 Q How?

17 A Well, in a diagnosis of idiopathic kidney cancer
18 is the diagnosis of exclusion, and so when you consider
19 causes or potential causes in both Mr. Downs and Ms. Tukes,
20 you would consider all those risk factors that we looked at
21 in SEER and -- that are on the Mayo Clinic website, and so
22 I'd go through each one of those potential risk factors
23 first, and if none of those shows up to be a risk factor, I
24 mean, if none of those risk factors that are present there
25 show up in the individual patient's case, then it makes the

1 case for it potentially being idiopathic.

2 Q So is it your opinion that the only way to have an
3 idiopathic cause is if there are no known risk factors?

4 MR. LEE: Objection to form.

5 THE WITNESS: Yes. As a reasonable clinician
6 would conclude that if there are risk factors present,
7 that there would be a potential contributing cause and
8 they wouldn't make that diagnosis of idiopathic when
9 there's an obvious potential risk factor present that
10 would increase the risk of kidney cancer.

11 BY MS. SPRAYREGEN:

12 Q So turning to Mr. Downs' report again.

13 Can you please turn to page 18? It's close to
14 where we were.

15 And you write -- and this is the first full
16 paragraph: "Mr. Downs was slightly overweight when he was
17 diagnosed with kidney cancer, so he was only at a minimally
18 increased risk due to his weight."

19 Did I read that correctly?

20 A I just want to make sure. So --

21 Q Page 18.

22 A Page 18.

23 Q The first full paragraph.

24 A Where it says: "Mr. Downs was a short-term
25 smoker"?

1 Q I have "Mr. Downs was slightly overweight."

2 A That's interesting. Are you using yours or her
3 copy?

4 MR. LEE: Mine is the same as yours.

5 MS. SPRAYREGEN: What?

6 MR. LEE: Mine is the same as yours. For
7 what it's worth.

8 THE WITNESS: So, yes, it says: "Mr. Downs
9 was a short-term smoker."

10 BY MS. SPRAYREGEN:

11 Q No, no. Mine says -- maybe mine is wrong.

12 It says: "Mr. Downs was slightly overweight when
13 he was diagnosed with kidney cancer so he was only at a
14 minimally increased risk due to his weight."

15 A Can I see your version? Because our two are the
16 same.

17 MS. SPRAYREGEN: Can we go off the record?

18 THE VIDEOGRAPHER: The time is 12:39 p.m.,
19 and we are going off the record.

20 (Off the record from 12:39 to 12:40 p.m.)

21 THE VIDEOGRAPHER: The time is 12:40 p.m. We
22 are going back on the record.

23 Please proceed, Counsel.

24 MS. SPRAYREGEN: Sure.

25

1 BY MS. SPRAYREGEN:

2 Q So the second full paragraph on page 18 reads --
3 in all copies: "Mr. Downs was slightly overweight when he
4 was diagnosed with kidney cancer. So he was only at a
5 minimally increased risk due to his weight."

6 Did I read that correctly?

7 A Yes, you did.

8 Q How did you determine that Mr. Downs' weight was
9 only minimally -- only minimally increased his risk of
10 kidney cancer?

11 A Based on a review of that analysis of his risk
12 factors for kidney cancer.

13 Weight being -- particularly weight, where his BMI
14 was only 27, it's only minimally increased risk at that BMI.

15 If you're talking about BMIs that are 32 and
16 above, then there's a much more significantly increased
17 risk, and it's actually, for every -- for every point of BMI
18 over the overweight category, the risk increases, I won't
19 say exponentially, but significantly increase risk the
20 higher the BMI over 30.

21 Q And then on page 8 of the report, but we're coming
22 back to page 18, so keep page 18 handy.

23 Let me know when you're there.

24 A I'm there.

25 Q Under Section C: "Non-Camp Lejeune Personal Risk

1 Factor Analysis for Mr. Downs' kidney Cancer.

2 The first Number 1, I guess, paragraph, if you
3 will, the second sentence says: "He was 82 years old when
4 he developed kidney cancer. So he was at slight increased
5 risk due to his age. However, age is not thought of as a
6 significant risk factor for the causation of kidney cancer."

7 Did I read that correctly?

8 A You did, yes.

9 Q And then turning back to page 18.

10 A Okay.

11 Q The second full paragraph on page 18 reads:

12 "Mr. Downs was a short-term smoker who smoked about a pack a
13 day for five years based on various reports in his medical
14 record and deposition. There are medical records indicating
15 that Mr. Downs may have smoked for 15 years, but Mr. Downs
16 disputes the accuracy of those records. Mr. Downs quit
17 smoking approximately 50 years before his kidney cancer
18 diagnosis if his deposition testimony is accurate. Thus,
19 the length of smoking cessation largely eliminated his risk
20 of kidney cancer. This would be true even with an
21 assumption he smoked for 15 years and quit 40 years before
22 his kidney cancer diagnosis."

23 Did I read that correctly?

24 A Yes, you did.

25 Q So you'd agree that it's your opinion that smoking

1 is less of a risk factor for Mr. Downs because it has been a
2 long time since Mr. Downs smoked?

3 A Yes. I would say his smoking cessation eliminated
4 his risk for kidney cancer.

5 Q That was my next question.

6 Is it your position that a long period of time
7 since an individual quit smoking reduces the risk of
8 developing kidney cancer, or that all else equal, that
9 individual still has a higher risk than someone who has
10 never smoked?

11 A I know that there are some physicians on your
12 side, Counselor, that have stated that there's a risk, but
13 the meta-analysis and systematic that I reviewed yesterday
14 regarding smoking says that at 48 to 50 years of smoking
15 cessation that the risk is well below zero -- or well below
16 1, 1 being no risk. Well below 1. Approaching .5 in terms
17 of risk ratio.

18 So it's -- well, it's definitely approaching being
19 protective. Being -- having smoking cessation for that
20 duration of time.

21 Q What meta-analysis are you referring to?

22 A It's in my list of kidney cancer references.

23 Q So is it on --

24 A It's a new study that I pulled up a couple of days
25 ago.

1 Q So it's not on your list --

2 A No.

3 Q -- of materials considered?

4 A It's not -- it's on my list, which we can add.

5 Q Do you know the name of the author?

6 A You know, I'm blanking on the name. I'm sorry.
7 But it's definitely in the backpack, so I'm able to give you
8 a copy.

9 Q I understand. But just so that I understand.

10 The meta-analysis that you're referring to says
11 that someone who smoked but quit a very long time ago does
12 not have an increased risk of kidney cancer over someone who
13 never smoked; is that what you're saying?

14 A Well, no. I don't think -- I don't think you can
15 get to the point that -- you can't go below zero risk. So
16 the person whose smoking cessation is 50 years is
17 approaching that zero risk.

18 And there's a chart in the -- in the meta-analysis
19 article that talks about smoking, you know, with 20, 30, 40
20 and higher pack-years of smoking on the positive side is
21 markedly increased risk. And likewise, the reverse is true,
22 40, 50 years of smoking cessation, the risk approaches zero.

23 Q If increased time or a very long time since
24 ceasing exposure to tobacco reduces its risk, would you
25 agree that the same logic applies to time since last

1 exposure to TCE, PCE, benzene, and vinyl chloride?

2 A No, I don't necessarily, because I think the
3 genotoxic nature of these chemicals; the TCE, PCE, and vinyl
4 chloride, and benzene, they result in genetic damage.

5 And, you know, over time as that exposure
6 continued, one allele gets damaged, then a second allele
7 gets damaged, and so you get a cumulative exposure.

8 And over time, you know, especially as they age
9 and they have other risk factors, that's what triggers the
10 carcinogenesis, and so I -- I don't say that -- I don't
11 agree that it's the same.

12 Q And you're saying that the genotoxic nature of
13 chemicals that -- withdrawn.

14 Could the court reporter please read back to me
15 the question -- the answer that Mr. Mallon -- Dr. Mallon,
16 excuse me, I'm so sorry, just gave.

17 (Madam Court Reporter read back the
18 previously answered question.)

19 BY MS. SPRAYREGEN:

20 Q So is it your argument that the genotoxic nature
21 of TCE, PCE, benzene, and perhaps vinyl chloride, that
22 results in genetic damage, is different from the genotoxic
23 nature of exposure to cigarette smoke?

24 A So is one worse than the other? I'd say
25 they're -- because of the nature of the carcinogenesis, and

1 these exposures working together, in combination, in an
2 additive fashion, I think that those chemicals pose a
3 greater risk.

4 Q There are a lot of toxic chemicals in cigarettes,
5 aren't there?

6 A A lot of toxic chemicals.

7 Q But you think the fact that TCE, PCE, benzene, and
8 vinyl chloride work together, provides more of a risk 50
9 years later than smoking does; is that your -- than the --
10 than the many chemicals involved in cigarettes?

11 MR. LEE: Objection to form.

12 MS. SPRAYREGEN: I will rephrase.

13 Yeah. Can the court reporter read back the
14 last answer and my mangled question?

15 (Madam Court Reporter read back the prior
16 question and the answer to the question.)

17 BY MS. SPRAYREGEN:

18 Q So is it your argument that because there were
19 many different chemicals in the water at Camp Lejeune the --
20 the fact that Mr. Downs was exposed long ago does not
21 decrease his risk from the water?

22 A Well, I haven't seen any studies that looked at
23 the diminution of risk for these carcinogenic chemicals
24 causing kidney cancer, but I have seen recent studies that
25 showed that the risk of kidney cancer from smoking does

1 diminish over time.

2 So, I mean, that's my personal knowledge base.

3 Q So it's not about the mixture of chemicals. It's
4 the fact that you've read studies that talk about smoking
5 decreasing, but you haven't read any studies talking about
6 the long time since exposure to chemicals diminishing the
7 risk from that exposure?

8 A That's correct. Also, these chemicals we know are
9 known carcinogens with -- with the carcinogenic risk
10 potential. And while there may be several chemicals in
11 cigarette smoke, they're not all carcinogens.

12 Q But there are many carcinogens in cigarette smoke,
13 aren't there?

14 A I'm sorry. Was that a question?

15 Q Yeah. That was a question.

16 Are there many carcinogens in cigarette smoke?

17 A I don't know the exact number. Would you happen
18 to know?

19 Q I don't.

20 Do you know of any studies showing the time since
21 exposure to Camp Lejeune does not affect risk?

22 A You know, I've been doing this for almost 10
23 years, and I haven't seen a study that demonstrates that the
24 risk has decreased over time.

25 Q Do you know of any studies that consider time

1 since exposure to any VOCs and whether or not that affects
2 risk?

3 A Could you repeat the question? I'm not sure I
4 heard you correctly.

5 Q No, no, that's okay.

6 Did you consider any studies showing that time
7 things exposure to VOCs do not affect risk?

8 A I haven't seen any articles.

9 Q Did you consider my studies showing that VOCs
10 remain in the body longer than carcinogens from cigarettes?

11 A You know, the -- I've read over 200 articles
12 relating to exposure in kidney cancer risk, and I don't
13 recall a single article that talks about risk diminishing
14 over time.

15 Q Is there a reason to believe, on a biological
16 basis, that times since smoking cigarettes, since --
17 withdrawn.

18 Is there a reason to believe, on a biological
19 basis, that time since cessation of smoking cigarettes would
20 be different from times since last exposure to VOCs?

21 A I think you just asked me that question, and my
22 answer at the time was the risk from the TVOCs at Camp
23 Lejeune were greater than that posed from cigarette smoke.

24 Q So I want to turn to Ms. Tukes' report. Can you
25 go to page 12? And the second, I guess, number, it's

1 numbered Number 2, under Section E: "Non-Camp Lejeune
2 Personal Risk Factor Analysis" for Ms. Tukes' kidney cancer
3 reads: "Ms. Tukes is African American so she was at a small
4 increased risk of kidney cancer due to her ethnicity
5 compared to Caucasian women in the general population."

6 Did I read that correctly?

7 A Yes.

8 Q Can you turn to page 17? And the very last
9 paragraph, which continues onto the next page reads:
10 "Ms. Tukes was slightly overweight when she was diagnosed
11 with kidney cancer. She would have been at slightly
12 increased risk due to her weight. However, this is usually
13 not a significant risk factor and Ms. Tukes was not
14 significantly overweight. Ms. Tukes' weight fluctuated over
15 time, yet she continued to be diagnosed with new primary RCC
16 tumors. This suggests her slightly increased weight prior
17 to and following her first diagnosis of kidney cancer in
18 2010 was not relevant as a cause of that cancer. Otherwise,
19 she would have had a reduction in the development of cancer
20 when her BMI or weight changed."

21 Did I read that correctly?

22 A Yes. Because her weight went down after she was
23 diagnosed. I mean, not a lot, but it went down some, but
24 yet she still continued developing kidney cancer. That's
25 why that was written there.

1 Q Is it your opinion that a person's risk of
2 developing kidney cancer diminishes after they've lost
3 weight? Withdrawn. Take that back. I'm withdrawing that.

4 Actually, if a person was once overweight but then
5 they lost weight, would you say that their risk of
6 developing kidney cancer is lower after they've lost weight
7 than it was when they had -- were overweight?

8 A Well, given -- given where Ms. Tukes was in terms
9 of her body mass index, if she lost a pound or two, her risk
10 fact wouldn't go down substantially because it wasn't high
11 in the first place.

12 So, I mean, you know, a pound or two here or there
13 isn't going to diminish her risk much more than what it was
14 at her current weight.

15 Q So basically you think that her weight was just a
16 low grade risk factor?

17 A Exactly. And Dr. Stadler thought the same thing.

18 Q I'm just trying to -- I know. And you also think
19 the fact that she was African American is kind of a low
20 grade risk factor, if you will?

21 A Yes, I believe that's true.

22 Q Or a low level risk factor is a better way of
23 saying it, I think?

24 A Low level.

25 Q Yeah.

1 A Yes.

2 Q If Ms. Tukes' exposure were lower than what you
3 believe it to be, would you consider her exposure to be a
4 lower level risk factor of her kidney cancer?

5 A If her -- if her exposure was lower, I would say
6 that her risk would be lower, yes.

7 Q But you don't consider her current -- withdrawn.
8 As you understand the exposure data, you don't
9 consider her risk to be low; is that correct, from exposure?
10 I'll strike that, and actually not -- try to do a
11 non-mangled question.

12 As you understand Ms. Tukes' exposure to the water
13 at Camp Lejeune, you don't consider that to be a low level
14 risk factor; is that correct?

15 A I consider Ms. Tukes' exposure at Camp Lejeune to
16 be a significant risk factor that caused her cancer.

17 Q Is it your opinion -- withdrawn.

18 It's your opinion that Ms. Tukes' kidney cancer
19 was not hereditary, right?

20 A Yes. I believe that she had genetic changes that
21 increased her genetic predisposition for and development of
22 kidney cancer.

23 She was more susceptible because of those genetic
24 changes, and even though she was exposed to levels that Dr.
25 Bove found were at increased risk for kidney cancer, I think

1 she was more susceptible and that contributed to her kidney
2 cancer development at an earlier age.

3 Q So I want to just look at one thing on page 18 of
4 the Tukes report.

5 A I'm there.

6 Q So you write in the middle of the page:
7 "Ms. Tukes did not have a confirmed history of kidney
8 cancer. It was not confirmed her mother had a primary
9 kidney cancer rather than metastatic disease. Ms. Tukes
10 tested negatively for a genetic predisposition to kidney
11 cancer. This makes it very highly unlikely that her kidney
12 cancer was hereditary."

13 Did I read that correct?

14 A Yes, you did.

15 Q I'm turning to page 19. And is it also your
16 opinion that Ms. Tukes' two genetic variants of PMS2 and
17 SMARCA4, and I quote: Made her more susceptible to cancer
18 following carcinogenic exposure?

19 A Yes.

20 Q Do you rely on Dr. Irving Allen's report to reach
21 that conclusion?

22 A Yes. And also I think Dr. Garbarini spoke to that
23 to some extent, not to the extent Dr. Allen did.

24 Q Do you have an independent opinion of whether
25 Ms. Tukes was genetically more susceptible to developing

1 kidney cancer due to environmental exposures?

2 A I do have an independent opinion that Ms. Tukes
3 was more susceptible to kidney cancer because of her
4 exposures at Camp Lejeune, yes.

5 Q No, no. What I asked was: Do you have an
6 independent opinion about whether Ms. Tukes was genetically
7 more susceptible to developing kidney cancer?

8 A So, could you clarify your question, Counselor,
9 because I think what we're trying to get at is two separate
10 things.

11 You're asking if she has hereditary kidney cancer,
12 and I'm saying her genetic variability, because of those two
13 variants, increased her susceptibility, which is two
14 different things.

15 Q I guess my question is: Independent of reading
16 Dr. Irving Allen and the other doctor's opinion that you
17 referenced, do you have an opinion about whether Ms. Tukes
18 was genetically more susceptible to developing kidney cancer
19 after exposure?

20 A So I rely on Dr. Allen's report for forming my
21 opinion regarding her genetic susceptibility. I haven't
22 seen any reason to doubt the veracity of what Dr. Allen
23 reported, and I think that Dr. Allen was very clear in his
24 explanation of why Ms. Tukes was more genetically
25 susceptible to exposure.

1 She, Ms. Tukes, was tested for hereditary genetic
2 changes not once, but twice, through a panel of genetic
3 testing that included not only 30 genes initially, but
4 subsequent -- subsequent testing expanded a much larger
5 number of genetic alterations, and both times the test came
6 back negative.

7 So there's nothing in the record to suggest that
8 she had a heritable genetic condition.

9 I know that Dr. Stadler alluded to her potentially
10 having a papillary hereditary genetic condition, but my
11 understanding is testing of the MET gene, which was done on
12 Ms. Tukes, was negative and that ruled out papillary
13 hereditary carcinoma in her case.

14 MS. SPRAYREGEN: How long have we been on the
15 record? No, no. Since the last break. And not the
16 mini break when we couldn't figure out if we were
17 reading from the same report. About 50 minutes.

18 Do you want to take a break? Now is a good
19 time --

20 MR. LEE: Do you want to go off the record?

21 MS. SPRAYREGEN: Yeah. Can we go off the
22 record?

23 THE VIDEOGRAPHER: The time is 1:09 p.m. We
24 are going off the record.

25 (Noon recess taken from 1:09 to 1:59 p.m.)

1 THE VIDEOGRAPHER: The time is 1:59 p.m. We
2 are going back on the record.

3 Please proceed, Counsel.

4 BY MS. SPRAYREGEN:

5 Q Before we broke for lunch, we were talking about
6 Dr. Allen, right?

7 A Yes.

8 Q So I just want to clarify one thing.

9 Do you have an independent opinion about whether
10 Ms. Tukes was genetically more susceptible to developing
11 kidney cancer due to environmental exposures, or do you rely
12 on Dr. Allen for this conclusion?

13 A Well, let me say this, Counselor. I think that
14 Ms. Tukes' exposures to environmental contaminants at Camp
15 Lejeune was sufficient, in and of itself, to cause her
16 kidney cancer, and even if you take her genetics out of the
17 picture, she was at risk and developed kidney cancer because
18 of her environmental exposures.

19 Q Do you rely on Dr. Allen's report for the
20 conclusion or for the opinion, I should say, that Ms. Tukes
21 was genetically more susceptible to developing kidney
22 cancer?

23 A Yes. That was the basis of my determination
24 regarding her genetic susceptibility.

25 Q You also discussed in your report that Ms. Tukes

1 underwent a genetic assessment in 2018, right?

2 A Yes.

3 Q And that this test evaluated a panel of 30 genes,
4 right?

5 A And subsequent genes, yes.

6 Q So the test was limited to a panel of 30 genes; is
7 that right?

8 A The -- she had more than one panel that was
9 tested. The first panel consisted of 30.

10 There was subsequent genetic testing that included
11 more genes that were looked at.

12 Q Would you agree that there are over 20,000 genes
13 in the human body?

14 A I think that she was tested for those specific
15 genes that are linked to kidney cancer in people.

16 Q Would you agree that there are 20,000 or more
17 genes in the human body?

18 A Yes.

19 Q Would you agree that even if -- where there were
20 no reportable genetic variants -- strike that.

21 Would you agree that even were there no reportable
22 genetic variants -- strike that.

23 Would you agree that even where no reportable
24 genetic variants were identified by these diagnostic tests,
25 a patient may still be at risk for RCC based on other

1 factors?

2 A Yes.

3 Q And that one of those other factors could be
4 genetic causes not evaluated by these tests?

5 A I think it's a hypothetical. I know that the
6 thoroughness or completeness of the genetic testing that Ms.
7 Tukes underwent, not once but twice, she received the full
8 panel of genetic tests that was -- that was current at the
9 time for genetic testing.

10 In other words, everything that is known she was
11 tested for and tested negative.

12 MS. SPRAYREGEN: I'm going to introduce
13 Exhibit Number 10.

14 (Mallon Exhibit 10 marked for
15 identification.)

16 BY MS. SPRAYREGEN:

17 Q Have you seen these records before?

18 A I don't know that I have.

19 Q These are the results of Ms. Tukes' genetic
20 testing, and it looks like the Bates numbers have not been
21 copied. So this might be hard.

22 But can you turn to the page that is 31 at the
23 bottom. It's the pagination of the U --

24 A Yes. Page 31. Okay.

25 Q And so one of the tests she took was by Invitae;

1 is that right?

2 A Yes.

3 Q So had you seen the disclaimer noting that -- and
4 this is on page 31, it's hard to read. "This individual may
5 still be at risk for certain medical conditions based on
6 other factors, including genetic causes not evaluated with
7 this test."

8 A Where does it say: "Not evaluated with these
9 test"?

10 Q It's the -- it's hard to read, I agree.
11 It's the second -- there's only three lines.

12 A Yeah, I see it. Yeah, okay.

13 Q The second line.

14 A I see that, yes.

15 Q "Genetic causes not evaluated with this test."
16 Do you see that?

17 A Mm-hmm.

18 Q So would you agree that even the test had a
19 disclaimer that there are possible causes that the test
20 doesn't evaluate for?

21 A This says: "No reportable genetic variants were
22 identified by this analysis." So I agree with that.

23 Individuals may still be at risk for certain
24 medical conditions based on other factors, such as family
25 history, genetic causes, not evaluated by this test or other

1 environmental influences.

2 So what I'm not aware of, Counselor, is what other
3 causes -- what other genetic causes not evaluated by this
4 test you're referring to, because to my knowledge, this test
5 tested for all known environmental -- all known genetic
6 causes of kidney cancer.

7 Q Genetic causes that we do not know yet?

8 A Well, that's conjecture, or you're projecting in
9 the future what future tests may be available to identify
10 genetic conditions, but the current state of knowledge is
11 they tested for everything they knew that was possible.

12 Q I agree. But are you agreeing or are you
13 disagreeing with the possibility that there are genes out
14 there that influence whether someone has a genetic
15 predisposition or increased risk for kidney cancer that we
16 don't know of yet?

17 MR. LEE: Objection to form.

18 THE WITNESS: In answer to your question, I
19 looked up the testing. I looked up the likelihood that
20 there could be a possible genetic test not accounted
21 for here, and it is mathematically a very slim chance
22 of this not picking up a genetic condition, I think, as
23 I recall, it was one in a thousand, maybe even smaller
24 risk, that something like this would occur.

25 Q Are you talking about the test making a mistake or

1 or the possibility that there are genes out there that we
2 don't know of yet?

3 A I was talking about a mistake that the possibility
4 exists that there might be one in a thousand chance that
5 they missed a genetic variant that --

6 Q So you're talking about a mistake in the test --

7 A Correct.

8 Q -- not a possibility of a gene?

9 A Correct.

10 Q -- that we don't know of that causes --

11 A Because I can't -- I can't offer an opinion on a
12 hypothetical that hasn't happened and we don't know exists.
13 You're talking about something that may develop in the
14 future, yeah, I can't comment on that.

15 MS. SPRAYREGEN: I'm going to introduce
16 Exhibit Number 11.

17 (Mallon Exhibit 11 marked for
18 identification.)

19 THE WITNESS: I like these clean copies.

20 BY MS. SPRAYREGEN:

21 Q Are you familiar with the NCCN Guidelines?

22 A First time I've seen them, Counsel.

23 Q Are you aware that the NCCN Guidelines are
24 commonly used by physicians in treating cancer?

25 A As the title would imply, yes.

1 Q This is the first time you've seen them, but you
2 are aware that they were commonly used by physicians in
3 treating cancer?

4 A Well, it specifically says "Practice Guidelines."
5 In other words, clinical practitioners in oncology,
6 presumably for treating kidney cancer. So the title gives
7 me that information.

8 Q But you weren't aware that these guidelines are
9 commonly used by physicians in treating kidney cancer prior
10 to seeing this exhibit; is that correct?

11 MR. LEE: Objection to form.

12 THE WITNESS: That is correct.

13 BY MS. SPRAYREGEN:

14 Q Are you aware that the NCCN Guidelines allow for a
15 diagnosis of hereditary RCC syndrome based on clinical
16 phenotype alone even in the absence of an identified
17 pathogenic variant?

18 A I see that as -- that it is a consideration. It's
19 not an indication of that.

20 These are the criteria for future genetic risk
21 evaluation for hereditary RCC syndromes. They're criteria
22 that providers need to consider for whether or not a patient
23 should be tested for genetic, you know, hereditary genetic
24 changes.

25 Q For the record, the witness is reading from page

1 bearing the Bates Number HERED-RCC-1. And also for the
2 record, the highlighting is by me.

3 And the part of the record that you were just
4 referring to, can you turn back to that?

5 A Yes, I'm on it.

6 Q Okay. And it says: "An individual with RCC with
7 any of the following criteria: Diagnoses under the age of
8 46 years, bilateral or multifocal tumors in greater than one
9 or second-degree relative with RCC."

10 And those people are individuals with RCC with any
11 of the following criteria -- withdrawn.

12 And those people are people who should be
13 evaluated for genetic risk; is that correct?

14 A Yes.

15 Q So --

16 A If I may. I would also add that Ms. Tukes doesn't
17 meet that criteria.

18 Q It says: "With any of the following criteria."
19 Does she meet none of those criteria?

20 A Well, I think she meets a couple. She meets the
21 first two of the three.

22 Q So by --

23 A We haven't established that she has a first or
24 second-degree relative with kidney cancer.

25 Q I understand. But you would agree that Ms. Tukes

1 was diagnosed under the age of 46?

2 A Yes.

3 Q And you would agree that she has bilateral and
4 multifocal tumors; is that correct?

5 A That is correct.

6 Q And were you aware that bilateral cancer is a
7 clinical feature consistent with an inherited nature?

8 A I understand that that's a consideration that, you
9 know, clinicians and geneticists think about when they're
10 thinking of hereditary kidney cancer.

11 Q Were you aware of that before reading?

12 A Before seeing this, yes.

13 Q Were you aware of that before -- were you aware of
14 that when you were forming your opinion on Ms. Tukes?

15 A Yes.

16 Q And were you aware when you were forming your
17 opinion on Ms. Tukes that multifocal cancer is a clinical
18 feature consistent with an inherited nature?

19 A I'm sorry, would you repeat the question?

20 Q Were you aware, when you were forming your
21 opinion, that multifocal cancer is a clinical feature
22 consistent with an inherited nature?

23 MR. LEE: Objection to form. You can answer.

24 THE WITNESS: Do you have another way of
25 wording that question, Counselor?

1 BY MS. SPRAYREGEN:

2 Q Are you aware that having multiple tumors is a
3 clinical feature that is consistent with an inherited nature
4 of kidney cancer?

5 A I'm aware, and I was aware at the time that having
6 bilateral kidney cancer and multifocal cancer of different
7 types was a criteria for testing someone for hereditary
8 kidney cancer.

9 Q So is it your position that these clinical
10 features, the bilateral multifocal cancer and that she was
11 diagnosed at a young age, which are suggestive of hereditary
12 RCC, should be disregarded if there is no pathogenic
13 mutation found?

14 MR. LEE: Objection to form.

15 THE WITNESS: Yes. In answer to your
16 question, that's exactly what I'm saying.

17 She was tested not once, but twice, for those
18 genetic mutations that would identify someone as having
19 a hereditary kidney cancer syndrome, and she tested
20 negative for the MET gene, which is associated with the
21 papillary renal cell carcinoma.

22 And so to my mind, that ruled out a
23 hereditary cancer as a -- as a likelihood.

24 BY MS. SPRAYREGEN:

25 Q Do you know if the NCCN recommends that clinical

1 features be disregarded in interpreting genetic test
2 results?

3 A So these -- if I may, these are clinical practice
4 guidelines. I used to write and oversee the development of
5 clinical practice guidelines for providers in the military,
6 specifically the Army, related to preventive and
7 occupational medicine and other clinical practice guidelines
8 as well.

9 So what they are, they're guidelines, they're
10 meant to be advisory in nature and not meant to be directive
11 in any way. They allow variation in practice.

12 And so these are consideration that providers
13 should take into account when they're managing their
14 patients.

15 This is not something that they have to go step by
16 step and say: "Well, they meet this, they meet this, and
17 they meet this, and I have to do this testing."

18 Q Do you know of any authority that allows a genetic
19 test to outweigh clinical presentations?

20 A I think the genetic testing provides guidance to a
21 provider that is another piece of information that providers
22 should consider when considering whether there's a
23 hereditary cancer present.

24 The fact that she doesn't have a first or
25 second-degree relative, and the fact that her genetic

1 testing is negative, are both supportive of Ms. Tukes not
2 having a hereditary kidney cancer.

3 Q You mentioned earlier today that you received
4 records on Mr. Downs' cancer that are recent; is that
5 correct?

6 A Yes.

7 Q Did you receive those records before or after
8 submitting or drafting your report?

9 A After.

10 Q Is there anything in those records that changes
11 any opinions you have had in your report?

12 A No. If anything, it strengthens my opinion in
13 regards to Mr. Downs and his kidney cancer.

14 Q What opinion does it strengthen?

15 A Well, I think that the opinion of Dr. Stadler was
16 very helpful in terms of recognizing that some of the
17 potential risk factors that I identified, he, in fact,
18 pointed to and said these represent minimal potential risks,
19 and so it led me to conclude that the environmental
20 exposures are a stronger component of his kidney cancer than
21 those other risk factors.

22 Q You were just talking about Dr. Stadler's report,
23 and I was asking you if the medical records that you
24 received from Mr. -- of Mr. Downs' treatment and care
25 changed your opinions in the report that you submitted on

1 February 7th, right?

2 A Well, my understanding, Dr. Stadler's report is
3 included in the package of new information that I received
4 post writing my report. So I didn't draw a distinction
5 between the 4,000 pages of medical records and the report of
6 Dr. Stadler.

7 Q So limiting this question to just the 4,000 pages
8 of medical records that you reviewed after writing your
9 report, okay, did those 4,000 pages of medical records
10 change any of your opinions in your report?

11 A No.

12 Q You based your opinions, in part, on Dr. Reynolds'
13 report of 6, 2025; is that correct?

14 A Could you be more specific?

15 Q To the extent you assert that exposure to
16 contaminated water at Camp Lejeune caused Mr. Downs and
17 Mrs. Tukes' cancer, is that opinion based, in part, on
18 Dr. Reynolds' exposure calculations?

19 A Yes.

20 Q And Dr. Reynolds based her calculations of
21 Mr. Downs and Ms. Tukes' cumulative exposure to the
22 contaminants of concern on the ATSDR's water model; is that
23 right?

24 A That's correct.

25 Q Are you aware of the statement in the ATSDR's

1 water modeling reports that their models are not accurate
2 enough to be determined -- to determine an individual's
3 health effects?

4 A I have read that statement, yes.

5 Q You have read that statement?

6 A I'm sorry?

7 Q I said you have read that statement?

8 A Yes.

9 Q So why did you rely on Dr. Reynolds' opinions in
10 light of the fact ATSDR said its water models were not
11 accurate enough to estimate -- were not accurate enough
12 estimates to be used to determine an individual's health
13 effects?

14 A I don't know that it said it couldn't be used to
15 determine health effects. Could you show me where it says
16 that?

17 Q Sure.

18 A I'm getting ahead of myself. Are you going to
19 mark this as an exhibit?

20 MS. SPRAYREGEN: Yeah. This is -- for the
21 record, I am introducing Exhibit Number 12.

22 (Mallon Exhibit 12 marked for
23 identification.)

24 MS. SPRAYREGEN: And also for the record,
25 Exhibit Number 12 are -- is the parts of the "Analysis

1 of Groundwater Flow, Contaminant Fate and Transport,
2 and Distribution of Drinking Water at Tarawa Terrace
3 and Vicinity, U.S. Marine Corps Base Camp Lejeune,
4 North Carolina; Historical Reconstruction and Present
5 Day Conditions. Chapter A: Summary of Findings."

6 And what I've introduced is the Q&A, as well
7 as the Table of Contents.

8 BY MS. SPRAYREGEN:

9 Q So if you could turn to page, I believe it is A98
10 at the end. There is some highlighting on it, and the
11 highlighting is marked.

12 Do you see the highlighted sentence that says:
13 "The ATSDR's exposure assessment cannot be used to determine
14 whether you or your family suffered any health effects as a
15 result of past exposure to PCE contaminated drinking water
16 at Camp Lejeune."

17 Do you see that?

18 A I do see that.

19 Q Were you aware of that statement before you had
20 written your report?

21 A Was I aware of this particular statement? That's
22 a good question.

23 I didn't read this particular Q&A when I looked
24 over the ATSDR reports. So, no, I wasn't aware of that.

25 Q You say "this particular statement." Are you

1 aware of statements that are similar to that?

2 A No.

3 Q If ATSDR's water modeling results were incorrect,
4 would Dr. Reynolds' calculations be impacted?

5 MR. LEE: Objection to form.

6 MS. SPRAYREGEN: It's a hypothetical.

7 THE WITNESS: Well, I disagree with your
8 presumption that his calculations are incorrect.

9 This doesn't say that. This says to an
10 individual who's reading this Q&A, you can't -- you
11 can't use this particular document to predict what
12 health effects might occur.

13 BY MS. SPRAYREGEN:

14 Q No, no, I understand. I've moved on from the
15 document. I'm asking you a hypothetical question.

16 Don't -- the document is irrelevant to my
17 question.

18 A Okay. So if you'll rephrase your question.

19 Q Of course. I will say it again. Now that you
20 know that this is a hypothetical.

21 If the ATSDR's water modeling results were
22 incorrect, would Dr. Reynolds' calculations be impacted?

23 A Could you specify how you think they might be
24 incorrect?

25 Q Forget how they might be incorrect. I'm asking

1 you about a hypothetical, but I will --

2 A Because it's important the nature of the error
3 before I can comment on how the hypothetical might, in fact,
4 play out.

5 Q So the hypothetical is not about the facts, but I
6 am just asking you, and I will ask you a different question.

7 If one could show that the actual concentrations
8 were 15 percent lower than the values in the ATSDR's water
9 models calculated, Dr. Reynolds' exposure calculations would
10 be too high in that instance, right?

11 MR. LEE: Object to the form of the question
12 to the extent you appear to be trying to mislead the
13 witness concerning this hypothetical, but go ahead.

14 MS. SPRAYREGEN: I'm really not. Just to be
15 clear. I'll try and restate the question.

16 THE WITNESS: I appreciate it.

17 MS. SPRAYREGEN: I'm not trying to mislead.
18 I'm asking in my hypothetical.

19 BY MS. SPRAYREGEN:

20 Q So if it were the case that the actual
21 concentrations of the water at Camp Lejeune were 15 percent
22 lower than the values the ATSDR's water model calculated,
23 then Dr. Reynolds' exposure calculations would also be too
24 high; is that right?

25 MR. LEE: Objection to form. You can answer,

1 if you understand the question.

2 THE WITNESS: I think I understand the
3 question. I would say that the water modeling was
4 based on 1982 and 1985 water testing. And they
5 back-extrapolated to come back with monthly exposure
6 levels based on those real-world data, and so I don't
7 support the contention that the water models are
8 15 percent off.

9 They're just -- they're exposure models based
10 on real water data. They crunched the numbers based on
11 what ATSDR recommended as the approach for water
12 modeling in conjunction with EPA.

13 And so unless you can identify some error
14 that was inconsistent with appropriate methods that
15 ATSDR used, I have to go on the facts that I know in
16 the case, which are the water modeling was based on
17 factual data and what that tells me is there are risks
18 related --

19 MR. LEE: I'm sorry. Allow him to finish his
20 response.

21 THE WITNESS: If I may, Counselor.

22 That those exposure levels caused the cancer
23 for both Mr. Downs and Ms. Tukes.

24 BY MS. SPRAYREGEN:

25 Q Okay. I'm not questioning the ATSDR water model

1 right now. I'm asking a hypothetical. Not about whether or
2 not it's accurate. I'm not asking you to evaluate whether
3 it's accurate, and I'm not -- I'm not positing that it's
4 inaccurate.

5 I'm asking you a hypothetical question, which is:
6 If the model were inaccurate or if -- forget inaccurate.
7 Forget the model.

8 If the actual concentrations were lower than the
9 values the ATSDR's water models calculated in Dr. Reynolds'
10 exposure calculations based on those -- that model would
11 also be too high; is that right?

12 MR. LEE: Objection to the form of the
13 question.

14 THE WITNESS: So, I don't know that I'm
15 conveying the information directly enough.

16 Specifically, if I reduced Mr. Downs' and
17 Ms. Tukes' exposure levels by 15 percent, her levels of
18 exposure and Mr. Downs' levels of exposures are still
19 high enough to meet what Bove identified as significant
20 risk of kidney cancer in both individuals with a
21 15 percent reduction in the current levels following
22 your hypothetical.

23 MS. SPRAYREGEN: That wasn't my question.

24 MR. LEE: Objection to the form of the
25 question. I don't know whether that was a question you

1 were asking now or not, but.

2 MS. SPRAYREGEN: So I'm going to go ahead and
3 introduce Exhibit 13.

4 (Mallon Exhibit 13 marked for
5 identification.)

6 BY MS. SPRAYREGEN:

7 Q So Exhibit Number 13 is Dr. Reynolds' report, the
8 appendices relevant to Mr. Downs and Mrs. Tukes.

9 And then because some of the charts were very,
10 very hard to read, I created a Word document with --

11 A I did the same thing.

12 Q -- with copied charts, and so --

13 A Yeah.

14 Q -- they're just copies but made bigger.

15 A So I'm sorry. I don't see Ms. Tukes' report. I
16 see Downs.

17 Q There's no appendix on there?

18 A That was -- that was in the stapled version, so
19 it's there.

20 Q Right. In the stapled version, yes.

21 I only blew up Mr. Downs' -- I blew up one of
22 Ms. Tukes' charts and several of Mr. Downs' charts because I
23 found these two charts easier to see.

24 A I have those.

25 Q Okay.

1 A So this page, this summary page for Downs; is that
2 in the attached version?

3 Q Yes. The summary pages are not in the attached
4 version because they were able to be read.

5 I only tried to blow up things that I couldn't see
6 because --

7 A I understand.

8 Q To the extent I could, I only did that because I
9 found those charts literally impossible to see, and when I'm
10 viewing them on my computer, I blow them up. And so for the
11 deposition that wasn't an option, so I did the best
12 foreground I could.

13 A I have that information, so I'm good.

14 Q Okay. Great.

15 So I take it you've seen the charts in
16 Dr. Reynolds' report before?

17 A Yes. Mm-hmm.

18 Q And looking at your report, your Downs report,
19 stick with that for now. On page 16 to 17.

20 A So Downs, 16 and 17?

21 Q Yes.

22 A All right. I'm there.

23 Q The chart in your report -- in your Downs report,
24 on page 16 to 17, is copied from Dr. Reynolds' chart; is
25 that correct?

1 A Yes.

2 Q And this is under -- in Dr. Reynolds' report, this
3 is under Appendix 6, the first page; is that correct?

4 Dr. Reynolds' report. Not the blown-up version of
5 it.

6 A Which page in the report?

7 Q Dr. Reynolds' report, Appendix 6.

8 A Oh, I see.

9 Q After her report. It's the first page after all
10 the writing.

11 A Gotcha. So that would be this?

12 Q Yes. That is the same chart that is in your
13 report; is that correct?

14 A Yes.

15 Q And Dr. Reynolds provided several different --

16 A This got cut off.

17 MR. LEE: Mine is cut off as well.

18 THE WITNESS: But I can see that it's
19 similar. It's three out of four. It's cut off like
20 mid-page. It's missing Chart 4.

21 MS. SPRAYREGEN: Sorry. We can look at the
22 chart on page 16. It says 17 of your report.

23 MR. LEE: I only see part of Chart 3 as well,
24 but fair enough.

25 MS. SPRAYREGEN: I think he's already said

1 that it's the same chart. So we can look at the chart
2 on page 3. I don't know what the printer was doing.

3 THE WITNESS: Okay. 16 and 17 are the same,
4 sounds good.

5 BY MS. SPRAYREGEN:

6 Q So Dr. Reynolds provided several different summed
7 exposure totals; is that right?

8 A Yes.

9 Q And the very first column is the contaminants of
10 concern in this case; is that right?

11 A Yes.

12 Q And then the first column with numbers, I guess
13 you could say, the next column over shows the cumulative
14 ug/L months, which is cumulative microgram per liter months;
15 is that right?

16 A Yes.

17 Q What do you understand cumulative ug/L months to
18 be?

19 A Cumulative ug/L per liter months represents a
20 summation of the monthly contaminant concentrations that
21 Mr. Downs and Ms. Tukes were exposed to over the time that
22 they were present at Camp Lejeune.

23 Q Would you -- I would just add one word to that,
24 and is that mean. It's the summation of the mean monthly
25 concentrations; is that right?

1 A That makes sense, yes.

2 Q Have you ever -- strike that.

3 So you would agree that Dr. Reynolds calculated
4 this value by adding the mean monthly concentrations of
5 contaminants in drinking water for each month that Plaintiff
6 was exposed; is that right?

7 A That's correct. Based on the supporting
8 documentation.

9 Q Have you ever seen exposure assessments presented
10 in terms of cumulative ug/L months before?

11 A Yes.

12 Q I know the answer, but I've got to ask. Where?

13 A Well, Dr. Bove, in his reports. And also in
14 several of the published articles leading up to the
15 preparation of the report. Several of the authors refer to
16 exposure levels in microgram per liter months and microgram
17 per liter years.

18 Q So my question to you is which articles, other
19 than the Bove articles, have examined exposure presented in
20 cumulative ug/L months?

21 A Let me take a minute here and find a couple for
22 you. Andrew in particular.

23 Q Andrew what?

24 A Andrew 2022.

25 Q And what is the title?

1 A You're asking me to -- that's a stretch,
2 Counselor. It's looking at exposures to environmental
3 contaminants. And I forget which -- oh, that was a drinking
4 water study, so.

5 Q Okay. So that's one. And that looked at exposure
6 in cumulative ug/L months; is that what you're saying?

7 A Yes.

8 Q Any others?

9 A He looked at range of exposures. He did it by
10 percentile. Less than 50, 50 to 75, and greater than 75.
11 And looked at microgram per liters.

12 Q Microgram per liter months?

13 A I have here written down micrograms per liter. I
14 don't necessarily say that it's months, but if you take the
15 duration that if someone was exposed and multiply it by the
16 microgram per liter, you're going to come up with a
17 microgram per liter month metric that multiplied over like
18 12 years, or however long that they were at the site, you
19 can come up a total microgram per liter.

20 Q Any others beside Andrew have looked at cumulative
21 exposure in terms of microgram per liter months?

22 A Yeah. Let me find some for you. We've already
23 talked -- spoken about Dr. Bove -- or Bove's exposure
24 metrics.

25 Well, as I sit here, that's Bove. So I'm just

1 looking at my short list of studies. I can just come up
2 with Andrew as we speak right this moment, but if given the
3 opportunity, I'm sure I can find a few more studies that
4 would support it.

5 Q So you rely on Dr. Reynolds' calculations,
6 basically the cumulative microgram per liter months, or
7 ug/L-M, which is column 1 that we've just been discussing,
8 of your Downs' report, to calculate cumulative -- cumulative
9 exposure; is that right?

10 A In microgram per liter months, that's correct.
11 But there's another metric that we haven't spoken about, and
12 that's total micrograms, or total milligrams of exposure
13 that can be derived from the cumulative consumption total.
14 So Charts 2, 3, and 4.

15 Q I'm going to get right to that, but before I do,
16 would you say the same for Mr. and Mrs. Tukes as Mr. Downs,
17 that you rely on Dr. Reynolds' calculations in the first
18 column of the chart that we've been discussing?

19 A Yes. I used those figures to come up with the
20 risk related to kidney cancer for both Mr. Downs and
21 Ms. Tukes.

22 Q And you just mentioned Dr. Reynolds' Charts 1
23 through 4; is that right?

24 A Yes.

25 Q Do you know how Dr. Reynolds used the numbers in

1 the first column, microgram per liter months, to get to the
2 numbers in Chart 1?

3 A Well, her assumption was that there was one liter
4 of water consumption for residential exposure and one liter
5 for workplace exposure, and so depending on the particular
6 individual, it was an assumption really as a format for
7 developing the exposure models that are represented in
8 Charts 2, 3, and 4.

9 So that was a template. The chart 1 was a
10 template for developing the detailed risk assessment for --
11 detailed exposure assessment for Charts 2, 3, and -- or,
12 yeah, 2, 3, and 4.

13 Q And what was your understanding of how Chart 2
14 differs from Chart 1?

15 A Well, so at the title at the top of -- at the top
16 of the table, Chart 2 specifically says: "ATSDR RME with
17 proportional work/resident time."

18 So that's a split of time spent at home and time
19 spent at work, and so that was proportionally developed. So
20 if you spend eight hours at work and 12 hours or 24 hours at
21 home, depending on your work situation, she apportioned risk
22 proportionately to how much time you spent at each location.

23 So -- and she had -- she had assumptions from the
24 military in terms of the field manuals, gave assumptions for
25 water consumption, and I think ATSDR had some models for how

1 much water was consumed, both at work and at residence.

2 And so she integrated the two to come up with an
3 estimated RME calculation, which is essentially a maximum
4 anticipated exposure based on the consumption that were
5 based from those manuals.

6 The next column over, the CTE, is meant to be the
7 central tendency estimate of exposure based on
8 proportionately work resident titles.

9 Q What is your understanding of the difference
10 between Charts 2 and Chart 3?

11 A So one is -- one is a near maximal consumption.
12 And the other is the average consumption.

13 Q And what is your understanding of Chart 4?

14 A Chart 4 -- I can't read the title for that.

15 Q Let's look at the report. It's on page 16.

16 A On page 16. So this was the exposure estimate
17 based on the deposition description of how much was consumed
18 and where it was consumed from Ms. Tukes and -- or
19 Mr. Downs.

20 So Chart 2 and 3 are proportionately estimates
21 based on water modeling essentially from the ATSDR and the
22 Army field manuals, or Marine Corps field manuals.

23 Chart 4 is what they actually said they consumed.

24 Q And for PCE, there is a --

25 A Is that a T or a P?

1 Q P. I'm sorry.

2 For PCE, not TCE, PCE, there are two models.

3 There is the tech flow and P model, and the MT3M -- MT3DMS
4 model, excuse me; is that right?

5 A Excuse me. Yes. Two models.

6 Q Do you know what the difference is between these
7 two models?

8 A I do.

9 Q Excellent. What is it?

10 A Well, the -- the MT3DMS model is a probabilistic
11 exposure estimate based on drinking water concentrations and
12 the tech flow model is a similar model, but it's based on
13 contaminants in the soil above the groundwater, and it's a
14 time fade analysis that looks at how long it takes from
15 contamination into or, you know, from point of discharge to
16 the time where it actually makes its way into the
17 groundwater. So that's the difference between the two.

18 Q So is it your belief that -- I'm sorry.

19 Withdrawn.

20 Could the court reporter please read back what was
21 just said?

22 (Madam Court Reporter read back the requested
23 portion of the record.)

24 BY MS. SPRAYREGEN:

25 Q So the tech flow model is a time fade analysis,

1 but the MT3DMS model is not?

2 A Well, they're both time fade analyses. It's just
3 that one works with the drinking water portion and one is
4 above the drinking water. That's my simple understanding.

5 Q I wanted to make sure that you didn't think only
6 one was a time fade analysis.

7 Have you ever seen these models before drafting
8 your report in this case?

9 A No. These models are discussed in Morris Maslia's
10 work in the ATSDR report and in his report and his
11 deposition.

12 So I've seen that information before. Long before
13 I wrote this report, I had the opportunity to read his
14 process analysis for how he developed the models and put the
15 risk estimates together.

16 MS. SPRAYREGEN: I'm sorry. Again, could the
17 court reporter read back what was just said?

18 (Madam Court Reporter read back the requested
19 portion of the record.)

20 BY MS. SPRAYREGEN:

21 Q So I'm just trying to understand. You had or had
22 not seen these models before writing your specific causation
23 report?

24 A I have.

25 Q You have. Okay. I thought you had testified that

1 you had not?

2 A (Shook head in response.)

3 Q Okay. Maybe I misheard you earlier.

4 A It's okay.

5 Q Got it. Substantively, what do you understand the
6 cumulative consumption metric used in Charts 1, 2, 3, and 4
7 to be?

8 MR. LEE: Objection. Form. You can answer.

9 THE WITNESS: Could you repeat the question,
10 Counselor? You can tell it's getting later in the day.

11 BY MS. SPRAYREGEN:

12 Q What -- what is your, in plain words,
13 understanding of the cumulative consumption as used in
14 Charts 1 through 4 in the Reynolds' model?

15 A Which column is that?

16 Q It's the title column: "Cumulative Consumption."

17 I'm turning back to page 13. Sorry, excuse me.

18 Turning back to page 16, in the blue highlight, it says:

19 "Cumulative Consumption" under Charts 1, 2, 3, and 4.

20 Do you see that?

21 A Yes.

22 Q And what do you understand that cumulative
23 consumption to be measuring?

24 MR. LEE: Objection to form first. You can
25 answer the question again.

1 THE WITNESS: As I read this, the title at
 2 the top of the column: "Cumulative Consumption," is an
 3 estimate that Dr. Reynolds put together based on the
 4 concentration times the -- the time, the number of
 5 days, if you will. So number of days times the
 6 concentration, to come up with a microgram level of
 7 contaminant as it relates to reach of the contaminants
 8 of concern at Camp Lejeune.

9 BY MS. SPRAYREGEN:

10 Q So what are the units of all the numbers?

11 A So --

12 Q -- in the columns in Charts 1, 2, 3, and 4?

13 A So as I read across, like with TCE, it's after the
 14 first column. So Chart 1, 2, 3, and 4, in those columns,
 15 those numbers represent milligrams of TCE consumed over the
 16 duration of time that each Ms. Tukes and Mr. Downs, during
 17 the time they were at Camp Lejeune.

18 And this is done for not only TCE, but for Hadnot
 19 Point and then again for Tarawa Terrace.

20 MS. SPRAYREGEN: Again, can the reporter read
 21 back what was just written -- what was just said?

22 (Madam Court Reporter read back the answer to
 23 the previously asked question.)

24 MR. LEE: When you get to a good point,
 25 Sharon, we'll take another break. It's been about an

1 hour.

2 THE VIDEOGRAPHER: The time is 2:54 p.m.

3 We're going off the record.

4 (Recess taken from 2:54 to 3:06 p.m.)

5 THE VIDEOGRAPHER: The time is 3:06 p.m.

6 We're going back on the record.

7 Please proceed, Counsel.

8 BY MS. SPRAYREGEN:

9 Q Dr. Mallon, you just said before we went on the
10 record that you have a correction to make.

11 What is that correction?

12 A Well, the court reporter read back that I said
13 milligrams. And, in fact, both are correct. The
14 7,866 micrograms is 7.86 milligrams. So I was just pointing
15 out that the equivalent, if you will, 8,000 micrograms and
16 8 milligrams.

17 Q So your testimony is that the numbers in the core
18 are micrograms of the VOC consumed over the time that the
19 plaintiff was at Camp Lejeune; is that correct?

20 A It says micrograms, but it's equivalent to the
21 milligrams that I just spoke about.

22 Q And this is a total mass number; is that correct?

23 A Total mass, that's correct.

24 Q Have you ever calculated a number like that
25 before?

1 A Yes.

2 Q And have you ever seen a mass number of micrograms
3 or milligrams total mass used to determine exposure?

4 A Yes.

5 Q Where?

6 A Well, Aschengrau, for one, reports milligrams of
7 exposure.

8 Q Other than Aschengrau?

9 A Well, hold on. Let me look. Do a quick search
10 here for you. See if there's others.

11 So Andrew reports micrograms per liter. And Moore
12 reports parts per billion, which is essentially micrograms
13 per liter converted to parts per billion. So Callahan
14 reports 25 to 280 parts per million.

15 So parts per million is a concentration. So it's
16 a mass divided by the volume.

17 Q So all the numbers that you've just given me,
18 ug/L, ug/L, or micrograms per liter, which is the same as
19 parts per billion and parts per million, are all
20 concentrations; is that right?

21 A Parts per billion, yes. They imply concentration.

22 Q Which is different from the total mass; is that
23 right?

24 A But easily derivable from a concentration.

25 Q Right. But you need additional information to get

1 from one to the other?

2 A The -- you may need additional information.

3 Well, let me back up and -- could you repeat that
4 question again? Because Andrew, for example, and
5 Aschengrau, prevent -- or present information -- well,
6 Andrew is a concentration, but Aschengrau reports a mass,
7 milligrams of exposure.

8 Q I agree that Aschengrau reports a mass of
9 milligrams of exposure. I was asking if any other of the
10 studies that you know of reported mass of milligrams of
11 exposure?

12 A Yes. There are others. I just don't cite them in
13 these crib notes.

14 Q As of right now, the only study that you can think
15 of that reports exposure in a mass is Aschengrau; is that
16 correct?

17 A The one definitive study that I can point my
18 finger at right this second, yes.

19 Q And have you ever personally calculated this
20 number?

21 A Quite often we've dealt with parts per billion,
22 parts per million as concentrations. So mass means some
23 volume of air or liquid as a concentration.

24 That's mostly what we dealt with. This is for
25 Army studies.

1 Q When determining cumulative exposure, do you agree
2 that it is important to consider exposure frequency and
3 duration in addition to amount?

4 A I would say it's important to incorporate dose and
5 duration over time. So, yes.

6 I will say that -- could you repeat your question?

7 Q When determining cumulative exposure, do you agree
8 that it is important to consider exposure frequency and
9 duration in addition to the amount?

10 A Yes. And I would say in this case, Dr. Reynolds
11 did do that, because she looked at the period over which
12 Ms. Downs and Mr. -- Mr. Downs and Ms. Tukes were exposed.
13 So she took the concen -- she took the concentrations that
14 they were exposed to and converted it from a concentration
15 to a mass volume, a mass figure.

16 So she incorporated that into her calculation.

17 Q Are you aware of whether Dr. Reynolds' use of
18 total mass of ingested chemicals, which we've just been
19 discussing and which are the results of the Charts 1 through
20 4, is standard exposure -- is a standard exposure metric in
21 risk assessment?

22 MR. LEE: Objection to form of the question.

23 MS. SPRAYREGEN: I can clean it up.

24 BY MS. SPRAYREGEN:

25 Q Are you aware of whether Dr. Reynolds used a total

1 mass of ingested chemicals is a standard exposure metric in
2 risk assessment?

3 A Well, Dr. Reynolds complied with standard practice
4 as it relates to risk assessment, as she stated in her
5 report.

6 I -- I think that her report is consistent with
7 the standard practice in her profession, and I rely on those
8 figures in coming up with an exposure estimate for both
9 Ms. Tukes and Mr. Downs and have nothing further to add.

10 Q How do you know whether it's standard practice?

11 A She outlined in her report exactly what she did,
12 and she applied the standard -- the standards in her
13 profession, which say to use ATSDR's modeling, and to -- and
14 to apply to the other standards as it relates to risk
15 assessment.

16 So we can go to her report, and I can show you
17 where she says that.

18 Q My question was if you're not an expert in risk
19 assessment, how do you know that what she did is standard
20 practice in the field of risk assessment?

21 A I have nothing to show the opposite is true. So
22 I'm assuming that she complies with the standards that she
23 identified when she completed her report.

24 Q Would you agree that the most reliable
25 epidemiological studies provide cumulative exposure

1 estimates in ppm years, which is an inhalation exposure
2 concentration times the number of years exposed, and ppb
3 month, or ppb year, which is ingested water concentration
4 times the number of months or years exposed?

5 MR. LEE: Objection to form.

6 THE WITNESS: Let me say this. I think that
7 I have nothing to doubt the quality of the work that
8 she presented.

9 I think she provided exposure estimates that
10 were consistent with and to be used in conjunction with
11 Dr. Bove's environmental assessment, and so to the
12 extent that she provided metrics that we could use to
13 compare and come up with an exposure risk made my job
14 easier.

15 Once I knew what the cumulative concentration
16 was for -- for both these Plaintiffs, for each of those
17 chemicals of concern, it made my job easier to go to
18 Bove Table 6 and Bove Table 7 and come up a hazard
19 ratio that showed that their exposures contributed to
20 their kidney cancer, so I appreciate the fact that she
21 tailored her analysis to provide data that I could use
22 to complete my job.

23 BY MS. SPRAYREGEN:

24 Q So can you turn to page 16 of the Downs report?

25 A I'm there.

1 Q I'm sorry, I said 16. I meant 17. I'm sorry. I
2 was also on 16.

3 So the second sentence on that page reads: "This
4 effect was amplified by the fact that according to
5 Dr. Reynolds, Mr. Downs would have ingested between 23,000
6 ppb and 59,000 ppb of PCE."

7 Did I read that correctly?

8 A You did.

9 Q Would you agree that the unit there is not ppb, as
10 we've been discussing? I'll withdraw that.

11 The numbers 23,000 ppb and 59,000 ppb, is that
12 from the chart that we were looking at that was copied from
13 Dr. Reynolds' report on pages 16 to 17 of your report under
14 the row "Tarawa Terrace PCE" using the tech flow MP model?

15 A So I see the tech flow model and I see the MT3
16 model. And the 23,000 ppb relates to the MT3. So, yes, I
17 see that.

18 Q Actually, the 23,000 that I'm looking at refers to
19 Chart 3 under the PCE tech flow model; is that correct? It
20 might be easier if you turn back to page 16.

21 A Okay.

22 Q So you see --

23 A Which column?

24 Q So I'm looking at the PCE tech flow model and
25 Chart 3, and that's where I see the 23,000 coming from?

1 A For Hadnot Point. Or for Tarawa Terrace.

2 Q Tarawa Terrace, yes.

3 A Yes.

4 Q And I believe that was the 23,000 that you were
5 referring to on page 17 of your report; is that right?

6 A Yes.

7 Q And my understanding of the 59,000 that you were
8 referring to on page 17 of your report is the Chart 2 of the
9 tech flow model for PCE; is that right?

10 A Yes.

11 Q And my question was: Isn't the proper unit for
12 that not ppb?

13 MR. LEE: Objection. Form.

14 THE WITNESS: So I think you're right,
15 Counselor. I think that it should be -- it should have
16 been milligrams instead of ppb.

17 As we discussed previously this afternoon.

18 BY MS. SPRAYREGEN:

19 Q And then my other question for you is: Why did
20 you choose to use the number from the tech flow model rather
21 than the MT3DMS model?

22 A We were trying to be more conservative and not
23 overstate the risks.

24 Q Did anyone ask you to use the information from
25 the --

1 A No.

2 MR. LEE: When you get in this line of
3 discussion, to the extent it involves conversation with
4 counsel, I'm going to ask you not to answer the
5 question, but thus far, you can go ahead and continue
6 responding.

7 THE WITNESS: Okay. Thank you.

8 MS. SPRAYREGEN: Let me rephrase.

9 BY MS. SPRAYREGEN:

10 Q Was that a determination you made to use the tech
11 flow model rather than the MT3DMS yourself?

12 A Yes.

13 Q And just for the record, can you turn to page 11
14 of the Tukes report?

15 A I'm there.

16 Q The last paragraph at the very bottom of the page
17 says: "Using the tech flow model and assuming the ingestion
18 statistics in Ms. Tukes' deposition, Ms. Tukes was exposed
19 to 58,000 -- 5,875 ppb of PCE through ingestion alone."

20 After I corrected myself, did I read that
21 correctly?

22 A I think so. Which line are you reading from?

23 Q The very bottom -- the page 11 of the Tukes
24 report.

25 A Under --

1 Q Under the chart.

2 A Under Chart 4.

3 Q Under the chart, under the chart there's some
4 writing.

5 A Right. This corresponds to that. That's where I
6 was just trying to make sure I was tracking where that came
7 from.

8 Q So you see where it says --

9 A Yes, I do.

10 Q Okay. And the 5,875 is using the deposition
11 estimates and the PCE tech flow model; is that correct?

12 A Yes.

13 Q And would you, again, agree that the units are not
14 ppb?

15 A It is correct. They should be micrograms.

16 Q I think this is my last unit question. Can you go
17 back to the Downs report?

18 A Yes.

19 Q And please turn to page 12.

20 A 12.

21 Q So the very last sentence, the very last section
22 of the page, do you see where it says: "Section 7.
23 Mr. Downs' exposure at Camp Lejeune"?

24 A Yes.

25 Q And what is written is: "Mr. Downs lived at

1 Tarawa Terrace and worked at Hadnot Point. Mr. Downs had
2 exposure to the following concentrations in the water during
3 his time at Camp Lejeune in his 589 days on base.
4 43 microgram liter TCE. 939 microgram liter PCE. And 122
5 microgram liter of vinyl chloride at Tarawa Terrace. He was
6 exposed to approximately 282 microgram liter TCE at Hadnot
7 Point."

8 Did I read that correctly?

9 A Yeah, you did.

10 MR. LEE: Objection.

11 BY MS. SPRAYREGEN:

12 Q Would you agree that the numbers that I just read,
13 43, 939, 122, and 282, are cumulative exposures measured in
14 microgram per liter months and not concentrations?

15 The chart is on page 16.

16 Oh, no, it's not. Excuse me. My bad. I
17 misdirected you.

18 A They're on page 16.

19 Q Oh, I was right.

20 A And so in answer to your question, it is a
21 concentration that's reported, the cumulative concentration,
22 micrograms per liter months. So what's missing is the month
23 part there.

24 Q So you're not offering the opinion that the
25 chemicals of concern interact synergistically; is that

1 correct?

2 A I believe I state in my report that I felt the --
3 the chemicals of concern created an additive effect, but not
4 a synergistic effect.

5 Q Turning to page 15 of the Downs report.

6 You described Mr. Downs' exposure to toxins in the
7 water at Camp Lejeune as, quote: Substantial; is that
8 right?

9 A Yes.

10 Q And if you turn to page 10 to 11 of the Tukes
11 report, you also describe Mrs. Tukes' exposure to the toxins
12 in the water at Camp Lejeune as substantial; is that
13 correct?

14 A Which page for Ms. Tukes?

15 Q 10 to 11.

16 A And where is that sentence, on page 10?

17 Q So the section is titled: "D. Ms. Tukes'
18 Exposure to the Water at Camp Lejeune was Substantial."

19 A Yes, I can read that.

20 Q And then on the next page, the first full --
21 excuse me. The second paragraph.

22 The second sentence says: "I will not repeat the
23 deposition testimony of Ms. Tukes, other than to say that
24 her exposure to the water at Camp Lejeune was substantial in
25 terms of the amount of exposure, see prior total chemicals

1 exposed, the duration of exposure, 19 months' time period,
2 the frequency of exposure, see description of how often she
3 was exposed to the chemicals daily, and the intensity of
4 exposure, see levels in the water of Camp Lejeune during the
5 time period Ms. Tukes was present."

6 Did I read that correctly?

7 A Yes.

8 Q So would you agree with me that you described both
9 Ms. Tukes' and Mr. Downs' exposure to the toxins in the
10 water at Camp Lejeune as substantial?

11 A Yes, mm-hmm.

12 Q You don't quantify substantial exposure; is that
13 correct?

14 A I don't specifically state that in the report, no.

15 Q Do you have an opinion of what amount of exposure
16 constitutes substantial exposure?

17 A I know that in terms of the criteria for
18 causation, if the exposure wasn't causal, there could be a
19 second tier, where the exposure was high enough to be
20 considered substantial.

21 You know, the fact is that her -- Ms. Tukes'
22 exposures were substantial and sufficient to be causal, so
23 it was both.

24 Q My question is: Your reports do not identify a
25 threshold amount over which an exposure becomes, quote:

1 Substantial, do they?

2 MR. LEE: Objection to form. You can answer.

3 MS. SPRAYREGEN: I can rephrase.

4 BY MS. SPRAYREGEN:

5 Q Is it correct to say that your reports do not
6 identify a threshold amount over which an exposure becomes
7 substantial?

8 A My reports do not offer any level or threshold to
9 identify substantial, that's correct.

10 Q Do you have an opinion on the level of exposure to
11 TCE necessary to cause kidney cancer?

12 A Yes. I believe that the levels identified in Dr.
13 Bove's 2014 and 2024 reports identify levels that are
14 sufficient to cause cancer.

15 Further, there are other -- there are other papers
16 that I cite in my report that provide additional information
17 regarding TCE exposure and kidney cancer.

18 ATSDR identifies exposures with monotonic
19 exposure, a dose-response curve.

20 The Mandel study 1995, the Callahan study in 2019,
21 when they identify bromine, and in Callahan with PCE, but,
22 let's see, Purdue identifies PCE and TCE levels that were
23 sufficient to cause cancer.

24 Aschengrau, as we talked about.

25 MS. SPRAYREGEN: Could the reporter back the

1 answer?

2 (Madam Court Reporter read back the answer to
3 the previously asked question.)

4 BY MS. SPRAYREGEN:

5 Q Dr. Mallon, you said you were reading from the
6 wrong page. Do you want to retract what you just said?

7 A To some extent, I need to revise what I said.

8 The ATSDR study in 2018 does show, both for PCE
9 and TCE, that the levels of exposure were sufficient to
10 cause cancer.

11 And then the other studies I quoted, the EPA 2020
12 study, meta-analysis, the meta summary risk, identified 41
13 studies that looked at exposure to TCE and found an elevated
14 meta relative risk of 1.22, with a significant odds ratio of
15 1.07 to 1.38.

16 So there were other studies as well, the Scott
17 2011 study. 1.27 with significant odds ratio, or a
18 confidence interval for both low and high exposure. Karami
19 in 2012, same thing. Chirag Patel.

20 Those are higher risk exposures, but there are
21 other lower -- lower levels of exposure that were also
22 statistically significant and had dose-response effects that
23 were positive.

24 Q So are you saying that all the studies that you
25 just identified show levels of a contaminant that are

1 sufficient to cause cancer?

2 A Yes. And so there are several studies that show
3 concentrations in the water, and -- for example, Parker
4 Rosen, with their 1981 study at Woburn, which is another
5 ecologic study, showed levels of TCE that are consistent
6 with what Dr. Bove showed in his study at 267 parts per
7 billion, and TCE at 21 parts per billion, and they found an
8 increased risk for kidney cancer.

9 And likewise, Andrew showed levels on the same
10 order of magnitude of zero to 25 for the low risk category.
11 A medium level risk of 15 to 75 percentile showed an
12 elevated risk of 1.47 with a significant confidence
13 interval, .9 to 2.4. That was for the five-year. Also the
14 10-year and the 15-year studies where they evaluated latency
15 period.

16 MS. SPRAYREGEN: I'm going to go ahead and
17 introduce the next exhibit. What number are we on?

18 What I'm going to hand you is exhibit
19 number -- no, that's the wrong one. We don't want that
20 one.

21 THE WITNESS: Do you want that one back?

22 MS. SPRAYREGEN: I think so. Give me one
23 second. Did I hand it to you already?

24 THE WITNESS: No. You didn't give it -- you
25 gave it to Randy.

1 MS. SPRAYREGEN: There should be a supplement
2 involved. There's no supplement there?

3 THE WITNESS: I've seen the supplement,
4 Counsel. There's supplemental tables to that.

5 MS. SPRAYREGEN: Right.

6 THE WITNESS: So is this the 2014 study?

7 MS. SPRAYREGEN: I have the report and the
8 supplement here. I'm not sure what was just handed to
9 you.

10 So I think maybe give that back to me, and I
11 will hand out the actual 2014 study with supplement.

12 THE WITNESS: Yeah. This is missing the
13 supplement.

14 MS. SPRAYREGEN: Yeah. This is it. Could we
15 go off the record? I'm sorry.

16 THE VIDEOGRAPHER: The time is 3:37 p.m. We
17 are going off the record.

18 (Off the record from 3:37 to 3:39 p.m.)

19 THE VIDEOGRAPHER: The time is 3:39 p.m.
20 We're going back on the record.

21 Please proceed, Counsel.

22 (Mallon Exhibit 14 marked for
23 identification.)

24 BY MS. SPRAYREGEN:

25 Q So Exhibit Number 14, is that what we're on? Is

1 the Bove 2014a study; is that correct?

2 A That's what I'm looking at.

3 Q Excellent. And can you turn to Table 6, which
4 you've referenced a couple times in your report, it's on
5 page 10.

6 A I'm there, Counsel.

7 Q What level, according -- withdrawn.

8 What level do you believe is sufficient to
9 increase one risks of -- withdrawn.

10 The first row of numbers are about PCE; is that
11 correct?

12 A Correct.

13 Q And what level of PCE do you believe or do you
14 opine is sufficient to cause kidney cancer based on this
15 table?

16 A I notice there are no hazard ratios related to
17 these particular levels, so you can't look at this table
18 necessarily and surmise what the hazard is related to each
19 of these individual exposure levels.

20 And that's why Dr. Bove provided Table 7 to be
21 used in conjunction with Table 6.

22 So, for example, Mr. Downs had a high level of PCE
23 exposure in the thousand microgram per liter month level of
24 exposure. That would put him in the high exposure category.

25 So I looked there to inform where I should look in

1 the Table 7, to figure out what his kidney cancer risk is
2 related to his PCE level exposure.

3 In looking at the high level exposure, reading
4 down in Table 7 for PCE, reading across, I'm looking at a
5 hazard ratio of 1.59.

6 Q I understand all that, but I'm asking you not to
7 think about Mr. Downs. Okay? We will talk about Mr. Downs
8 in a little bit.

9 You have argued that there, or you just told me
10 earlier in this deposition that the Bove 2014 identifies a
11 level of exposure to TCE and PCE that is sufficient to cause
12 kidney cancer; is that correct?

13 A That's correct.

14 Q And so I'm asking you, what is the level,
15 according to this paper, that is sufficient to cause kidney
16 cancer?

17 A So based on -- based on the levels that Dr. Bove
18 identified in Table 6, there is a risk of kidney cancer that
19 corresponds to each of those levels of exposure; low, medium
20 and high, identified in Table 7.

21 Q Okay.

22 A So I would say any exposure identified, or low,
23 medium, and high exposure on Table 6, is associated with
24 kidney cancer risk.

25 Q Okay. So looking Table 6 for low exposures, the

1 levels associated with that are greater than 1 microgram per
2 liters to 155-microgram per liters, and that's for PCE.

3 Did I read that correctly?

4 A Yes, you did.

5 Q Is it your argument that anything greater than one
6 level, 1 microgram per liter month of PCE is sufficient to
7 cause kidney cancer?

8 A It is my opinion that levels higher than 1, in the
9 range between 1 and 155 micrograms per liter months, can be
10 sufficient to cause kidney cancer, that's correct.

11 Q But is it your contention that 1 microgram per
12 liter month of exposure to PCE is sufficient to cause kidney
13 cancer?

14 MR. LEE: Objection to the form of the
15 question. You can answer it again.

16 THE WITNESS: Would you repeat the question,
17 Counsel?

18 MS. SPRAYREGEN: Sure.

19 BY MS. SPRAYREGEN:

20 Q So the lowest value in the low exposure category
21 for PCE is 1.0001 microgram per liter months, or something
22 to that effect; is that correct?

23 A If you -- yeah, potentially you could go that low.

24 Q Is it your opinion that just anything over 1
25 microgram per liter month is sufficient to cause -- to cause

1 kidney cancer?

2 MR. LEE: Objection.

3 THE WITNESS: I think dealing with the real
4 world exposures that Ms. Tukes had, for example, where
5 her level of exposure is in the low exposure category,
6 it's towards the higher end of that, but I believe that
7 those exposures were sufficient to cause her kidney
8 cancer, that's correct.

9 BY MS. SPRAYREGEN:

10 Q I'm not asking about Ms. Tukes. I'm asking about
11 what is the lowest level of exposure to PCE that is
12 sufficient to cause kidney cancer?

13 A You're asking me to define a threshold and that's
14 not my area of expertise to identify thresholds.

15 My area of expertise is relating exposures that
16 Mrs. Tukes had and her likelihood of developing kidney
17 cancer.

18 Q So you think that anyone who had an exposure
19 between 1 microgram per liter months and 155 microgram per
20 liter months of PCE is at an increased risk of being
21 diagnosed with kidney cancer based on their time at Camp
22 Lejeune; is that your opinion?

23 A It's my opinion that the levels that Dr. Bove
24 found in the exposure in drinking water at Camp Lejeune were
25 sufficient to cause kidney cancer, and there are other

1 publications in the medical literature which show comparable
2 levels of exposure to what was occurring at Camp Lejeune
3 that do show people who develop kidney cancer at those
4 concentration levels. And so it's not only Dr. Bove, but
5 the other medical literature from Andrew, and others, also
6 say the same thing.

7 Q Do you have an opinion on what the lowest level of
8 concentration amount of TCE is that is sufficient to cause
9 kidney cancer?

10 MR. LEE: Objection. Asked and answered.

11 You can answer it again.

12 BY MS. SPRAYREGEN:

13 Q You can answer it again. I actually didn't ask
14 about TCS.

15 A If she can read back the -- my answer, because
16 that's the one I'm going to stick with.

17 (Madam Court Reporter read back the
18 previously answered question.)

19 BY MS. SPRAYREGEN:

20 Q So are you saying you don't have an opinion,
21 further than what you've already said?

22 A Correct.

23 Q So going to the Downs report on page 16.

24 A I'm there.

25 Q I'm sorry, I got the page wrong. Going to the

1 Tukes report -- I did get that page wrong.

2 Sorry, I did. I was in the wrong report, wrong
3 page. Please turn to page 10. I now know where I am.

4 A Same report?

5 Q Downs report, page 10. I'm back on track.

6 A I'm there.

7 Q Excellent. Paragraph A, you write: "Mr. Downs'
8 exposure to PCE was approximately 939 ug/L months during his
9 time at Tarawa Terrace;" is that right?

10 Withdrawn.

11 Did I read that correctly?

12 A You did.

13 Q And that number, 939 microgram per liter months of
14 PCE comes from Dr. Reynolds' chart; is that correct?

15 A That is correct.

16 Q And if you -- and then on page 11, in the middle
17 of the page, under "TCE Exposure and Kidney Cancer Risks;"
18 do you see that?

19 A Which section, I'm sorry.

20 Q Number 3. Section 3 on page 11.

21 A 3.

22 Q Downs report, page 11.

23 A 3A, B, C, or D?

24 Q On page 11. I only have -- oh, I was going to
25 read from -- I'm sorry. I was going to read from A.

1 You write: "Mr. Downs had TCE exposure at Tarawa
2 Terrace that ranged from 1 to 3-microgram per liter months
3 and this totaled 43 ug/L months over 19 months at Tarawa
4 Terrace. Mr. Downs also had 9 to 19 ug/L months of TCE
5 exposure at Hadnot Point, which totaled 282 ug/L months
6 cumulative exposure while at Hadnot Point for 19 months."

7 Did I read that correctly?

8 A You did.

9 Q And these numbers come from Dr. Reynolds' charts;
10 is that right?

11 A I believe so.

12 Q The first column?

13 A Yeah, I see that.

14 Q I'm doing my best not to interrupt you, and for
15 the court reporter's sake, will you please not interrupt me?
16 I understand that you know where I'm going.

17 Thank you.

18 A I'll do my best.

19 Q I feel you. I really do.

20 And on page 12, under Section 4A, you write:

21 "Mr. Downs' monthly exposure to vinyl chloride ranged from 5
22 to 8 ug/L over 19 months of exposure and the total
23 cumulative vinyl chloride exposure was 122 ug/L months."

24 Did I read that correctly?

25 A Yes.

1 Q And again, these numbers come from Dr. Reynolds'
2 chart, the first column; is that correct?

3 A Yes.

4 Q And finally on page 9 of Mr. Down's report, you
5 write: "Mr. Downs' TVOC exposures at Camp" -- strike that.

6 You write --

7 A You're on paragraph B?

8 Q Yeah, I'm on paragraph B.

9 "The total volume -- the total volatile organic
10 compounds, TVOCs levels in the drinking water at Tarawa
11 Terrace on Camp Lejeune when Mr. Downs was present ranged
12 from 31.7 micrograms per liter ug/L to 64.4 ug/L for the
13 tech flow model. Mr. Downs' total volatile organic compound
14 TVOC exposure amounted to 1104 ug/L month exposure to TVOC
15 during his 19 months at Tarawa Terrace."

16 Did I read that correctly?

17 A Yes.

18 Q And that number, 1104 ug/L-M, comes from adding
19 the TCE exposure and -- withdrawn.

20 And that number comes from adding -- yes, the TCE
21 exposure at Hadnot Point and the -- all the --

22 A Down the first column.

23 Q Down the first column.

24 A Sorry.

25 Q Yes. Is that correct? Withdrawn.

1 Adding up the TCE exposure at Hadnot Point -- let
2 me start over.

3 That number comes from adding TCE of 43 and PCE of
4 939 and VCE of 122; is that right?

5 A What was the number that we started with?

6 Q 1104.

7 A It's close. My math is telling me it's slightly
8 more than 100, but it's within the ballpark.

9 Q We can put a pin in that number and we'll do that
10 after the break.

11 So putting aside the TVOC numbers, the --
12 certainly the PCE, TCE, and vinyl chloride numbers that you
13 referenced in your report, all come from Dr. Reynolds' chart
14 of cumulative ug/L months, that first column; is that right?

15 A Yes.

16 Q And then this is where you wanted to go earlier.
17 You compare those numbers to the numbers in Dr. Bove's
18 paper, the 2014a paper; is that correct?

19 A Yes.

20 Q And you determined that Mr. Downs is in the high
21 category of exposure based on Table 6; is that correct?

22 A For the PCE level.

23 Q For the PCE, yes.

24 A You're correct.

25 Q Are you waiting -- was more coming? Or was that a

1 "yes," and that was the end of it?

2 A I believe I said you're correct.

3 Q Okay. I thought you were saying something else.

4 And your determination that Mr. Downs was in the
5 low level of exposure to TCE is based on looking at
6 Dr. Reynolds' numbers of 43-microgram per liter months at
7 Hadnot Point and 282-microgram per liter months at Tarawa
8 Terrace, and then going to the Bove Table 6, and seeing that
9 that number is somewhere between 1 and 3,100-microgram per
10 liter months; is that right?

11 A Yes.

12 Q And then -- strike that.

13 And then on -- please turn to page 10 of your
14 downs report.

15 A I'm there.

16 Q Paragraph B says: "Based on Bove, et al. 2014a,
17 Table 7, the high exposure category for cumulative PCE
18 exposure was 1.59, 95 percent confidence interval, 0.66 to
19 3.86. So Mr. Downs had a 5" -- excuse me. "A 1.59-fold
20 elevated risk of kidney cancer due to his PCE exposure."

21 After I corrected myself; did I read that
22 correctly?

23 A Yes.

24 Q Would you agree that using the conventional
25 definition of statistical significance, the hazard ratio of

1 1.59 is not statistically significant?

2 A I recall in our general causation deposition
3 discussion, we've reviewed this point before, and both from
4 the Savitz report and deposition, and the Madigan report and
5 rebuttal, we identified that the -- you can't make a
6 dichotomous decision regarding statistical significance
7 because you have to look at the full range of data within
8 the confidence interval and look at where the true risk
9 estimate is going to be based on your review of the complete
10 set of data that's within the bounds of the confidence
11 interval.

12 And as I look at the data there for Mr. Downs and
13 where it is, there is a portion of the confidence interval
14 that is below 1, but the bulk of the data going from 1 to
15 386, the bulk meaning 85 percent or more of the data points,
16 which represent the true value of where the point estimate
17 is, it's much more likely that the true value is above 1 and
18 between 1.0 and 3.6, then it would be between 1 and .66.

19 Q Would you agree that the lower boundary of the
20 confidence interval is less than 1 and the upper boundary of
21 the confidence interval is greater than 1?

22 A That's correct.

23 Q And looking at Table 7, this is where you got your
24 1.59 hazard ratio from; is that correct?

25 A That is correct.

1 Q And for the record, that 1.59 hazard ratio is for
2 high exposure of kidney cancer in -- for PCE, high exposure
3 of kidney cancer; is that correct?

4 A That is correct.

5 Q And then when you look at medium exposure of
6 kidney cancer, you see that the hazard ratio is 1.82; is
7 that correct?

8 A That is correct.

9 Q And so the hazard ratio of 1.82 for the medium
10 category is, in fact, higher than the hazard ratio for the
11 high category; is that correct?

12 A That is correct.

13 Q You would normally expect someone who had higher
14 exposure to have a higher risk than someone who had a medium
15 exposure; is that correct?

16 A Well, there can be a number of reasons why a high
17 exposure risk ratio might be lower than the medium level
18 exposure, depending on the characteristics of the people
19 that are in the high exposure group.

20 There can be any number of explanations why the
21 risk ratio would be lower in that high exposure category,
22 not the least of which would be a healthy veteran or a
23 healthy marine effect.

24 Also, there may be potentially some exposure
25 misclassification that would -- that would reduce the risk

1 ratio from the high exposure category.

2 Q Does the fact that the hazard ratio for the medium
3 category is higher than the hazard ratio for the high
4 category give you pause in claiming that Mr. Downs had a
5 1.59-fold elevated risk of kidney cancer due to his PCE
6 exposure?

7 A It does not. That 1.59 risk ratio provides
8 assurance that my medical opinion is accurate and correct,
9 that he had a markedly elevated risk of developing kidney
10 cancer based on his exposure.

11 MS. SPRAYREGEN: How long have we been on the
12 record?

13 MR. LEE: 55.

14 MS. SPRAYREGEN: Let's go off the record and
15 take a break.

16 THE VIDEOGRAPHER: The time is 4:04 p.m. We
17 are going off the record.

18 (Recess taken from 4:04 to 4:18 p.m.)

19 THE VIDEOGRAPHER: The time is 4:18 p.m.
20 We're going back on the record.

21 Please proceed, Counsel.

22 BY MS. SPRAYREGEN:

23 Q Dr. Mallon, can you please take out the Tukes
24 report and turn to page 14?

25 A Too much paperwork here. It got it. Page 14 you

1 said?

2 Q Yeah. The Bove 2014a, please.

3 Okay. You state on page 14, under Section 2, the
4 second sentence: "Ms. Tukes' exposure to PCE was 82.85 ug/L
5 per liter months which falls in the middle of the low
6 exposure category."

7 Did I read that correctly?

8 A Yes.

9 Q And the number, 82.85 ug/L per liter months comes
10 from Dr. Reynolds's chart; is that correct, the first
11 column?

12 A Yes.

13 Q And when you say "falls in the middle of the low
14 exposure category," you are referring to the Bove Table 6
15 low exposure for PCE; is that correct?

16 A Yes.

17 Q And then turn to page 16, please.

18 A Okay.

19 Q You say in paragraph A that the -- "Ms. Tukes had
20 exposure to TCE at Tarawa Terrace for 13 months. The levels
21 of TCE at Tarawa Terrace during that time were less than 1
22 microgram per liter month; is that correct? Withdrawn.

23 Did I read that correctly?

24 A You did read it correctly. Let me just
25 double-check my figures.

1 I've got -- using Kelly Reynolds records, 3
2 micrograms per liter months. So that might be a typo.

3 Kelly Reynolds' charts are right here in the full
4 report, so I should have double-checked that. Page 11,
5 3.65.

6 Q That is the cumulative exposure from both Hadnot
7 Point and Tarawa Terrace; is that correct?

8 A That's correct. 3.65.

9 Q And am I correct to say that all of that comes
10 from Tarawa Terrace? If you look at page 9 to 10 of your
11 report, you have the mean monthly exposures at Tarawa
12 Terrace only, and if you look at the TCE column, they all
13 sum to 3.65?

14 A That's correct.

15 Q And you did not compare Ms. Tukes' exposures to
16 the charts in Bove 2014a; is that correct?

17 I can make that more specific.

18 You did not compare Ms. Tukes' TCE exposure to the
19 charts in Bove 2014a; is that correct?

20 A Well, I'm looking right here at the comparison,
21 Counsel.

22 Q That would place her in the low category for TCE;
23 is that correct?

24 A That's correct. I think for Ms. Tukes, if I may
25 add a little supplemental.

1 For Ms. Tukes, her greatest risk was related to
2 her benzene exposure, where she had 16 micrograms per liter
3 months, which puts her in the middle exposure category.

4 Q And all of that was from Hadnot Point; is that
5 correct?

6 A Yes.

7 Q And so -- you would put Ms. Tukes in the medium
8 category for benzene, the low category for vinyl chloride?

9 A All the others.

10 Q The low category for TCE and the low category for
11 PCE; is that correct?

12 A Yes.

13 Q And we're discussing the cumulative exposure in
14 the first column of the chart, the Reynolds' chart; is that
15 correct?

16 A Yes.

17 Q And as we discussed, this is the -- adding up the
18 mean monthly concentrations for -- is that -- withdrawn.

19 As we discussed, these numbers are the
20 cumulative -- withdrawn.

21 Strike that.

22 You used the sum of the mean monthly
23 concentrations expressed in ug/L months for each chemical;
24 is that right?

25 A Yes.

1 Q These cumulative exposure numbers do not take into
2 account any time that Mr. Downs, if we're looking at him for
3 his TCE exposure, was not at Hadnot Point; would that be
4 right?

5 A Let me jump back to that report. It's whatever
6 Dr. Reynolds said in her reply.

7 Q So my understanding is that Dr. Reynolds' Charts 1
8 through 4 take into account, or attempt to take into
9 account, time spent away from each area of the base; is that
10 also your understanding?

11 A Yes.

12 Q But her calculation of the total microgram per
13 liter months does not take into account time spent away from
14 the area of the base if the person was on that area for --
15 withdrawn.

16 Did not take into account -- I'll take that back.

17 But her calculations of cumulative exposure, based
18 on microgram per liter months, do not take into account time
19 spent away from the base; is that also your understanding?

20 A What you said is correct. Recognizing that
21 Mr. Downs, in his testimony, said even though he was on
22 leave, he never left Camp Lejeune. He took leave at his
23 home address, and so there would be no reason for Ms., you
24 know, for Dr. Reynolds to make any adjustment in his
25 exposure assessment because he was present at Camp Lejeune

1 the entire time.

2 Q I understand. But he was present at Hadnot Point
3 for that period of time and not at -- I'm sorry --
4 withdrawn.

5 But he was present at -- I'll start again. It's
6 getting late for all of us.

7 During the time that he was on leave, Mr. Down has
8 testified that he was at Tarawa Terrace, but that he wasn't
9 at Hadnot Point; is that correct?

10 MR. LEE: Objection to form. You may answer.

11 THE WITNESS: Well, so Hadnot Point has not
12 only a work location, but there are other facilities
13 located on Hadnot Point where Mr. Downs had to go from
14 time to time.

15 I believe, if I'm not mistaken, the
16 recreational facilities was there. The base hospital
17 was there.

18 And so regardless of the fact he wasn't
19 working there, the base recreation was there, you know,
20 and other things; the movie theater, the PX and
21 commissary. So there were times that he was going
22 there even though he was not working there.

23 BY MS. SPRAYREGEN:

24 Q Understood. But in Charts 1 through 4,
25 Dr. Reynolds does not include any exposure for the time that

1 Mr. Downs was on leave and at Tarawa Terrace or Hadnot
2 Point; is that correct?

3 A We could go to her supplemental tables and look to
4 see if she adjusted for that, you know, the fact is that we
5 might not have been at work for eight hours, but there were
6 so many other things at Hadnot Point that she didn't need to
7 make a correction because he was there doing other things.

8 Q So I can show you in the supplemental charts that
9 she has a zero for the weeks that he was at -- zero under
10 the Hadnot Point column for the weeks he was on leave, and a
11 1 for the Tarawa Terrace column for the weeks that he was on
12 leave.

13 So does that sound right to you?

14 A Yes. So she did some adjustment for that.

15 Q So, right. But my point is: She adjusted for
16 that in the Charts 1 through 4, but not in the summation of
17 the mean monthly concentrations of the months that Mr. Downs
18 was on base; is that right?

19 A I think that's -- I think what you said is
20 correct. But I think what she did was incorrect.

21 I think she -- she adjusted for exposure in her
22 mind she didn't perceive was occurring. When in actuality
23 it didn't require adjustment, so she overcorrected and was
24 more conservative than she needed to be in terms of the
25 exposure assessment.

1 Q I'm not asking you to evaluate what was right or
2 wrong about what Dr. Reynolds did. I'm just asking you to
3 say if you agree with me that she took account of where
4 Mr. Downs was on base in Charts 1 through 4, but not in her
5 summation of the mean monthly concentrations?

6 MR. LEE: Object to the form of the question
7 and the commentary. You can answer, if you understand.

8 THE WITNESS: I don't understand what you
9 said.

10 MR. LEE: I object to the form of the
11 question and her commentary, but I said you can answer
12 her question if you understand it.

13 THE WITNESS: So could you repeat the
14 question, Counselor? I want to be accurate in my
15 answer.

16 BY MS. SPRAYREGEN:

17 Q My understanding is, Dr. Reynolds, when
18 calculating cumulative consumption in Charts 1 through 4,
19 took it from the fact that Mr. Downs or assumed, I should
20 say, that Mr. Downs was not at Hadnot Point during the weeks
21 that he was on leave; is that correct?

22 A Yes.

23 Q But when she was adding up the mean monthly
24 concentrations for all the time that Mr. Downs was on base,
25 she did not make any adjustments for his time away from

1 Hadnot Point; is that correct?

2 A Yes. And the reason she didn't make any
3 corrections is was he was there on base. So there was no
4 need for a correction.

5 Q And Dr. Reynolds also did not take into account in
6 the summation of the mean monthly concentrations that
7 Mr. Downs was only on base for 14 days for the month of
8 February 20 -- 1960; is that correct?

9 A That sounds correct, yes. Well, you know, I'm
10 remembering those tables. And I know she identified that he
11 was only there for half the time -- half the month, but I'm
12 not remembering the exact details of that cumulative
13 exposure month whether she adjusted that figure or not, I
14 don't recall.

15 Q So my understanding is she took account and
16 adjusted for it in Charts 1 through 4, but not in the
17 summation of the months, the cumulative, the mean monthly
18 concentrations for the months that he was on base; does that
19 sound right to you?

20 A I think that's reasonable. Recognizing that --
21 except for that first period of time where he just wasn't
22 there. He wasn't there on base. He didn't show up until
23 midway through the month. The rest of it would be accurate.

24 Q Do you know whether Dr. Reynolds used the same
25 methodology as Dr. Bove to calculate ug/L months for Marines

1 at Camp Lejeune?

2 A I believe there's a similar methodology because he
3 relied on Morris, and so his exposure modeling, ATSDR
4 modeling, so a similar kind of reconciling of exposure
5 concentration for a period of time to come up with the
6 exposure levels he did.

7 Q I'm going to repeat my question.

8 Do you know whether Dr. Reynolds used the same
9 methodology as Dr. Bove to calculate ug/L months for Marines
10 at Camp Lejeune?

11 A Conjecture on my part, but I believe they used the
12 same methodology, yes.

13 Q You believe they do?

14 A Yes.

15 Q All right. Can you go to 2014a on page 3, please?

16 A What number?

17 MR. LEE: Exhibit 14. Exhibit Number 14.

18 THE WITNESS: So that's Bove?

19 MS. SPRAYREGEN: Yeah. Turn to Bove 2014a.

20 THE WITNESS: Okay. And what page?

21 MS. SPRAYREGEN: Page 3.

22 THE WITNESS: Page 3. You're pushing me.

23 Late in the afternoon. I've been relying on my
24 separate chart.

25 Yeah, I got it. Page 3?

1 MR. SPRAYREGEN: Yeah, page 3.

2 So on page 3, the second column, the first
3 full paragraph, let me know when you're there.

4 THE WITNESS: Second column --

5 MS. SPRAYREGEN: Second column.

6 THE WITNESS: First full paragraph.

7 BY MS. SPRAYREGEN:

8 Q First full paragraph. Second sentence: "Each
9 individual was assigned estimated monthly average
10 contaminant concentrations in the drinking water system
11 serving the individual's residence during the period of
12 residence."

13 Does that -- did I read that correctly?

14 A Yes.

15 Q So it looks like Dr. Bove looked only at the
16 residences. Is that -- is that your understanding from that
17 paragraph?

18 A As I read this paragraph sentence -- in that
19 sentence, yes.

20 Q And can you turn to page 4? And the very last
21 word on page 4, continuing onto page 5 is: "Estimated
22 monthly average contaminant concentrations in the water
23 system serving the individual's residence and occupancy
24 dates were used to calculate cumulative exposure, quote:
25 UGL months to each contaminant and the total amount of these

1 contaminants, quote: TVOC.

2 Did I read that correctly?

3 A Yes.

4 Q So based on what I've read, does it look like Dr.
5 Bove looked only at the residences to determine the
6 cumulative exposure?

7 A Yes. So his estimates are more conservative than
8 Dr. Reynolds.

9 Q So I want to go -- I'm going back to the reports,
10 and I want to turn to the Tukes report on page 10.

11 A Okay. I'm there.

12 Q Paragraph 2 says: "The current US EPA maximum
13 contamination levels, MCLs for TCE, PCE, and benzene, are 5
14 ppb established in 1989 for TCE and benzene, and in 1982" --
15 withdrawn, strike that.

16 "And in 1992 for PCE, the MCL for vinyl chloride
17 is 2 ppb."

18 After I corrected myself; did I read that
19 correctly?

20 A Yes.

21 Q So are you aware that the EPA uses maximum
22 contaminant levels, MCLs, to set regulatory limits for
23 contaminants in public drinking water supplies?

24 A Yes.

25 Q Are you aware of how the EPA establishes MCLs?

1 A I have a general sense of how they do it.

2 Q Are you aware that MCLs represent concentrations
3 in drinking water considered safe to consume daily over a
4 70-year lifetime?

5 A That sounds correct.

6 Q Are you aware that MCLs are set using health
7 protective assumptions to ensure safety for even the most
8 vulnerable populations?

9 A Yes. They do include protection factors.

10 Q Were you aware that the EPA uses cumulative dose
11 averaged over a lifetime to evaluate cancer risk?

12 A Yes.

13 Q So an exposure to drinking water to a
14 concentration in excess of the MCL for a period of time
15 shorter than 70 years does not necessarily constitute a
16 health risk, right?

17 MR. LEE: Objection to form.

18 THE WITNESS: So there's a lot of variables
19 that go into that estimation and they have set a -- an
20 acceptable level of cancer risk for the population.

21 And as some of your experts have pointed out,
22 using population risk assessments are inappropriate for
23 using individual specific causation assessments.

24 So I can't comment on how the EPA levels
25 correlate to Mr. Downs' and Mrs. Tukes' exposure risk

1 because it would be considered inappropriate.

2 BY MS. SPRAYREGEN:

3 Q Would you agree that for Mrs. Tukes the
4 concentrations of TCE, vinyl chloride, and benzene, reported
5 in Dr. Reynolds' report for Mrs. Tukes were below the MCLs
6 for every single month?

7 A I wouldn't agree with that. I would say they
8 exceeded the MCLs almost every month for the time that she
9 was there.

10 Q Can we turn to page 9 of your report?

11 And the chart that goes from page 9 to page 10 of
12 your report is from Dr. Reynolds; is that correct?

13 A Yes.

14 Q And it contains for every -- withdrawn.

15 The first column for TCE is her exposure to TCE
16 while at Tarawa Terrace for each month; is that correct?

17 A Yes.

18 Q And every number in the TCE column is below 5; is
19 that correct?

20 MR. LEE: Objection to form.

21 THE WITNESS: It is. And Dr. Reynolds did a
22 calculation and determined that her average mark and
23 gram per liter month was 3.6.

24 So just below the MCL level for TCE, but
25 clearly above the MCL for benzene.

1 BY MS. SPRAYREGEN:

2 Q Would you agree that actually the 3.65 is the sum
3 of the mean monthly concentrations?

4 A I think you're right about that.

5 Q And that for each individual month, the
6 concentration was below the MCL?

7 A Yes, for TCE.

8 Q For TCE. And --

9 A Not the case for PCE.

10 Q But also the case for vinyl chloride. Every
11 single month the mean monthly concentration was below the
12 MCL for vinyl chloride; is that correct?

13 A Look at the full table.

14 Q The MCL for vinyl chloride, as we've discussed, is
15 2; is that correct?

16 A Correct. So half of the MCL for vinyl chloride.
17 And in every month exceeded the MCL by 50 percent for PCE --
18 well, depending on which model you use, if you use the tech
19 flow, it's right at the MCL, but if you're looking at the
20 MTD3, it's two to three times the MCL.

21 Q Looking at vinyl chloride, though, would you agree
22 that every single month the mean monthly exposure was below
23 the MCL?

24 A At the level of 1, the MCL being 2, yes.

25 Q And you only have this chart for Tarawa Terrace in

1 your report, but all of Ms. Tukes' benzene exposure is from
2 Hadnot Point; is that right?

3 A That's a good question. It could be.

4 I don't have the breakdown in front of me. If I
5 look at Kelly Reynolds.

6 Q If you go to the Reynolds report, which is Exhibit
7 Number 13.

8 A So for -- I was looking at Downs.

9 Counselor, if you could ask the question, we might
10 save some time.

11 Q I just need to find my piece of paper. If I can
12 figure it out. If I can see it.

13 A You were asking me about benzene exposure.

14 Q All of Ms. Tukes' benzene exposure is from Hadnot
15 Point; is that correct?

16 A I think so.

17 Q And would you agree that for every single month
18 her exposure was less than 5 ppb?

19 A May I look at the chart that you're looking at?

20 Q Actually, I don't have it in front of me, and I
21 can't find it.

22 A I think she was at Camp Lejeune for how many
23 months?

24 Q She was at Hadnot Point, according to the Reynolds
25 chart, for, I believe one month?

1 MR. LEE: Objection. Form.

2 MS. SPRAYREGEN: We can move on.

3 THE WITNESS: So if her cumulative exposure
4 was 60 micrograms per liter month and she was there for
5 one month, she would obviously have exceeded that 5
6 microgram per liter concentration.

7 MS. SPRAYREGEN: We can move on.

8 I believe it's the part that got cut off,
9 that's what the problem is.

10 I will possibly come back to that.

11 BY MS. SPRAYREGEN:

12 Q But Ms. Tukes, you found, was in the low --
13 withdrawn, I'll take that back.

14 Looking at page -- so on page 16 of the Tukes
15 report, if you would please go there?

16 A Page 16.

17 Q Mm-hmm. You write, under TCE Exposure and Kidney
18 Cancer: "Ms. Tukes exposure to TCE, although minimal, would
19 have contributed additively or synergistically to her risk
20 of kidney cancer."

21 Did I read that correctly?

22 A Yes.

23 Q So is it your opinion that if Mrs. Tukes had been
24 exposed to TCE but none of the other chemicals at Camp
25 Lejeune -- withdrawn.

1 If Mrs. Tukes had been exposed to TCE, but none of
2 the other chemicals at Camp Lejeune, would that have been
3 sufficient to cause her kidney cancer?

4 A Yes.

5 Q If Mrs. Tukes had been exposed to all the other
6 chemicals; PCE, benzene, and vinyl chloride, but not TCE,
7 would that still -- would it still be your opinion that
8 Mrs. Tukes' kidney cancer was caused by her exposure?

9 A I'll give some consideration to your question,
10 Counselor. Could you repeat your question?

11 Q If Mrs. Tukes had been exposed to all the over
12 chemicals; PCE, benzene, and vinyl chloride, but not TCE,
13 would it still be your opinion that Mrs. Tukes' kidney
14 cancer was caused by her exposure?

15 A To what?

16 Q PCE, benzene, and vinyl chloride, but not TCE?

17 A Yes.

18 Q And the same for vinyl chloride. It's your
19 opinion that her exposure was sufficient to cause her kidney
20 cancer; is that correct?

21 A Yes. Each of these are known carcinogens and they
22 have a carcinogenic effect that triggers a carcinogenic
23 pathway, and once that gets started, all these other
24 chemicals are additive in nature and so it's a combination,
25 the additive effect.

1 So while one may not be as high as the other, it's
2 the combination that added together, so total VOCs, for
3 example, had been found to increase risk, and Bove, in his
4 article, talks about that, the TVOC risk estimate is as
5 high, if not higher, than some of the individual ones in
6 terms of risk.

7 Not only that, it was a dose-response curve that
8 was positive. So individually there's risk, but when it's
9 all combined together, there's that much greater risk and
10 Bove's data support that.

11 Q Is it your opinion that Mrs. Tukes' exposure to
12 vinyl chloride was sufficient to cause her kidney cancer?

13 A Yes.

14 Q And is it your opinion that Mrs. Tukes' exposure
15 to benzene was sufficient to cause her kidney cancer?

16 A Yes. Particularly given her medium exposure risk.
17 If I go back to what I just said about the additive effect,
18 we can't take one exposure out of the -- out of the mix
19 because she was exposed to all four of the chemicals.

20 Q I was asking hypotheticals.

21 MR. LEE: Objection to form.

22 BY MS. SPRAYREGEN:

23 Q If Mrs. Tukes had only been exposed to vinyl
24 chloride, would it be your opinion that that was sufficient
25 to cause her kidney cancer?

1 MR. LEE: Objection to the form of the
2 question.

3 THE WITNESS: You know, we've had this
4 conversation earlier today. I think that the reality
5 is: I can't take her out of that context. And the
6 context is: She was exposed to all four, so I can't --
7 you're asking me to project an opinion on something
8 that is not reality, and so what I can speak to is what
9 she was exposed to and what her risk is, and that's all
10 I'm going to say.

11 BY MS. SPRAYREGEN:

12 Q I was asking you because -- withdrawn.

13 Would you consider what Dr. Reynolds did to be a
14 risk assessment?

15 MR. LEE: Objection to the form of the
16 question.

17 THE WITNESS: I think Dr. Reynolds provided
18 me and the plaintiffs with information that was
19 necessary to do a determination of her cancer risk
20 based on her exposures.

21 I don't choose or don't want to characterize
22 what she did as a risk assessment because I'm not an
23 expert in that area, and so I can tell you that the
24 information she provided was useful for me, for me to
25 do my job, and say that she was exposed to carcinogens.

1 Those carcinogens markedly increased her risk for
2 developing kidney cancer, and I opined that those
3 exposure"s caused her kidney cancer.

4 BY MS. SPRAYREGEN:

5 Q Do you know what "excess lifetime cancer risk" is?

6 A I've heard the phrase before. Yes.

7 Q What is it? Withdrawn.

8 Is excess lifetime cancer risk the additional risk
9 of getting cancer over a lifetime as a result of exposure to
10 a specific carcinogenic chemical or radiation above the
11 normal background risk?

12 A I think that's a fair characterization of excess
13 risk.

14 Q Did Dr. Reynolds calculate Mr. Downs' or
15 Mrs. Tukes' excess lifetime cancer risk?

16 MR. LEE: Objection.

17 THE WITNESS: Not that I recall in her
18 report.

19 MS. SPRAYREGEN: I'm introducing Exhibit
20 Number 15. 15.

21 (Mallon Exhibit 15 marked for
22 identification.)

23 BY MS. SPRAYREGEN:

24 Q Have you seen Exhibit Number 15 before?

25 A Yes.

1 Q Is it the Notice of Deposition and subpoena and
2 request for documents for this deposition?

3 A Yes, it is.

4 Q Have you reviewed the request for production of
5 documents?

6 A Yes.

7 Q What searches did you perform to locate responsive
8 documents?

9 A I did a very thorough search for all the documents
10 requested.

11 Q What did you do?

12 A And did not find any.

13 Q What did you do for that thorough search?

14 A I looked at all the records that I had. Well, for
15 one thing, I knew that her paragraph one, I had no contact
16 with any of those individuals, and it was only after I had
17 written my report that I saw any reports or depositions for
18 many of the people listed.

19 Well, you know, Dr. Allen, I think I had access to
20 his report. That I reference in my report. I'd have to
21 look.

22 I don't know who Wise is. I don't know who Lotan
23 is. I don't know who Fay, Sautner, Suarez, Martel, I don't
24 know any of those people. And had no opportunity to speak
25 to any of those people.

1 The same with paragraph O through Y. No family
2 member contact. So, no contact whatsoever, Counsel.

3 (Mallon Exhibit 16 marked for
4 identification.)

5 BY MS. SPRAYREGEN:

6 Q Have you seen Exhibit Number 16 before?

7 A Yes, I believe I have.

8 Q And can you turn to page 9, please?

9 A Page 9. Okay. I'm there.

10 Q The first phrase of Request Number 6 is: "A copy
11 of all lectures, presentations, or talks, that you have
12 presented relating to these Camp Lejeune water contamination
13 cases."

14 Did I read that correctly?

15 A Yes.

16 Q And in the response, the last sentence says you
17 believe you do not possess any documents responsive to this
18 request; is that -- is that true?

19 A Yes.

20 Q And you -- I mangled that question.

21 Is it -- forget whether or not I read it
22 correctly.

23 Is it true you don't have any documents responsive
24 to the request?

25 A Correct.

1 Q And Request 8 is: "A current copy of all medical
2 questionnaires and/or intake forms you utilize in your
3 medical practice with your kidney cancer patients to provide
4 to your" -- withdraw.

5 Request Number 8 is: "A current copy of any and
6 all medical questionnaires and/or intake forms you utilize
7 in your medical practice with your kidney cancer patients,
8 or provide to your kidney cancer patients in your medical
9 practice for their completion."

10 Did I read that correctly?

11 A Yes.

12 Q And is it accurate that you do not use medical
13 questionnaires in your practice?

14 A I do not maintain a questionnaire that I give to
15 the individuals whose cases I review. The VA has medical
16 questionnaires that they provide to examiners who are
17 reviewing the claims of veterans, but I don't personally
18 administer those. Those are usually done by other providers
19 and that information is included in the medical records from
20 the VA, but I don't generate the form. I only have the
21 opportunity to review the form that's generated by the VA.

22 (Mallon Exhibit 17 marked for
23 identification.)

24 BY MS. SPRAYREGEN:

25 Q So Exhibit Number 17 is what you produced in

1 response to the request for documents and subpoena; is that
2 correct?

3 A This does look like that, yes.

4 Q And I will note for the record that for once the
5 highlighting is not made by me but was -- came to us with
6 the highlighting.

7 A I believe the highlighting was done by the Bell
8 Legal Group.

9 Q That was one of my questions.

10 So can you please turn to -- oh, of course the
11 Bates numbers are off. I was going to say page number
12 with -- ending in 0012.

13 You might not be able to figure that out, so --

14 A Does it say February 5, 2025 at the top of the
15 page? That's what my page says. At the bottom it says
16 0012.

17 The top of the page it says 5 February for kidney
18 invoice.

19 Q One second. There's a problem, but there are
20 Bates numbers on this one.

21 Please turn to page number -- ending in 0017.

22 A 0017?

23 Q Yeah. In the middle of the page it says: "After
24 the general causation report was completed, an additional
25 six articles were located that required review and

1 incorporated into the general causation report. Six hours
2 total."

3 Did I read that correctly?

4 A Yes.

5 Q Who located the articles?

6 A I did.

7 Q Can you please turn back to the page ending in
8 0012?

9 A I'm there.

10 Q Okay. So the last entry on that page, it says:
11 "Number 2. Report writing and multiple revisions to
12 specific causation reports for Tukes was 10 hours."

13 A That's correct.

14 Q And then the next line is: "Reviewed new exposure
15 charts from Cathy Reynolds. Incorporated tech flow and
16 MT3DMS model exposure estimates for two PCE in two reports.
17 Three hours."

18 Did I read that correctly?

19 A Yes.

20 Q How did you incorporate the tech flow and MT3DMS
21 models into your exposure estimates into your reports?

22 A The first step was to read a report and to
23 understand the attachments, which were micro, so blowing
24 them up so I could read them and make sense of them and
25 recognize and understand what it was he was trying to say

1 and what tech flow meant and what MTSD3 meant in terms of
2 the water modeling.

3 Once I was able to make sense of that and
4 understand what the report was saying in terms of her
5 exposure, then I could integrate that information into my
6 final Tukes and my final Downs report.

7 Q What reports -- withdrawn.

8 Is the only reports that you reviewed in that
9 entry those from Dr. Reynolds, or did you actually review
10 reports and values from models -- withdrawn.

11 Is the only charts and reports that you reviewed
12 in that entry from Dr. Reynolds?

13 A Well, in fairness, I have to go back to Morris
14 Maslia and figure out what the heck those two modeling
15 reports are, so that took a fair amount of time to
16 understand what Dr. Maslia did in understanding those two
17 models.

18 I mean, he wrote extensively. He published
19 extensively on the modeling that he did.

20 There were several documents that I had to review
21 to get comfortable with his modeling effort, what I thought
22 it was appropriate, and so I had to do the background
23 reading and understand the basis for what he was saying and
24 why he was saying it.

25 And so I had a better context then for

1 understanding what Dr. Reynolds was saying and understanding
2 the difference between what was reported, particularly for
3 the tech flow, and the MTSD3 modeling for PCE.

4 Not the easiest of reports to review and
5 comprehend.

6 Q So you have been looking at notes throughout the
7 deposition today; is that correct?

8 A I'm sorry?

9 Q You have been looking at notes throughout the
10 deposition today; is that correct?

11 A I do have a couple of notes, yes.

12 Q Other than these notes, did you bring anything
13 with you to the deposition?

14 A Just what's here.

15 Q Can I get a copy of those? I'll take those at the
16 next break.

17 A Okay.

18 Q And do you have any support staff or graduate
19 students who assist you with your work on this -- who
20 assisted you with your work on this case?

21 A You know, I'm interested in hiring some people, so
22 if you have some recommendations, I would be happy to take
23 them. I don't currently have any, but I may be expanding my
24 business.

25 Q So no one assisted you with your reports on this

1 case?

2 A That's correct.

3 Q What did -- what did you do to prepare for today's
4 deposition?

5 A I had the opportunity to talk to --

6 MR. LEE: I'm going to object and just to be
7 clear. She's not asking you about any conversation you
8 had with Jim or myself, or any of the other attorneys.
9 Obviously, you can respond to her questions generally.
10 But not related to the content of our discussions.

11 THE WITNESS: I understood.

12 MR. LEE: I knew you knew that, I want to
13 make sure I was clear, because it's late in the day.

14 THE WITNESS: So we had a couple of Zoom
15 calls that might have lasted an hour. Prior to our
16 meeting yesterday, we spent some time yesterday just
17 helping me understand the rules of engagement.

18 BY MS. SPRAYREGEN:

19 Q I don't want to know what you talked about.

20 A I know.

21 Q You said had you a couple of Zoom calls and met in
22 person yesterday; is that correct?

23 A Yes.

24 Q And were you saying that each of those Zoom calls
25 was an hour, about an hour?

1 A I think that's accurate.

2 Q And how long was yesterday's meeting?

3 A We went from 10:00 until 2:00.

4 Q Did you review any documents with counsel during
5 these meetings?

6 A No.

7 Q Did you take any notes during any of these
8 meetings, other than the ones you brought to us today?

9 A No.

10 MS. SPRAYREGEN: All right. I think we've
11 been going for an hour. I'd like to take a break.

12 THE VIDEOGRAPHER: The time is 5:13 p.m. We
13 are going off the record.

14 (Recess taken from 5:13 to 5:28 p.m.)

15 THE VIDEOGRAPHER: The time is 5:28 p.m., and
16 we are going back on the record.

17 Please proceed, Counsel.

18 (Mallon Exhibit 18 marked for
19 identification.)

20 BY MS. SPRAYREGEN:

21 Q I'm going to show you what we're going to -- what
22 we're marking as Exhibit 18, which is Dr. Bove's 2024 Cancer
23 Incidence Study.

24 You're familiar with this document?

25 A Yes.

1 Q Would you agree that Mr. Downs, as we discussed
2 earlier, has clear cell renal carcinoma?

3 A I'm sorry, I didn't hear your question, Counselor.

4 Q Is that a joke?

5 A No.

6 Q I can't tell.

7 A No, I wish.

8 Q I wasn't sure if you were kidding.

9 We discussed earlier today that Mr. Downs has
10 clear cell renal carcinoma; is that correct?

11 A Yes.

12 Q So can you please turn to Table 3 in Exhibit 18?
13 And for the record, the highlights are mine.

14 A You said 3, are you talking Table 4?

15 Q No, Table 3.

16 A This one?

17 Q I would give you the page number, but there aren't
18 really any.

19 A Okay. I'm there.

20 Q So Table 3 in Exhibit 18 says: "Comparison of
21 Cancer Outcomes at Camp Lejeune versus Camp Pendleton.
22 Among Marines, Navy personnel subgroup who began active duty
23 and were stationed at either base between 1975 and 1985. N
24 equals 318,305."

25 Did I read that correctly?

1 Should we shut the door?

2 A Yes, I think that will help. That's better.

3 So of the highlighted lines, which one are you
4 referring to?

5 Q I wasn't referring to either. I just read the
6 title of the table. So I'll do it again.

7 Table 3 says: "Comparison of Cancer Outcomes at
8 Camp Lejeune versus Camp Pendleton among the Marine, Navy
9 personnel subgroup, who began active duty and were stationed
10 at either base between 1975 and 1985. N equals 318,305."

11 Did I read that correctly?

12 A Yes.

13 Q And if you're looking at the second to last
14 column, it's looking at the adjusted HR, comparing those at
15 Camp Lejeune to Camp Pendleton; is that correct?

16 A That is correct.

17 Q And for renal cell -- sorry.

18 For renal cell and clear cell carcinoma, that
19 would be the pink line. The adjusted HR is 1.03 with
20 confidence intervals of .91 and 1.16; is that correct?

21 A That's what it says, yes.

22 Q And for renal cell carcinoma NOS, the adjusted HR
23 is 1.12, with a confidence interval of .94 and 1.34; is that
24 correct?

25 A For the adjusted, yes.

1 Q Yes. And for clear cell only, the adjusted HR is
2 .97 with confidence intervals, 0.82 to 1.14.

3 Did I read that correctly?

4 A Yes.

5 Q And your report for Mr. Downs cites only the
6 adjusted HR for renal cell carcinoma NOS; is that right?

7 A Yes, that's correct.

8 Q And if you look at -- and that is the highest of
9 the three adjusted HRs that I read to you; is that correct?

10 MR. LEE: Objection to form. You can answer.

11 THE WITNESS: That's correct. Although the
12 papillary is, in fact, the highest at 1.18.

13 BY MS. SPRAYREGEN:

14 Q But Mr. Downs did not have papillary --

15 A To the best of our knowledge.

16 Q -- renal cancer; is that correct?

17 A Yes.

18 Q And if you turn to Table 5, please, the title for
19 Table 5 is: "Cancer Outcomes by Duration stationed at Camp
20 Lejeune compared with Camp Pendleton between 1975 and 1985.
21 Marines, Navy personnel subgroup. N equals 318,305."

22 Did I read that correctly?

23 A Yes.

24 Q And would you agree that Dr. Bove is showing this
25 table to look at whether there is a dose-response

1 relationship?

2 A I believe that's the intent, yes.

3 Q And would you agree that for renal -- for kidney
4 and renal pelvis, that is the yellow line, there is no
5 monotonic dose-response relationship?

6 A There's definitely what appears to be a linear
7 relationship, although it seems to be reverse.

8 Q I should have -- thank you.

9 There's no increasing monotonic dose-response
10 relationship; is that correct?

11 A That's correct.

12 Q And for RCC and clear cell, there is no monotonic
13 relationship, dose-response relationship; is that correct?

14 A Correct.

15 Q And for RCC NOS, there's also no increasing
16 monotonic dose-response relationship; is that correct?

17 A I would say two points can make a line. So it
18 does increase from the low duration to the medium duration,
19 going from 1.12 to 1.16.

20 Q But the high duration is 1.03; is that right?

21 A It does sag at the end, yes.

22 Q So that would mean that there is no increasing
23 monotonic dose-response relationship?

24 A You know, we got into this a little bit at the
25 last deposition, and, you know, if we did a P test for

1 trend, we might find that there's a relationship. That's
2 hard to say definitively that that doesn't exist in this
3 case without seeing a test for trend.

4 Q Again, though, you would agree that Mr. Downs had
5 clear cell renal cell carcinoma; is that correct?

6 A Can we take a look at the pathology report,
7 Counselor?

8 Q We can look at your report, page 6, which says
9 that he had clear cell renal carcinoma. Should we do that?

10 A Yeah, let's take a look.

11 Q So in -- on page 6 of the Downs report, in
12 paragraph number 4, it says: "Dustin v. Shackleton, M.D.,
13 wrote a surgical pathology report dated 7/29/2016, and
14 indicated that Mr. Downs' right kidney mass after
15 nephrectomy was noted to be a clear cell renal cell
16 carcinoma that was 4 centimeters in size with extensive
17 fibrosis, patchy hemorrhage, inflammation, and focal
18 necrosis."

19 So according to page 6 of your report, which
20 looked at Dr. Shackleton's records, Mr. Downs had clear cell
21 renal cell carcinoma; is that right?

22 A That's correct.

23 Q And when discussing Mr. Down -- withdrawn.

24 And when discussing the Bove report in your
25 report, you do not note that -- withdrawn.

1 And would you agree that in your report, you only
2 discuss RCC NOS, or the numbers for RCC NOS in this 2024
3 study?

4 A Sorry. Yes.

5 Q And would you agree in your -- that when looking
6 at the low exposure category, which you focus on in your --
7 withdrawn.

8 In your report, do you discuss the low exposure
9 category from this table?

10 A Which page of the report were you referring to,
11 Counselor?

12 Q Page 11. The last sentence of paragraph F on
13 page 11 of the report says: "For personnel with low
14 exposure levels, the risk ratio for RCC NOS was 1.12.
15 Confidence interval, .91 to 1.38."

16 Did I read that correctly?

17 A The last sentence there?

18 Q The last sentence in paragraph F.

19 A Yeah, that's correct.

20 Q And you're looking at the number for RCC NOS for
21 low duration in Table 5 of the Bove 2024 Cancer Incidence
22 Study; is that correct?

23 A Yes.

24 Q And that number of 1.12 for RCC NOS is the -- and
25 its confidence interval, is the only number that you refer

1 to from Table 5 in this report; is that correct?

2 A That's correct.

3 MS. SPRAYREGEN: I'm going to look at -- I'm
4 going to introduce the next exhibit, Exhibit Number 19.

5 (Mallon Exhibit 19 marked for
6 identification.)

7 BY MS. SPRAYREGEN:

8 Q So Exhibit Number 19 is a study by Aschengrau, et
9 al., entitled: "Cancer Risk and Tetrachloroethylene-
10 contaminated Drinking Water in Massachusetts;" is that
11 correct?

12 A Yes.

13 Q And the date on this study -- this study was
14 published in the September/October 1993 -- withdrawn.
15 Strike that.

16 This study was published in September -- in the
17 September/October issue that came out in 1993; is that
18 correct?

19 A Yes.

20 Q Can you turn to your Downs report on page 10?

21 A Okay. I'm there.

22 Q Is this the study that you're referencing in
23 paragraph C?

24 A Yes.

25 Q For the record, if you go to footnote 13. I

1 believe it says that the study was published in 2010; is
2 that an error?

3 A In terms of my reference?

4 Q Yeah, reference. If not the materials considered,
5 but the footnote number 13, which is page 22 of the report.

6 So that does make things a little easier.

7 A Page 22, Number 19.

8 Q And Number 13 is Aschengrau study.

9 A Right.

10 Q And it says it was published in 2010; is that a
11 typo?

12 A Yeah, it must be. Because I know it was '93.

13 Q And you write in the first sentence of paragraph C
14 that the study, and I quote: Noted an elevated kidney
15 cancer risk with PCE in the range of 27 to 44 mg of PCE in
16 the drinking water at Cape Cod.

17 Did I read that correctly?

18 A Yes.

19 Q And then the very last sentence of that same
20 paragraph is: "It should also be noted that the 27 to 44 mg
21 numbers listed by Aschengrau were up to the 90 percentile."

22 Did I read that correctly?

23 A That's correct.

24 Q And if you turn to page 289 in Exhibit Number 19.

25 Thank you.

1 A 289?

2 Q Page 289 is the page with the tail at the bottom.
3 I see you there.

4 A Mm-hmm.

5 Q The first full paragraph has some highlighting in
6 the last sentence of that paragraph.

7 Do you see that?

8 A Yes.

9 Q So the last sentence in that paragraph is, quote:
10 Relative delivered dose, RDD, estimates obtained from the
11 Webler-Brown model ranged from .01 to 90.6 mg with latency
12 and from .01 to 209 mg without latency. The 90th percentile
13 among exposed controls were 27.1 and 44.1 mg respectively."

14 Did I read that correctly?

15 A Yes.

16 Q Would you interpret that sentence to mean -- and I
17 agree it's poorly worded, that the 27 mg and the 44 mg
18 numbers, in fact, refer to those exposed in the 90th
19 percentile?

20 A Could you repeat the question, Counsel?

21 Q When you read: "The 90th percentile among exposed
22 controls were 27.1 and 44.1 mg respectively," do you
23 interpret that sentence to mean that those were exposed
24 or -- sorry. Those who were exposed but where the control
25 cases were exposed to 27.1 mgs and those who were exposed,

1 but were the -- and were the actual cases -- withdrawn.

2 How do you -- what do you interpret that sentence
3 as?

4 A That's a good question. The relative delivered
5 dose estimates obtained from that model range from .1 to
6 90 milligrams with latency from .1 to 204 milligrams without
7 latency.

8 It's so poorly worded it's hard to know exactly
9 what she's trying to say there.

10 Q My understanding was that the 27.1 and the
11 44.1-milligram numbers referred to those in the 90th
12 percentile of exposure.

13 Does that sound right to you?

14 MR. LEE: Object to the form of the question.

15 You can answer.

16 BY MS. SPRAYREGEN:

17 Q Would you agree with that interpretation?

18 A I'm trying to get there. Help me in terms of how
19 you informed that opinion, because I'm not sure where it
20 says that.

21 Q I was looking at the wording of that sentence, so
22 I can just ask you again.

23 How do you interpret that sentence?

24 A I'm doing my best to interpret it. It says one
25 comment about exposures here, but they don't provide an

1 exposure range.

2 Q I'll represent to you that that is the only
3 sentence in this article that discusses milligrams and
4 numbers in terms of exposures?

5 A Could you repeat that again? Because I didn't
6 hear you.

7 Q I said I can represent to you that there are no
8 other discussions of milligrams and how they relate to
9 exposures in this article.

10 So given that, would you interpret that sentence
11 to be that those who are exposed, those in the control group
12 who were exposed to 27.1 milligrams were in the 90th
13 percentile?

14 A See, that's why this sentence makes no sense,
15 because the controls weren't exposed. You don't expose your
16 control to these chemicals, and why would you even think
17 that? That's what's confusing.

18 Q Does it seem as though -- withdrawn.

19 Withdrawn. I take that back.

20 Does it appear -- withdrawn. So if you turn to
21 page 290.

22 Under "Discussion," the last sentence of the first
23 paragraph under "Discussion" reads: Quote: No kidney
24 cancer cases were considered exposed when latency was taken
25 into account and no meaningful increases in the risk of

1 kidney cancer were detected without latency.

2 Did I read that correctly?

3 A You did read that correctly.

4 Q So if we agree with the latency in this study,
5 these results do not provide support for the opinion that
6 PCE exposure can cause kidney cancer; would you agree with
7 that?

8 MR. LEE: Objection to form.

9 THE WITNESS: No, I don't think so. I'm not
10 sure what that sentence says.

11 BY MS. SPRAYREGEN:

12 Q So let me turn to the table on page 289.

13 A 289.

14 Q Yes. Do you see in the very first column in the
15 first row says: "With latency"?

16 A Yes.

17 Q And then it discusses bladder cancer, kidney
18 cancer, and leukemia; is that correct?

19 A Yes.

20 Q And then under that it says: "Without latency,"
21 and then it notes the odds ratios for bladder cancer, kidney
22 cancer, and leukemia; is that right?

23 A Yes.

24 Q And so if you look at the "with latency" category
25 and you go to the kidney cancer section, if you will; do you

1 see that?

2 A Yes.

3 Q And do you see under "Cases," and it says, it says
4 "N equals 35"?

5 A I see that.

6 Q And then under: "PCE Exposure History," there's a
7 zero for any, low, and high; do you see that?

8 A So we're talking about the kidney cancer line?

9 Q Yeah.

10 A So for -- any for cancer cases, I see six. For
11 low, six. For high, zero. I see that.

12 Q I'm looking at Table 4. Are you looking at Table
13 4?

14 A I am.

15 Q And then you're looking --

16 A You're looking at cases with latency. I was
17 looking at cases without latency.

18 Q Right. I'm looking with latency.

19 Because you said you didn't know what the sentence
20 meant when I said that low kidney cancer cases were
21 considered exposed when latency was taken into account.

22 Do you remember saying that?

23 A Yes.

24 Q So now I'm showing you that in the table, when
25 they're looking at the -- comparing those with kidney

1 cancer -- I'm sorry, those with kidney cancer, who are
2 exposed to those who were not exposed with kidney cancer,
3 taking into account latency, there were no exposed
4 individuals with kidney cancer?

5 A There are no exposed cases, that looks like what
6 it says.

7 Q All the exposed cases who developed kidney cancer
8 were eliminated when they considered latency is how I
9 understand this table.

10 MR. LEE: Objection. Form.

11 THE WITNESS: I see your point.

12 BY MS. SPRAYREGEN:

13 Q So would you turn to page 287?

14 A 287?

15 Q Yeah. And under "Data Analysis," I quote: The
16 crude, unadjusted analysis examined PCE exposure in relation
17 to each cancer site. Exposure was examined as a
18 dichotomous, quote: Ever versus never variable, or as an
19 unexposed low and high relative delivered dose, RDD. We
20 defined low RDD as a level up through the 90th percentile
21 among the exposed and high RDD was defined as a level above
22 90th percentile among the exposed.

23 Did I read that correctly?

24 A Yeah.

25 Q So based on what I read, would you agree that --

1 withdrawn.

2 So would you agree that the study looked at ever
3 versus never exposed and also looked at a -- those with low,
4 high, and no exposure?

5 A It does say low and high exposure, yes.

6 Q And it also looked at low -- I'm sorry. They also
7 looked at ever versus never exposed; is that correct?

8 A That's correct, yes.

9 Q And then -- so now looking at this, is it your
10 understanding that the 27 mgs and the 44 mgs represent those
11 who were in the high exposure categories?

12 A And just remind me where that was in the --

13 Q It is on 289 in the first column.

14 A I'm just trying to still figure out where the 90th
15 percentile for controls were exposed. It's not represented
16 in this table.

17 Q We can leave that aside.

18 So I want to turn to page -- the same page. I
19 want to stay on page 289 and look at the second column, the
20 last sentence, in the first full paragraph reads: "No
21 kidney cancer cases were considered exposed to high RDD;" is
22 that correct?

23 A Are we talking about Table 4?

24 Q I'll rephrase my question.

25 The last sentence in the paragraph on page 289, in

1 the first paragraph on page 289 says, quote: No kidney
2 cancer cases were considered exposed to high RDDs.

3 Did I read that directly?

4 A Yes.

5 Q And so you can go back down to the table.

6 Would you agree that when looking at cases not
7 taking into account latency, the odds ratio of those who are
8 exposed, who are ever -- who are ever exposed to those who
9 were not exposed was 1.23; is that correct?

10 A So this is any exposure?

11 Q Yeah.

12 A In the first column?

13 Q Yes.

14 A It does say that. 1.23.

15 Q And would you agree that the lower boundary of
16 that confidence interval is .40?

17 A It does say .40.

18 Q And if you look at the next column over, which is
19 the odds ratio for those who were in the low exposure
20 category, it is -- the point estimate is 1.36; is that
21 correct?

22 A Yes, that's correct.

23 Q And again, the lower boundary of that confidence
24 interval is .45; is that correct?

25 A Yes, that's correct.

1 Q Can you turn to page 290?

2 A I'm just trying to figure out how much data is
3 below that portion of the curve.

4 So 290, yes.

5 Q So the first -- the last sentence of the first
6 paragraph under "Discussion" reads: "No kidney cancer cases
7 were considered exposed when latency was taken into account
8 and no meaningful increases in the risk of kidney cancer
9 were detected without latency."

10 Did I read that correctly?

11 A Yes.

12 Q I'm assuming -- would you disagree with these
13 authors?

14 A How I read this sentence, Counselor, is that they
15 noted an increase risk of kidney cancer in the cohort that
16 they looked at. When they added latency as a consideration,
17 there were no additional risks that came out during the
18 latency determination, but that doesn't take away from the
19 fact that the underlying population was exposed and
20 developed kidney cancer as a result of those exposures.

21 Q Can you turn to page 287 of this study?

22 So under -- on page 287, in the first column,
23 under "PCE exposure estimates," the second sentence reads:
24 "The relative delivered dose, RDD, was defined as the
25 estimated mass of PCE in milligrams that entered a given

1 house as a solute in drinking water over a specified period
2 of time."

3 Did I read that correctly?

4 A Yes.

5 Q Do you know what the specified time period is? So
6 I will lay my cards on the table. I could not find the
7 answer in this article.

8 MR. LEE: Objection to the form of the
9 question.

10 THE WITNESS: I appreciate your comment,
11 Counsel. This study was conducted over a period of
12 years. And as a minimum during the duration of the
13 study, they defined the exposure that the cohort was
14 exposed to because once they found the chemicals in the
15 drinking water, they did their best to eliminate the
16 exposure.

17 BY MS. SPRAYREGEN:

18 Q So would you agree that we don't know what the
19 time period is that the authors looked at?

20 MR. LEE: Objection to form.

21 BY MS. SPRAYREGEN:

22 Q Would you agree that in this sentence --
23 withdrawn.

24 Would you agree that -- strike that.

25 As we were discussing, the sentence reads: "The

1 estimated mass of PCE in milligrams that entered a given
2 house as a solute in drinking water over a specified time
3 period;" is that correct?

4 A Yes.

5 Q But as you sit here right now, you don't know what
6 the specified time period is; is that correct?

7 A Well, what I do know is that they installed those
8 pipes in the 1960s, and from that point until they started
9 conducting the study in 1985, there was an opportunity for a
10 breakdown of those pipes and contamination of the drinking
11 water.

12 And in here, it says that the Massachusetts
13 Department of Public Health report elevations in cancer
14 mortality. The study showing up in 1969.

15 So certainly from 1960 to 1969 there was a period
16 of exposure during which people were exposed to
17 concentrations that were sufficient to cause their kidney
18 cancer.

19 And did you have a question beyond that?

20 Q So is it your opinion that the specified time
21 period was 1960 to 1969?

22 A Nine years.

23 Q Can you turn to page 290? The last paragraph
24 under "Discussion," the second sentence reads: "Given that
25 the exposures occurred many years ago, it is impossible to

1 know with absolute certainly the precise PCE levels to which
2 subjects were exposed."

3 Did I read that correctly?

4 A You did read that correctly.

5 Q And we do agree that the study did not directly
6 measure an individual's exposure?

7 A This study doesn't specifically say that they did
8 individual exposure assessments for every individual in the
9 cohort, that's correct.

10 However, through exposure modeling, they were able
11 to identify that there was a range of exposures that they
12 estimated to be between 25 and 44 parts per million. No,
13 milligrams, sorry.

14 Q Where are you looking?

15 A So they had information and they did modeling
16 based on the contaminants in the pipes, the breakdown, the
17 type of pipe, the length of the pipe, and so they could
18 model the estimated exposure based on their exposure
19 assumptions to come up with an exposure range that
20 Dr. Aschengrau and company established as a range of
21 exposures.

22 Q Would you agree that the study did not directly
23 measure an individual's exposure?

24 A Yes. I will say that it goes on to say they did
25 have the opportunity to sample public water supplies and

1 drinking water concentrations.

2 As I was saying, it talks about, they had
3 contaminant levels -- excuse me a second.

4 I'll have to call you back. Sorry.

5 Q That's okay.

6 A So as I was saying, they looked at the public
7 water supplies and there were sample levels that they used
8 to -- in terms of exposure.

9 Q Looking at sample levels in terms of exposure is
10 not directly measuring an individual's exposure; is that
11 correct?

12 A I'm getting to that point, Counselor.

13 The highest TCE levels were detected at 33 and 35
14 parts per billion. TCE being a breakdown product of TCE and
15 PCE.

16 So they had indirect measures of exposure through
17 TCE levels -- or TCA levels, sorry.

18 So it says here on page 285: "Exposure to PCE
19 from public drinking water distribution systems was examined
20 in relation to three of the cancer cases."

21 So they did have some exposure information related
22 to some of the cancers, not all of the cancers, but some of
23 the cancers where they had exposure levels.

24 Q Where are you looking?

25 A At the bottom of the very first column on

1 page 285. Like the -- three or four lines from the bottom
2 of the page.

3 It says: "Exposure to PCE from public drinking
4 water distribution systems."

5 Do you see where I'm reading? Right here.

6 "Exposure to PCE."

7 Q Okay.

8 A Not the whole cohort, but they had some exposure
9 information on the people who developed cancer.

10 Q And I want to go back to that sentence on page 289
11 that we previously didn't understand.

12 The sentence reads, again: "The relative
13 delivered dose, RDD, estimates obtained from the
14 Webler-Brown model range from .01 to 90.6 mg with latency
15 and from .01 to 209.4 mg without latency. The 90th
16 percentile among exposed controls were 27.1 and 44.1 mg
17 respectively."

18 Did I read that correctly?

19 A Counselor, with all due respect, I believe you
20 read that sentence correctly, but I believe there's a
21 typographical error in this report, specifically as it
22 relates to controls.

23 I would think you need to cross out the word
24 "controls" and make that "cases," that would make much more
25 sense to me, just in the internal flow of the logic of the

1 paper.

2 Q So I'm actually struggling with this, I admit.
3 And -- withdrawn. Strike that.

4 So how do you interpret that -- withdrawn. Strike
5 that.

6 What do you interpret this sentence to be saying?

7 A I think, as we talked about a little bit earlier,
8 the 90th percentile among exposed cases was an exposure that
9 ranged from 27 to 44 milligrams.

10 Otherwise, that sentence makes no sense.

11 Q So your last -- going back to your report on
12 page 10, can you pull that out for me for one second?

13 A Yes.

14 Q The last sentence on page 10 of your report says:
15 "It should also be noted that the 27 to 44 mg numbers listed
16 by Aschengrau were up to the 90th percentile."

17 Did I read that correctly?

18 A Yes, you did.

19 Q Is it now your opinion that the 27 and 44 mg
20 numbers are those in -- represent cases in the 90th
21 percentile?

22 A It says "the 90th percentiles among exposed cases"
23 were that. And my sentence says -- I'm just trying to sort
24 out what you're trying to draw a distinction on here.

25 Q And my -- sorry.

1 When you say "they were up to the 90th
2 percentile," my understanding was that these numbers were
3 for the 90th percentile, not under the 90th percentile?

4 A I believe it would be appropriate to cross out "up
5 to the," and just say "were at the 90th percentile."

6 So yes. It's at the 90th percentile because
7 that's what the report says.

8 MS. SPRAYREGEN: Can we take a break?

9 THE VIDEOGRAPHER: The time is 6:17 p.m. We
10 are going off the record.

11 (Recess taken from 6:17 to 6:28 p.m.)

12 THE VIDEOGRAPHER: The time is approximately
13 6:28 p.m. We're going back on the record.

14 Please proceed, Counsel.

15 MS. SPRAYREGEN: I have no other questions.

16 MR. LEE: Good deal. Are you ready?

17 EXAMINATION

18 BY MR. LEE:

19 Q Let's begin, Dr. Mallon, by having you, for the
20 Court, just describe a bit about what your background and
21 experience is, including your experience working with
22 Marines and their family members, dealing with some of the
23 issues you talked about today as it relates to providing
24 care and making a decision with the VA?

25 A So, you know, going back to my time in the Army,

1 doing a lot of work in environmental -- occupational and
2 environmental exposure assessments, bringing that forward to
3 work with the -- and I did that for 30 years, and then once
4 I left the Army, I started working for the VA, through the
5 Veteran's Evaluation Services.

6 For the last eight and a half years now, I've
7 helped the VA evaluate disability claims related to service
8 members; Marine Corps vets, and Army, and other service
9 members, disability claims related to Camp Lejeune and other
10 environmental exposures; Agent Orange, burn pit exposures, a
11 variety of different things, writing medical opinions to
12 support the VA in terms of getting -- giving every veteran a
13 chance to have their disability claim reviewed.

14 In a synopsis, that's kind of it in a nutshell.

15 Q And how do you spend your time now with those
16 evaluations, in your CV you mentioned you spend a certain
17 number of hours a week, what does that really entail?

18 A Well, on average, I've been getting about five
19 cases a week, and I probably put in probably four to five
20 hours per case, reviewing the case file. Average case file
21 is anywhere from 2,000 to 10,000 pages, and I look at the
22 medical records, look at the medical documentation, look at
23 the medical opinions from other physicians who had the
24 opportunity to weigh in on the case.

25 And oftentimes, the VA ask me to be the decider of

1 fact, if you will, between separate medical opinions that
2 have been submitted.

3 So -- and in some instances, I've been asked to be
4 a referee, if you will, of medical opinions, weighing both
5 the for and the against.

6 Q And to be clear, what exactly are you deciding?

7 A I'm deciding for the VA, answering their questions
8 regarding whether the exposure the veteran is claiming
9 contributed to the specific outcome that they're requesting
10 in terms of disability.

11 Q And what are some of the outcomes specifically
12 that you looked at recently?

13 A Well, most recently, looking at a variety of
14 disabilities; kidney cancer, leukemia, prostate cancer,
15 noncancer cases regarding liver disease, hepatic steatosis,
16 individual chronic kidney disease, a variety of other
17 autoimmune conditions, scleroderma, among others.

18 So it's a full mix of both cancer and noncancer
19 cases.

20 Q And to be clear, best estimate, the percentage of
21 times you make a determination with your VA position that
22 there is an association and times when you've determined
23 that there's not, what's the percentage?

24 A It's a balance. I think I spoke earlier today and
25 said it was probably 20 percent for and 80 to 90 percent

1 against.

2 But as -- as we've said, you know, there's a
3 number of things that go into that determination that
4 consists of reviewing the risk factors, reviewing evidence
5 of exposure, not only environmental exposure, but are there
6 other workplace exposures that contribute to the risk, and I
7 try to give the VA a big picture review of the risk factors,
8 the exposures, to come up with a more likely than not
9 determination of whether their exposure caused their
10 disease.

11 Q And to be clear, the vast majority of the times,
12 you determined there was not an association for causation?

13 A I would say that it's -- I would say that's true.

14 Q Okay. And I'm going to skip around very quickly
15 and briefly here in appreciation and respect for your time.

16 Let's cover the most recent topic that was
17 discussed, that being the Aschengrau study.

18 Can you put in context what Aschengrau, the study
19 itself, means, again, a study from 1993, as it relates to
20 the total body of literature and materials that you
21 reviewed, again, taking into consideration your knowledge,
22 skill, training, education, and experience, including your
23 current position?

24 MS. SPRAYREGEN: Objection to form. You can
25 answer.

1 THE WITNESS: Well, I think that as we look
2 at PCE and Aschengrau study, I think the big picture,
3 going back to my general causation report and
4 deposition, I try to get a sense for where Aschengrau
5 was in terms of what it provided. It provided
6 information on a consistency of association, going back
7 to those Bradford Hill criteria, a consistency of
8 association, and also exposure levels at levels lower
9 than what was in the predominant thought in the medical
10 literature that conditions, kidney cancer, since that's
11 the topic of today, was related to only high levels of
12 exposure.

13 And so Aschengrau was only one of many
14 studies to include Mandel, Callahan, Purdue,
15 Aschengrau, Cohn, Fagliano, Bove, and other studies
16 which show that low levels of exposure are equally
17 likely, if not greater, increasing the risk for kidney
18 cancer.

19 It's not only the high risk, but also the
20 low -- the low level chemical exposures that increase
21 risk.

22 BY MR. LEE:

23 Q And again, the Aschengrau study was Exhibit Number
24 19. If you have that front of you, can you --

25 A It's here.

1 Q I'm going to have you read a couple things into
2 the record, since you've been doing a lot of that today.

3 Look at page 287.

4 A 287. Okay.

5 Q Let me know when you're there.

6 A I'm there.

7 Q Under "Discussion," the paragraph that begins:
8 "Analysis were conducted."

9 Let me know if you see where I'm at, it's on the
10 right-hand side under "Discussion. Analysis."

11 A Yes.

12 Q And if you can read the last sentence in that
13 paragraph into the record?

14 A Where it says: "The RDD"?

15 Q The latent period.

16 A Can you point to it?

17 Q One paragraph below the one you're at.

18 A Oh, okay.

19 Q And read the last sentence in that paragraph.

20 A "The latent period used was five years for
21 leukemia and 15 years for bladder and kidney cancer."

22 Q And now skip to page 290, please.

23 A 290.

24 Q The right-hand side, the paragraph that begins
25 with: "Furthermore." Let me know when you're there, at the

1 top.

2 A I'm there.

3 Q Can you read that sentence into the record?

4 A "Furthermore, the use of average latent periods,
5 15 years for solid tumors and five years for leukemia, for
6 analyses that considered exposures as cancer indicators also
7 contributes to the non-differential exposure
8 misclassification. Inasmuch as individual --

9 Q Stop there. Two questions.

10 First, as it relates to the latency of solid
11 tumors, based on your knowledge, skill, training, and
12 experience, is that considered a short latency period,
13 medium, or extended latency period, in terms of assessing
14 and evaluating whether an individual has a solid tumor,
15 specifically in this instance, kidney cancer related to
16 exposure?

17 MS. SPRAYREGEN: Objection to form.

18 THE WITNESS: My sense is the 15-year latency
19 period is short. My experience with kidney cancer
20 would suggest an average latency period is longer than
21 what Aschengrau identified.

22 BY MR. LEE:

23 Q What is your experience?

24 A I would say 20 to 30 years.

25 Q So what impact does that have as it relates to the

1 results that Aschengrau came to in a 1993 study, given that
2 they use a short latency period?

3 A Well, I think it undercounts the potential kidney
4 cancer. So it biases the results towards the null, if you
5 will. And with a longer latency period, there's much more
6 opportunity for case detection and more likely would
7 increase the odds ratios of what were presented in this
8 report.

9 Q If you would now, I'm going to ask just a couple
10 of quick questions concerning some reports that you had
11 related to Downs and Tukes.

12 Can you -- one was Exhibit 1. The other was
13 Exhibit 2. If can you grab, let me know which one you have,
14 that one first.

15 A Okay. One is Downs. I got that in front of me.

16 Q Great. Let's turn to page 17, please.

17 A 17. I'm there.

18 Q Below the graph that's there, there is some
19 discussion concerning the first two sentences.

20 And as it relates to the documentation that you
21 have in this record, and there was some follow-up, I want to
22 make sure the record's clear for others who read the
23 deposition, as it relates to the second sentence, read that
24 into the record, and then I want to ask you whether there
25 are any revisions or changes you would make as it relates to

1 what you have written.

2 A You said the second sentence?

3 Q Please.

4 A So the effect was amplified by the fact that,
5 according to Dr. Reynolds, Mr. Downs would have ingested
6 23,000 parts per billion and 59,000 parts per billion of
7 PCE.

8 Q And Counsel went through this in detail and showed
9 you in the graph where the numbers were and that these were
10 not completely accurate, but they were relatively correct as
11 it relates to the documentation.

12 A As it relates to the parts per billion, is that an
13 accurate representation of the information in the chart
14 above?

15 A I think it's not quite correct. The correct
16 information there should be micrograms.

17 Q Okay.

18 A Rather than parts per billion.

19 Q And why do you say that?

20 A Well, it's based on the information from Dr.
21 Reynolds' reports.

22 Q And to the extent you have the same documentation
23 in the Tukes report, would that be something we correct as
24 well?

25 A Correct. It's exactly the same.

1 Q You can put those down, please.

2 Can you look at Exhibit 12, which was a document
3 that was titled: "Analysis of Groundwater Flow Contaminant
4 in Fate and Transport."

5 Again, that's Exhibit Number 12.

6 A Yeah, I got it.

7 Q Can you look at the first page and tell me at the
8 bottom what year this particular document indicates it was
9 at least considered and potentially published?

10 A It says "July of 2007."

11 Q Look at the next page as well. What year does
12 that confirm?

13 A The same thing.

14 Q What year are we in currently?

15 A The last time I checked, 2025.

16 Q In light of the fact this study was done in 2007,
17 and Counsel had you look at page 898. Can you go to that
18 page?

19 A Yes, I'm getting there. 898. Got it.

20 Q She's highlighted a certain section and asked you
21 to read that into the record. I want you to read that to
22 yourself, and then I'm going to ask you a follow-up
23 question.

24 A Okay. I read it.

25 Q Based upon the documentation, again, in 2007,

1 which stated that exposure assessment cannot be used to
2 determine whether you or a family member suffered any health
3 effects as a result of past exposure of PCE-contaminated
4 drinking water at Camp Lejeune, if you look down at the same
5 page, last paragraph, can you read into the record what it
6 says, beginning with "Many factors"?

7 A It says: "Many factors determine whether people
8 will suffer adverse health effects because of chemical
9 exposures. These factors include dose, duration. When,
10 during the course of exposures the exposure occurred." I
11 meant life events, genetic traits, and other factors, such
12 as occupational exposures, environmental exposures, gender,
13 diet, lifestyle, overall state of health.

14 Q Do you know whether or not the ATSDR has
15 subsequent publications that actually address the very issue
16 that's being described in this 2007 publication?

17 A Yes. It's my understanding that they've revised
18 this 2007 report and they added the word "solely" in the --
19 that paragraph that the defense mentioned.

20 So it says: "ATSDR exposure assessment cannot
21 solely be used to determine whether you've suffered a health
22 effect."

23 Q So as it relates to your current knowledge, skill,
24 training, experience, and education, would you explain for
25 the Court what are some of the other variables, and to the

1 extent you want to repeat what you read, what is some of the
2 other considerations, separate and apart from simply looking
3 at the exposure data that you use in your practice and,
4 frankly, used in this case in your specific causation
5 report, to make decisions that are documented?

6 A Well, all of the bulleted points under that -- I
7 forget which, the third full paragraph under that section,
8 all of the bullet points are currently part of my assessment
9 that I use.

10 So that includes dose, duration. When during the
11 course of life events the exposure occurs. Genetic traits.
12 And then other personal risk factors.

13 Q And Doctor, again, I know you've been involved in
14 both leukemia and also involved in kidney cancer obviously.

15 In the leukemia work that you did, did you come
16 across publications related to the atomic bomb studies and
17 the latency period with respect to various type of cancers?

18 A Yes.

19 Q And what was -- what is your recollection, to the
20 extent you have one, as it relates to whether or not 50 or
21 60 years out, individuals who were exposed to those, if you
22 will, unfortunate chemicals that came about as a result of
23 that bomb, whether they still show a higher rate of various
24 types of cancers?

25 A In fact, they do.

1 Q Explain that, for the record.

2 A Well, I worked for the Department of Energy for a
3 period of time reviewing energy exposure cases for nuclear
4 workers, people who were involved in building a bomb and
5 subsequent work with -- at the Department of Energy, and we
6 would review those cases, and these were cases that were
7 submitted for review, gosh, when I was first a residency
8 director, I was moonlighting doing some of that work.

9 Q So how many years after the bombing, based on your
10 recollection of the studies you've seen in your personal
11 experience, that continue to show an increased rate of
12 various types of cancers?

13 A It was -- we were seeing people that were 40, 50
14 years out from exposure and they were developing cancer even
15 then.

16 Q Now, you mentioned earlier -- the final series of
17 questions, that you looked at various publications and
18 studies.

19 And it's in your MCL, did you consider the Yu
20 study in your assessment and evaluation for consideration of
21 the levels at which individuals can develop cancer?

22 A You're referring to the BETX?

23 Q Correct.

24 A Yes, I did.

25 Q And what is your recollection of what that study

1 represents as it relates to the level of exposure that
2 individuals can be subject to it and go on to develop
3 various types of cancers?

4 A Extremely low levels of exposure and a marked
5 elevated risk of kidney cancer and leukemia based on the Yu
6 study.

7 MR. LEE: Thank you. No further questions at
8 this time.

9 EXAMINATION

10 BY MS. SPRAYREGEN:

11 Q Earlier today, I asked you about the highlighted
12 sentence in Exhibit 12; is that correct?

13 A I believe so.

14 Q And I --

15 A Exhibit 12 being the -- this one?

16 Q Yes. Exhibit 12 being the ATSDR Analysis of
17 Groundwater, Flow Contaminant, Fate and Transport, and
18 Distribution of Drinking Water at Tarawa Terrace and
19 Vicinity," as the title goes on. Yes?

20 A Yes.

21 Q So earlier today I asked you some questions about
22 the highlighted sentence on page 898; is that correct?

23 A Yes.

24 Q And I believe you said that you were not aware of
25 the highlighted sentence; is that correct?

1 A That's correct.

2 Q But now you remember that the highlighted sentence
3 excludes one particular word; is that correct?

4 A I became aware -- yes, that there was a subsequent
5 version of this -- of what you presented.

6 Q And how did you come to remember that there was a
7 subsequent version of Exhibit 12?

8 A I was advised by -- I was advised by Counsel that
9 that was the case.

10 MS. SPRAYREGEN: I have no other questions.

11 THE VIDEOGRAPHER: The time is 6:46 p.m. We
12 are going off the record.

13 (Deposition concluded at 6:46 p.m.)

 - - -

14

15

16

17

18

19

20

21

22

23

24


25

CERTIFICATE

I, Jennifer A. Dunn, Certified Realtime Reporter, Registered Merit Reporter, do hereby certify that prior to the commencement of the examination, TIMOTHY MALLON, M.D., was duly remotely sworn by me to testify to the truth, the whole truth and nothing but the truth.

I DO FURTHER CERTIFY that the foregoing is a verbatim transcript of the testimony as taken stenographically by me at the time, place and on the date hereinbefore set forth, to the best of my ability via Remote Zoom teleconference technology.

I DO FURTHER CERTIFY that I am neither a relative nor employee nor attorney nor counsel of any of the parties to this action, and that I am neither a relative nor employee of such attorney or counsel, and that I am not financially interested



JENNIFER A. DUNN

Certified Realtime Reporter

Registered Merit Reporter

CA Certified Shorthand Reporter #14461

Illinois Certified Shorthand Reporter

Missouri Certified Court Reporter #485

Texas Certified Shorthand Reporter #12050

Dated: July 7, 2025

Golkow Technologies,

A Veritext Division

www.veritext.com

877-370-3377

Case 7:23-cv-00897-RJ Document 508-3 Filed 08/26/25 Page 237 of 317

INSTRUCTIONS TO WITNESS

Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made.

After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition.

It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you.

If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in court.

ACKNOWLEDGMENT OF DEPONENT

I, TIMOTHY MALLON, M.D., do hereby certify that I have read the foregoing pages and that the same is a correct transcription of the answers given by me to the questions therein propounded, except for the corrections or changes in form or substance, if any, noted in the attached Errata Sheet.

TIMOTHY MALLON, M.D.

DATE

(Reported by: Jennifer A. Dunn, CRR, RMR, CSR)

Subscribed and sworn to before me this
_____ day of _____, 20 _____.

My commission expires: _____

Notary Public

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

ERRATA SHEET

WITNESS: Timothy Mallon, M.D.

IN RE: Camp Lejeune Water Litigation

Upon reading the deposition and before subscribing thereto,
the deponent indicated the following changes should be made:

PAGE	LINE	CHANGE
------	------	--------

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

REASON: _____

_____	_____	_____
-------	-------	-------

_____	_____	_____
-------	-------	-------

Witness signature

&	158:8,9,11,24	1.59 165:18,19	1100 1:17 2:21
& 1:20 2:12 4:7 4:8,11	159:19 162:2	166:1,24 167:1	6:9
0	165:9 166:14	168:5,7	1101 1:17 6:8
0.66 165:18	166:14,17,18	1.59. 157:5	1104 163:14,18
0.82 200:2	166:20,21	1.8 83:22 84:2	164:6
0000000436	169:21 172:7	1.82 167:6,9	112 4:17
4:16	173:24 174:11	10 4:15 30:24	11:09 48:10,11
0000000516	174:16 175:4	49:6,18 51:8	12 4:19 24:24
4:15	175:18 176:16	51:12 52:6	24:25 25:5,12
0012 192:12,16	182:24 207:5,6	71:9,12 80:18	25:15 26:3
193:8	228:12	89:4 99:22	83:11 100:25
0017 192:21,22	1,800 84:4,8	109:13,14	120:21,22,25
00897 1:5	1.0 166:18	150:10,15,16	131:18 133:20
01 206:11,12	1.0001 158:21	154:14 156:5	148:19,20
219:14,15	1.03 199:19	161:3,5 165:13	162:20 230:2,5
01553 4:15,16	201:20	170:10 179:10	234:12,15,16
02236 6:10	1.07 153:15	181:11 193:12	235:7
02903 2:13	1.12 199:23	204:20 220:12	120 4:19
04 25:18	201:19 203:24	220:14	12050 236:24
09-00006156...	1.12. 203:14	10,000 222:21	122 149:4,13
4:23	1.14. 200:2	100 164:8	162:23 164:4
1	1.16 199:20	100,000 80:13	126 5:3
1 4:3,18 10:25	1.16. 201:19	83:16 84:3,7	12:05 80:20,22
11:6 12:1	1.18. 200:12	109 4:15	12:18 80:22,23
82:23 94:2	1.22 153:14	10:00 197:3	12:39 92:18,20
95:16,16,16	1.23 213:9	10:58 48:8,10	12:40 92:20,21
114:1 132:7,22	1.23. 213:14	11 4:3,4,5,6,7,8	12th 22:19
133:2,9,14	1.27 153:17	4:17 30:24,25	23:25
137:6,14,19	1.34 199:23	41:8 112:16,17	13 5:3 31:2
138:12,14	1.36 213:20	147:13,23	126:3,4,7
142:19 158:1,6	1.38. 153:15	150:10,15	137:17 169:20
	203:15	161:16,20,22	183:7 204:25
	1.47 154:12	161:24 170:4	205:5,8
		203:12,13	

14 5:4 30:19 83:16,18 155:22,25 168:24,25 169:3 176:7 177:17,17 14461 236:21 15 5:5 30:8,14 48:5 80:13 82:24 94:15,21 123:8,21 124:8 125:17,21 150:5 154:11 154:14 188:20 188:20,21,24 226:21 227:5 227:18 155 5:4 158:2,9 159:19 15753 4:23 16 5:7 30:22,25 31:2 83:16,18 127:19,20,24 128:22 129:3 134:15,16 137:18 144:24 145:1,2,13,20 149:15,18 160:23 169:17 171:2 184:14 184:16 190:3,6 17 5:9 101:8 127:19,20,24 128:22 129:3	145:1,13 146:5 146:8 191:22 191:25 228:16 228:17 18 5:10 31:1 89:13,14 91:13 91:21,22 93:2 93:22,22 94:9 94:11 104:3 197:18,22 198:12,20 188 5:5 19 5:11 30:19 88:25 104:15 151:1 162:3,4 162:6,22 163:15 204:4,5 204:8 205:7,24 225:24 190 5:7 191 5:9 1950s 51:15 1960 176:8 216:15,21 1960s 216:8 1969 216:14,15 216:21 197 5:10 1975 198:23 199:10 200:20 1981 154:4 1982 124:4 179:14	1985 51:14 124:4 198:23 199:10 200:20 216:9 1989 179:14 1990 55:18 1990s 76:24 1991 76:3 1992 179:16 1993 204:14,17 224:19 228:1 1995 55:16 152:20 1996 41:6 1:09 106:23,25 1:59 106:25 107:1 <hr/> 2 <hr/> 2 4:4 10:24 11:1,9,10,12,16 22:9 83:19,24 101:1 132:14 133:8,11,12,13 133:16 134:10 134:20 137:6 137:19 138:12 138:14 146:8 169:3 179:12 179:17 182:15 182:24 193:11 228:13 2,000 222:21	2.3 84:1,10 2.3. 84:1 2.4. 154:13 2.5 67:12,20,24 68:2 20 40:7 41:18 96:19 176:8 223:25 227:24 238:15 20,000 108:12 108:16 200 32:20,22 33:12,12 100:11 2000 24:1 20005 2:21 20036 1:18 2004 24:10,24 27:19 2005 27:21 83:15 2007 230:10,16 230:25 231:16 231:18 2010 24:10 25:18 101:18 205:1,10 2011 153:17 2012 24:1 153:19 2014 152:13 155:6,11 157:10
---	---	---	---

2014a 5:4 45:25 47:3,14 156:1 164:18 165:16 169:2 170:16,19 177:15,19 2016 22:19 24:1,24 40:10 2017 35:2 2018 47:16 108:1 153:8 2019 152:20 202 2:22 2020 153:11 2022 9:7 130:24 2023 81:22 82:14,16 2024 5:10 9:12 47:17 49:21,23 82:18,19 83:2 152:13 197:22 203:2,21 2025 1:11 4:10 6:2,6 10:4,5 81:18 82:10,20 82:22 83:1,1 119:13 192:14 230:15 236:25 204 5:11 207:6 209 206:12 209.4 219:15 21 154:7	21044 7:19 219 2:4 22 205:5,7 221 3:5 23,000 145:5,11 145:16,18,25 146:4 229:6 234 3:6 236 3:7 237 3:8 238 3:9 239 3:10 24 1:11 6:2 133:20 24th 6:6 25 4:10 140:14 154:10 217:12 267 154:6 27 71:25 93:14 205:15,20 206:17 212:10 220:9,15,19 27.1 206:13,22 206:25 207:10 208:12 219:16 273-8330 2:14 27603 2:9 280 140:14 282 149:6,13 162:5 165:7 285 218:18 219:1 287 211:13,14 214:21,22	226:3,4 289 205:24 206:1,2 209:12 209:13 212:13 212:19,25 213:1 219:10 290 41:12,14,16 41:17 208:21 214:1,4 216:23 226:22,23 29440 2:5 2:00 197:3 2:54 139:2,4 2nd 2:13 81:18	3.6. 181:23 3.65 170:13 182:2 3.65. 170:5,8 3.86. 165:19 30 4:10 49:10 50:17 90:7 93:20 96:19 106:3 108:3,6 108:9 222:3 227:24 237:11 31 109:22,24 110:4 31.7 163:12 318,305 198:24 199:10 200:21 32 93:15 32557 236:17 33 218:13 330 84:11 35 71:23 210:4 218:13 386 166:15 3:06 139:4,5 3:37 155:16,18 3:39 155:18,19 3a 161:23
		3	
		3 4:5 11:1,2 12:12 69:21 87:21 128:23 129:2 132:14 133:8,11,12 134:10,20 137:6,19 138:12,14 145:19,25 161:20,20,21 162:2 170:1 177:15,21,22 177:25 178:1,2 198:12,14,15 198:20 199:7 3,100 165:9 3.6 166:18	
			4
			4 4:6 11:2,3 12:16 57:8,9 83:8 87:21 128:20 132:14 132:23 133:8

133:12 134:13 134:14,23 137:6,14,19 138:12,14 142:20 148:2 172:8 173:24 174:16 175:4 175:18 176:16 178:20,21 198:14 202:12 202:16 210:12 210:13 212:23 4,000 13:25 119:5,7,9 40 94:21 96:19 96:22 213:16 213:17 233:13 400 32:17 401 2:14 41 153:12 410 2:9 43 149:4,13 162:3 164:3 165:6 44 205:15,20 206:17 212:10 217:12 220:9 220:15,19 44.1 206:13,22 207:11 219:16 45 213:24 46 114:8 115:1 48 95:14	485 236:23 4:04 168:16,18 4:18 168:18,19 4a 162:20 5 5 4:7 11:3,4 12:20 30:9,10 81:24 87:22 95:16 162:21 165:19 178:21 179:13 181:18 183:18 184:5 192:14,17 200:18,19 203:21 204:1 5,875 147:19 148:10 50 70:18 94:17 95:14 96:16,22 98:8 106:17 131:10,10 182:17 232:20 233:13 50/50 51:6,7 529-3351 2:10 546-2408 2:5 55 168:13 552-9843 2:22 58,000 147:19 589 149:3 59,000 145:6,11 146:7 229:6	5:13 197:12,14 5:28 197:14,15 6 6 4:8 11:4,5,6 13:1,2 34:5 46:3,8 47:3,6 47:14 87:22 119:13 128:3,7 144:18 156:3 156:21 157:18 157:23,25 164:21 165:8 169:14 190:10 202:8,11,19 60 184:4 232:21 600 17:13 64.4 163:12 6508 7:18 66 166:18 67 28:18 69 4:11 6:17 221:9,11 6:28 221:11,13 6:46 235:11,13 7 7 3:4 4:10 11:5 29:25 30:1 41:8,10 144:18 148:22 156:20 157:1,4,20 165:17 166:23 236:25	7,866 139:14 7.86 139:14 7/29/2016 202:13 70 28:19 180:4 180:15 74 41:15,16 74th 41:12 75 131:10,10 154:11 7:23 1:5 7th 15:15,19 119:1 8 8 4:11 69:9,10 69:21 93:21 139:16 162:22 191:1,5 8,000 139:15 80 223:25 80,000 82:9 80,900 83:6 81 4:13 81,000 83:6 81,600 82:19 82 94:3 82.85 169:4,9 843 2:5 85 166:15 898 230:17,19 234:22
--	--	--	---

9	a		
9 4:13 30:25 81:2,3,4,6 154:13 162:4 163:4 170:10 181:10,11 190:8,9 90 44:2 49:6 205:21 207:6 223:25 90.6 206:11 219:14 90th 206:12,18 206:21 207:11 208:12 211:20 211:22 212:14 219:15 220:8 220:16,20,22 221:1,3,3,5,6 91 199:20 203:15 919 2:10 93 205:12 939 149:4,13 161:8,13 164:4 94 199:23 95 165:18 97 200:2 99 56:6 77:23 9:43 1:18 6:2,7	a.m. 1:18 6:2,7 48:8,10,11 a98 121:9 ability 44:25 236:10 able 8:3 47:6 58:4,18 89:21 96:7 127:4 192:13 194:3 217:10 above 1:18 89:4,7 93:16 135:13 136:4 166:17 181:25 188:10 211:21 229:14 absence 113:16 absolute 217:1 absolutely 32:15 academics 21:17 accept 84:12 acceptable 180:20 access 59:10 189:19 account 68:2 84:15 117:13 172:2,8,9,13,16 172:18 175:3 176:5,15	208:25 210:21 211:3 213:7 214:7 accounted 111:20 accounts 83:7 accreditation 28:17 29:1 accredited 28:16,19 accuracy 94:16 accurate 9:1 13:14 31:24 77:23 94:18 120:1,11,11 125:2,3 168:8 175:14 176:23 191:12 197:1 229:10,13 237:14 accurately 8:4 acgme 28:23 29:1 acknowledg... 238:1 act 35:21 action 57:2,5 236:14,16 active 198:22 199:9 activities 23:7 23:10 actual 123:7,20 125:8 155:11	207:1 actuality 174:22 actually 47:22 87:4 93:17 102:4 103:10 134:23 135:16 145:18 160:13 182:2 183:20 194:9 220:2 231:15 ad 9:5 add 59:3 96:4 114:16 129:23 143:9 170:25 added 186:2 214:16 231:18 adding 130:4 163:18,20 164:1,3 171:17 175:23 addition 142:3 142:9 additional 13:25 35:24 57:15,25 58:14 58:16,17 66:15 140:25 141:2 152:16 188:8 192:24 214:17 additionally 58:8 additive 98:2 150:3 185:24

185:25 186:17 additively 184:19 address 7:16,18 35:5 42:3 172:23 231:15 addressed 14:2 adjusted 174:4 174:15,21 176:13,16 199:14,19,22 199:25 200:1,6 200:9 adjustment 172:24 174:14 174:23 adjustments 175:25 administer 191:18 administration 34:6 admit 83:3 220:2 adult 34:15 adverse 231:8 advised 235:8,8 advisors 75:6 advisory 117:10 affect 71:19 99:21 100:7 affects 100:1	afghanistan 32:24 56:16 african 66:2 101:3 102:19 afternoon 146:17 177:23 age 7:2 65:16 65:19 94:5,5 97:8 104:2 114:7 115:1 116:11 agent 222:10 aggressive 61:13,16 aggressiveness 61:7 ago 16:24 40:7 75:14 81:15 95:25 96:11 98:20 216:25 agree 11:23 12:9 20:13,18 39:9 59:25 60:1 61:3,6,14 61:17,24 64:3 64:11,13,18,21 64:24 65:13,16 66:1,6,22 67:1 67:4,5 68:3,13 68:17,20,22,24 71:1,7,12,18,23 72:2,17,22,25 73:10,13,15,23 74:13,19,20,22	74:24 75:3,6,8 75:14 77:1,21 78:17 79:8 80:7,11 82:4 83:5,21 84:13 85:2 94:25 96:25 97:11 108:12,16,19 108:21,23 110:10,18,22 111:12 114:25 115:3 130:3 141:8 142:1,7 143:24 145:9 148:13 149:12 151:8 165:24 166:19 175:3 181:3,7 182:2 182:21 183:17 198:1 200:24 201:3 202:4 203:1,5 206:17 207:17 209:4,6 211:25 212:2 213:6,15 215:18,22,24 217:5,22 agreed 74:22 77:1,6 79:4 agreeing 111:12 ahead 16:13 58:24 120:18 123:13 126:2	147:5 154:16 air 32:21 141:23 al 165:16 204:9 aligns 57:11 allele 86:7,25 87:3 97:6,6 allen 20:18 85:13 104:23 105:16,22,23 107:6,12 189:19 allen's 20:16 104:20 105:20 107:19 allow 47:13 113:14 117:11 124:19 allows 117:18 alluded 106:9 alterations 33:5,6,7 37:3 37:19,22 106:5 alternations 37:24 america 2:22 american 28:21 101:3 102:19 americans 66:2 66:3 aml 50:20 amount 67:25 71:16 142:3,9 150:25 151:15
--	--	--	--

151:25 152:6 160:8 178:25 194:15 amounted 163:14 amplified 145:4 229:4 analyses 57:13 136:2 227:6 analysis 4:19 32:15 93:11 94:1 95:13,21 96:10,18 101:2 110:22 120:25 135:14,25 136:6,14 144:21 153:12 211:15,16 226:8,10 230:3 234:16 analyzed 33:1 andrew 130:22 130:23,24 131:20 132:2 140:11 141:4,6 154:9 160:5 answer 7:22 8:5,18,18,21 18:25 19:2 20:5 29:13 30:16 36:2 51:5 54:7 61:8 61:15 71:17 74:23 85:5	97:15 98:14,16 100:22 111:18 115:23 116:15 123:25 130:12 137:8,25 138:22 147:4 149:20 152:2 153:1,2 158:15 160:11,13,15 173:10 175:7 175:11,15 200:10 207:15 215:7 224:25 answered 41:18 79:11 97:18 160:10 160:18 answering 223:7 answers 30:22 238:4 anticipated 134:4 anybody 40:3 53:14 apart 62:25 232:2 apologize 77:7 appear 123:12 208:20 appears 201:6 appendices 126:8	appendix 126:17 128:3,7 applicable 88:11 applied 143:12 applies 76:17 96:25 apply 143:14 apportioned 133:21 appreciate 46:24 123:16 144:20 215:10 appreciation 224:15 approach 57:13 124:11 approaches 96:22 approaching 95:16,18 96:17 appropriate 124:14 194:22 221:4 237:4 approximately 10:8 82:9 94:17 149:6 161:8 221:12 april 4:10 area 39:16 60:10 159:14 159:15 172:9 172:14,14 187:23	areas 51:24,25 53:3,11 argued 157:9 argument 97:20 98:18 158:5 arising 60:2 army 40:12 54:23 90:8 117:6 134:22 141:25 221:25 222:4,8 arrange 25:22 26:6 arranged 27:23 article 46:1,3 58:19 75:21 87:7 96:19 100:13 186:4 208:3,9 215:7 articles 66:12 86:3 87:13,15 100:8,11 130:14,18,19 192:25 193:5 aschengrau 5:11 140:6,8 141:5,6,8,15 152:24 204:8 205:8,21 217:20 220:16 224:17,18 225:2,4,13,15 225:23 227:21
---	--	---	---

228:1	56:24 58:5	assumed	attempt 172:8
aside 164:11	108:1 121:13	175:19	attended 54:25
212:17	133:10,11	assuming	attorney 8:17
asked 20:25	142:21 143:2,4	143:22 147:17	36:13 236:13
21:3 30:20	143:15,19,20	214:12	236:15 237:11
56:23 61:10	144:11 172:25	assumption	attorneys 8:17
79:11 100:21	174:25 187:14	94:21 133:3,6	196:8
105:5 138:23	187:22 231:1	assumptions	attributed 64:6
153:3 160:10	231:20 232:8	133:23,24	author 96:5
223:3 230:20	233:20	180:7 217:19	authored 54:5
234:11,21	assessments	assurance	56:16
asking 20:4	56:14 84:17	47:19 168:8	authority
26:17 51:17	130:9 180:22	atomic 232:16	117:18
66:17,18 77:7	180:23 217:8	atsdr 47:16	authorize
87:11 105:11	222:2	51:13 53:11	28:22
118:23 122:15	assigned 9:24	120:10 121:24	authors 130:15
122:25 123:6	178:9	124:11,15,25	214:13 215:19
123:18 125:1,2	assignment	133:16,25	autoimmune
125:5 126:1	9:23 10:13,15	134:21 136:10	223:17
131:1 141:9	assist 195:19	152:18 153:8	available 10:16
157:6,14	assisted 195:20	177:3 231:14	42:10,20 43:4
159:10,10,13	195:25	231:20 234:16	44:3 45:8,22
175:1,2 183:13	associate 26:2	atsdr's 56:1,3	47:8 85:22
186:20 187:7	associated 62:9	119:22,25	111:9
187:12 196:7	116:20 157:23	121:13 122:3	ave 1:17
aspect 28:25	158:1	122:21 123:8	avenue 2:9 6:9
assert 119:15	association	123:22 125:9	average 134:12
assessing	32:3 223:22	143:13	178:9,22
227:13	224:12 225:6,8	attached 127:2	181:22 222:18
assessment	associations	127:3 237:8	222:20 227:4
54:15,20,22	42:15	238:6	227:20
55:1,3,7,9,10	assume 8:13	attachments	averaged
55:12,19,22	67:19	193:23	180:11
56:5,9,11,17,21			

aviation 44:23 aware 9:3 51:10 52:1,3,7 52:10,11,14 53:4,8 62:8,13 85:25 111:2 112:23 113:2,8 113:14 115:6 115:11,13,13 115:16,20 116:2,5,5 119:25 121:19 121:21,24 122:1 142:17 142:25 179:21 179:25 180:2,6 180:10 234:24 235:4	135:20,22 136:17,18 137:17,18 138:21,22 139:6,12 141:3 145:20 148:17 152:25 153:2 154:21 155:10 155:20 160:15 160:17 161:5 168:20 172:5 172:16 179:9 184:10,13 186:17 193:7 194:13 197:16 208:19 213:5 218:4 219:10 220:11 221:13 221:25 225:3,6 background 80:11 84:15,18 188:11 194:22 221:20 backpack 96:7 bad 41:11 149:16 bailey's 19:21 19:24 balance 79:19 223:24 ball 56:6 ballpark 164:8 base 4:21 45:6 45:10 46:21	51:25 52:17 99:2 121:3 149:3 172:9,14 172:19 173:16 173:19 174:18 175:4,24 176:3 176:7,18,22 198:23 199:10 based 34:21,23 43:5,5 46:21 48:1 49:2 70:24 85:9 89:21 93:11 94:13 108:25 110:5,24 113:15 119:12 119:17,20 124:4,6,9,10,16 125:10 130:7 134:4,5,7,17,21 135:11,12 138:3 156:14 157:17,17 159:21 164:21 165:5,16 166:9 168:10 172:17 179:4 187:20 211:25 217:16 217:18 227:11 229:20 230:25 233:9 234:5 basically 34:16 36:10 102:15 132:6	basis 33:9 76:21 78:18 100:16,19 107:23 194:23 bates 109:20 114:1 192:11 192:20 bearing 114:1 began 198:22 199:9 beginning 231:6 begins 226:7,24 behalf 7:4 belief 135:18 believe 14:20 15:13,17 20:9 20:25 28:1 29:7 36:8 41:18 53:2 64:5 66:9 69:2 81:17 83:18 86:24 100:15 100:18 102:21 103:3,20 121:9 146:4 150:2 152:12 156:8 156:13 159:6 162:11 165:2 173:15 177:2 177:11,13 183:25 184:8 190:7,17 192:7 201:2 205:1
b			
b 4:1 5:1 72:24 161:23 163:7,8 165:16 b's 72:4 back 17:6 22:9 40:9 48:12 51:15 54:21 63:24 75:19 76:22 80:24 92:22 93:22 94:9 97:14,17 98:13,15 102:3 106:6 107:2 114:4 124:5,5			

219:19,20 221:4 234:13 234:24 bell 2:2 9:14 192:7 belllegalgrou... 2:3 benzene 38:24 97:1,4,21 98:7 171:2,8 179:13 179:14 181:4 181:25 183:1 183:13,14 185:6,12,16 186:15 best 8:8 43:4 127:11 162:14 162:18 200:15 207:24 215:15 223:20 236:10 bet 89:14 better 78:9 102:22 194:25 199:2 betx 233:22 beyond 49:18 55:23 59:24 66:16 216:19 biases 228:4 big 61:22 224:7 225:2 bigger 126:14 bilateral 114:8 115:3,6 116:6	116:10 billion 140:12 140:13,19,21 141:21 154:7,7 218:14 229:6,6 229:12,18 bioenvironm... 32:21 43:21 biological 100:15,18 biology 37:4,7 biomarker 85:25 86:5,6 biomarkers 33:5 biostatistics 22:18 23:25 24:9 31:1,4,6,7 31:10 bird's 16:8,11 16:19,22 bit 28:13 82:18 157:8 201:24 220:7 221:20 bladder 209:17 209:21 226:21 blanking 96:6 blessing 28:23 blew 126:21,21 blood 33:1,2 65:13 85:2,3 85:16,21,22 86:14,17	bloodborne 40:17 blow 127:5,10 blowing 193:23 blown 128:4 blue 137:18 bmi 71:23,24 93:13,14,17,20 101:20 bmis 93:15 board 28:21 31:9,9 boards 31:9 bodies 78:17 body 57:2 100:10 102:9 108:13,17 224:20 boisclair 2:12 bomb 232:16 232:23 233:4 bombing 233:9 bottom 23:7 41:15 70:2 109:23 147:16 147:23 192:15 206:2 218:25 219:1 230:8 boundary 166:19,20 213:15,23 bounds 166:10 bove 5:4,10 45:22,25 47:3	47:14 49:11,20 49:23 103:25 125:19 130:13 130:19 131:23 131:25 144:18 144:18 154:6 156:1,20 157:10,17 159:23 160:4 165:8,16 169:2 169:14 170:16 170:19 176:25 177:9,18,19 178:15 179:5 186:3 200:24 202:24 203:21 225:15 bove's 131:23 144:11 152:13 164:17 186:10 197:22 boyer 2:19 6:20 6:20 boylan 2:9 bradford 225:7 branch 2:16 break 8:22 48:6 48:7 80:18 106:15,16,18 138:25 164:10 168:15 195:16 197:11 221:8 breakdown 75:14 76:17
---	--	---	---

183:4 216:10 217:16 218:14 breaks 8:21 69:3 breathing 32:22 breed 62:25 briefly 224:15 bring 195:12 bringing 222:2 broadly 73:22 73:23 broke 107:5 bromine 152:21 brought 197:8 brown 206:11 219:14 bs 37:1,6 bu 2:20 building 233:4 bulk 166:14,15 bullet 22:25 23:23 24:10 34:9 35:5 232:8 bulleted 232:6 burn 32:3,18 32:23 33:3 37:20,22,24 43:20 222:10 business 195:24	c c 2:1 6:1 93:25 161:23 204:23 205:13 ca 236:21 calculate 132:8 176:25 177:9 178:24 188:14 calculated 123:9,22 125:9 130:3 139:24 141:19 calculating 175:18 calculation 134:3 142:16 172:12 181:22 calculations 119:18,20 122:4,8,22 123:9,23 125:10 132:5 132:17 172:17 calculator 84:12 california 1:20 call 218:4 callahan 140:13 152:20 152:21 225:14 called 29:15 71:15	calls 196:15,21 196:24 camp 1:5 4:21 6:11 9:3 35:20 35:25 41:21 42:8,23 44:6 44:10,16,18 45:13 48:2,17 48:19,24 49:4 50:6,9 51:2,3 51:13 52:4,12 52:15,16 53:1 53:4,8,12,18 85:10 89:5,9 89:19,23 93:25 98:19 99:21 100:22 101:1 103:13,15 105:4 107:14 119:16 121:3 121:16 123:21 129:22 138:8 138:17 139:19 148:23 149:3 150:7,12,18,24 151:4,10 159:21,24 160:2 163:5,11 172:22,25 177:1,10 183:22 184:24 185:2 190:12 198:21,21 199:8,8,15,15	200:19,20 222:9 231:4 239:3 cancer 4:12,13 4:14,18 5:10 5:11 9:25 10:21 14:11 15:6,21 16:8 16:11,20,23 17:8,17 18:1 38:15,19 40:19 40:22,24 41:2 41:22 42:7,24 48:18,19,23 50:19,23,23 51:7 54:6,8,12 59:2,25 60:2,9 61:7 64:3,6,8 64:14,19,19,22 64:25 65:10,14 65:17 66:3,19 66:23,24 67:2 67:3,7,8,10,11 67:13,24 68:3 68:5,9,11,14,15 68:18,19,21,25 69:1,18 70:15 71:8 72:3,18 72:19,25 73:4 73:8,24 74:2 74:16,21 75:4 75:9,11 76:14 77:9,12,13 78:1,24 79:5,6
---	---	--	--

79:9,9,13,14,16	119:17 124:22	218:20 219:9	100:10 185:21
80:4,8,12,13,14	125:20 132:20	223:14,14,18	187:25 188:1
81:7 82:6,9,10	144:20 152:11	225:10,18	carcinoma 60:1
83:7,8,16,22	152:14,17,23	226:21 227:6	60:14,17,17,18
84:4,8,16	153:10 154:1,8	227:15,19	61:4,12,14,18
85:14,17,24	156:14 157:1	228:4 232:14	61:18,20,25
86:1,9,11,19,22	157:12,16,18	233:14,21	62:3,7,9,15,16
87:2 88:8,11	157:24 158:7	234:5	62:18,24 63:5
89:6,8,17,21,22	158:10,13	cancer's 85:4	63:6,8,17,17,18
90:10,17 91:10	159:1,8,12,17	cancers 60:2	63:19 106:13
91:17 92:13	159:21,25	61:13 69:19	116:21 198:2
93:4,10,12	160:3,9 161:17	70:5,9,17,18	198:10 199:18
94:1,4,6,17,20	165:20 167:2,3	71:3 74:5,8	199:22 200:6
94:22 95:4,8	167:6 168:5,10	75:7 76:8 82:5	202:5,9,16,21
95:22 96:12	180:11,20	84:20 90:14	cards 215:6
98:24,25	184:18,20	218:22,22,23	care 39:11
100:12 101:2,4	185:3,8,14,20	232:17,24	118:24 221:24
101:11,17,18	186:12,15,25	233:12 234:3	carefully 237:2
101:19,24	187:19 188:2,3	cape 205:16	carl 56:16
102:2,6 103:4	188:5,8,9,15	capture 77:20	carolina 1:1 2:5
103:16,18,22	191:3,7,8	carcinogen	2:9 4:21 6:13
103:25 104:2,8	197:22 198:21	50:22 78:14	121:4
104:9,11,12,17	199:7 200:16	carcinogenesis	carries 71:23
105:1,3,7,11,18	200:19 203:21	73:22,23 97:10	carson 2:18
107:11,16,17	204:9 205:15	97:25	6:18
107:22 108:15	208:24 209:1,6	carcinogenic	carson.m.gar...
111:6,15	209:17,18,21	55:22 98:23	2:19
112:24 113:3,6	209:22,25	99:9 104:18	case 1:5 10:3,8
113:9 114:24	210:8,10,20	185:22,22	10:11,14 11:21
115:6,10,17,21	211:1,1,2,4,7	188:10	12:7 13:9 16:6
116:4,6,6,8,10	211:17 212:21	carcinogens	20:7 34:25
116:19,23	213:2 214:6,8	50:12,14 73:17	43:10,14,20
117:23 118:2,4	214:15,20	78:18,21 85:10	50:12 52:19
118:13,20	216:13,18	99:9,11,12,16	54:5 57:11

61:23 63:3 73:17,20 85:24 90:25 91:1 106:13 123:20 124:16 129:10 136:8 142:10 182:9,10 195:20 196:1 202:3 222:20 222:20,20,24 228:6 232:4 235:9 cases 1:7 14:16 33:12 34:18 36:11 45:19 49:19 54:9 62:16 70:18 74:25 75:2 78:10 82:9 83:8,16 90:9 190:13 191:15 206:25 207:1 208:24 210:3 210:10,16,17 210:20 211:5,7 212:21 213:2,6 214:6 218:20 219:24 220:8 220:20,22 222:19 223:15 223:19 233:3,6 233:6 categories 212:11	categorizing 65:5 category 93:18 154:10 156:24 158:20 159:5 164:21 165:17 167:10,11,21 168:1,3,4 169:6,14 170:22 171:3,8 171:8,10,10 203:6,9 209:24 213:20 cathy 193:15 caucasian 101:5 causal 35:6 42:3 151:18,22 causation 4:3,4 9:24 10:1,14 10:19 11:11,18 12:4 13:9 14:7 14:12,14,17 15:10,25 16:3 16:6,12,18,20 16:23 17:7,17 17:21,25 18:3 18:17,20,23 19:5 20:7 36:7 41:20 45:23,24 46:9 47:1,22 57:14,16 58:1 58:3,5,13,18 59:17,20 60:22	66:7 87:24,24 94:6 136:22 151:18 166:2 180:23 192:24 193:1,12 224:12 225:3 232:4 cause 64:3 70:9 70:18 73:24 74:6,10,11,13 74:14 77:2,2,4 89:6,20 90:13 91:3,7 101:18 107:15 152:11 152:14,23 153:10 154:1 156:14 157:11 157:15 158:7 158:10,12,25 158:25 159:7 159:12,25 160:8 185:3,19 186:12,15,25 209:6 216:17 caused 72:25 73:8,9 74:17 78:11 79:16 80:4 84:20 85:4,18 86:12 86:23,24 87:1 89:23 103:16 119:16 124:22 185:8,14 188:3 224:9	causes 69:25 70:1,4,15,17 74:8,21 75:4,7 75:9,12,15 77:9,12,13,18 77:18 78:8 88:18,20 90:19 90:19 109:4 110:6,15,19,25 111:3,3,6,7 112:10 causing 98:24 ceasing 96:24 cell 60:1,14,17 60:17,18 61:3 61:12,13,16,17 61:18,21,24,25 62:3,7,7,9,17 62:23,24 63:5 63:5,6,16,18,22 63:22 64:1 76:5,8,13,18,18 76:19 116:21 198:2,10 199:17,18,18 199:22 200:1,6 201:12 202:5,5 202:9,15,15,20 202:21 censured 57:2 center 40:12,12 54:23 centimeters 202:16
--	---	--	--

central 134:7	238:6 239:6	132:22 133:8	162:23 164:12
certain 15:14	chapter 4:22	133:11 134:10	171:8 179:16
32:3 61:12	121:5	137:6,14,19	181:4 182:10
110:5,23	characteristics	138:12 142:19	182:12,14,16
222:16 230:20	167:18	162:9 170:3,16	182:21 185:6
certainly 25:18	characterizati...	170:19 172:7	185:12,16,18
32:11 164:12	188:12	173:24 174:8	186:12,24
216:15 217:1	characterize	174:16 175:4	choose 146:20
certificate 3:7	187:21	175:18 176:16	187:21
236:1	characterized	193:15 194:11	chronic 223:16
certifications	45:21	check 169:25	cigarette 97:23
38:3,6	chart 83:14,15	checked 170:4	99:11,12,16
certified 1:19	96:18 127:23	230:15	100:23
1:20,21 28:18	127:24 128:12	chemical 33:7	cigarettes 98:4
236:2,19,21,22	128:20,22,23	73:17 84:19	98:10 100:10
236:23,24	129:1,1 132:18	86:24 171:23	100:16,19
certify 236:3,7	133:2,9,13,14	188:10 225:20	cite 69:12
236:12 238:2	133:16 134:10	231:8	141:12 152:16
cessation 72:10	134:13,14,20	chemicals	cited 69:14
94:19 95:3,15	134:23 138:14	32:17 50:18	cites 200:5
95:19 96:16,22	145:12,19,25	97:3,13 98:2,4	civil 2:16
100:19	146:8 148:1,2	98:6,10,19,23	claim 35:16
chance 48:4	148:3,3 149:15	99:3,6,8,10	36:3,5 222:13
111:21 112:4	161:14 163:2	142:18 143:1	claimants
222:13	164:13 169:10	144:17 149:25	10:20
change 30:6	171:14,14	150:3,25 151:3	claiming 168:4
65:22 79:2	177:24 181:11	184:24 185:2,6	223:8
119:10 239:8	182:25 183:19	185:12,24	claims 35:12,18
changed 60:23	183:25 229:13	186:19 208:16	49:3 54:9
101:20 118:25	charts 81:22	215:14 232:22	191:17 222:7,9
changes 103:20	82:15 83:12	chirag 153:19	clarification
103:24 106:2	126:9,12,22,22	chloride 38:22	8:13 51:4
113:24 118:10	126:23 127:9	97:1,4,21 98:8	clarified 60:22
228:25 237:7	127:15 132:14	149:5 162:21	

clarify 8:12 29:17 39:14 54:17 61:9 72:5 88:16 105:8 107:8 clarity 71:6 class 26:20,20 31:10 classes 30:17 clean 19:3 112:19 142:23 clear 53:25 61:18,21,24,25 62:7,17,23 63:5,6,10,16,22 64:1 65:2 70:4 70:14,17,19 74:8 75:7 76:5 76:8,13,18,18 89:19 105:23 123:15 196:7 196:13 198:2 198:10 199:18 200:1 201:12 202:5,9,15,20 223:6,20 224:11 228:22 clearly 59:1 181:25 clinic 4:11 40:11 69:12,17 74:7 75:5 90:21	clinical 4:17 23:12,16 25:11 40:11 113:5,15 115:7,17,21 116:3,9,25 117:3,5,7,19 clinician 39:9 39:15,16 91:5 clinicians 115:9 clja 4:23 close 84:2 91:13 164:7 closed 51:14 closely 45:21 closer 50:17 club 23:11 cochrane 58:7 58:11 cod 205:16 coding 37:3 cohn 225:15 cohort 214:15 215:13 217:9 219:8 collect 44:1 collected 32:22 33:1 43:24 college 54:18 55:8,15 columbia 7:19 column 129:9 129:12,13 132:7,18 133:1 134:6 137:15	137:16 138:2 138:14 145:23 162:12 163:2 163:22,23 164:14 169:11 170:12 171:14 174:10,11 178:2,4,5 181:15,18 199:14 209:14 212:13,19 213:12,18 214:22 218:25 columns 138:12,14 combination 44:19 98:1 185:24 186:2 combined 186:9 come 25:23 26:6 27:23 58:19 124:5 131:16,19 132:1,19 134:2 138:6 144:13 144:18 162:9 163:1 164:13 177:5 184:10 217:19 224:8 232:15 235:6 comes 161:14 163:18,20 164:3 169:9	170:9 comfortable 194:21 coming 93:21 143:8 145:25 164:25 commencem... 236:4 comment 66:16 112:14 123:3 180:24 207:25 215:10 commentary 175:7,11 commissary 173:21 commission 238:17 commit 73:25 common 61:17 75:12 82:6 commonly 44:14 112:24 113:2,9 communicate 14:4 communicated 53:22 54:3 comp 34:7 company 217:20 comparable 160:1
---	--	--	---

compare 144:13 164:17 170:15,18	118:20 components 32:11 33:2	178:22 180:2 181:4 182:3 216:17 218:1	confidence 153:18 154:12 165:18 166:8
compared 33:14,15,18 82:5 89:9 101:5 200:20	compound 163:13 compounds 163:10	concern 42:12 42:16 43:7 73:21 119:22 129:10 138:8 144:17 149:25 150:3	166:10,13,20 166:21 199:20 199:23 200:2 203:15,25 213:16,23
comparing 199:14 210:25	comprehend 195:5	concerning 123:13 228:10 228:19	confirm 85:8 230:12
comparison 170:20 198:20 199:7	comprehensive 77:17,17	conclude 89:21 91:6 118:19	confirmed 104:7,8
compensated 34:21	computer 127:10	concluded 235:13	confused 63:14
complete 13:14 56:18 83:2 144:22 166:9	concen 142:13 concentration 138:4,6 140:15 140:21,24 141:6,23 142:14 144:2,3 144:15 149:21 149:21 160:4,8 177:5 180:14 182:6,11 184:6	conclusion 104:21 107:12 107:20	confusing 208:17
completed 143:23 192:24	concentrations 123:7,21 125:8 129:20,25 130:4 135:11 140:20 141:22 142:13 149:2 149:14 154:3 171:18,23 174:17 175:5 175:24 176:6 176:18 178:10	condition 106:8 106:10 111:22	congress 34:17
completely 14:1 47:10 63:2,8 229:10		conditions 4:12 4:22 35:17,19 35:23,24,25 73:15 110:5,24 111:10 121:5 223:17 225:10	conjecture 111:8 177:11
completeness 109:6		conduct 84:19	conjunction 124:12 144:10 156:21
completion 191:9		conducted 1:16 215:11 226:8	connecticut 1:17 6:9
complicated 85:6		conducting 57:13 90:12 216:9	connection 35:6 42:4
complied 143:3			consensus 53:15
complies 143:22			conservative 146:22 174:24 179:7
component 33:8 38:12 45:2 69:6			consider 21:13 32:6,9 39:23 39:24 40:1 55:2 90:13,18

90:20 99:25 100:6,9 103:3 103:7,9,13,15 113:22 117:22 142:2,8 187:13 233:19 consideration 53:15 113:18 115:8 117:12 185:9 214:16 224:21 233:20 considerations 232:2 considered 4:5 4:6,7,9 12:13 12:17,23 13:4 13:7,8,15,23 14:21,25 21:14 21:19,21,23,24 53:13 58:20 65:19 87:16,17 87:21 90:15 96:3 151:20 180:3 181:1 205:4 208:24 210:21 211:8 212:21 213:2 214:7 227:6,12 230:9 considering 117:22 consisted 108:9 consistency 225:6,7	consistent 28:6 82:17 115:7,18 115:22 116:3 143:6 144:10 154:5 consists 224:4 constitute 180:15 constitutes 151:16 consume 180:3 consumed 46:16,20 134:1 134:17,18,23 138:15 139:18 consumption 132:13 133:4 133:25 134:4 134:11,12 137:6,13,16,19 137:23 138:2 175:18 cont 5:1 contact 189:15 190:2,2 contacted 9:8 contain 11:20 12:6 13:8 52:8 contains 181:14 contaminant 4:20 52:23 121:1 129:20 138:7 153:25	178:10,22,25 179:22 218:3 230:3 234:17 contaminants 73:21 107:14 119:22 129:9 130:5 131:3 135:13 138:7 179:1,23 217:16 contaminated 5:12 51:11,12 51:20 52:9,12 52:15,20,25 53:5,9,13,16 119:16 121:15 204:10 231:3 contamination 51:15 135:15 179:13 190:12 216:10 content 25:22 27:24 196:10 contention 82:13 124:7 158:11 contents 121:7 context 47:15 73:22 187:5,6 194:25 224:18 continue 78:8 147:5 233:11 continued 97:6 101:15,24	continues 72:9 101:9 continuing 75:8 178:21 contribute 42:12 224:6 contributed 89:7 104:1 144:19 184:19 223:9 contributes 227:7 contributing 89:20 91:7 contributor 65:20 control 206:24 208:11,16 controls 33:12 206:13,22 208:15 212:15 219:16,22,24 conventional 165:24 conversation 60:21 147:3 187:4 196:7 converted 140:13 142:14 conveying 125:15 coordinate 34:14
--	--	---	---

copied 109:21 126:12 127:24 145:12 copies 93:3 112:19 126:14 copy 13:14 92:3 96:8 190:10 191:1,5 195:15 core 139:17 corps 4:21 121:3 134:22 222:8 correct 15:2 16:21 18:7,8 19:13 20:10 21:9,25 27:15 27:16 28:3 29:9 36:13,14 36:15,17,18,19 36:20 37:9,10 37:12,13,15,16 37:18 38:4,5,7 38:8,10,16,17 38:20,21,22,24 39:1,2,3,4,5,6,7 39:8 44:7 46:3 48:20 49:25 54:16 59:7,8 59:15 60:4,7 60:25 61:25 65:11,12 67:19 68:12 74:15 77:4 80:6 90:3	99:8 103:9,14 104:13 112:7,9 113:10,12 114:13 115:4,5 118:5 119:13 119:24 127:25 128:3,13 130:7 132:10 139:13 139:19,22,23 141:16 145:19 148:11,15 150:1,13 151:13 152:5,9 156:1,11,12 157:12,13 158:10,22 159:8 160:22 161:14,15 163:2,25 164:18,21,24 165:2 166:22 166:24,25 167:3,4,7,8,11 167:12,15 168:8 169:10 169:15,22 170:7,8,9,14,16 170:19,23,24 171:5,11,15 172:20 173:9 174:2,20 175:21 176:1,8 176:9 180:5 181:12,16,19	182:12,15,16 183:15 185:20 190:25 192:2 193:13 195:7 195:10 196:2 196:22 198:10 199:15,16,20 199:24 200:7,9 200:11,16 201:10,11,13 201:14,16 202:5,22 203:19,22 204:1,2,11,18 205:23 209:18 212:7,8,22 213:9,21,22,24 213:25 216:3,6 217:9 218:11 229:10,15,15 229:23,25 233:23 234:12 234:22,25 235:1,3 238:4 corrected 29:16 147:20 165:21 179:18 correction 139:10,11 174:7 176:4 corrections 176:3 237:3,5 238:5	correctly 23:4 23:21 41:25 53:7 57:17 89:11,25 91:19 93:6 94:7,23 100:4 101:6,21 145:7 147:21 149:8 151:6 158:3 161:11 162:7,24 163:16 165:22 169:7,23,24 178:13 179:2 179:19 184:21 190:14,22 191:10 193:3 193:18 198:25 199:11 200:3 200:22 203:16 205:17,22 206:14 209:2,3 211:23 214:10 215:3 217:3,4 219:18,20 220:17 correlate 180:25 corresponds 148:5 157:19 cory 2:19 6:20 council 28:17 counsel 2:14,22 6:15 9:15,20 14:1,4 29:1
---	--	---	---

48:13 80:25	226:1 228:9	97:14,17 98:13	129:14,17,19
87:9 92:23	course 22:5,23	98:15 135:20	130:10,20
107:3 112:22	23:2,11,11,13	135:22 136:17	131:6,20 132:6
139:7 147:4	23:14,17,19,20	136:18 138:22	132:8,8,13
155:4,21 156:6	24:1,12,21,25	139:12 153:2	137:6,13,16,19
158:17 168:21	25:2,7,10,13,16	160:17 162:15	137:22 138:2
170:21 190:2	25:20,22 26:8	221:20 231:25	142:1,7 143:25
197:4,17	26:9,12,14,15	236:23 237:15	144:15 149:13
206:20 215:11	26:18,19,24,24	courtroom 7:12	149:21 162:6
221:14 229:8	27:3,3,4,8,10	cover 224:16	162:23 164:14
230:17 235:8	27:12,12,17,18	covered 13:20	165:17 170:6
236:13,15	27:20,21,22,25	25:25 31:7	171:13,20
counselor 30:3	28:2,7,10,10	created 126:10	172:1,17
39:12 40:9	29:3,4,5,9,16	150:3	175:18 176:12
51:22 55:10	29:19,19,19	crib 141:13	176:17 178:24
62:4 69:3	30:16 31:5,20	criteria 28:24	179:6 180:10
77:20 81:14	36:24 54:21,22	37:21 113:20	184:3
85:6,20 95:12	54:25,25 55:7	113:21 114:7	current 22:11
105:8 107:13	55:13,14,23,25	114:11,17,18	22:13,13,15
111:2 115:25	75:20 76:1,2	114:19 116:7	27:19 77:25
124:21 131:2	76:22 122:19	151:17 225:7	78:3 82:16
137:10 146:15	192:10 231:10	cross 219:23	102:14 103:7
175:14 183:9	232:11	221:4	109:8 111:10
185:10 198:3	courses 23:3	crr 238:11	125:21 179:12
202:7 203:11	24:2,2,5,13,18	crude 211:16	191:1,5 224:23
214:14 218:12	26:11,25 30:15	crunched	231:23
219:19	30:20,21 31:18	124:10	currently 35:11
counter 34:7	37:8,11 54:19	crystal 56:6	195:23 230:14
couple 27:5	55:8 75:23	csr 238:11	232:8
28:3,9 75:13	court 1:1,21	cte 134:6	curriculum
81:15 95:24	3:7 6:12,23	cuff 51:6	25:22,25 55:13
114:20 130:21	7:11,20 8:3,9	cumulative 5:3	75:23 76:1
156:4 195:11	10:24 16:15	46:14,19 97:7	curve 152:19
196:14,21	36:10 57:5	119:21 129:13	186:7 214:3

cut 64:16 128:16,17,19 184:8 cv 1:5 22:9,10 22:11,13,15 23:6,23 24:3,6 24:8,19 26:25 27:14 33:24 34:3 41:19 42:2 56:13 222:16	date 1:18 6:6 81:14 204:13 236:9 237:7 238:8 dated 202:13 236:25 dates 22:18 178:24 day 4:22 40:13 40:13 50:17 81:20 94:13 121:5 137:10 196:13 238:15 days 49:11 81:15 95:24 138:5,5 149:3 176:7 237:12 dc 1:17 2:21 6:10 deal 221:16 dealing 159:3 221:22 dealt 141:21,24 dean 9:10 decider 222:25 deciding 223:6 223:7 decision 166:6 221:24 decisions 232:5 declined 53:19 decrease 98:21 decreased 99:24	decreasing 99:5 deemed 237:14 defendant's 5:8 defendants 7:4 defense 231:19 define 39:15 88:17,19 159:13 defined 211:20 211:21 214:24 215:13 definitely 95:18 96:7 201:6 definition 60:4 165:25 definitive 141:17 definitively 202:2 degree 114:9 114:24 117:25 degrees 38:9,11 65:3 delivered 206:10 207:4 211:19 214:24 219:13 demonstrates 99:23 department 2:16 22:17 23:24 24:9 216:13 233:2,5	depending 133:5,21 167:18 182:18 deployed 32:16 32:20,24 33:13 33:14,16,18 43:21,23 44:1 56:14 deployment 33:17 43:18 depo 41:9,10 deponent 6:14 238:1 239:6 deposed 36:9 deposes 7:3 deposing 237:11 deposition 1:15 4:10 5:5,8 6:8 8:16 10:16 17:3,4,8,12,14 17:16,21 18:4 18:10,12,17,19 18:19,23 19:1 19:15,17 21:1 21:20 28:1 29:25 94:14,18 127:11 134:17 136:11 147:18 148:10 150:23 157:10 166:2,4 189:1,2 195:7 195:10,13 196:4 201:25
d			
d 3:1 6:1 56:6 150:17 161:23 daily 39:19,21 78:18 151:3 180:3 damage 97:4 97:22 damaged 97:6 97:7 data 81:22 82:14,15,16,19 83:1,2 84:3 103:8 124:6,10 124:17 144:21 166:7,10,12,14 166:15 186:10 211:15 214:2 232:3 database 58:11 databases 58:7			

225:4 228:23 235:13 237:2,9 237:12,13 239:5 depositions 21:5 189:17 derivable 140:24 derived 132:13 describe 150:11 221:20 described 26:18 37:23 57:19 150:6 151:8 231:16 description 4:2 5:2 134:17 151:2 desire 22:1 detail 45:9 47:5 229:8 detailed 133:10 133:11 details 176:12 detected 86:7 209:1 214:9 218:13 detection 228:6 determination 36:12 46:21 47:7 70:25 107:23 147:10 165:4 187:19 214:18 223:21	224:3,9 determinations 45:23 determine 42:6 42:23 46:13,19 84:19 85:18 86:12,22 93:8 120:2,12,15 121:13 140:3 179:5 231:2,7 231:21 determined 120:2 164:20 181:22 223:22 224:12 determining 48:1 84:14 142:1,7 develop 66:24 67:3,6 68:10 68:15,19,21,24 79:5 80:8 84:4 84:8 85:14 112:13 160:3 233:21 234:2 developed 41:22 79:9,9 85:17 94:4 107:17 133:19 136:14 211:7 214:20 219:9 developing 64:14,19,22,25 65:14,17 66:3	67:12 68:4,9 80:12 83:22 85:23 86:8 88:8 95:8 101:24 102:2,6 104:25 105:7 105:18 107:10 107:21 133:7 133:10 159:16 168:9 188:2 233:14 development 50:19 67:10 89:17 101:19 103:21 104:2 117:4 develops 64:8 67:11 79:5 86:19 diabetes 64:24 65:4 diagnosed 40:5 41:1 48:18 91:17 92:13 93:4 101:10,15 101:23 115:1 116:11 159:21 diagnoses 114:7 diagnosis 39:10 88:4,15,19,22 89:22 90:2,6 90:12,17,18 91:8 94:18,22	101:17 113:15 diagnostic 108:24 dichotomous 166:6 211:18 diet 231:13 differ 60:8,12 60:25 difference 60:11 63:25 88:14 134:9 135:6,17 195:2 different 26:8 26:10,14,18,22 28:12 32:17 52:1,4,5 58:2 60:5,7 62:24 63:2,2,8,9 71:13,24 77:15 85:15 88:18,20 97:22 98:19 100:20 105:14 116:6 123:6 128:15 129:6 140:22 222:11 differential 88:4,14,15,17 88:18,19,22,23 89:22 90:2,6 90:12 227:7 differentiate 63:21 differently 58:7
--	--	--	---

differs 133:14	disability 40:4	208:23 214:6	230:2,8
difficult 16:16	222:7,9,13	216:24 226:7	documentation
63:15	223:10	226:10 228:19	34:19,24 35:14
diminish 99:1	disagree 122:7	discussions	35:15 130:8
102:13	214:12	196:10 208:8	222:22 228:20
diminishes	disagreeing	disease 4:11	229:11,22
102:2	111:13	50:9 84:14	230:25
diminishing	discharge	104:9 223:15	documented
99:6 100:13	135:15	223:16 224:10	232:5
diminution	disciplinary	diseases 32:4	documents 5:6
98:23	57:1,4	dispute 83:9	13:22 189:2,5
direct 33:7	disclaimer	disputes 94:16	189:8,9 190:17
directive	110:3,19	disputing 82:23	190:23 192:1
117:10	discuss 46:3	disregarded	194:20 197:4
directly 39:10	90:11 203:2,8	116:12 117:1	doing 8:7 36:11
86:14 125:15	discussed 7:20	distinction	40:4 41:19
213:3 217:5,22	23:24 27:23	119:4 220:24	46:8 47:11
218:10	31:16 45:25	distribution	49:24 84:16
director 22:23	59:19 65:24	4:20 121:2	99:22 129:2
23:2,11,13,15	74:5 90:9	218:19 219:4	162:14 174:7
23:17,19 24:1	107:25 136:9	234:18	207:24 222:1
24:12,21,25	146:17 171:17	district 1:1,1	226:2 233:8
25:2,7,10,13,20	171:19 182:14	6:12,13	237:6
26:2,8,14,24,24	198:1,9 224:17	divided 140:16	door 199:1
27:3,12,17,19	discusses 208:3	division 2:16	dose 71:16,18
27:20,22 28:2	209:17	doctor 33:21	72:6,7 142:4
28:7,8,10,10,11	discussing 46:9	39:9 232:13	152:19 153:22
28:24 29:2,3,5	132:7,18	doctor's 105:16	180:10 186:7
29:8,16,16,18	142:19 145:10	document 1:6	200:25 201:5,9
29:19,19,20	171:13 202:23	11:17 12:3	201:13,16,23
30:16 34:10,20	202:24 215:25	22:11 30:9	206:10 207:5
233:8	discussion 45:3	41:13 122:11	211:19 214:24
disabilities	80:10 147:3	122:15,16	219:13 231:9
223:14	166:3 208:22	126:10 197:24	232:10

double 169:25	142:12,12	20:9,14,16,18	165:6 168:23
170:4	143:9 144:24	20:20,22,24	169:10 172:6,7
doubt 105:22	145:5 148:17	21:3,6,8,11	172:24 173:25
144:7	148:23,25	29:25 45:22	175:2,17 176:5
dowling 2:7,8	149:1 150:5,6	46:22 49:20	176:24,25
dowlingfirm....	151:9 156:22	56:16 58:4	177:8,9 178:15
2:8	157:7,7 160:23	59:21 85:13	179:4,8 181:5
down's 163:4	161:5,7,22	97:15 102:17	181:12,21
downs 4:3,5,7,8	162:1,4,21	103:24 104:20	187:13,17
10:1,3,8 11:11	163:5,11,13	104:22,23	188:14 189:19
12:4,7,14,23	164:20 165:4	105:16,20,22	194:9,12,16
13:4,10,15,22	165:14,19	105:23 106:9	195:1 197:22
13:23 14:18,22	166:12 168:4	107:6,12,19	200:24 202:20
15:12 16:19	172:2,21	118:15,22	217:20 221:19
22:5 46:25	173:13 174:1	119:2,6,12,18	229:5,20
53:20,22,25	174:17 175:4	119:20 120:9	draft 19:15,17
57:20 60:18	175:19,20,24	122:4,22 123:9	21:1
61:24 66:18	176:7 180:25	123:23 125:9	drafting 15:9
84:20 88:5,25	183:8 188:14	126:7 127:16	118:8 136:7
89:5 90:19	194:6 198:1,9	127:24 128:2,4	draw 119:4
91:12,16,24	200:5,14 202:4	128:7,15 129:6	220:24
92:1,8,12 93:3	202:11,14,20	130:3,13	drinking 4:20
93:8 94:1,12	204:20 228:11	131:23 132:5	5:12 44:20
94:15,15,16	228:15 229:5	132:17,22,25	121:2,15 130:5
95:1,2 98:20	dr 5:6,8 6:14	138:3 139:9	131:3 135:11
118:4,13,24	7:7 13:19	142:10,17,25	136:3,4 159:24
119:16,21	14:11,14 15:5	143:3 144:11	163:10 178:10
124:23 125:16	15:8,8,18,21,25	145:5,13	179:23 180:3
125:18 126:8	16:2,8,11,19,22	152:12 153:5	180:13 204:10
126:16,21,22	17:8,11,16,20	154:6 156:20	205:16 215:1
127:1,18,20,23	17:25 18:3,6,9	157:17 159:23	215:15 216:2
129:21 132:8	18:16,22 19:4	160:4 161:14	216:10 218:1
132:16,20	19:10,12,14,18	162:9 163:1	218:19 219:3
134:19 138:16	19:21,23,24	164:13,17	231:4 234:18

due 37:22,24 89:18 91:18 92:14 93:5 94:5 101:4,12 105:1 107:11 165:20 168:5 219:19 duly 7:2 236:5 dunn 1:19 6:24 236:2,18 238:11 duration 27:10 44:14 47:18,19 48:2 49:2,14 49:15,22 50:14 50:23 68:1 71:19 72:6,7 95:20 131:15 138:16 142:3,5 142:9 151:1 200:19 201:18 201:18,20 203:21 215:12 231:9 232:10 dustin 202:12 duty 198:22 199:9	137:3 157:10 164:16 187:4 198:2,9 220:7 223:24 233:16 234:11,21 early 51:15 76:24 easier 29:23 126:23 144:14 144:17 145:20 205:6 easiest 195:4 easily 140:24 eastern 1:1 6:13 ecologic 154:5 economist 36:15,17 ecosystem 74:2 edt 1:18 6:2 education 28:17 29:2 224:22 231:24 effect 86:6 145:4 150:3,4 158:22 167:23 185:22,25 186:17 229:4 231:22 effects 38:15,19 120:3,13,15 121:14 122:12 153:22 231:3,8	effort 194:21 eight 41:19 84:16 133:20 174:5 222:6 either 19:23 20:2 71:21 198:23 199:5 199:10 elements 63:22 elevated 49:19 89:18 153:13 154:12 165:20 168:5,9 205:14 234:5 elevations 216:13 eliminate 215:15 eliminated 94:19 95:3 211:8 empathize 21:6 employed 90:2 employee 236:13,15 encounter 43:23 energy 233:2,3 233:5 engagement 196:17 engine 44:23 engineer 32:21 43:21	ensure 180:7 entail 222:17 entered 21:14 214:25 216:1 entire 173:1 entitled 5:11 204:9 entry 193:10 194:9,12 environmental 2:17 23:12 26:12 27:2,11 28:15 32:19 43:19,22 45:1 45:4,17,20 56:13,17 69:7 75:19 78:11,13 105:1 107:11 107:14,18 111:1,5 118:19 131:2 144:11 222:1,2,10 224:5 231:12 epa 54:21,22 55:7,25 124:12 153:11 179:12 179:21,25 180:10,24 epa's 55:11,19 55:21,24 epidemiologic 33:19 epidemiologi... 143:25
e			
e 2:1,1 3:1 4:1 5:1 6:1,1 43:1 56:6 101:1 earlier 50:19 104:2 118:3			

epidemiology 27:3,11 30:15 30:18,23 31:8 32:7 33:10,21 33:23 67:8 81:8 82:19	estimate 82:21 120:11 134:7 134:16 135:11 138:3 143:8 166:9,16 186:4 213:20 223:20	109:4 110:6,8 110:15,25 111:3 114:13 154:14	130:19 211:16 211:17 218:19
equal 95:8	estimated 134:3 178:9,21 214:25 216:1 217:12,18	evaluating 42:22 46:16 47:25 48:16 227:14	examiners 191:16
equally 225:16			examining 75:11 88:20
equals 198:24 199:10 200:21 210:4	estimates 120:12 134:20 136:15 144:1,9 148:11 179:7 193:16,21 206:10 207:5 214:23 219:13	evaluation 34:1 35:2 41:20,23 47:2,12,25 48:16 49:24 54:10 113:21 222:5 233:20	example 7:23 65:4 67:5 78:10 141:4 154:3 156:22 159:4 186:3
equivalent 31:13 139:15 139:20		evaluations 48:22 51:1 222:16	exceeded 181:8 182:17 184:5
errata 3:10 30:2 237:4,6,8 237:11 238:7 239:1	estimation 180:19	events 231:11 232:11	excellent 135:9 156:3 161:7
error 123:2 124:13 205:2 219:21	et 165:16 204:8	evidence 42:9 224:4	except 176:21 238:5
es 34:4	ethnicity 101:4		exception 13:16
especially 97:8	etiologies 60:12 60:24 61:1	exact 72:15 99:17 176:12	excess 180:14 188:5,8,12,15
esq 2:3,4,8,12 2:17,18,19,20	etiology 54:6,8 54:11 60:16 84:14 88:15,17 88:18,23	exactly 81:10 87:6 102:17 116:16 143:11 207:8 223:6 229:25	excludes 53:14 235:3
essentially 35:13,18 39:20 49:17 134:3,21 140:12	evaluate 48:17 110:20 125:2 175:1 180:11 222:7	examination 3:4,5,6 7:5 221:17 234:9 236:4	exclusion 90:18
established 114:23 179:14 217:20	evaluated 40:17,17 50:2 50:4 108:3	examined 53:20,24 54:2	excuse 11:12 22:22 41:8 46:14 97:16 135:4,5 137:17 149:16 150:21 165:19 218:3
establishes 179:25			exhibit 4:3,4,5 4:6,7,8,10,11 4:13,15,17,19 5:3,4,5,7,9,10

5:11 10:25 11:1,2,3,4,5,9 11:10,12,16 12:1,12,16,20 13:1,2 22:9 29:25 30:1 41:7,8,10 69:9 69:10,21 80:16 81:2,3,4,6 82:24 87:20 109:13,14 112:16,17 113:10 120:19 120:21,22,25 126:3,4,7 154:17,18 155:22,25 177:17,17 183:6 188:19 188:21,24 190:3,6 191:22 191:25 197:18 197:22 198:12 198:20 204:4,4 204:5,8 205:24 225:23 228:12 228:13 230:2,5 234:12,15,16 235:7 exhibits 10:23 11:6 21:14 87:21 exist 202:2	exists 112:4,12 expanded 106:4 expanding 195:23 expect 167:13 experience 26:16,22 54:20 75:11 90:5 221:21,21 224:22 227:12 227:19,23 231:24 233:11 expert 5:3,9 54:6,15 55:2 60:10 143:18 187:23 expertise 55:9 159:14,15 experts 14:7 16:6 17:7 19:8 20:7 22:4 57:12 180:21 expires 238:17 explain 28:13 32:13 71:2 231:24 233:1 explains 64:8 explanation 105:24 explanations 167:20 exponentially 93:19	expose 208:15 exposed 32:17 32:23 33:12 78:17 85:14 87:4 98:20 103:24 129:21 130:6 131:15 142:12,14 144:2,4 147:18 149:6 151:1,3 184:24 185:1,5 185:11 186:19 186:23 187:6,9 187:25 206:13 206:18,21,23 206:24,25,25 208:11,12,15 208:24 210:21 211:2,2,3,5,7 211:21,22 212:3,7,15,21 213:2,8,8,9 214:7,19 215:14 216:16 217:2 219:16 220:8,22 232:21 exposure 5:3 33:5,7,18 35:6 35:25 36:2 42:10,17,20,25 43:2,4,9,14 44:12,14,20 45:1,2,4,12,21	46:22 47:13,18 47:19,21 48:1 49:16 54:14,15 54:20 55:24 56:13 58:3 73:18 75:17 76:19 78:13,21 80:8 84:21 85:4,5,19 86:2 86:5,12 87:1 89:5,19,23 96:24 97:1,5,7 97:23 99:6,7 99:21 100:1,7 100:12,20 103:2,3,5,8,9 103:12,15 104:18 105:19 105:25 119:15 119:18,21 121:13,15 123:9,23 124:5 124:9,22 125:10,17,18 129:7 130:9,16 130:19 131:5 131:21,23 132:9,12 133:4 133:5,7,11 134:4,7,16 135:11 140:3,7 141:7,9,11,15 142:1,2,7,8,20 142:20 143:1,8
--	---	--	---

143:25 144:1,9 144:13 148:23 149:2 150:6,11 150:18,24,25 151:1,2,4,9,12 151:15,16,18 151:19,25 152:6,10,17,19 153:9,13,18,21 156:19,23,24 156:24 157:2,3 157:11,19,22 157:23 158:12 158:20 159:5,5 159:11,18,24 160:2 161:8,17 162:1,5,6,21,22 162:23 163:14 163:14,19,21 164:1,21 165:5 165:17,18,20 167:2,2,5,14,15 167:17,18,19 167:21,24 168:1,6,10 169:4,6,14,15 169:20 170:6 170:18 171:2,3 171:13 172:1,3 172:17,25 173:25 174:21 174:25 176:13 177:3,4,6 178:24 179:6	180:13,25 181:15 182:22 183:1,13,14,18 184:3,17,18 185:8,14,19 186:11,14,16 186:18 188:3,9 193:14,16,21 194:5 203:6,8 203:14 207:12 208:1 209:6 210:6 211:16 211:17 212:4,5 212:11 213:10 213:19 214:23 215:13,16 216:16 217:6,8 217:10,18,18 217:19,23 218:8,9,10,16 218:18,21,23 219:3,6,8 220:8 222:2 223:8 224:5,5 224:9 225:8,12 225:16 227:7 227:16 231:1,3 231:10,20 232:3,11 233:3 233:14 234:1,4 exposures 10:20 32:3 37:20,22,24 40:16 42:4,15	43:9,20,22 44:22,24 46:5 59:2 78:11 85:9 98:1 105:1,4 107:11 107:14,18 118:20 125:18 131:2,9 144:19 149:13 151:22 152:18 153:20 157:25 159:4,7 159:15 163:5 170:11,15 187:20 207:25 208:4,9 214:20 216:25 217:11 217:21 222:10 222:10 224:6,8 225:20 227:6 231:9,10,12,12 expressed 171:23 extended 227:13 extensive 51:16 202:16 extensively 194:18,19 extent 34:23 40:3 42:13 44:3 45:8 77:25 86:13 104:23,23 119:15 123:12	127:8 144:12 147:3 153:7 229:22 232:1 232:20 extrapolated 124:5 extremely 234:4 f f 203:12,18 facilities 173:12,16 fact 48:23 50:5 50:9 52:11,14 68:10 82:13 87:4 90:13 98:7,20 99:4 102:10,19 117:24,25 118:17 120:10 123:3 139:13 144:20 145:4 151:21 167:10 168:2 173:18 174:4 175:19 200:12 206:18 214:19 223:1 229:4 230:16 232:25 factor 58:5 64:7,13,19,21 64:24 65:5,7 65:14,17,18,22
--	--	---	--

65:23 66:1 72:8 78:25 79:15,17,20,21 80:3,9 89:20 90:23 91:9 94:1,6 95:1 101:2,13 102:16,20,22 103:4,14,16 factors 42:11 55:24 64:5 65:3,9,11,20,23 66:13,19,23 67:2 68:14,18 68:20,25 69:18 71:1 77:16,25 78:1 88:7,10 89:7,16 90:20 90:22,24 91:3 91:6 93:12 97:9 109:1,3 110:6,24 118:17,21 180:9 224:4,7 231:6,7,9,11 232:12 facts 4:13 123:5 124:15 factual 124:17 fade 135:14,25 136:2,6 fagliano 225:15 fail 237:13	fair 8:14,23 14:2 45:11 47:24 78:23 128:24 188:12 194:15 fairly 82:6 fairness 194:13 falls 169:5,13 familiar 45:16 45:19 69:20 112:21 197:24 family 64:18 69:6 75:16 76:19 110:24 121:14 190:1 221:22 231:2 far 82:25 83:6 147:5 fashion 98:2 fate 4:20 121:1 230:4 234:17 fay 189:23 feature 115:7 115:18,21 116:3 features 116:10 117:1 february 10:5 15:15,19 119:1 176:8 192:14 192:17 fed 52:6,8,20 fee 5:9	feeding 52:22 52:23 feel 162:19 felt 65:4 150:2 fibrosis 202:17 field 28:14 133:24 134:22 134:22 143:20 fifth 23:6 figure 82:23 83:9 106:16 142:15 157:1 176:13 183:12 192:13 194:14 212:14 214:2 figures 132:19 143:8 169:25 file 35:14,16 36:3 222:20,20 filed 6:12 files 34:25 final 194:6,6 233:16 finally 163:4 financially 236:16 find 48:23 50:9 51:2 75:25 130:21 131:22 132:3 183:11 183:21 189:12 202:1 215:6 findings 4:22 121:5	finger 141:18 finish 16:15 22:2 55:4 124:19 finished 8:4 82:21 83:1 firm 9:13 first 4:7 7:2 9:3 9:8,18,20 12:22 16:25 17:1 19:2 21:19,23 42:17 57:10 74:22,24 82:8 90:23 91:15,23 94:2 101:17 102:11 108:9 112:22 113:1 114:21 114:23 117:24 128:3,9 129:9 129:12 132:17 133:1 137:24 138:14 150:20 156:10 162:12 163:2,22,23 164:14 169:10 171:14 176:21 178:2,6,8 181:15 190:10 193:22 205:13 206:5 208:22 209:14,15 212:13,20 213:1,12 214:5
--	---	--	---

Golkow Technologies,
A Veritext Division

gained 78:5	genetic 4:15	84:24 85:1	69:18 79:19
garand 2:18	37:21 62:9,10	107:16	90:22 92:17
6:18,18	62:13 69:6	genotoxic	96:15 100:25
garbarini	72:25 73:4,9,9	50:13,18 85:9	102:10 106:20
104:22	85:7,21 86:7	97:3,12,20,22	106:21 117:15
geiger 53:1,4,9	86:16,21 97:4	georgetown 2:5	123:13 124:15
gender 231:12	97:22 103:20	getting 120:18	126:2 143:16
gene 62:15	103:21,23	137:10 173:6	144:17 147:5
106:11 112:8	104:10,16	188:9 218:12	148:16 154:16
116:20	105:12,21	222:12,18	155:15 158:23
general 9:24	106:1,2,5,8,10	230:19	164:16 168:14
14:7,11,14,17	107:24 108:1	gilbert's 18:9	173:13 174:3
15:25 16:2,6	108:10,20,22	give 8:25 26:6	177:15 179:9
16:11,19,22	108:24 109:4,6	27:24 30:21,21	180:19 183:6
17:7,17,21,25	109:8,9,19	31:17 96:7	184:15 186:17
18:3,17,20,22	110:6,15,21,25	154:22,24	194:13 204:25
30:23 53:10,15	111:3,5,7,10,14	155:10 168:4	209:25 213:5
57:14 58:12,18	111:20,22	185:9 191:14	219:10 224:3
59:20 60:22	112:5 113:20	198:17 224:7	230:17 234:2
75:1,3 76:11	113:23,23	given 53:17	goes 40:18
80:8 87:23,24	114:13 116:18	77:18 81:12	49:18 181:11
101:5 166:2	117:1,18,20,25	89:15 102:8,8	217:24 234:19
180:1 192:24	231:11 232:11	132:2 140:17	going 10:22
193:1 225:3	genetically	186:16 208:10	17:6 19:3
generally 59:3	75:16 104:25	214:25 216:1	22:24 29:24
71:13 196:9	105:6,18,24	216:24 228:1	48:9,12 51:15
generate	107:10,21	238:4	55:6 63:24
191:20	geneticist 36:19	gives 26:19	69:8 71:5,21
generated	36:20	28:23 44:25	72:12 75:19
191:21	geneticists	49:12 113:6	76:22 80:15,16
genes 106:3	115:9	giving 222:12	80:21,24 82:20
108:3,5,6,11,12	genetics 33:4	glad 87:14	87:8 92:19,22
108:15,17	36:21,23,23	go 16:13 47:6	102:13 106:24
111:13 112:1	37:3,8,15 38:3	57:7 58:24	107:2 109:12

112:15 120:18 126:2 131:16 132:15 139:3,6 147:4 154:16 154:18 155:17 155:20 160:16 160:23,25 161:24,25 162:16 165:8 166:9,14 168:17,20 173:21 177:7 179:9 187:10 192:11 196:6 197:11,13,16 197:21,21 201:19 204:3,4 220:11 221:10 221:13,25 224:14 225:3,6 226:1 228:9 230:22 235:12 golkow 6:5 good 7:7,8 13:20 39:19 49:10 60:13 62:19 106:18 121:22 127:13 129:4 138:24 183:3 207:4 221:16 goodman 14:20 15:8	goodman's 14:11 17:8 google 58:15,16 58:23 59:7,10 59:19 75:25 gordon 2:25 6:4 gosh 233:7 gotcha 30:13 128:11 grab 228:13 grade 102:16 102:20 graduate 28:17 29:2 54:18 55:8 195:18 graduated 41:5 gram 181:23 graph 228:18 229:9 great 44:13 127:14 228:16 greater 47:22 49:15 50:21 67:25 79:23,23 98:3 100:23 114:8 131:10 158:1,5 166:21 186:9 225:17 greatest 67:10 171:1 groundwater 4:19 121:1 135:13,17	230:3 234:17 group 2:2 9:14 33:14,16 167:19 192:8 208:11 group's 46:5 guess 60:10 94:2 100:25 105:15 129:12 guest 26:6 27:23 guidance 49:13 49:21 55:12,19 117:20 guidelines 4:17 4:17 55:21 112:21,23 113:4,8,14 117:4,5,7,9 h h 4:1 5:1 56:1 hadnot 138:18 146:1 149:1,6 162:5,6 163:21 164:1 165:7 170:6 171:4 172:3 173:2,9 173:11,13 174:1,6,10 175:20 176:1 183:2,14,24 hairs 85:20	half 70:9 176:11,11 182:16 222:6 hand 154:18,23 155:11 226:10 226:24 handbook 55:24 handed 69:13 155:8 handout 74:7 handy 93:22 happen 99:17 happened 112:12 happy 46:17 195:22 hard 48:25 51:5 77:20 109:21 110:4 110:10 126:10 202:2 207:8 hatten's 17:25 18:3,6 hazard 60:10 144:18 156:16 156:18 157:5 165:25 166:24 167:1,6,9,10 168:2,3 hazards 33:17 head 7:24 137:2
---	---	--	---

health 33:14,15 34:6 35:6 36:3 38:13 42:12,15 43:18 54:23 120:3,12,15 121:14 122:12 180:6,16 216:13 231:2,8 231:13,21 healthy 167:22 167:23 hear 8:16 18:13 198:3 208:6 heard 53:1 81:13 100:4 188:6 hearing 53:6 heck 194:14 held 6:8 34:5 help 22:16 199:2 207:18 helped 222:7 helpful 118:16 helping 196:17 hemorrhage 202:17 hepatic 223:15 hered 4:18 114:1 hereditary 62:14 103:19 104:12 105:11 106:1,10,13 113:15,21,23	115:10 116:7 116:11,19,23 117:23 118:2 hereinbefore 236:10 heritable 106:8 high 46:6 65:5 65:13 66:3 102:10 123:10 123:24 125:11 125:19 151:19 153:18 156:22 156:24 157:3 157:20,23 164:20 165:17 167:2,2,11,16 167:19,21 168:1,3 186:1 186:5 201:20 210:7,11 211:19,21 212:4,5,11,21 213:2 225:11 225:19 higher 84:1 93:20 95:9 96:20 153:20 158:8 159:6 167:10,13,14 168:3 186:5 232:23 highest 200:8 200:12 218:13	highlight 137:18 highlighted 121:12 199:3 230:20 234:11 234:22,25 235:2 highlighting 114:2 121:10 121:11 192:5,6 192:7 206:5 highlights 198:13 highly 104:11 hill 225:7 hiring 195:21 histologic 61:4 histological 76:16 histologically 63:25 histology 61:6 historical 4:21 121:4 history 64:18 69:6 71:7,9 72:2,16,17 75:16 76:19 79:15 80:2 104:7 110:25 210:6 hiv 40:17 hmm 20:15 66:21 89:15	110:17 127:17 151:11 184:17 206:4 hold 34:17 140:9 home 133:18 133:21 172:23 hope 78:7 hospital 173:16 hour 48:5 80:17 139:1 196:15,25,25 197:11 hours 133:20 133:20,20 174:5 193:1,12 193:17 222:17 222:20 house 215:1 216:2 hr 199:14,19,22 200:1,6 hrs 200:9 hrsa 34:13 hrsa's 34:13 human 108:13 108:17 hygiene 43:5 hypertension 89:18 hypothesized 85:13 hypothetical 109:5 112:12
---	--	---	---

122:6,15,20 123:1,3,5,13,18 125:1,5,22 hypotheticals 186:20	124:13 151:24 152:6,9,13,21 159:14 217:11 idiopathic 69:5 74:11,16 76:5 76:8,11,16,19 78:10 79:21,24 80:10 90:17 91:1,3,8 iler 43:1,8,17 43:25 44:4,9 ilers 43:13 illinois 1:20 236:22 immunologist 39:7 impact 227:25 impacted 122:4 122:22 imperative 237:10 imply 112:25 140:21 important 7:21 123:2 142:2,4 142:8 impossible 78:20 127:9 216:25 inaccurate 125:4,6,6 inappropriate 180:22 181:1	inasmuch 227:8 incidence 5:10 80:13 83:19 84:10 197:23 203:21 incident 47:17 include 45:3 56:9 173:25 180:9 225:14 231:9 included 43:10 57:14 59:1 106:3 108:10 119:3 191:19 includes 232:10 including 53:12 85:10 110:6 221:21 224:22 inconsistent 124:14 incorporate 142:4 193:20 incorporated 30:17 142:16 193:1,15 incorrect 122:3 122:8,22,24,25 174:20 increase 33:17 64:9 65:10 67:12 71:8 72:3,18 83:19 91:10 93:19	156:9 186:3 201:18 214:15 225:20 228:7 increased 49:17 50:16 66:15 67:20,24 68:2 71:24 84:24 85:9,23 86:8 91:18 92:14 93:5,9 93:14,16 94:4 96:12,21,23 101:4,12,16 103:21,25 105:13 111:15 154:8 159:20 188:1 233:11 increases 68:8 68:9 93:18 208:25 214:8 increasing 201:9,15,22 225:17 independent 104:24 105:2,6 105:15 107:9 index 102:9 indicate 85:3 86:1 indicated 202:14 239:6 indicates 230:8 indicating 85:2 94:14
i			
identifiable 79:14 identification 11:7,16 30:1 69:10 81:3 109:15 112:18 120:23 126:5 155:23 188:22 190:4 191:23 197:19 204:6 identified 35:19 80:4 108:24 110:22 113:16 118:17 125:19 143:23 152:12 153:12 153:25 157:18 157:20,22 166:5 176:10 227:21 identifies 152:18,22 157:10 identify 6:15 35:22 74:17 75:9 79:17 111:9 116:18			

indication 113:19 indicative 86:8 87:1,3 indicators 227:6 indirect 218:16 individual 36:4 42:11 43:2,3 44:15 46:22 78:23 90:25 95:7,9 110:4 114:6 122:10 133:6 156:19 178:9 180:23 182:5 186:5 217:8,8 223:16 227:8,14 individual's 47:13 120:2,12 178:11,23 217:6,23 218:10 individually 186:8 individuals 44:6,9 46:15 46:20 66:22 67:1 68:4,24 110:23 114:10 125:20 189:16 191:15 211:4 232:21 233:21 234:2	industrial 43:5 infinity 77:20 inflammation 202:17 influence 111:14 influences 64:9 111:1 inform 156:25 information 13:11,17 32:25 42:10 43:5,24 44:1 45:22 46:13,18 47:8 47:11 58:5 113:7 117:21 119:3 125:15 127:13 136:12 140:25 141:2,5 146:24 152:16 187:18,24 191:19 194:5 217:15 218:21 219:9 225:6 229:13,16,20 informed 207:19 ingested 142:18 143:1 144:3 145:5 229:5 ingestion 44:20 147:17,19 inhalation 44:20 144:1	inherited 115:7 115:18,22 116:3 initially 106:3 injuries 34:14 40:16 injury 23:14 25:8 34:7,18 34:22,24,25 installed 216:7 instance 78:24 123:10 227:15 instances 223:3 institute 81:7 instructions 237:1 instructs 8:17 intake 191:2,6 integrate 194:5 integrated 134:2 intend 11:21 12:7 intensity 151:3 intent 201:2 interact 149:25 interaction 9:19 interest 50:12 59:2 73:18 interested 195:21 236:16 interesting 92:2	interface 86:18 internal 219:25 internship 40:21 interpret 206:16,23 207:2,23,24 208:10 220:4,6 interpretation 83:14 207:17 interpreting 117:1 interrupt 8:2,5 162:14,15 interval 153:18 154:13 165:18 166:8,11,13,20 166:21 199:23 203:15,25 213:16,24 intervals 199:20 200:2 intro 23:18 25:14 30:25 introduce 10:23 29:24,24 69:8 80:16 81:1 109:12 112:15 126:3 154:17 204:4 introduced 121:6 introducing 120:21 188:19
---	--	--	---

investigation 32:6,9,14 invitae 109:25 invited 53:19 invoice 192:18 involved 39:10 43:14 98:10 155:2 232:13 232:14 233:4 involves 32:11 147:3 iraq 32:24 56:15 irrelevant 122:16 irving 104:20 105:16 island 2:13 issue 66:8 204:17 231:15 issues 221:23	johnstone's 19:14 joke 198:4 josephson 21:3 josephson's 20:24 21:8 journal 23:11 journals 56:20 56:23 judgment 70:24 july 22:19 23:25 24:1,10 230:10 236:25 jump 16:17 22:1 172:5 june 1:11 6:2,6 22:19 24:1,1 24:10 81:18 justice 2:16 35:21	10:21 14:11 15:6,21 16:8 16:11,20,23 17:8,17 18:1 38:15,19 40:19 40:22,24 41:1 42:7,24 48:18 48:19,23 50:22 50:23 51:7 54:6,8,12 59:2 60:3,5,7,9 63:23 64:3,6,8 64:14,18,19,22 64:25 65:10,14 65:17 66:3,19 66:23,24 67:2 67:3,7,8,10,11 67:12,24 68:3 68:5,9,10,14,15 68:18,19,21,25 68:25 69:18 70:5,9,15,17,18 71:2,8 72:18 72:19 73:4 74:8,21 75:4,7 75:9,11 77:9 77:12,13 78:1 79:5,6,9,9,13 79:14 80:8,12 80:14 82:5,9 83:7,16,22 84:4,8,20 86:1 86:9,11,14,15 86:19,22 87:2	88:8,11 89:6,8 89:17,21,22 90:10,13,17 91:10,17 92:13 93:4,10,12 94:1,4,6,17,20 94:22 95:4,8 95:22 96:12 98:24,25 100:12 101:2,4 101:11,17,24 102:2,6 103:4 103:18,22,25 104:1,7,9,10,11 105:1,3,7,11,18 107:11,16,17 107:21 108:15 111:6,15 113:6 113:9 114:24 115:10 116:4,6 116:8,19 118:2 118:13,20 125:20 132:20 144:20 152:11 152:17 154:8 156:14 157:1 157:12,15,18 157:24 158:7 158:10,12 159:1,7,12,16 159:21,25 160:3,9 161:17 165:20 167:2,3 167:6 168:5,9
j	k		
january 10:4 jennifer 1:18 6:24 236:2,18 238:11 jim 2:4 6:21 196:8 job 1:23 36:11 78:9 144:13,17 144:22 187:25 johnson 52:12 52:15,16	karami 153:18 keep 93:22 keeping 19:3 keller 1:16 kelly 46:22 58:4 170:1,3 183:5 kevin 9:10 kidding 198:8 kidney 4:12,13 4:18 9:25		

184:17,20	44:23 49:10,11	176:9,10,24	132:7 140:18
185:3,8,13,19	49:15 50:20	177:8 178:3	140:18 161:8
186:12,15,25	51:5,12,19	187:3 188:5	162:3,4,5,22,23
188:2,3 191:3	55:5 58:14	189:19,22,22	163:12,12,14
191:7,8 192:17	60:24 62:22,23	189:23,24	163:18 164:14
201:3 202:14	62:25 63:16,17	195:21 196:19	169:4,9 171:23
205:14 208:23	63:25 66:18	196:20 201:24	176:25 177:9
209:1,6,17,21	67:15 72:7	201:25 205:12	labeled 33:25
209:25 210:8	75:24 76:11,18	207:8 210:19	lack 34:24
210:20,25	77:9,19,22	215:5,18 216:5	lag 8:8 81:19
211:1,2,4,7	78:6,7 79:19	216:7 217:1	lakind 19:23
212:21 213:1	79:20 83:3	221:25 224:2	lakind's 19:18
214:6,8,15,20	84:7,16 93:23	226:5,9,25	language 57:20
216:17 223:14	95:11 96:5,6	228:13 231:14	large 26:15
223:16 225:10	96:19 97:5,8	232:13	38:12
225:17 226:21	99:8,17,18,20	knowledge	largely 94:19
227:15,19	99:22,25	76:4,7,15	larger 106:4
228:3 232:14	100:11 102:12	77:25 78:4,5	lasted 196:15
234:5	102:18 106:9	99:2 111:4,10	late 13:11,18
kind 25:24	109:5,18 111:7	200:15 224:21	173:6 177:23
86:15 102:19	111:16 112:2	227:11 231:23	196:13
177:4 222:14	112:10,12	known 70:13	latency 154:14
knew 45:18,20	113:23 115:9	74:10,13 77:2	206:11,12
82:20 87:8	116:25 117:18	77:4,12 78:2	207:6,7 208:24
111:11 144:15	120:14 122:20	79:23 88:10	209:1,4,15,20
189:15 196:12	124:15 125:14	91:3 99:9	209:24 210:16
196:12	125:25 129:2	109:10 111:5,5	210:17,18,21
know 7:9 8:12	130:12 132:25	185:21	211:3,8 213:7
9:13 11:9 19:2	135:6,15	I	214:7,9,16,18
19:7 22:11	141:10 143:10	I 2:3,21 43:1	219:14,15
26:3,9,11 27:1	143:19 151:17	56:6 129:14,17	227:10,12,13
29:23 30:4	151:21 161:3	129:19 130:10	227:18,20
33:3,25 38:11	162:16 172:24	130:20 131:6	228:2,5 232:17
40:13,18 44:13	173:19 174:4		

latent 226:15 226:20 227:4 law 9:13 26:9,9 26:11,12,13,13 26:18 lawful 7:2 lay 215:6 lead 73:4 86:23 leading 75:5 130:14 leaf 7:19 learn 10:3,11 78:8 learned 10:8 learning 31:6 leave 172:22,22 173:7 174:1,10 174:12 175:21 212:17 lecture 26:19 26:20 lecturer 23:20 25:16 26:1 27:4,7 31:5,21 lecturers 27:23 lectures 26:5 27:9,22 29:4 30:17,21,22 31:17,17,25 190:11 led 118:19 lee 2:3 3:5 6:21 6:21 29:10 34:10 48:4	61:8 65:1 67:16 70:20 71:17 73:2 80:17 81:4 91:4 92:4,6 98:11 106:20 111:17 113:11 115:23 116:14 122:5 123:11 123:25 124:19 125:12,24 128:17,23 137:8,24 138:24 142:22 144:5 146:13 147:2 149:10 152:2 158:14 159:2 160:10 168:13 173:10 175:6,10 177:17 180:17 181:20 184:1 186:21 187:1 187:15 188:16 196:6,12 200:10 207:14 209:8 211:10 215:8,20 221:16,18 225:22 227:22 234:7 left 27:20 172:22 222:4	legal 2:2 5:9 9:14 192:8 lejeune 1:5 4:21 6:11 9:3 35:20 36:1 41:21 42:8,23 44:6,10,16,18 45:13 48:2,18 48:19,24 49:4 50:6,10 51:2,3 51:13 52:4 53:12,18 85:11 89:5,10,20,24 93:25 98:19 99:21 100:23 101:1 103:13 103:15 105:4 107:15 119:16 121:3,16 123:21 129:22 138:8,17 139:19 148:23 149:3 150:7,12 150:18,24 151:4,10 159:22,24 160:2 163:11 172:22,25 177:1,10 183:22 184:25 185:2 190:12 198:21 199:8 199:15 200:20 222:9 231:4	239:3 length 94:19 217:17 letter 3:8 leukemia 9:25 50:3,5,5,8,11 50:22 51:1,2,7 209:18,22 223:14 226:21 227:5 232:14 232:15 234:5 level 45:9 47:5 55:8 73:8 102:22,24 103:4,13 138:6 152:8,10 154:11 156:7,8 156:13,22,23 157:2,3,11,14 158:6 159:5,11 160:7 164:22 165:5 167:17 180:20 181:24 182:24 211:20 211:21 225:20 234:1 levels 103:24 124:6,22 125:17,17,18 125:21 130:16 151:4 152:12 152:13,22 153:9,21,25 154:5,9 156:17
---	---	--	--

156:19 157:17 157:19 158:1,8 159:23 160:2,4 163:10 169:20 177:6 179:13 179:22 180:24 203:14 217:1 218:3,7,9,13,17 218:17,23 225:8,8,11,16 233:21 234:4 licensing 57:2 lie 71:22 life 78:20 231:11 232:11 lifestyle 231:13 lifetime 83:21 84:5,9 180:4 180:11 188:5,8 188:9,15 light 120:10 230:16 likelihood 47:22 68:8 85:8 111:19 116:23 159:16 likely 66:2 68:14,18,21 69:6 70:25 85:13 89:6,23 166:17 224:8 225:17 228:6 likewise 96:21 154:9	limited 108:6 limiting 119:7 limits 179:22 line 24:15,16 37:5 41:18 42:2 74:7 110:13 147:2 147:22 193:14 199:19 201:4 201:17 210:8 239:8 linear 201:6 lines 30:19,24 30:25 31:2 110:11 199:3 219:1 linked 108:15 lipscomb 17:20 lipscomb's 16:2 liquid 141:23 list 4:5,6,7,9 12:13,17,23 13:4 14:21 15:11 21:21,23 40:18 58:20 59:6 77:16,17 87:10,13,15,16 95:22 96:1,4 132:1 listed 13:19,23 14:3 21:13,18 21:19 23:10 24:3,19 26:25 189:18 205:21	220:15 lists 13:7,23 21:14,24 56:13 77:24 87:18,21 liter 46:14,15 46:19 129:14 129:19 130:16 130:17 131:12 131:13,16,17 131:19,21 132:6,10 133:1 133:3,4 140:11 140:13,18 149:4,4,5,6,14 149:22 156:23 158:6,9,12,21 158:25 159:19 159:20 161:13 162:2 163:12 165:6,7,10 169:5,9,22 170:2 171:2 172:13,18 181:23 184:4,6 literally 127:9 literature 37:15,18,25 38:15,19 42:13 42:14 58:23 77:24 160:1,5 224:20 225:10 liters 131:11 158:2,2	litigation 1:5 2:17 6:12 9:4 9:23 10:14 34:17 35:20,20 36:6 239:3 little 28:13 45:25 49:12 82:18 84:1 157:8 170:25 201:24 205:6 220:7 live 78:20 lived 45:7 148:25 liver 223:15 locate 189:7 located 173:13 192:25 193:5 location 133:22 173:12 logic 96:25 219:25 long 45:18 95:2 95:6 96:11,23 98:20 99:6 106:14 131:18 135:14 136:12 168:11 197:2 longer 47:21 49:14 50:23 100:10 227:20 228:5 longitudinal 43:2
---	---	---	--

look 12:12,16 12:20 13:1 33:4 34:18 35:15 49:11,14 49:16 57:7 60:20 66:7 69:15,20 75:5 83:14 85:16,17 85:22 87:19 104:3 128:21 129:1 134:15 140:9 156:17 156:25 166:7,8 166:12 167:5 170:10,12 174:3 179:4 182:13 183:5 183:19 189:21 192:3 200:8,25 202:6,8,10 204:3 209:24 212:19 213:18 222:21,22,22 225:1 226:3 230:2,7,11,17 231:4 looked 13:10 32:25 47:18,19 55:20 60:14,16 60:23 84:17,23 86:4,4 90:20 98:22 108:11 111:19,19 121:23 131:5,9	131:11,20 142:11 153:13 156:25 178:15 179:5 189:14 202:20 212:2,3 212:6,7 214:16 215:19 218:6 223:12 233:17 looking 10:19 33:6 35:3 37:3 42:12 45:12,13 49:23 67:8 81:22 86:16 127:18 131:2 132:1 145:12 145:18,24 156:2 157:3,4 157:25 165:5 166:23 170:20 172:2 182:19 182:21 183:8 183:19 184:14 195:6,9 199:13 199:14 203:5 203:20 207:21 210:12,12,15 210:16,17,18 210:25 212:9 213:6 217:14 218:9,24 223:13 232:2 looks 45:2 69:15 82:1,3 109:20 135:14	178:15 211:5 lost 102:2,5,6,9 lot 10:10 35:18 69:17 72:8 98:4,6 101:23 180:18 222:1 226:2 lotan 189:22 lotan's 20:20 love 71:21 low 46:5 102:16,19,22 102:24 103:9 103:13 153:18 154:10 157:19 157:22,25 158:20,23 159:5 165:5 169:5,13,15 170:22 171:8 171:10,10 184:12 201:18 203:6,8,13,21 210:7,11,20 211:19,20 212:3,5,6 213:19 225:16 225:20,20 234:4 lower 60:15 102:6 103:2,4 103:5,6 123:8 123:22 125:8 153:21,21	166:19 167:17 167:21 213:15 213:23 225:8 lowest 158:20 159:11 160:7 lunch 107:5 m m 1:15 2:18 3:3 4:10 132:7 163:18 m.d. 1:15 3:3 7:1 202:12 236:5 238:2,8 239:2 m.p.h. 1:16 3:3 7:1 ma'am 32:5 34:11 madam 97:17 98:15 135:22 136:18 138:22 153:2 160:17 made 8:19 12:10 71:5 104:17 126:14 144:13,17 147:10 192:5 237:5 239:6 madigan 18:22 21:6 166:4 magnitude 65:19 154:10
---	--	--	---

maintain 191:14 majority 45:11 49:3 224:11 make 8:8 22:12 25:24 28:24 29:23 36:11 47:7,9 68:14 68:18,20 70:24 79:2 91:8,20 136:5 139:10 148:6 166:5 170:17 172:24 174:7 175:25 176:2 193:24 194:3 196:13 201:17 205:6 219:24,24 223:21 228:22 228:25 232:5 237:3 makes 29:6 75:22 90:25 104:11 130:1 135:16 208:14 220:10 making 111:25 221:24 mallon 1:15 3:3 4:10 5:6,8 6:14 7:1,7,18 11:6 69:10 81:3 97:15,15 109:14 112:17	120:22 126:4 139:9 153:5 155:22 168:23 188:21 190:3 191:22 197:18 204:5 221:19 236:5 238:2,8 239:2 mallon's 29:25 managing 117:13 mandated 25:25 mandel 152:20 225:14 mandell 2:12 2:12,12 mangled 98:14 103:11 190:20 manuals 133:24 134:5 134:22,22 manuscripts 56:24 margulis 20:22 marine 4:21 121:3 134:22 167:23 199:8 222:8 marines 176:25 177:9 198:22 200:21 221:22 mark 50:17 120:19 181:22	marked 11:6 11:15 30:1 69:10 81:3 109:14 112:17 120:22 121:11 126:4 155:22 188:21 190:3 191:22 197:18 204:5 234:4 markedly 49:19 50:16 96:21 168:9 188:1 markers 86:16 86:21 marking 197:22 martel 189:23 maryland 7:19 mas 36:25 maslia 194:14 194:16 maslia's 45:16 136:9 mass 102:9 139:22,23 140:2,3,16,22 141:6,8,10,15 141:22 142:15 142:15,18 143:1 202:14 214:25 216:1 massachusetts 5:13 204:10	216:12 master's 37:1 38:12 materials 4:5,6 4:7,9 12:13,17 12:22 13:3,7,8 13:14,23 14:21 21:13,14,21,23 21:24 58:20 87:16,17,21 96:3 205:4 224:20 math 164:7 mathematically 111:21 matter 6:11 9:9 69:19 matters 72:8 maximal 134:11 maximum 134:3 179:12 179:21 mayo 4:11 69:12,17 74:7 75:5 90:21 mccabe 15:13 17:16 mccabe's 15:5 15:18,21,25 mcl 179:16 180:14 181:24 181:25 182:6 182:12,14,16
---	--	--	---

182:17,19,20 182:23,24 233:19 mcls 179:13,22 179:25 180:2,6 181:5,8 mdlg7448979 1:23 mean 19:25 25:20 27:7 51:21 55:10 57:25 60:15 64:7,16 78:14 86:18 90:24 99:2 101:23 102:12 129:24 129:24 130:4 170:11 171:18 171:22 174:17 175:5,23 176:6 176:17 182:3 182:11,22 194:18 201:22 206:16,23 meaning 166:15 meaningful 208:25 214:8 means 70:17 141:22 224:19 meant 117:10 117:10 134:6 145:1 194:1,1 210:20 231:11	measure 217:6 217:23 measured 149:13 measures 34:7 218:16 measuring 137:23 218:10 mechanic 44:22 44:23,24 medical 13:10 13:17 14:1 22:23,24 23:1 28:17 29:2 34:19,20,23 35:13,14,15,23 36:4,24 39:20 39:22,24 40:2 40:12,12 42:13 42:14 54:1,8 75:6,20 76:22 94:13,14 110:5 110:24 118:23 119:5,8,9 160:1,5 168:8 191:1,3,6,7,8 191:12,15,19 222:11,22,22 222:23 223:1,4 225:9 medicine 22:18 22:22 23:1,3 23:13,19,25 24:9,12 25:14	28:15,22 31:9 40:11 54:23 75:20 90:8 117:7 medium 46:5 154:11 157:19 157:23 167:5,9 167:14,17 168:2 171:7 186:16 201:18 227:13 meet 37:20 49:4 114:17,19 117:16,16,17 125:19 meeting 196:16 197:2 meetings 197:5 197:8 meets 28:25 114:20,20 member 56:8 80:7 190:2 231:2 members 221:22 222:8,9 memorandum 43:1,10 men 84:1 mention 42:17 mentioned 27:13 43:17 118:3 132:22 222:16 231:19	233:16 merit 1:19 236:3,20 met 28:23 62:15 106:11 116:20 196:21 meta 95:13,21 96:10,18 153:12,12,14 metastasis 13:12,18 metastatic 104:9 methodologies 58:1 methodology 57:10,15,19,22 84:13 176:25 177:2,9,12 methods 124:14 metric 131:17 132:11 137:6 142:20 143:1 metrics 131:24 144:12 mg 205:15,20 206:11,12,13 206:17,17,22 219:14,15,16 220:15,19 mgs 206:25 212:10,10
--	--	---	--

michael 7:18	192:23	minimum 26:4	mixture 99:3
michigan 26:13	midway 176:23	215:12	mm 20:15
micro 33:6	mike 2:8,8	minute 80:18	66:21 89:15
193:23	milieu 74:2	130:21	110:17 127:17
microgram	military 40:12	minutes 48:5	151:11 184:17
46:14,15,19	43:6 44:16,21	106:17	206:4
129:14 130:16	56:18 117:5	misclassificat...	model 45:17
130:16 131:11	133:24	167:25 227:8	56:1,3 119:22
131:12,16,17	milligram	misdirected	123:22 124:25
131:19,21	207:11	149:17	125:6,7,10
132:6,10 133:1	milligrams	misheard 72:13	135:3,4,10,12
138:6 149:4,4	132:12 138:15	137:3	135:12,25
149:5,6,14	139:13,14,16	mislead 123:12	136:1 137:14
156:23 158:1,2	139:21 140:3,6	123:17	145:14,15,16
158:6,11,21,25	141:7,9,10	misremember	145:19,24
159:19,19	146:16 207:6,6	28:4	146:9,20,21
161:13 162:2	208:3,8,12	misremember...	147:11,17
165:6,7,9	214:25 216:1	30:12	148:11 163:13
169:22 172:12	217:13 220:9	missed 112:5	182:18 193:16
172:18 184:6	million 84:11	missing 87:1	206:11 207:5
micrograms	140:14,15,19	128:20 149:22	217:18 219:14
131:13 132:12	141:22 217:12	155:12	modeling 45:17
139:14,15,18	mind 49:4,9	mission 34:14	45:20 120:1
139:20 140:2	88:22 116:22	missouri 1:21	122:3,21 124:3
140:11,12,18	174:22	236:23	124:12,16
148:15 149:22	mine 26:23	misspoke 29:15	134:21 143:13
158:9 163:12	92:4,6,11,11	84:7	177:3,4 194:2
170:2 171:2	128:17 198:13	mistake 111:25	194:14,19,21
184:4 229:16	mini 106:16	112:3,6	195:3 217:10
microrna 37:19	minimal 118:18	mistaken	217:15
mid 128:20	184:18	173:15	models 56:6
middle 104:6	minimally	mix 186:18	120:1,10 123:9
161:16 169:5	91:17 92:14	223:18	124:7,9 125:9
169:13 171:3	93:5,9,9,14		133:7,25 135:2

135:5,7 136:7 136:9,14,22 193:21 194:10 194:17 molecular 33:3 33:4,4 37:2,4 37:11,18,21,24 37:25 38:6 73:8 moment 132:2 moments 75:13 monotonic 152:18 201:5,9 201:12,16,23 month 10:9 130:5 131:17 144:3 149:22 156:23 158:6 158:12,25 163:14 169:22 176:7,11,13,23 181:6,8,16,23 182:5,11,17,22 183:17,25 184:4,5 monthly 124:5 129:20,24 130:4 162:21 170:11 171:18 171:22 174:17 175:5,23 176:6 176:17 178:9 178:22 182:3 182:11,22	months 44:15 46:14,15,19 49:17 129:14 129:14,17,19 130:10,16,20 131:6,12,14,21 132:6,10 133:1 144:4 149:14 149:22 151:1 158:9,21 159:19,20 161:8,13 162:2 162:3,3,4,5,6 162:22,23 163:15 164:14 165:6,7,10 169:5,9,20 170:2 171:3,23 172:13,18 174:17 176:17 176:18,25 177:9 178:25 183:23 moonlighting 233:8 moore 140:11 morning 7:7,8 morris 45:16 45:21 136:9 177:3 194:13 mortality 47:17 216:14 mos 44:24,25 45:13	mother 104:8 move 39:17 184:2,7 moved 122:14 movie 173:20 moving 35:1 mp 145:14 mrna 33:6 mt3 145:15,16 mt3dms 135:3 135:10 136:1 146:21 147:11 193:16,20 mt3m 135:3 mtd3 182:20 mtsd3 194:1 195:3 multifactorial 64:4 multifocal 114:8 115:4,17 115:21 116:6 116:10 multiple 61:4 64:9 116:2 193:11 multiplied 131:17 multiply 84:10 131:15 mutation 74:3 116:13 mutations 73:1 73:3,4,9,9,11	73:13,16,18,23 74:1 116:18 n n 2:1,9 3:1 6:1 198:23 199:10 200:21 210:4 name 6:4 7:10 7:16 21:4 96:5 96:6 named 72:7 narrower 50:15 nathan 2:20 nathan.bu 2:20 national 40:12 81:7 nature 50:13 97:3,12,20,23 97:25 115:7,18 115:22 116:3 117:10 123:2 185:24 navy 198:22 199:8 200:21 nccn 4:17,17 112:21,23 113:14 116:25 near 134:11 nearly 65:5 necessarily 13:19 97:2 131:14 156:18 180:15
--	--	--	---

necessary 152:11 187:19 237:3 necrosis 202:18 need 56:17 113:22 140:25 141:2 153:7 174:6 176:4 183:11 219:23 needed 174:24 negative 49:7 106:6,12 109:11 116:20 118:1 negatively 104:10 neither 236:12 236:14 nephrectomy 202:15 never 21:3 31:4 37:8,11,14,17 38:14,18 54:1 95:10 96:13 172:22 211:18 212:3,7 new 75:9 82:9 83:8,16 95:24 101:15 119:3 193:14 nice 43:8 nine 51:10 216:22	ninth 22:21 nodding 7:24 non 33:16,18 93:25 101:1 103:11 227:7 noncancer 41:22 223:15 223:18 noon 106:25 normal 188:11 normally 167:13 north 1:1 2:9 4:21 6:13 121:4 northwest 6:9 nos 60:21 199:22 200:6 201:15 203:2,2 203:14,20,24 notary 238:19 note 192:4 202:25 noted 89:7 202:15 205:14 205:20 214:15 220:15 237:8 238:6 notes 141:13 195:6,9,11,12 197:7 209:21 notice 1:16 5:5 5:8 156:16 189:1	noting 110:3 nuclear 233:3 null 228:4 number 4:2 5:2 10:23 26:21 44:15 94:2 99:17 100:25 101:1 106:5 109:13 112:16 114:1 120:21 120:25 126:7 138:4,5 139:22 139:24 140:2 141:20 144:2,4 146:20 154:17 154:19 155:25 161:13,20 163:18,20 164:3,5,9 165:9 167:16 167:20 169:9 177:16,17 181:18 183:7 188:20,24 190:6,10 191:5 191:25 192:11 192:21 193:11 198:17 202:12 203:20,24,25 204:4,8 205:5 205:7,8,24 222:17 224:3 225:23 230:5	numbered 22:16 69:22 101:1 numbers 41:15 80:15 109:20 124:10 129:12 132:25 133:2 138:10,15 139:17 140:17 145:11 149:12 156:10 162:9 163:1 164:11 164:12,17,17 165:6 171:19 172:1 192:11 192:20 203:2 205:21 206:18 207:11 208:4 220:15,20 221:2 229:9 nutshell 222:14 nw 1:17 2:21
			o o 6:1 190:1 oath 7:12 obese 68:10 obesity 64:21 68:7 object 123:11 175:6,10 196:6 207:14 objection 8:17 8:19 29:10

61:8 65:1 67:16 70:20 71:17 73:2 91:4 98:11 111:17 113:11 115:23 116:14 122:5 123:25 125:12,24 137:8,24 142:22 144:5 146:13 149:10 152:2 158:14 159:2 160:10 173:10 180:17 181:20 184:1 186:21 187:1 187:15 188:16 200:10 209:8 211:10 215:8 215:20 224:24 227:17 objections 5:7 obligated 7:13 obtain 59:22 obtained 206:10 207:5 219:13 obvious 91:9 obviously 184:5 196:9 232:14 occupancy 178:23	occupation 90:7 occupational 22:22,24 23:1 23:2,12,18 24:12 25:14 27:2,11 28:15 40:11,16,16 43:6 44:17,22 45:2,4 69:7 117:7 222:1 231:12 occur 73:11,14 73:18,24 74:1 74:4 78:15 111:24 122:12 occurred 47:21 78:24 216:25 231:10 occurrence 73:16 occurring 47:23 160:2 174:22 occurs 232:11 october 9:12 35:2 204:14,17 odds 153:14,17 209:21 213:7 213:19 228:7 oeh 30:25 oem 23:11,17 25:11	offer 11:21 12:7 112:11 152:8 offered 20:14 20:18 54:7,11 offering 149:24 oftentimes 222:25 oh 11:12 128:8 131:3 149:16 149:19 161:24 192:10 226:18 okay 8:9,19 10:22 16:14,22 17:6 23:9 28:7 30:5,11 34:4 41:16 76:1 81:11,16,23 87:19,23 88:3 94:10 100:5 109:24 110:12 114:6 119:9 122:18 124:25 126:25 127:14 129:3 131:5 136:25 137:3,4 145:21 147:7 148:10 157:7 157:21,25 165:3 169:3,18 177:20 179:11 190:9 193:10 195:17 198:19 204:21 218:5	219:7 224:14 226:4,18 228:15 229:17 230:24 old 94:3 older 65:16 once 84:17 102:4 106:2 109:7 116:17 144:15 185:23 192:4 194:3 215:14 222:3 oncologist 39:1 oncology 4:17 113:5 one's 87:1 ones 59:1 61:22 62:12 186:5 197:8 ongoing 45:20 opine 156:14 opined 188:2 opinion 36:4,12 42:7 54:6,11 91:2 94:25 102:1 103:17 103:18 104:16 104:24 105:2,6 105:16,17,21 107:9,20 112:11 115:14 115:17,21 118:12,14,15 119:17 149:24
---	--	--	--

151:15 152:10 158:8,24 159:22,23 160:7,20 168:8 184:23 185:7 185:13,19 186:11,14,24 187:7 207:19 209:5 216:20 220:19 opinions 11:20 11:23 12:6,9 20:13,18 49:7 54:8 57:11,16 58:1 118:11,25 119:10,12 120:9 222:11 222:23 223:1,4 opportunity 16:7 40:21 132:3 136:13 189:24 191:21 196:5 216:9 217:25 222:24 228:6 opposite 143:21 option 127:11 orange 222:10 order 65:19 154:10 organic 163:9 163:13	organize 25:21 29:4 organized 26:11 origin 74:16 original 21:23 63:24 237:10 outcome 36:3 42:12 223:9 outcomes 33:14 33:15 35:7 41:22 42:4,15 198:21 199:7 200:19 223:11 outlined 143:11 outlying 53:2 53:11 output 52:24 outside 90:6 outweigh 117:19 overall 231:13 overcorrected 174:23 oversee 117:4 overstate 146:23 overweight 91:16 92:1,12 93:3,18 101:10 101:14 102:4,7 own 74:4	p p 2:1,1 6:1 56:1 134:25 135:1,3 201:25 p.m. 80:20,22 80:23 92:18,20 92:21 106:23 106:25 107:1 139:2,4,5 155:16,18,19 168:16,18,19 197:12,14,15 221:9,11,13 235:11,13 pack 71:7,12 71:13 72:3,23 72:23 79:15,22 80:2 94:12 96:20 package 119:3 packs 71:9 page 3:2,9 4:2 5:2 17:13 22:14,17 23:6 24:3,8,19 30:8 30:9,10,14,22 31:1 33:24 34:2,3 35:1,3 41:8,12,12,14 41:15,17 57:8 57:9 69:21 70:2 81:24 82:1,3,8,23	83:11,13,24 88:25 89:13,14 91:13,21,22 93:2,21,22,22 94:9,11 100:25 101:8,9 104:3 104:6,15 109:22,24 110:4 113:25 121:9 127:1,1 127:19,24 128:3,6,9,20,22 129:2 134:15 134:16 137:17 137:18 144:24 145:3,20 146:5 146:8 147:13 147:16,23 148:19,22 149:15,18 150:5,10,14,16 150:20 153:6 156:5 160:23 160:25 161:1,3 161:3,5,16,17 161:20,22,24 162:20 163:4 165:13 168:24 168:25 169:3 169:17 170:4 170:10 177:15 177:20,21,22 177:25 178:1,2 178:20,21,21
--	---	--	--

179:10 181:10 181:11,11 184:14,14,16 190:8,9 192:11 192:15,15,17 192:21,23 193:7,10 198:17 202:8 202:11,19 203:10,12,13 204:20 205:5,7 205:24 206:2,2 208:21 209:12 211:13 212:18 212:18,19,25 213:1 214:1,21 214:22 216:23 218:18 219:1,2 219:10 220:12 220:14 226:3 226:22 228:16 230:7,11,17,18 231:5 234:22 239:8 pages 13:25 14:2 22:16 69:22 119:5,7 119:9 127:3 145:13 222:21 238:3 pagination 109:23 panel 106:2 108:3,6,8,9	109:8 pants 49:13 paper 56:12,16 56:19 58:17 157:15 164:18 164:18 183:11 220:1 papers 56:11 56:19 152:15 paperwork 168:25 papillary 61:22 62:7,13,14,16 62:17,18,23,23 63:5,8,20,22 64:1,1 76:8,14 76:18 106:10 106:12 116:21 200:12,14 paragraph 57:10 89:4,15 91:16,23 93:2 94:2,11 101:9 147:16 150:21 161:7 163:7,8 165:16 169:19 178:3,6,8,17,18 179:12 189:15 190:1 202:12 203:12,18 204:23 205:13 205:20 206:5,6 206:9 208:23 212:20,25	213:1 214:6 216:23 226:7 226:13,17,19 226:24 231:5 231:19 232:7 park 2:13 parker 154:3 part 28:18 31:8 33:10 34:13 35:12 37:6 43:9,12 52:17 55:13 75:23 90:2 114:3 119:12,17 128:23 149:23 177:11 184:8 232:8 particular 29:5 49:21 50:12 63:3 73:21 75:1,3 80:1,2,5 85:17 121:21 121:23,25 122:11 130:22 133:5 156:17 230:8 235:3 particularly 49:18 50:20 93:13 186:16 195:2 parties 236:14 parts 120:25 140:12,13,14 140:15,19,19	140:21 141:21 141:22 154:6,7 217:12 218:14 229:6,6,12,18 past 121:15 231:3 patchy 202:17 patel 153:19 pathogenic 113:17 116:12 pathogens 40:18 pathologist 63:1,2 pathologists 62:25 pathology 37:12,18 38:1 38:7 62:5 63:3 63:4,7,12,20 202:6,13 pathway 185:23 patient 40:3,6 40:19,23 41:1 68:15,19 72:3 72:4 80:1,3,5 108:25 113:22 patient's 71:8 79:14,16 90:25 patients 34:15 39:11,18,21 40:1,13,15,15 40:22 75:12
--	---	--	---

117:14 191:3,7 191:8 pause 168:4 paused 34:18 pce 38:19 97:1 97:3,21 98:7 121:15 134:24 135:2,2 145:6 145:14,19,24 146:9 147:19 148:11 149:4 152:21,22 153:8 156:10 156:13,22 157:2,4,11 158:2,6,12,21 159:11,20 161:8,14 164:3 164:12,22,23 165:17,20 167:2 168:5 169:4,15 171:11 179:13 179:16 182:9 182:17 185:6 185:12,16 193:16 195:3 205:15,15 209:6 210:6 211:16 214:23 214:25 216:1 217:1 218:15 218:18 219:3,6 225:2 229:7	231:3 pediatric 34:15 peer 37:14,17 37:25 38:14,18 56:20 pelvis 4:14 82:5 82:10 201:4 pending 8:22 pendleton 198:21 199:8 199:15 200:20 people 26:21 33:12,13 34:21 35:17 49:3 67:6,13 68:10 72:15 83:17 84:4,7 108:15 114:10,12,12 160:3 167:18 189:18,24,25 195:21 216:16 219:9 231:7 233:4,13 perceive 174:22 percent 44:2 49:6,6 51:8 67:20 70:18 77:23 83:8,19 83:22 123:8,21 124:8 125:17 125:21 165:18 166:15 182:17 223:25,25	percentage 48:22 50:8,25 70:13,14 76:4 76:7,15 223:20 223:23 percentile 131:10 154:11 205:21 206:12 206:19,21 207:12 208:13 211:20,22 212:15 219:16 220:8,16,21 221:2,3,3,5,6 percentiles 220:22 perform 54:20 189:7 performed 88:4 performing 90:5 period 34:16 83:3 95:6 142:11 151:1,5 154:15 173:3 176:21 177:5 178:11 180:14 215:1,5,11,19 216:3,6,15,21 226:15,20 227:12,13,19 227:20 228:2,5 232:17 233:3	periods 227:4 person 72:23 72:24 86:17 96:16 102:4 172:14 196:22 person's 44:22 64:10 72:18,19 102:1 personal 93:25 99:2 101:2 232:12 233:10 personally 84:22 141:19 191:17 personnel 198:22 199:9 200:21 203:13 perspective 45:16 ph.d. 33:21 phast 56:1 phenotype 113:16 phrase 188:6 190:10 physically 54:1 physician 35:15 physicians 74:10 95:11 112:24 113:2,9 222:23 picking 111:22
---	--	---	---

picture 107:17 224:7 225:2 piece 117:21 183:11 pin 164:9 pink 199:19 pipe 217:17,17 pipes 216:8,10 217:16 pis 33:20 pit 32:3,18 33:3 37:20,22,24 43:20 222:10 pits 32:23 place 27:13 102:11 170:22 236:9 plain 137:12 plaintiff 88:11 130:5 139:19 plaintiff's 9:15 9:20 plaintiffs 2:14 5:7 6:22 16:6 20:7,11 22:4 45:19 144:16 187:18 plant 52:25 plants 51:23 52:1,4,5,7,21 52:24 play 30:13 123:4	please 6:15 7:16 8:4,11,18 8:21 11:9,14 12:1,12,16,20 13:1 16:15 22:2,8,14 33:24 39:14 48:13 55:3 57:7 68:16 79:1 80:25 91:13 92:23 97:14 107:3 135:20 139:7 148:19 155:21 161:3 162:15 165:13 168:21 168:23 169:2 169:17 177:15 184:15 190:8 192:10,21 193:7 197:17 198:12 200:18 221:14 226:22 228:16 229:3 230:1 237:2,6 pllc 2:7 plus 44:21 90:7 pm 23:16 25:11 pmo542 23:12 25:3 27:15 pmo549 23:20 31:22 pmo558 23:18	pmo642 23:16 pmo655 23:14 pmo973 23:11 24:22,25 pms2 104:16 point 22:21,25 23:23 24:10 34:9 35:5 50:15 84:4,9 87:14 93:17 96:15 135:15 138:19,24 141:17 146:1 149:1,7 162:5 162:6 163:21 164:1 165:7 166:3,16 170:7 171:4 172:3 173:2,9,11,13 174:2,6,10,15 175:20 176:1 183:2,15,24 211:11 213:20 216:8 218:12 226:16 pointed 118:18 180:21 pointing 139:14 points 166:15 201:17 232:6,8 poorly 206:17 207:8	population 101:5 180:20 180:22 214:19 populations 180:8 portion 135:23 136:3,19 166:13 214:3 pose 98:2 posed 100:23 positing 125:3 position 53:11 95:6 116:9 223:21 224:23 positions 34:5 positive 49:6 62:16 96:20 153:23 186:8 possess 190:17 possibility 67:4 78:4 111:13 112:1,3,8 possible 59:13 80:2,7 110:19 111:11,20 possibly 184:10 post 119:4 postman 1:17 potent 50:21 potential 75:9 77:9,13,17,18 80:9 84:24 88:20 89:16 90:19,22 91:7
--	--	--	--

91:9 99:10 118:17,18 228:3 potentially 64:15,17 69:5 91:1 106:9 158:23 167:24 230:9 pound 102:9,12 ppb 144:2,3 145:6,6,9,11,11 145:16 146:12 146:16 147:19 148:14 179:14 179:17 183:18 ppm 144:1 practice 4:17 113:4 117:3,5 117:7,11 143:3 143:7,10,20 191:3,7,9,13 232:3 practices 57:12 practitioners 113:5 precepted 40:10 preceptor 22:21,22 23:1 precise 217:1 predict 122:11 predisposition 62:10,10 103:21 104:10	111:15 predominant 225:9 premise 32:15 74:22,24 preparation 31:8 130:15 prepare 10:15 34:9 196:3 prepared 58:4 preparing 22:5 presence 78:25 86:7,25 87:3 present 2:24 4:22 32:18 35:3 36:3 63:3 81:20 85:10 86:17,25 90:24 91:6,9 117:23 121:4 129:22 141:5 151:5 163:11 172:25 173:2,5 presentation 53:17 presentations 26:7 117:19 190:11 presented 130:9,19 144:8 190:12 228:7 235:5 pressure 65:13	presumably 113:6 presumption 122:8 presumptive 35:19,23,24 pretty 33:19 51:16 prevalent 71:2 prevent 141:5 preventing 78:9 prevention 23:14 25:8 preventive 22:18 23:18,25 24:9 25:14 28:21 31:9 54:23 117:6 previous 87:9 previously 27:23 58:12 79:12 97:18 138:23 146:17 153:3 160:18 219:11 primary 101:15 104:8 printed 81:15 printer 129:2 printout 4:11 4:13 69:13 81:7	prior 9:15 23:7 23:10 34:5 36:6 98:15 101:16 113:9 150:25 196:15 236:4 probabilistic 135:10 probably 9:5 10:4 25:9 26:4 26:10 27:5,9 37:20 40:7 44:2 69:17 84:11 222:19 222:19 223:25 problem 184:9 192:19 proceed 48:13 80:25 92:23 107:3 139:7 155:21 168:21 197:17 221:14 proceeding 7:11 process 13:11 13:18 136:14 produced 191:25 produces 42:25 product 218:14 production 5:6 189:4 profession 143:7,13
--	---	---	---

professional 56:8 professor 26:9 26:15,19 37:5 program 4:13 27:19 28:2,8 28:11,11,16,16 28:18,24,25 29:2,8,15,18,20 29:21,22 34:10 34:16,18,20 40:10 41:5 54:22 55:16 81:8 project 33:23 36:25 37:2 187:7 projecting 111:8 projection 82:22 promotion 54:23 propensity 85:23 proper 146:11 proportional 133:17 proportionally 133:19 proportionately 133:22 134:8 134:20	propounded 238:5 prostate 223:14 protection 180:9 protective 95:19 180:7 protuberation 74:1 provide 29:4 34:19 54:19 55:9 59:16 75:24 143:25 144:21 152:16 191:3,8,16 207:25 209:5 provided 30:16 47:18 87:17 128:15 129:6 144:9,12 156:20 187:17 187:24 225:5,5 providence 2:13 provider 117:21 providers 113:22 117:5 117:12,21 191:18 provides 47:6 49:12,21 98:8 117:20 168:7	providing 221:23 public 38:13 80:8 179:23 216:13 217:25 218:6,19 219:3 238:19 publication 231:16 publications 22:12 58:17 160:1 231:15 232:16 233:17 publicly 53:18 published 37:14,17,25 38:14,18 47:16 56:20 77:24 130:14 194:18 204:14,16 205:1,10 230:9 pubmed 58:6 58:10,16 pull 19:9 220:12 pulled 95:24 purdue 152:22 225:14 pursuant 1:16 pushing 177:22 put 34:16 45:15 46:22 47:15 136:14 138:3 156:24 164:9	171:7 222:19 224:18 230:1 puts 171:3 putting 164:11 px 173:20 q q&a 121:6,23 122:10 quality 144:7 quantified 44:12,14 quantify 43:13 47:13 70:13 151:12 quarters 49:16 49:18 question 7:22 8:4,11,14,18,18 8:22 16:15 20:3 22:2 29:13 30:14 36:22 39:12,19 41:17 44:13 49:10 50:25 54:7,17 60:13 61:10 62:19,20 63:24 66:25 68:16 70:21 71:6,10 72:5,6 73:5,6 76:13 78:4 79:1,11 80:1 83:20 85:6 86:10
--	--	--	--

88:16 95:5 97:15,18 98:14 98:16,16 99:14 99:15 100:3,21 103:11 105:8 105:15 111:18 115:19,25 116:16 119:7 121:22 122:15 122:17,18 123:6,11,15 124:1,3 125:5 125:13,23,25 125:25 130:18 137:9,25 138:23 141:4 142:6,22 143:18 146:11 146:19 147:5 148:16 149:20 151:24 153:3 158:15,16 160:18 175:6 175:11,12,14 177:7 183:3,9 185:9,10 187:2 187:16 190:20 198:3 206:20 207:4,14 212:24 215:9 216:19 230:23 questioning 124:25	questionnaire 191:14 questionnaires 191:2,6,13,16 questions 36:1 48:15 66:10 192:9 196:9 221:15 223:7 227:9 228:10 233:17 234:7 234:21 235:10 238:5 quick 140:9 228:10 quickly 22:10 224:14 quit 94:16,21 95:7 96:11 quite 141:21 229:15 quote 42:3 82:5 104:17 150:7 151:25 178:24 179:1 205:14 206:9 208:23 211:15,18 213:1 quoted 153:11 r r 2:1 6:1 43:1 race 66:1,7,14 races 66:4	radiation 188:10 raleigh 2:9 ran 56:1,3 randolph 2:3 randomly 73:11,14,24 74:3 randy 6:21 87:12 154:25 range 131:9 158:9 166:7 205:15 207:5 208:1 217:11 217:19,20 219:14 ranged 162:2 162:21 163:11 206:11 220:9 rate 84:10 232:23 233:11 rather 7:23 60:15 79:23 104:9 146:20 147:11 229:18 ratio 95:17 144:19 153:14 153:17 157:5 165:25 166:24 167:1,6,9,10,17 167:21 168:1,2 168:3,7 203:14 213:7,19	ratios 156:16 209:21 228:7 rcc 4:18 60:21 101:15 108:25 113:15,21 114:1,6,9,10 116:12 201:12 201:15 203:2,2 203:14,20,24 rccs 76:5 rdd 206:10 211:19,20,21 212:21 214:24 219:13 226:14 rdds 213:2 reach 104:20 138:7 read 17:15 22:25 23:4,21 24:11 41:25 45:18 55:11,18 55:21,24 57:17 63:4,21 65:6 66:12 70:11,12 82:17 89:11,25 91:19 93:6 94:7,23 97:14 97:17 98:13,15 99:4,5 100:11 101:6,21 104:13 110:4 110:10 120:4,5 120:7 121:23 126:10 127:4
---	--	--	---

134:14 135:20 135:22 136:13 136:17,18 138:1,13,20,22 139:12 145:7 147:20 149:8 149:12 150:19 151:6 153:2 158:3 160:15 160:17 161:11 161:25,25 162:7,24 163:16 165:21 169:7,23,24 178:13,18 179:2,4,18 184:21 190:14 190:21 191:10 193:3,18,22,24 198:25 199:5 199:11 200:3,9 200:22 203:16 205:17,22 206:14,21 209:2,3 211:23 211:25 213:3 214:10,14 215:3 217:3,4 219:18,20 220:17 226:1 226:12,19 227:3 228:22 228:23 230:21 230:21,24	231:5 232:1 237:2 238:3 reading 105:15 106:17 113:25 115:11 122:10 147:22 153:5 157:3,4 194:23 219:5 239:5 reads 89:4 93:2 94:11 101:3,9 145:3 208:23 212:20 214:6 214:23 215:25 216:24 219:12 ready 48:5 221:16 real 124:6,10 159:3 reality 187:4,8 really 22:1,2 30:5 33:4 65:21 123:14 133:6 162:19 198:18 222:17 realtime 1:19 236:2,19 reason 8:25 14:23 26:17 83:9 100:15,18 105:22 172:23 176:2 237:4 239:10,12,14 239:16,18,20 239:22	reasonable 91:5 176:20 reasons 167:16 rebuttal 18:17 18:20,23,25 20:16 21:11 166:5 recall 16:1 18:2 18:11 19:25 31:18,19 32:2 37:4 56:25 100:13 111:23 166:2 176:14 188:17 receipt 237:12 receive 118:7 received 109:7 118:3,24 119:3 recent 75:24 98:24 118:4 224:16 recently 66:12 223:12,13 recess 48:10 80:22 106:25 139:4 168:18 197:14 221:11 recognition 21:4 recognize 11:17 12:3 22:11 32:16 193:25	recognizing 44:19,21 47:21 118:16 172:20 176:20 recollection 232:19 233:10 233:25 recommendat... 34:20 recommendat... 34:10 195:22 recommended 124:11 recommends 116:25 reconciling 177:4 reconstruction 4:22 121:4 record 6:3 7:9 7:17 8:3 19:3 21:22 24:6 29:24 34:24 43:2,12 47:9 48:9,12 71:6 80:21,24 84:23 92:17,19,20,22 94:14 106:7,15 106:20,22,24 107:2 113:25 114:2,3 120:21 120:24 135:23 136:19 139:3,6 139:10 147:13
---	--	--	--

155:15,17,18 155:20 167:1 168:12,14,17 168:20 192:4 197:13,16 198:13 204:25 221:10,13 226:2,13 227:3 228:21,24 230:21 231:5 233:1 235:12 record's 228:22 records 13:10 14:1 35:23 39:20,22,24 40:2 54:1 94:14,16 109:17 118:4,7 118:10,23 119:5,8,9 170:1 189:14 191:19 202:20 222:22 recreation 173:19 recreational 173:16 reduce 167:25 reduced 125:16 reduces 72:11 95:7 96:24 reduction 101:19 125:21	reed 40:11 refer 24:2 36:6 74:10 130:15 203:25 206:18 referee 223:4 reference 87:14 189:20 205:3,4 referenced 86:4 105:17 156:4 164:13 references 87:10 95:22 referencing 204:22 referred 69:16 207:11 referring 17:2 24:5,18 31:21 60:16 62:17 63:11,12 76:10 95:21 96:10 111:4 114:4 146:5,8 169:14 199:4,5 203:10 233:22 refers 28:11 42:4 60:20 145:18 regarding 11:21 12:7 13:11,17 38:15 38:19 42:14 54:8 56:17 95:14 105:21	107:24 152:17 166:6 223:8,15 regardless 78:24 173:18 regards 36:2 43:6 118:13 registered 1:19 236:3,20 regulations 35:22 regulatory 179:22 relate 208:8 related 33:17 35:6,25 42:4,8 42:24 44:25 48:19,23 50:6 50:9,20 51:2 60:16 65:3 67:9 69:6,7,18 73:17 75:16,17 76:20 86:1 117:6 124:18 132:20 156:16 156:18 157:2 171:1 196:10 218:21 222:7,9 225:11 227:15 228:11 232:16 relates 1:6 36:4 50:22 62:5 78:1 138:7 143:4,14 145:16 219:22	221:23 224:19 227:10,25 228:20,23,25 229:11,12 231:23 232:20 234:1 relating 100:12 159:15 190:12 relation 211:16 218:20 relationship 10:20 71:16 201:1,5,7,10,13 201:13,16,23 202:1 relative 114:9 114:24 117:25 153:14 206:10 207:4 211:19 214:24 219:12 236:13,14 relatively 89:8 229:10 relevant 52:19 61:6,22 101:18 126:8 reliable 84:13 143:24 reliance 59:20 relied 177:3 rely 58:11 104:20 105:20 107:11,19 120:9 132:5,17
---	--	--	---

143:7	177:7 185:10	87:24 89:1,2	188:18 189:17
relying 177:23	206:20 208:5	89:13 91:12	189:20,20
remain 100:10	232:1	93:21 100:24	192:24 193:1
remaining 26:7	rephrase 71:11	104:4,20	193:11,22
remember	98:12 122:18	105:20 106:17	194:4,6 200:5
210:22 235:2,6	147:8 152:3	107:19,25	202:6,8,11,13
remembering	212:24	118:8,11,22,25	202:19,24,25
176:10,12	reply 172:6	119:2,4,5,9,10	203:1,8,10,13
remind 212:12	report 4:3,4 5:3	119:13 121:20	204:1,20 205:5
remote 236:10	9:24 10:5,9	126:7,15	216:13 219:21
remotely 236:5	11:11,18,20,24	127:16,18,18	220:11,14
renal 4:13	12:4,6,10	127:23,23	221:7 225:3
59:25 60:1,14	13:20 14:12,15	128:2,4,6,7,9	228:8 229:23
60:16,17,18	14:17,18,20,21	128:13,22	231:18 232:5
61:3,12,13,17	14:24,25 15:6	130:15 132:8	reportable
61:18,20,25,25	15:18,21 16:3	134:15 136:8	108:20,21,23
62:3,7,9,24	16:12,20,23	136:10,10,13	110:21
63:5,16,18,19	17:2,5,8,11,13	136:23 143:5,6	reported
76:8,14,18	17:13,17,19,21	143:11,16,23	105:23 141:10
82:5,9 83:22	18:1,9,11,14,15	144:24 145:13	149:21 181:4
116:21 198:2	18:17,23 19:5	145:13 146:5,8	195:2 238:11
198:10 199:17	19:10,12,14,15	147:14,24	reporter 1:19
199:18,22	19:19,21 20:2	148:17 150:2,5	1:20,21,21 3:7
200:6,16 201:3	20:9,16,20,22	150:11 151:14	6:23 7:20 8:3,9
201:4 202:5,9	20:24 21:8,11	152:16 155:7	10:24 97:14,17
202:15,21	22:8 45:3,9,16	156:4 160:23	98:13,15
repeat 19:16	45:18 47:16	161:1,2,4,5,22	135:20,22
62:19 66:25	51:13 57:7,15	163:4 164:13	136:17,18
68:16 71:10	57:20 58:8,11	165:14 166:4,4	138:20,22
73:6 79:1	58:18,25 59:6	168:24 170:4	139:12 152:25
100:3 115:19	59:22 60:20,22	170:11 172:5	153:2 160:17
137:9 141:3	63:7,12,20	179:10 181:5	236:3,3,19,20
142:6 150:22	66:7,10 69:12	181:10,12	236:21,22,23
158:16 175:13	69:14 77:16	183:1,6 184:15	236:24

reporter's 16:15 162:15	220:20	residency 24:23 26:2	190:16 192:1
reports 10:1,15 10:17 13:9 14:6,19,22 15:10,15,25 16:5,18 19:24 20:6 22:5 36:7 41:21,22 42:11 42:17,20 44:5 45:6,24 46:9 46:22 47:1,4 47:12 49:1 57:22 58:3,3 58:13 59:17,21 59:23 62:5 63:4 94:13 120:1 121:24 130:13 140:6 140:11,12,14 141:6,8,15 151:24 152:5,8 152:13 179:9 189:17 193:12 193:16,21 194:7,8,10,11 194:15 195:4 195:25 228:10 229:21	representation 229:13 represented 133:7 212:15 represents 129:19 234:1 reproduce 59:13 request 5:5,6 189:2,4 190:10 190:18,24 191:1,5 192:1 requested 135:22 136:18 189:10 requesting 223:9 require 47:5 74:1 174:23 required 56:18 192:25 requirements 28:24 29:1 research 33:9 33:11 34:6 36:24 37:2,5,6 residence 22:23 134:1 178:11 178:12,23 residences 178:16 179:5 residencies 25:14 28:19	resident 40:23 41:4 133:17 134:8 residential 133:4 residents 23:1 28:22 29:5 31:6,12 40:10 40:14 54:24 respect 78:3 219:19 224:15 232:17 respectively 206:13,22 219:17 respiratory 33:17 respond 196:9 responding 147:6 response 41:17 71:16 124:20 137:2 152:19 153:22 186:7	200:25 201:5,9 201:13,16,23 responses 5:7 responsive 189:7 190:17 190:23 rest 176:23 restate 123:15 result 33:7,21 97:4 121:15 188:9 214:20 231:3 232:22 results 81:8 97:22 109:19 117:2 122:3,21 142:19 209:5 228:1,4 retained 9:11 9:13,16,18,21 retract 153:6 return 237:10 reverse 96:21 201:7 review 14:6,11 14:14 15:5,24 16:2,5,8,11,22 17:8,11,16,20 17:25 18:3,11 18:14,15,16,19 18:20,22 19:4 19:10,12,14,18 19:21 20:2,6 20:12,16,20,22

20:24 21:11 31:5,7 34:10 34:14,19 35:12 35:23 36:11 39:20,22 42:9 42:11 43:6,12 56:23 59:21 93:11 166:9 191:15,21 192:25 194:9 194:20 195:4 197:4 224:7 233:6,7 reviewed 13:22 15:9 16:19 17:13,19 18:6 18:9,20,25 20:9 21:8 37:14,17,25 38:14,18 54:1 56:20 59:22 95:13 119:8 166:3 189:4 193:14 194:8 194:11 222:13 224:21 reviewer 35:15 reviewing 17:7 18:12 40:2 191:17 222:20 224:4,4 233:3 reviews 40:4 revise 153:7	revised 231:17 revisions 193:11 228:25 reynolds 5:3 20:9,14 46:22 58:4 59:21 119:12,18,20 120:9 122:4,22 123:9,23 125:9 126:7 127:16 127:24 128:2,4 128:7,15 129:6 130:3 132:5,17 132:22,25 137:14 138:3 142:10,17,25 143:3 145:5,13 161:14 162:9 163:1 164:13 165:6 170:1,3 171:14 172:6,7 172:24 173:25 175:2,17 176:5 176:24 177:8 179:8 181:5,12 181:21 183:5,6 183:24 187:13 187:17 188:14 193:15 194:9 194:12 195:1 229:5,21 reynolds's 169:10	rhode 2:13 ridge 2:4 right 10:6,7 11:11 12:14,18 12:24 13:5,24 15:16 16:20 31:3 32:4 42:18 46:1,6 47:20 51:8 57:20,23 59:14 60:6,8 66:17 69:23 74:6,11 76:13 77:3,5 77:14 78:15 79:6,18 80:15 82:2,2,14 83:13 84:21 88:5,8,12 90:10 103:19 107:6 108:1,4 108:7 110:1 119:1,23 123:10,24 125:1,11 126:20 127:22 129:7,10,15,25 130:6 132:2,9 132:15,23 135:4 140:20 140:23,25 141:14,18 146:5,9,14 148:5 149:19 150:8 155:5	161:9 162:10 164:4,14 165:10 170:3 170:20 171:24 172:4 174:13 174:15,18 175:1 176:19 177:15 180:16 182:4,19 183:2 197:10 200:6 201:20 202:14 202:21 205:9 207:13 209:22 210:18 216:5 219:5 226:10 226:24 risk 5:12 42:11 49:15,16,17,18 50:13,16,21 54:22,25 55:3 55:7,9,10,12,19 55:22 56:5,9 56:11,20,24 60:23 64:5,10 64:13,19,21,24 65:3,3,5,6,6,9 65:10,10,13,17 65:18,19,20,20 65:22,23,23 66:1,3,13,15,18 66:23 67:2,9 67:12,20,24,25 68:2,9,13,17,20 68:25 69:18
--	--	--	--

71:1,8,13,19,24	114:13 118:17	rlee 2:3	sautner 189:23
71:24 72:3,4,8	118:21 125:20	rme 133:16	save 183:10
72:10,18,19,24	132:20 133:10	134:3	saved 59:10
77:16,24 78:1	133:21 136:15	rmr 238:11	savitz 166:4
78:25 79:15,16	142:21 143:2,4	rna 33:7	savitz's 18:16
79:19,21,23,24	143:14,18,20	roberts 2:4	saw 15:13 17:5
80:3,9,11	144:13 153:12	6:21	21:1 37:20
83:21 84:15,17	153:14,20	rosen 154:4	39:17 40:13
84:18,24 85:9	154:8,10,11,12	roughly 83:15	62:4 63:4
86:8,21 88:7	157:1,18,24	row 2:13	189:17
88:10 89:7,9	159:20 165:20	145:14 156:10	saying 13:13,21
89:16,18 90:20	166:8 167:14	209:15	15:1 28:7 65:9
90:22,23,24	167:17,21,25	ruled 88:7,10	65:21 67:5
91:3,6,9,10,18	168:5,7,9	106:12 116:22	78:3 79:25
92:14 93:5,9	171:1 180:11	rules 196:17	85:15 87:5
93:11,14,17,18	180:16,20,22	run 56:5	96:13 97:12
93:19,25 94:5	180:25 184:19	s	102:23 105:12
94:6,19 95:1,4	186:3,4,6,8,9	s 2:1 4:1 5:1 6:1	116:16 131:6
95:7,9,12,15,16	186:16 187:9	56:1 188:3	153:24 160:20
95:17 96:12,15	187:14,19,22	safe 180:3	165:3 194:4,23
96:17,21,22,24	188:1,5,8,8,11	safely 33:22	194:24 195:1
97:9 98:3,8,21	188:13,15	safety 23:14	196:24 210:22
98:23,25 99:7	203:14 204:9	25:8 180:7	218:2,6 220:6
99:9,21,24	205:15 208:25	sag 201:21	says 7:4 22:21
100:2,7,12,13	214:8,15 224:4	sake 16:14 55:4	22:25 24:11
100:22 101:2,4	224:6,7 225:17	162:15	30:14 35:5,11
101:12,13	225:19,21	sample 43:22	42:3 49:10
102:1,5,9,13,16	232:12 234:5	86:11,23	57:10 69:25
102:20,22	risks 67:10	217:25 218:7,9	70:4,14,16
103:4,6,9,14,16	69:7 72:23	samples 32:22	81:17 82:7,8
103:25 107:17	86:16 118:18	33:1,2	83:7 89:14,15
108:25 110:5	124:17 146:23	sampling 32:19	91:24 92:8,11
110:23 111:15	156:9 161:17	32:19 43:5	92:12 94:3
111:24 113:20	214:17		95:14 96:10

110:21 113:4 114:6,18 120:15 121:12 122:9 128:22 133:16 137:18 139:20 143:17 147:17 148:8 148:22 150:22 165:16 179:12 190:16 192:15 192:15,17,23 193:10 198:20 199:7,21 202:8 202:12 203:13 205:1,10 207:20,24 209:10,15,20 210:3,3 211:6 213:1 216:12 218:18 219:3 220:14,22,23 221:7 226:14 230:10 231:6,7 231:20 schedule 5:9 scholar 58:15 58:16,23 59:7 59:10,19 school 26:9,11 26:12,13 36:24 75:20 76:23 science 75:8 scientific 54:19 55:9	scleroderma 223:17 scott 153:16 search 58:15,22 59:1,9 75:25 140:9 189:9,13 searches 58:6 58:10,12 59:7 59:9,14,20 189:7 searching 58:22 seat 49:13 second 4:8 13:3 21:20,23 33:24 34:3 77:7 93:2 94:3,11 97:6 100:25 110:11 110:13 114:9 114:24 117:25 141:18 145:3 150:21,22 151:19 154:23 169:4 178:2,4 178:5,8 192:19 199:13 212:19 214:23 216:24 218:3 220:12 228:23 229:2 section 2:17 34:5 89:4 93:25 101:1 148:21,22 150:17 161:19	161:20 162:20 169:3 209:25 230:20 232:7 see 14:23 15:3 15:21,24 19:23 20:3,4,5 22:20 24:14 30:22 34:6 35:3,8 41:6 42:13 69:15,25 70:6 70:24 81:25 82:11 92:15 110:12,14,16 113:18 121:12 121:17,18 126:15,16,23 127:5,9 128:8 128:18,23 137:20 140:10 145:15,15,17 145:22,25 148:8,22 150:25 151:2,4 152:22 161:18 162:13 167:6 174:4 183:12 206:3,7 208:14 209:14 210:1,3 210:5,7,10,11 211:11 219:5 226:9 seeing 40:15,15 113:10 115:12 165:8 202:3	233:13 seem 208:18 seems 86:15 201:7 seen 15:20 50:19 98:22,24 99:23 100:8 105:22 109:17 110:3 112:22 113:1 127:15 130:9 136:7,12 136:22 140:2 155:3 188:24 190:6 233:10 seer 4:13 81:9 81:10,12,20 82:4 90:21 selected 23:16 25:11,23 33:13 send 35:14 senior 36:24 37:2,6 sense 29:6 50:24 61:1 130:1 180:1 193:24 194:3 208:14 219:25 220:10 225:4 227:18 sentence 94:3 121:12 145:3 148:21 150:16 150:22 169:4 178:8,18,19
--	---	--	--

190:16 203:12 203:17,18 205:13,19 206:6,9,16,23 207:2,21,23 208:3,10,14,22 209:10 210:19 212:20,25 214:5,14,23 215:22,25 216:24 219:10 219:12,20 220:6,10,14,23 226:12,19 227:3 228:23 229:2 234:12 234:22,25 235:2 sentences 228:19 separate 105:9 177:24 223:1 232:2 september 204:14,16,17 series 233:16 served 22:23 23:2 24:12 48:17 service 43:18 51:23 222:7,8 serviced 51:25 services 23:16 25:11 28:20	34:1 35:2 41:20,24 47:2 47:12 48:1,16 49:25 54:11 222:5 serving 178:11 178:23 set 54:23 72:22 166:10 179:22 180:6,19 236:10 setting 25:21 several 27:22 99:10 126:22 128:15 129:6 130:14,15 154:2 194:20 shackleton 202:12 shackleton's 202:20 shaking 7:24 sharon 2:17 6:16 7:10 48:4 80:17 138:25 sharon.v.spra... 2:18 she'd 55:4 sheet 3:10 30:2 237:4,6,8,11 238:7 239:1 sheets 87:9 shields 14:14 14:21 15:9	17:11 shook 137:2 short 42:16 91:24 92:9 94:12 132:1 227:12,19 228:2 shorter 180:15 shorthand 1:20 236:21,22,24 show 29:7,10 29:14 90:25 120:15 123:7 143:16,21 153:8,25 154:2 160:1,3 174:8 176:22 197:21 225:16 232:23 233:11 showed 98:25 144:19 154:5,6 154:9,11 229:8 shower 44:21 56:3 showing 11:15 99:20 100:6,9 200:24 210:24 216:14 shown 13:8 shows 49:17 90:23 129:13 shut 199:1 side 95:12 96:20 226:10	226:24 sign 237:6 signature 3:8,9 236:17 239:24 significance 165:25 166:6 significant 65:20 89:9,16 94:6 101:13 103:16 125:19 153:14,17,22 154:12 166:1 significantly 71:19 72:11 93:16,19 101:14 signing 237:7 similar 57:13 122:1 128:19 135:12 177:2,4 simple 136:4 simply 232:2 single 26:19 43:10 64:7 100:13 181:6 182:11,22 183:17 sit 131:25 216:5 site 131:18 211:17 situation 133:21
--	--	---	---

six 25:18,19 31:25 49:17 192:25 193:1 210:10,11 size 202:16 skill 224:22 227:11 231:23 skimmed 17:14 skip 224:14 226:22 slight 89:18 94:4 slightly 66:15 85:15 91:16 92:1,12 93:3 101:10,11,16 164:7 slim 111:21 small 89:8 101:3 smaller 111:23 smarca4 104:17 smith's 21:11 smoke 32:18 33:3 67:6,13 68:4 97:23 99:11,12,16 100:23 smoked 79:10 94:12,15,21 95:2,10 96:11 96:13	smoker 91:25 92:9 94:12 smokers 68:3 79:4,8 smokes 67:11 79:5 smoking 64:13 67:9,9,25 68:1 68:1 71:7,9,12 71:13,16 72:2 72:7,8,9,10,16 72:17,22,23,24 79:15,23 80:2 94:17,19,25 95:3,7,14,14,19 96:16,19,20,22 98:9,25 99:4 100:16,19 societies 56:8 society 71:2 78:8 soil 135:13 solely 231:18 231:21 solid 33:19,23 227:5,10,14 solute 215:1 216:2 sorry 16:13 18:13 19:16 36:16 52:13 58:24 59:4,12 63:14 64:16 87:11 96:6	97:16 99:14 115:19 120:6 124:19 126:15 128:21 135:1 135:18 136:16 137:17 145:1,1 155:15 160:25 161:2,19,25 163:24 173:3 195:8 198:3 199:17 203:4 206:24 211:1 212:6 217:13 218:4,17 220:25 sort 220:23 sound 31:3 174:13 176:19 207:13 sounds 26:18 129:4 176:9 180:5 source 69:18 75:18 south 2:5 space 237:4 speak 9:15 22:4 25:23 132:2 187:8 189:24 speaker 26:6 speakers 25:23 26:6 speaking 8:6 9:20	speaks 33:8 specialist 43:19 specialty 43:6 44:17 specific 4:3,4 10:1,13,19 11:11,12,17 12:3 13:9 15:10 16:18 19:4 20:7 36:7 41:20 42:6 43:7,25 44:24 45:24 46:9 47:1 56:15 57:15 58:1,2 59:6,17 75:21 76:13,18 79:3 108:14 119:14 136:22 170:17 180:23 188:10 193:12 223:9 232:4 specifically 19:25 29:3 31:11 32:18 33:6 36:1 57:13 60:14,20 64:2 66:2,8 73:16 113:4 117:6 125:16 133:16 151:14 217:7 219:21 223:11 227:15
---	--	---	---

specifics 37:4	106:14,21	197:20 200:13	150:2 151:14
specified 215:1	107:4 109:12	204:3,7 207:16	169:3 231:13
215:5 216:2,6	109:16 112:15	209:11 211:12	237:3
216:20	112:20 113:13	215:17,21	stated 57:14
specify 122:23	116:1,24	221:8,15	95:12 143:4
spell 53:6	120:20,24	224:24 227:17	231:1
spend 133:20	121:8 122:6,13	234:10 235:10	statement
222:15,16	123:14,17,19	square 7:19	64:11 70:8,10
spent 45:13	124:24 125:23	stadler 13:19	70:11,12 71:5
49:3,8 133:18	126:2,6 128:21	102:17 106:9	75:18,22 76:21
133:19,22	128:25 129:5	118:15 119:6	77:21 119:25
172:9,13,19	135:24 136:16	stadler's 19:4	120:4,5,7
196:16	136:20 137:11	118:22 119:2	121:19,21,25
split 26:3 85:20	138:9,20 139:8	staff 195:18	statements
133:18	142:23,24	stand 29:16	11:23 12:9
spoke 66:8	144:23 146:18	standard 57:12	122:1
72:13 75:13	147:8,9 149:11	72:22 142:20	states 1:1 2:22
104:22 139:21	152:3,4,25	142:20 143:1,3	6:12,17,19,20
223:24	153:4 154:16	143:7,10,12,19	7:10 14:7 19:8
spoken 53:17	154:22 155:1,5	standards	80:14 83:8
131:23 132:11	155:7,14,24	143:12,14,22	stationed 44:6
sprayregen	158:18,19	stapled 126:18	44:9,16,17
2:17 3:4,6 6:16	159:9 160:12	126:20	198:23 199:9
6:16 7:6,11	160:19 168:11	start 8:5 11:14	200:19
10:22 11:8	168:14,22	16:17 22:24	statistical
29:12 30:4,7	173:23 175:16	62:22 164:2	165:25 166:6
48:7,14 61:11	177:19,21	173:5	statistically
65:8 67:17,18	178:1,5,7	started 164:5	153:22 166:1
69:8,11 70:22	181:2 182:1	185:23 216:8	statistics 38:9
71:20 73:5,7	184:2,7,11	222:4	38:11 81:20
80:19 81:1,5	186:22 187:11	starting 41:17	147:18
91:11 92:5,10	188:4,19,23	stat 4:13	stay 212:19
92:17,24 93:1	190:5 191:24	state 7:16 45:6	stayed 45:10
97:19 98:12,17	196:18 197:10	75:6 111:10	

steatosis 223:15	49:21,23 59:16 59:22 98:22,24	studying 32:2	subsequently 9:25 15:4,5,23
stenographic... 236:9	99:4,5,20,25 100:6,9 132:1	suarez 189:23	substance 238:6
step 117:15,16 193:22	132:3 141:10 141:25 143:25	subgroup 198:22 199:9 200:21	substantial 89:20 150:7,12 150:18,24
steps 42:6	153:11,13,16 153:24 154:2	subject 57:1,4 234:2 237:7	151:10,12,16 151:20,22 152:1,7,9
stick 127:19 160:16	154:14 225:14 225:15 232:16	subjects 217:2	substantially 102:10
stop 227:9	233:10,18	submit 35:18 36:4,12 49:3	substantive 30:6
stops 72:9	study 5:4,10,11 33:19,21 86:4	submitted 10:5 10:9 15:15,18 41:23 43:11	substantively 137:5
street 2:4,21	95:24 99:23 131:4 141:14	54:9 58:20 118:25 223:2 233:7	subtype 61:18 62:2 63:6,10 63:18,19 76:16
strengthen 118:14	141:17 152:20 152:20 153:8	submitting 16:18 118:8	subtypes 61:4 61:12,13,20 62:3,8,24
strengthens 118:12	153:12,17 154:4,5,6	subpapillary 63:17	suffer 231:8
stretch 131:1	155:6,11 156:1 197:23 203:3	subpoena 5:8 189:1 192:1	suffered 121:14 231:2,21
strike 39:25 103:10 108:20 108:22 130:2 163:5 165:12 171:21 179:15 204:15 215:24 220:3,4	203:22 204:8 204:13,13,16 204:22 205:1,8 205:14 209:4 212:2 214:21 215:11,13 216:9,14 217:5 217:7,22 224:17,18,19 225:2,23 228:1 230:16 233:20 233:25 234:6	subscribed 238:14	sufficient 13:12 13:13 47:6 49:4,11 52:23 107:15 151:22 152:14,23 153:9 154:1 156:8,14 157:11,15 158:6,10,12,25
stronger 118:20		subscribing 239:5	
structured 33:11,11		subsequent 14:19,24 15:9 24:3 47:17 58:17 106:4,4 108:5,10 231:15 233:5 235:4,7	
struggling 220:2			
students 22:23 23:2 195:19			
studies 21:17 47:17 49:12,20			

159:7,12,25 160:8 185:3,19 186:12,15,24 216:17 suggest 84:23 106:7 227:20 suggestive 116:11 suggests 88:18 101:16 suite 6:9 sum 89:5 170:13 171:22 182:2 summarize 31:14 35:18 43:3 summary 4:22 43:1,8,17 121:5 127:1,3 153:12 summation 129:20,24 174:16 175:5 176:6,17 summed 129:6 superfunds 55:12,19 supervising 26:21 supplement 155:1,2,3,8,11 155:13	supplemental 4:7,8 12:22 13:3,17 21:20 21:20,24 58:20 155:4 170:25 174:3,8 supplied 52:3,4 supplies 179:23 217:25 218:7 support 34:13 124:7 132:4 186:10 195:18 209:5 222:12 supported 34:24 37:5 42:14 supporting 130:7 supportive 118:1 sure 14:1 22:12 25:24 28:25 32:12 51:21 52:18 53:6,10 59:4 61:10 62:4 75:24 79:2 80:19 90:7 91:20 92:24 100:3 120:17 132:3 136:5 148:6 155:8 158:18 196:13 198:8 207:19 209:10	228:22 surgeon 39:5 surgical 202:13 surmise 156:18 surroundings 53:12 surveillance 81:7 susceptibility 85:23 105:13 105:21 107:24 susceptible 103:23 104:1 104:17,25 105:3,7,18,25 107:10,21 swear 6:24 sworn 7:2 236:5 238:14 syndrome 113:15 116:19 syndromes 113:21 synergistic 150:4 synergistically 149:25 184:19 synopsis 222:14 syracuse 75:20 system 34:6 51:13 52:22 53:16 178:10 178:23	systematic 95:13 systems 51:11 51:18,20 218:19 219:4 t t 4:1 5:1 56:1 134:25 tab 10:24 11:1 11:2,3,4,5 table 46:3,8 47:3,6,14 121:7 133:16 144:18,18 156:3,15,17,20 156:21 157:1,4 157:18,20,23 157:25 164:21 165:8,17 166:23 169:14 182:13 198:12 198:14,15,20 199:6,7 200:18 200:19,25 203:9,21 204:1 209:12 210:12 210:12,24 211:9 212:16 212:23 213:5 215:6 tables 155:4 174:3 176:10
---	---	--	---

tail 206:2	157:7 196:5	task 56:18	tech 135:3,12
tailored 144:21	talked 27:1	taught 37:8,11	135:25 145:14
take 8:21,22	42:3 51:13	tca 86:5 218:17	145:15,19,24
11:9,14 12:1	76:9 131:23	tce 38:15 97:1,3	146:9,20
12:12,16,20	152:24 196:19	97:21 98:7	147:10,17
13:1 22:8	220:7 221:23	135:2 138:13	148:11 163:13
26:12 40:9	talking 21:22	138:15,18	182:18 193:15
42:6 48:5,7	46:24,25,25	149:4,6 152:11	193:20 194:1
69:15 80:18	50:14 55:4	152:17,22	195:3
81:12 84:14	72:15 73:20,21	153:9,13 154:5	technology
102:3 106:18	74:25 75:2	154:7 157:11	236:11
107:16 117:13	81:21 85:1,12	160:8 161:17	tel 2:5,10,14,22
127:15 130:21	86:20,21 87:12	162:1,4 163:19	teleconference
131:14 138:25	93:15 99:5	163:20 164:1,3	236:11
168:15,23	107:5 111:25	164:12 165:5	tell 7:2,13
172:1,8,8,13,16	112:3,6,13	169:20,21	137:10 187:23
172:16,18	118:22 198:14	170:12,18,22	198:6 230:7
176:5 184:13	210:8 212:23	171:10 172:3	telling 164:7
186:18 187:5	talks 27:24	179:13,14	tells 124:17
195:15,22	96:19 100:13	181:4,15,15,18	template 133:9
197:7,11 202:6	186:4 190:11	181:24 182:7,8	133:10
202:10 208:19	218:2	184:17,18,24	tendency 16:16
214:18 221:8	tarawa 4:20	185:1,6,12,16	134:7
taken 1:16 4:10	121:2 138:19	218:13,14,14	tends 50:14
48:10 54:18	145:14 146:1,2	218:17	tenth 24:16
55:8 80:22	149:1,5 161:9	tcs 160:14	term 26:3
106:25 139:4	162:1,3 163:10	teach 30:14	91:24 92:9
168:18 197:14	163:15 165:7	31:5,10 40:14	94:12
208:24 210:21	169:20,21	teaches 26:19	terms 13:16
214:7 221:11	170:7,10,11	teaching 23:7	25:25 30:20
236:8	173:8 174:1,11	23:10 26:9,14	31:4 40:17
takes 135:14	181:16 182:25	31:12	42:10 45:9,23
talk 41:18	234:18	team 45:22	47:20 49:7,21
72:12 99:4			50:13,19 58:6

58:22 59:1,9 65:5 66:14 76:11,19 86:6 95:16 102:8 118:16 130:10 131:21 133:24 150:25 151:17 174:24 186:6 194:1,4 205:3 207:18 208:4 218:8,9 222:12 223:10 225:5 227:13 terrace 4:21 121:2 138:19 145:14 146:1,2 149:1,5 161:9 162:2,4 163:11 163:15 165:8 169:20,21 170:7,10,12 173:8 174:1,11 181:16 182:25 234:18 test 62:14 85:25 86:11 106:5 108:3,6 110:7,9,15,18 110:19,25 111:4,4,20,25 112:6 117:1,19 201:25 202:3 tested 62:15 86:17 104:10	106:1 108:9,14 109:11,11 111:5,11 113:23 116:17 116:19 testified 17:6 28:1 29:7 31:20 136:25 173:8 testify 236:5 testifying 32:2 testimony 9:1 29:7 94:18 139:17 150:23 172:21 236:8 testing 4:15 62:14 84:23 85:7,21 86:13 86:21 106:3,4 106:11 108:10 109:6,9,20 111:19 116:7 117:17,20 118:1 124:4 tests 84:19 85:2 85:3,16,16,21 85:22,25 108:24 109:4,8 109:25 111:9 tetrachloroet... 5:12 204:9 texas 1:20 236:24	texts 21:17 thank 18:16 19:18 21:7 24:7 51:4 147:7 162:17 201:8 205:25 234:7 thanks 30:11 theater 173:20 thereto 239:5 thesis 37:6 thing 24:11 42:17 74:14 77:2 86:15 88:23 89:14 102:17 104:3 107:8 126:11 153:19 160:6 189:15 230:13 things 28:12 50:24 61:1 78:5,8 100:7 105:10,14 127:5 173:20 174:6,7 205:6 222:11 224:3 226:1 think 9:10,14 9:22 13:19,21 13:25 17:4,19 24:4 27:4,13 31:14 33:18,22 37:19 49:12,15 49:20,20 50:20	52:5 53:10,10 53:14 56:15 58:15,19 60:4 60:21 61:15,21 63:7 65:2 72:6 72:12 77:5 79:4,19 80:13 82:15,16 83:25 84:6 85:7 87:23 96:14,14 97:2 98:2,7 100:21 102:15 102:18,23 103:25 104:22 105:9,23 107:13 108:14 109:5 111:22 114:20 115:9 117:20 118:15 122:23 124:2 128:25 133:25 136:5 141:14 143:6 144:6,9 146:14,15 147:22 148:16 154:22 155:10 157:7 159:3,18 170:24 174:19 174:19,20,21 176:20 182:4 183:16,22 187:4,17 188:12 189:19 197:1,10 199:2
--	---	---	---

208:16 209:9 219:23 220:7 223:24 225:1,2 228:3 229:15 thinking 115:10 third 21:20 22:14 34:9 35:5 69:4,4,4,5 69:5,7 75:15 75:16,17 76:12 76:12,12 232:7 thirty 237:11 thomas 2:25 6:4 thorough 189:9 189:13 thoroughness 109:6 thought 19:25 20:4 28:5 36:22 84:1 87:11 94:5 102:17 136:25 165:3 194:21 225:9 thousand 111:23 112:4 156:23 three 26:5 51:10,20 52:5 54:24 81:25 110:11 114:21 128:19 182:20	193:17 200:9 218:20 219:1 threshold 49:5 49:8 151:25 152:6,8 159:13 thresholds 159:14 thrilled 47:16 tier 151:19 till 13:18 14:16 time 6:6 9:21 10:10,12 16:25 17:1 20:1 27:2 32:23 39:17 40:5 42:8,23 44:3 45:13 48:2,8,11,19,24 49:2,4,8 50:6,9 51:3,14 55:16 72:11 77:7 80:20,23 83:3 83:19 92:18,21 95:2,6,20 96:11,23,23,25 97:5,8 99:1,6 99:20,24,25 100:6,14,19,22 101:15 106:19 106:23 107:1 109:9 112:22 113:1 116:5 129:21 133:17 133:18,18,22 135:14,16,25	136:2,6 138:4 138:16,17 139:2,5,18 142:5 149:3 151:1,5 155:16 155:19 159:21 161:9 168:16 168:19 169:21 172:2,9,13,18 173:1,3,7,14,14 173:25 175:24 175:25 176:11 176:21 177:5 180:14 181:8 183:10 194:15 196:16 197:12 197:15 215:2,5 215:19 216:2,6 216:20 221:9 221:12,25 222:15 224:15 230:15 233:3 234:8 235:11 236:9 timeframe 55:18 times 24:21,23 25:2,7,10,13 85:7 100:16,20 106:5 138:4,5 144:2,4 156:4 173:21 182:20 223:21,22 224:11	timestamp 81:17 timothy 1:15 3:3 4:10 5:6,8 6:14 7:1,18 236:4 238:2,8 239:2 tissue 60:6,7 85:16 86:11,22 title 112:25 113:6 130:25 133:15 134:14 137:16 138:1 199:6 200:18 234:19 titled 4:13 150:17 230:3 titles 134:8 tobacco 96:24 today 9:1 21:15 28:6 118:3 187:4 195:7,10 197:8 198:9 221:23 223:24 225:11 226:2 234:11,21 today's 6:6 196:3 together 46:23 64:9 98:1,8 136:15 138:3 186:2,9 told 157:9
---	--	--	--

took 32:25 36:23 54:21 55:14 75:20 76:22 109:25 142:13,13 172:22 175:3 175:19 176:15 194:15	totals 129:7 towards 159:6 228:4 toxic 84:21 85:4,5,18 86:2 86:12 89:9 98:4,6 toxicity 50:18 toxicologic 33:9 toxicology 23:20 25:17 27:18,21 28:2 29:8,19 31:17 31:21,21,25 32:10,11,14 33:8 toxins 89:19 150:6,11 151:9 track 47:20 161:5 tracking 148:6 tracks 44:15,16 tract 60:2,15 60:15,19 train 28:22 training 31:8 36:21,23 38:12 40:20 224:22 227:11 231:24 traits 231:11 232:11 transcript 17:3 17:4,9,12,14,17	17:21,23 18:10 18:12,18,23 19:17 21:2 30:8,23 41:7,9 41:10 236:8 237:12,14 transcription 238:4 transitioning 19:8 transport 4:20 121:1 230:4 234:17 treat 39:10 40:21 60:9 treated 40:5,19 40:23 treating 112:24 113:3,6,9 treatises 21:17 treatment 39:11 51:23 52:1,4,5,7,21 52:24,25 118:24 treatments 60:8,11 trend 202:1,3 tribunal 57:5 tried 63:21 127:5 triggers 74:3 97:9 185:22	troop 33:18 troops 32:16,16 32:20,20,22 43:22,23 56:14 true 52:18 67:11,15 68:6 69:2 78:7 83:18 84:6,11 94:20 96:21 102:21 143:21 166:8,16,17 190:18,23 224:13 truth 7:3,3,3,14 236:6,6,6 truthful 9:1 try 8:2,12 22:2 103:10 123:15 224:7 225:4 trying 19:8 22:25 30:11,13 47:11 63:15 65:21 85:20 102:18 105:9 123:12,17 136:21 146:22 148:6 193:25 207:9,18 212:14 214:2 220:23,24 tuesday 1:11 6:2 tukes 4:4,6,7,8 4:15,15,16
---	--	--	---

10:2,11 11:13 11:14,18,21 12:18,23 13:4 14:18,22 15:12 15:12 16:19 22:6,8 46:25 53:24,25 54:3 57:7 60:17 62:3,5 63:5,13 66:17 84:20,25 85:24 88:5 89:13,17,19,19 89:22 90:19 100:24 101:2,3 101:10,13,14 102:8 103:2,12 103:15,18 104:4,7,9,16,25 105:2,6,17,24 106:1,12 107:10,14,20 107:25 109:7 109:19 114:16 114:25 115:14 115:17 118:1 119:17,21 124:23 125:17 126:8,15,22 129:21 132:16 132:21 134:18 138:16 142:12 143:9 147:14 147:18,18,23 150:10,11,14	150:17,23 151:5,9,21 159:4,10,16 161:1 168:23 169:4,19 170:15,18,24 171:1,7 179:10 180:25 181:3,5 183:1,14 184:12,14,18 184:23 185:1,5 185:8,11,13 186:11,14,23 188:15 193:12 194:6 228:11 229:23 tumor 227:14 tumors 101:16 114:8 115:4 116:2 227:5,11 turn 22:9,14 23:6 30:8 33:24 41:7 69:21 81:23 88:25 89:13 91:13 100:24 101:8 109:22 114:4 121:9 144:24 145:20 147:13 148:19 150:10 156:3 161:3 165:13 168:24 169:17 177:19 178:20	179:10 181:10 190:8 192:10 192:21 193:7 198:12 200:18 204:20 205:24 208:20 209:12 211:13 212:18 214:1,21 216:23 228:16 turning 83:11 91:12 94:9 104:15 137:17 137:18 150:5 tutoring 31:13 tv 9:5 tvoc 163:5,14 163:14 164:11 179:1 186:4 tvocs 100:22 163:10 twice 106:2 109:7 116:17 two 10:1,15,17 10:20 14:19 21:22 25:9 26:4 27:4,9 28:12 49:16 59:23 61:22 72:15 74:25 75:2 81:19 83:12 92:15 102:9,12 104:16 105:9 105:12,13	114:21 126:23 134:2 135:2,5 135:7,17 182:20 193:16 193:16 194:14 194:16 201:17 227:9 228:19 type 217:17 232:17 types 60:5 61:16 116:7 232:24 233:12 234:3 typo 170:2 205:11 typographical 219:21 u u 109:23 u.s. 2:16 4:21 17:7 90:8 121:3 ug 129:14,17 129:19 130:10 130:20 131:6 132:7 140:18 140:18 161:8 162:3,4,5,22,23 163:12,12,14 163:18 164:14 169:4,9 171:23 176:25 177:9
---	---	--	--

ugl 178:25	understand	212:10 221:2	unusual 32:19
ultimately	7:13,25 8:11	231:17	update 24:6
86:18	10:17 16:16	understood	58:14
unable 8:25	21:5 22:1	8:13 14:4	updated 82:15
unadjusted	26:22 30:11,12	67:14 83:25	uploaded 43:18
211:16	45:1 47:10	173:24 196:11	43:25 44:4
uncontaminat...	55:5 66:20	underwent	upper 60:2,15
52:22	74:20 75:4	108:1 109:7	60:19 166:20
under 7:12	79:17,25 86:20	unexplained	urologist 39:3
23:10,24 24:8	96:9,9 103:8	75:12,15	urothelial 60:2
28:21 34:5	103:12 114:25	unexposed	usdoj.gov 2:18
35:1 73:15	115:8 122:14	211:19	2:19,20
93:25 101:1	124:1,2 127:7	unfortunate	use 33:3 45:23
114:7 115:1	129:17 136:21	232:22	46:8 47:2,8
128:2,3 137:19	137:5,22 157:6	unfortunately	58:22 69:17
145:13,19	162:16 173:2	81:19	122:11 142:17
147:25 148:1,2	175:7,8,12	unidentified	143:13 144:12
148:3,3 161:17	193:23,25	78:11,14	144:21 146:20
162:20 169:3	194:4,16,23	uninformed	146:24 147:10
174:9 184:17	196:17 211:9	28:19	182:18,18
208:22,23	219:11	unit 145:9	191:12 227:4
209:20 210:3,6	understanding	146:11 148:16	228:2 232:3,9
211:15 214:6	44:24 53:13	united 1:1 2:22	used 57:11,22
214:22,23	62:2,6 69:3	6:12,17,18,20	58:18 59:7,9
216:24 221:3	70:8,10,16,23	7:10 14:6 19:8	112:24 113:2,9
226:7,10 232:6	81:21,23	80:14 83:8	117:4 120:12
232:7	106:11 119:2	units 138:10	120:14 121:13
undercounts	133:13 134:9	148:13	124:15 132:19
228:3	134:13 136:4	university	132:25 137:6
undergraduate	137:13 146:7	26:13 28:20	137:13 140:3
26:15 36:25,25	172:7,10,19	unknown 70:9	142:25 144:10
underlying	175:17 176:15	70:14 74:6	156:21 171:22
214:19	178:16 194:16	79:21,24 90:10	176:24 177:8
	195:1,1 207:10	90:14	177:11 178:24

218:7 226:20 231:1,21 232:4 237:14 useful 187:24 uses 179:21 180:10 using 47:13 58:16 83:4 92:2 145:14 147:17 148:10 165:24 170:1 180:6,22,23 usually 26:2 74:1 101:12 191:18 utilize 57:12 191:2,6	value 130:4 158:20 166:16 166:17 values 123:8,22 125:9 194:10 vance's 19:10 19:12 variability 105:12 variable 211:18 variables 180:18 231:25 variant 112:5 113:17 variants 104:16 105:13 108:20 108:22,24 110:21 variation 117:11 variety 30:17 35:17 222:11 223:13,16 various 51:24 51:25 66:12 94:13 232:17 232:23 233:12 233:17 234:3 vast 45:11 224:11 vce 164:4 veracity 105:22 verbally 7:22	verbatim 236:8 version 42:16 92:15 126:18 126:20 127:2,4 128:4 235:5,7 versus 198:21 199:8 211:18 212:3,7 ves 35:14 veteran 43:4,7 43:25 44:17 45:5,6 48:16 167:22 222:12 223:8 veteran's 33:25 35:2 36:5 41:20,23 42:7 43:13 47:2,12 47:25 48:16 49:24 54:10 222:5 veterans 35:12 39:20,23 40:1 41:21 42:22 45:12 47:20,25 48:17,23 50:2 50:4 54:9 191:17 vets 222:8 vicinity 4:21 121:3 234:19 video 6:8 videoconfere... 8:7	videographer 2:25 6:3,4,23 48:8,11 80:20 80:23 92:18,21 106:23 107:1 139:2,5 155:16 155:19 168:16 168:19 197:12 197:15 221:9 221:12 235:11 videotaped 1:15 viewing 127:10 vinyl 38:22 97:1,3,21 98:8 149:5 162:21 162:23 164:12 171:8 179:16 181:4 182:10 182:12,14,16 182:21 185:6 185:12,16,18 186:12,23 voc 139:18 vocs 43:14 100:1,7,9,20 186:2 volatile 163:9 163:13 volume 140:16 141:23 142:15 163:9 vulnerable 180:8
v			
v 2:17 202:12 va 35:12,13,22 36:1,7,11 41:23 42:25,25 43:9,10 44:15 47:5 49:10 53:14 54:9 75:12 84:17 90:3 191:15,20 191:21 221:24 222:4,7,12,25 223:7,21 224:7 vaccine 34:14 34:18,22			

w	103:12 119:16	79:4 131:22	139:9 197:3
wait 8:4	119:22 120:1	132:7,18	229:8
waiting 164:25	120:10 121:2	141:21 142:18	whatsoever
walter 40:11	121:15 122:3	145:10 166:3	190:2
want 16:17	122:21 123:8	182:14 187:3	window 50:15
22:12 24:6	123:21,22	197:10 224:2	wise 189:22
25:9 29:11,24	124:3,4,7,10,11	we.can't	wish 198:7
36:2 52:19	124:16,25	186:18	withdraw
80:18 91:20	125:9 130:5	webler 206:11	145:10 191:4
100:24 104:3	131:4 133:4,25	219:14	withdrawing
106:18,20	134:1,21	website 69:13	102:3
107:8 153:6	135:11 136:3,4	69:14 90:21	withdrawn
154:19,21	144:3 149:2	week 16:24	9:19 16:10,10
175:14 179:9	150:7,12,18,24	222:17,19	17:24 39:23
179:10 187:21	151:4,10 154:3	weeklong 54:21	50:3 51:24
196:12,19	159:24 163:10	54:25 55:14,23	54:14 55:11
212:18,19	178:10,22	weeks 26:4	59:5,25 62:21
219:10 228:21	179:23 180:3	174:9,10,11	62:22 66:6
228:24 230:21	180:13 190:12	175:20	67:17,22 68:23
232:1	194:2 204:10	weigh 222:24	79:13 97:13
wanted 136:5	205:16 215:1	weighed 79:20	100:17 102:3
164:16	215:15 216:2	weighing 223:4	103:7,17
washington	216:11 217:25	weight 42:9	114:11 135:19
1:17 2:21 6:9	218:1,7,19	89:18 91:18	156:7,9 161:10
water 1:5 4:20	219:4 231:4	92:14 93:5,8	163:19,25
5:12 6:11 9:4	234:18 239:3	93:13,13	169:22 171:18
44:20 51:10,11	watermodeling	101:12,14,16	171:20 172:15
51:18,20,20,23	4:23	101:20,22	173:4 179:15
52:1,4,5,7,9,12	way 31:15 91:2	102:3,5,6,14,15	181:14 184:13
52:15,20,22,23	102:22 115:24	wells 51:12,14	184:25 187:12
52:24,24 53:4	117:11 135:16	51:17 52:3,3,6	188:7 194:7,10
53:8,15 89:5,9	we've 7:9,20	52:8,20	202:23,25
89:23 98:19,21	28:23 59:19	went 36:10	203:7 204:14
	65:23 77:1	101:22,23	207:1 208:18

208:19,20	women 84:2	221:21 222:4	x
212:1 215:23	101:5	workplace	x 3:1 4:1 5:1
220:3,4	word 126:10	133:5 224:6	y
witness 3:9	129:23 178:21	works 136:3	y 190:1
6:24 30:2,5	219:23 231:18	world 124:6	yeah 10:10
61:9 65:2	235:3	159:4	15:17 16:10
71:18 73:3,6	worded 206:17	worse 97:24	20:23 21:4
91:5 92:8	207:8	worth 92:7	34:5 84:11
111:18 112:19	wording	write 56:12,12	87:19 88:24
113:12,25	115:25 207:21	91:15 104:6	98:13 99:15
115:24 116:15	words 71:21	117:4 161:7	102:25 106:21
122:7 123:13	109:10 113:5	162:1,20 163:5	110:12,12
123:16 124:2	137:12	163:6 184:17	112:14 120:20
124:21 125:14	work 8:9 32:2,9	205:13	126:13 131:22
128:18 129:3	32:13 33:22	writing 14:19	133:12 149:9
137:9 138:1	34:15 35:1	36:7 41:20	155:12,14
144:6 146:14	41:19 47:2	119:4,8 128:10	158:23 162:13
147:7 154:21	48:15 49:24	136:22 148:4	163:8 169:2
154:24 155:3,6	54:10 58:16	193:11 222:11	177:19,25
155:12 158:16	64:9 90:6,8	written 14:17	178:1 192:23
159:3 173:11	98:8 133:17,19	14:18,24 56:11	202:10 203:19
175:8,13	133:20,21	56:19 101:25	205:4,12 210:9
177:18,20,22	134:1,8 136:10	121:20 131:13	211:15,24
178:4,6 180:18	144:7 173:12	138:21 148:25	213:11 230:6
181:21 184:3	174:5 195:19	189:17 229:1	year 27:20 28:8
187:3,17	195:20 222:1,3	wrong 82:2,2	31:25 34:16
188:17 196:11	232:15 233:5,8	92:11 153:6	40:21 71:8,9
196:14 200:11	worked 41:21	154:19 160:25	71:13 72:3,23
209:9 211:11	45:7 149:1	161:1,2,2	72:23 79:15,22
215:10 225:1	233:2	175:2	80:2 81:19
227:18 237:1	workers 33:20	wrote 15:13	83:17 144:3
239:2,24	233:4	136:13 194:18	154:13,14,14
woburn 154:4	working 9:8	202:13	180:4 227:18
	98:1 173:19,22		

230:8,11,14	z
years 24:24	zachary 2:12
25:1,5,9,12,15	zero 95:15
25:16,18,19	96:15,17,22
27:4,5,6 28:3,9	154:10 174:9,9
31:25 40:7	210:7,11
41:19 71:12	zone 32:22
84:16 90:7	zoom 2:8,12,20
94:3,13,15,17	196:14,21,24
94:21,21 95:14	236:11
96:16,20,22	
98:9 99:23	
114:8 130:17	
131:18 144:1,2	
144:4 180:15	
215:12 216:22	
216:25 222:3,6	
226:20,21	
227:5,5,24	
232:21 233:9	
233:14	
yelling 55:5	
yellow 201:4	
yesterday	
95:13 196:16	
196:16,22	
yesterday's	
197:2	
young 116:11	
yu 233:19	
234:5	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS

COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted

fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.